Note: Descriptions are shown in the official language in which they were submitted.
WO 2023/028235
PCT/US2022/041532
EIF4E INHIBITORS AND USES THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS
100011 This application claims priority to U.S. Provisional
Application No. 63/260,556, filed
August 25, 2021, which is incorporated herein by reference in its entirety.
TECHNICAL FIELD OF THE INVENTION
100021 The present invention relates to compounds and methods useful
for inhibition of
Eukaryotic initiation factor 4E (eIF4E). The invention also provides
pharmaceutically acceptable
compositions comprising compounds of the present invention and methods of
using said
compositions in the treatment of various disorders.
BACKGROUND OF THE INVENTION
100031 Eukaryotic initiation factor 4E (eIF4E) is a 24 kDa protein
that plays a key role in the
initiation of translation of select mRNAs. At the initiation of mRNA
translation, eIF4E binds to
the 7-methylguanosine cap at the 5' end of mRNAs, and forms a complex (called
elF4F) with
proteins including the scaffolding protein eIF4G and the helicase eIF4A. The
formation of the 4F
complex is required for the initiation of cap-dependent translation, and
therefore the binding of
eIF4E to its cognate partners is a critical event in eIF4E mediated
translation.
100041 A number of studies have suggested that dysregulated eIF4E is
important in some
cancer phenotypes, and therefore eIF4E is a potential target in the field of
oncology.
SUMMARY OF THE INVENTION
100051 It has now been found that compounds of the present
invention, and pharmaceutically
acceptable compositions thereof, are effective as eIF4E inhibitors. In one
aspect, the present
invention provides a compound of Formula (I):
R3 R2
HN-<\ft
Ny
0-R1
X ( R4)
n
(I)
1
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
or a pharmaceutically acceptable salt thereof, wherein each variable is as
defined and described
herein.
100061 Compounds of the present invention, and pharmaceutically
acceptable compositions
thereof, are useful for treating a variety of diseases, disorders or
conditions, associated with eIF4E.
Such diseases, disorders, or conditions include cellular proliferative
disorders (e.g., cancer) such
as those described herein.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
I. General Description of Certain Embodiments of the Invention:
100071 Compounds of the present invention, and pharmaceutical
compositions thereof, are
useful as inhibitors of eIF4E. Without wishing to be bound by any particular
theory, it is believed
that compounds of the present invention, and pharmaceutical compositions
thereof, may inhibit
the activity of eIF4E and thus treat certain diseases, such as cancer.
100081 It has now been found that compounds of this invention, and
pharmaceutically
acceptable compositions thereof, are effective as eIF4E inhibitors. In one
aspect, the present
invention provides a compound of Formula I:
R3
( R4) n
(I)
or a pharmaceutically acceptable salt thereof, wherein:
Xis C, CR', or N;
R' is H, C1_6 alkyl optionally substituted 1-6 times by halogen, -OR, -N(R)2,
or
R2 is a 3-6 membered monocyclic saturated carbocyclic ling optionally
substituted 1-6 time by
halogen or -OR', C1_6 alkyl optionally substituted 1-6 time by halogen or -
OR', or C1-6 alkyl
optionally substituted 1 time by a 3-6 membered monocyclic saturated
carbocyclic ring or a
phenyl ring, wherein the 3-6 membered monocyclic saturated carbocyclic ring
and phenyl ring
are optionally substituted 1-6 times by halogen or -OR';
2
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
AR5) (R5) m R5)m R5)m ' R5) ( m
R5)m
m
C Z
S S S S S
- - -
\ /N
N \ /
0=C 0 0=C 0=C 0=C 0=C
\ \ \ \
\
R1 is OH OH OH OH OH
OH
R5)m R5)m 4R5)m R5)m
Z Z S
/ / _
0 S
¨ _NI ¨ ¨
\ /N
\ /N
\ /N
\ /
0=C 0=C 0=C 0=C
\O \ \ \
H OH ,or OH -
, , OH
each le is independently halogen, -OR', or C1.6 alkyl optionally substituted 1-
6 times by halogen;
each R5 is independently halogen or C1-6 alkyl optionally substituted 1-6
times by halogen;
each R is independently H, C1.6 alkyl optionally substituted 1-6 times by
halogen, -OR', or
or a 3-6 membered monocyclic saturated carbocyclic ring optionally substituted
1-6 times by
halogen;
each R' is independently H or C1-6 alkyl optionally substituted 1-6 times by
halogen;
m is 0 or 1; and
n is 0, 1, or 2.
2. Compounds and Definitions:
100091 Compounds of the present invention include those described
generally herein, and are
further illustrated by the classes, subclasses, and species disclosed herein.
As used herein, the
following definitions shall apply unless otherwise indicated. For purposes of
this invention, the
chemical elements are identified in accordance with the Periodic Table of the
Elements, CAS
version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general
principles of organic
chemistry are described in "Organic Chemistry", Thomas Sorrell, University
Science Books,
Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.:
Smith, M.B. and
March, J., John Wiley & Sons, New York: 2001, the entire contents of which are
hereby
incorporated by reference.
3
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
100101 The term "aliphatic" or "aliphatic group", as used herein,
means a straight-chain (i.e.,
unbranched) or branched, substituted or unsubstituted hydrocarbon chain that
is completely
saturated or that contains one or more units of unsaturation, or a monocyclic
hydrocarbon or
bicyclic hydrocarbon that is completely saturated or that contains one or more
units of
unsaturation, but which is not aromatic (also referred to herein as
"carbocycle," "cycloaliphatic"
or "cycloalkyl"), that has a single point of attachment to the rest of the
molecule. Unless otherwise
specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some
embodiments, aliphatic
groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic
groups contain 1-4
aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-
3 aliphatic carbon
atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic
carbon atoms. In some
embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a
monocyclic C3-C6
hydrocarbon that is completely saturated or that contains one or more units of
unsaturation, but
which is not aromatic, that has a single point of attachment to the rest of
the molecule. Suitable
aliphatic groups include, but are not limited to, linear or branched,
substituted or unsubstituted
alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl,
(cycloalkenyl)alkyl
or (cycloalkyl)alkenyl.
100111 As used herein, the term "bicyclic ring" or "bicyclic ring
system" refers to any bicyclic
ring system, i.e. carbocyclic or heterocyclic, saturated or having one or more
units of unsaturation,
having one or more atoms in common between the two rings of the ring system.
Thus, the term
includes any permissible ring fusion, such as ortho-fused or spirocyclic. As
used herein, the term
"heterobicyclic" is a subset of "bicyclic" that requires that one or more
heteroatoms are present in
one or both rings of the bicycle. Such heteroatoms may be present at ring
junctions and are
optionally substituted, and may be selected from nitrogen (including N-
oxides), oxygen, sulfur
(including oxidized forms such as sulfones and sulfonates), phosphorus
(including oxidized forms
such as phosphates), boron, etc. In some embodiments, a bicyclic group has 7-
12 ring members
and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
As used herein, the
term "bridged bicyclic" refers to any bicyclic ring system, i.e. carbocyclic
or heterocyclic,
saturated or partially unsaturated, having at least one bridge. As defined by
IUPAC, a "bridge" is
an unbranched chain of atoms or an atom or a valence bond connecting two
bridgeheads, where a
"bridgehead" is any skeletal atom of the ring system which is bonded to three
or more skeletal
atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has
7-12 ring
4
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur. Such
bridged bicyclic groups are well known in the art and include those groups set
forth below where
each group is attached to the rest of the molecule at any substitutable carbon
or nitrogen atom.
Unless otherwise specified, a bridged bicyclic group is optionally substituted
with one or more
substituents as set forth for aliphatic groups. Additionally or alternatively,
any substitutable
nitrogen of a bridged bicyclic group is optionally substituted. Exemplary
bicyclic rings include:
S.
CO Cy HNON-D
Exemplary bridged bicyclics include:
r\11-1
HN
ocNH
HN HN
4111 HNI,T OLT
0
CD NH NH CT1NH
ISINH
0
110
100121 The term "lower alkyl" refers to a C1-4 straight or branched
alkyl group. Exemplary
lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and
tert-butyl.
100131 The term "lower haloalkyl" refers to a C1.4 straight or
branched alkyl group that is
substituted with one or more halogen atoms.
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
[0014] The term "heteroatom" means one or more of oxygen, sulfur,
nitrogen, phosphorus, or
silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or
silicon; the quaternized
form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic
ring, for example N (as in
3,4-dihydro-2H-pyrroly1), NH (as in pyrrolidinyl) or NW (as in N-substituted
pyrrolidinyl)).
[0015] The term "unsaturated", as used herein, means that a moiety
has one or more units of
unsaturation.
[0016] As used herein, the term "bivalent Cis (or C1_6) saturated or
unsaturated, straight or
branched, hydrocarbon chain", refers to bivalent alkylene, alkenylene, and
alkynylene chains that
are straight or branched as defined herein.
[0017] The term "alkylene" refers to a bivalent alkyl group. An
"alkylene chain" is a
polymethylene group, i.e., ¨(CH2).¨, wherein n is a positive integer,
preferably from 1 to 6, from
1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain
is a polymethylene
group in which one or more methylene hydrogen atoms are replaced with a
substituent. Suitable
substituents include those described below for a substituted aliphatic group.
100181 The term "alkenylene" refers to a bivalent alkenyl group. A
substituted alkenylene
chain is a polymethylene group containing at least one double bond in which
one or more hydrogen
atoms are replaced with a substituent. Suitable substituents include those
described below for a
substituted aliphatic group.
[0019] As used herein, the term "cyclopropylenyl" refers to a
bivalent cyclopropyl group of
riss"'iLC-
the following structure:
[0020] The term "halogen" means F, Cl, Br, or I.
[0021] The term "aryl" used alone or as part of a larger moiety as
in "aralkyl," "aralkoxy," or
"aryloxyalkyl," refers to monocyclic or bicyclic ring systems having a total
of five to fourteen ring
members, wherein at least one ring in the system is aromatic and wherein each
ring in the system
contains 3 to 7 ring members. The term "aryl" may be used interchangeably with
the term "aryl
ring." In certain embodiments of the present invention, "aryl" refers to an
aromatic ring system
which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and
the like, which may
bear one or more substituents. Also included within the scope of the term
"aryl,- as it is used
herein, is a group in which an aromatic ring is fused to one or more
non¨aromatic rings, such as
indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl,
and the like.
6
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
100221 The terms "heteroaryl" and "heteroar¨," used alone or as part
of a larger moiety, e.g.,
"heteroaralkyl," or "heteroaralkoxy," refer to groups having 5 to 10 ring
atoms, preferably 5, 6, or
9 ring atoms; having 6, 10, or 14 it electrons shared in a cyclic array; and
having, in addition to
carbon atoms, from one to five heteroatoms. The term "heteroatom" refers to
nitrogen, oxygen, or
sulfur, and includes any oxidized form of nitrogen or sulfur, and any
quaternized form of a basic
nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl,
pyrrolyl, imidazolyl,
pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl,
thiazolyl, isothiazolyl,
thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl,
purinyl, naphthyridinyl, and
pteridinyl. The terms "heteroaryl" and "heteroar¨", as used herein, also
include groups in which a
heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or
heterocyclyl rings, where the
radical or point of attachment is on the heteroaromatic ring. Nonlimiting
examples include indolyl,
isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl,
benzimidazolyl, benzthiazolyl,
quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,
4H¨quinolizinyl,
carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl,
tetrahydroquinolinyl,
tetrahydroisoquinolinyl, and pyrido[2,3¨b]-1,4¨oxazin-3(4H)¨one. A heteroaryl
group may be
mono¨ or bicyclic. The term "heteroaryl" may be used interchangeably with the
terms "heteroaryl
ring," "heteroaryl group," or "heteroaromatic," any of which terms include
rings that are optionally
substituted. The term "heteroaralkyl" refers to an alkyl group substituted by
a heteroaryl, wherein
the alkyl and heteroaryl portions independently are optionally substituted.
100231 As used herein, the terms "heterocycle," "heterocyclyl,"
"heterocyclic radical," and
"heterocyclic ring" are used interchangeably and refer to a stable 5¨ to
7¨membered monocyclic
or 7-10¨membered bicyclic heterocyclic moiety that is either saturated or
partially unsaturated,
and having, in addition to carbon atoms, one or more, preferably one to four,
heteroatoms, as
defined above. When used in reference to a ring atom of a heterocycle, the
term "nitrogen" includes
a substituted nitrogen. As an example, in a saturated or partially unsaturated
ring having 0-3
heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N
(as in 3,4¨dihydro-
2H¨pyrroly1), NH (as in pyrrolidinyl), or NR (as in N¨substituted
pyrrolidinyl).
100241 A heterocyclic ring can be attached to its pendant group at
any heteroatom or carbon
atom that results in a stable structure and any of the ring atoms can be
optionally substituted.
Examples of such saturated or partially unsaturated heterocyclic radicals
include, without
limitation, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl,
piperidinyl, pyrrolinyl,
7
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
oxazolidinyl, piperazinyl,
dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and
quinuclidinyl. The
terms "heterocycle," "heterocyclyl," "heterocyclyl ring," "heterocyclic
group," "heterocyclic
moiety," and "heterocyclic radical," are used interchangeably herein, and also
include groups in
which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or
cycloaliphatic rings, such as
indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A
heterocyclyl group
may be mono- or bicyclic. The term "heterocyclylalkyl" refers to an alkyl
group substituted by a
heterocyclyl, wherein the alkyl and heterocyclyl portions independently are
optionally substituted.
[0025]
As used herein, the term "partially unsaturated" refers to a ring
moiety that includes at
least one double or triple bond. The term "partially unsaturated" is intended
to encompass rings
having multiple sites of unsaturation, but is not intended to include aryl or
heteroaryl moieties, as
herein defined.
[0026]
As described herein, compounds of the invention may contain "optionally
substituted"
moieties. In general, the term "substituted,- whether preceded by the term
"optionally- or not,
means that one or more hydrogens of the designated moiety are replaced with a
suitable substituent.
Unless otherwise indicated, an "optionally substituted" group may have a
suitable substituent at
each substitutable position of the group, and when more than one position in
any given structure
may be substituted with more than one substituent selected from a specified
group, the substituent
may be either the same or different at every position. Combinations of
substituents envisioned by
this invention are preferably those that result in the formation of stable or
chemically feasible
compounds. The term "stable," as used herein, refers to compounds that are not
substantially
altered when subjected to conditions to allow for their production, detection,
and, in certain
embodiments, their recovery, purification, and use for one or more of the
purposes disclosed
herein.
[0027]
Each optional substituent on a substitutable carbon is a monovalent
substituent
independently selected from halogen; -(CH2)0-4R ; -(CH2)0_40R`"; -0(CH2)0-4R ,
-0-(CH2)0_
4C(0)0W; -(CH2)0-4CH(OR )2; -(CH2)0-4SR ; -(CH2)0-4Ph, which may be
substituted with R ;
-(CH7)0_40(C117)0_1Ph which may be substituted with R`); -CH=CHPh, which may
be substituted
with IV; -(CH2)0_40(CH2)0_1-pyridyl which may be substituted with R`); -NO2; -
CN; -
N3 -(CH2)0-4N(R )2 ; -(CH2)0-4N(R )C (0)R ; -N(R )C(S)R ;
-(CH2)0-
4N(R )C(0)NR 2; -N(R )C(S)NR 2; -(CH2)0_4N(R )C(0)0R ;
8
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
N(R )N(R )C (0)R ; -N(R )N(R )C (0)NR 2; -N(R )N(R )C(0)0R ; -(CH2)0-4C(0)R ;
-
C(S)R ; -(CH2)0_4C(0)0R ; -(CH2)0_4C(0)SR ; -(CH2)0_4C(0)0 SiR 3; -(CH2)0_4
OC(0)R ; -
0C(0)(CH2)0_4SR-, SC(S)SR ; -(CH2)0_4SC(0)R ; -(CH2)0_4C(0)NR 2; -C(S)NR 2; -
C(S)SR ;
-SC(S)SR , -(CH2)0_40C(0)NR 2, -C(0)N(OR )R , -C(0)C(0)R , -C(0)CH2C(0)R , -
C(NOR )R ; -(CH2)0_4 SSR ; -(CH2)0_4 S(0)2R ; -(CH2)0_4 S(0)20R ; -(CH2)0_40
S(0)2R ; -
S(0)2NR 2; -S(0)(NR )R ; -S(0)2N=C(NR 2)2, -(CH2)0_4 S (0)R ; -N(R )S(0)2NR
2; -
N(R )S(0)2R ; -N(OR )R ; -C(NH)NR 2; -P(0)2R ; -P(0)R 2; -0P(0)R 2; -0P(0)(OR
)2;
SiR 3; -(C1_4 straight or branched alkylene)0-N(R )2; or -(C1_4 straight or
branched
alkylene)C(0)0-N(R )2.
100281
Each R is independently hydrogen, C1_6 aliphatic, -CH2Ph, -
0(CH2)0_11311, -CH2-(5-6
membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated,
or aryl ring having
0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or,
notwithstanding the
definition above, two independent occurrences of R , taken together with their
intervening atom(s),
form a 3-1 2-membered saturated, partially unsaturated, or aryl mono- or
bicyclic ring having 0-
4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which
may be substituted
by a divalent substituent on a saturated carbon atom of R selected from =0
and =S, or each R
is optionally substituted with a monovalent substituent independently selected
from halogen, -
(CH2)0_21e, -(haloR*), -(CH2)0_20H, -(CH2)0_201e, -(CH2)0_2CH(0R.)2; -
0(haloR*), -CN, -N3,
-(CH2)0_2C(0)R., -(CH2)0_2C(0)0H, -(CH2)0_2C(0)0R., -(CH2)o-2SR., -(CH2)o-2SH,
-(CH2)o-
2NH2, -(CH2)0_2NFIR., -(CH2)0_2NR.2, -NO2,
-C(0)SR., -(C1-4 straight or
branched alkylene)C(0)0R., or -S SR*.
100291
Each R. is independently selected from Ci_4 aliphatic, -CH2Ph, -
0(CH2)0_113h, or a 5-
6-membered saturated, partially unsaturated, or aryl ring having 0-4
heteroatoms independently
selected from nitrogen, oxygen, or sulfur, and wherein each R. is
unsubstituted or where preceded
by halo is substituted only with one or more halogens; or wherein an optional
substituent on a
saturated carbon is a divalent substituent independently selected from =0, =S,
=NNR*2,
=NNHC (0)R*, =NNHC (0)0R*, =NNHS (0)2R*, =NR*, =NOR*, -0(C (R *2 ))2_3 0-, or -
S (C (R*2 ))2_3 S-, or a divalent substituent bound to vicinal substitutable
carbons of an "optionally
substituted" group is -0(CR*2)2_30-, wherein each independent occurrence of R*
is selected from
9
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
hydrogen, C1_6 aliphatic or an unsubstituted 5-6-membered saturated, partially
unsaturated, or
aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen,
or sulfur.
100301 When R* is C1-6 aliphatic, R* is
optionally substituted with halogen, -
R', -(haloR*), -OH, -0R., -0(haloR*), -CN, -C(0)0H, -C(0)0R*,
-NRR*, -NR*2, or -
NO2, wherein each R. is independently selected from C1-4 aliphatic, -CH2Ph, -
0(CH2)0_1Ph, or a
5-6-membered saturated, partially unsaturated, or aryl ring having 0-4
heteroatoms independently
selected from nitrogen, oxygen, or sulfur, and wherein each R. is
unsubstituted or where preceded
by halo is substituted only with one or more halogens.
100311
An optional sub stituent on a substitutable nitrogen is independently -
Rt, -NR1 2, -
C(0)R1, -C(0)0R1, -C(0)C(0)R1 , -C(0)CH2C(0)R1, -S(0)2R1 , -S(0)2NR1 2, -
C(S)NR1 2, -
C(NH)NRI2, or -N(R1)S(0)2Rt; wherein each RI- is independently hydrogen, C1-6
aliphatic,
unsubstituted -0Ph, or an unsubstituted 5-6-membered saturated, partially
unsaturated, or aryl
ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or, two
independent occurrences of R, taken together with their intervening atom(s)
form an unsubstituted
3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring
haying 0-4
heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein
when Rt is C1-6
aliphatic, Rt is optionally substituted with halogen, -1e, -(haloR*), -OH, -
0R., -0(haloR*), -
CN, -C(0)0H, -C(0)0R., -NH2, -NHIR., -NR.2, or -NO2, wherein each R. is
independently
selected from C1_4 aliphatic, -CH2Ph, -0(CH2)0_113h, or a 5-6-membered
saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen,
or sulfur, and wherein each R. is unsubstituted or where preceded by halo is
substituted only with
one or more halogens.
100321
As used herein, the term "pharmaceutically acceptable salt" refers to
those salts which
are, within the scope of sound medical judgment, suitable for use in contact
with the tissues of
humans and lower animals without undue toxicity, irritation, allergic response
and the like, and
are commensurate with a reasonable benefit/risk ratio. Pharmaceutically
acceptable salts are well
known in the art. For example, S. M. Berge et al., describe pharmaceutically
acceptable salts in
detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by
reference.
Pharmaceutically acceptable salts of the compounds of this invention include
those derived from
suitable inorganic and organic acids and bases. Examples of pharmaceutically
acceptable,
nontoxic acid addition salts are salts of an amino group formed with inorganic
acids such as
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and
perchloric acid or with
organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid,
citric acid, succinic acid
or malonic acid or by using other methods used in the art such as ion
exchange. Other
pharmaceutically acceptable salts include adi pate, alginate, ascorbate,
aspartate, benzenesulfonate,
benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate,
fumarate,
glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate,
hexanoate, hydroiodide, 2¨
hydroxy¨ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate,
malate, maleate, malonate,
m eth an e sul fon ate, 2¨n ap hth al en e sul fon ate, ni coti n ate,
nitrate, ol eate, ox al ate, pal m i tate, p am oate,
pectinate, persulfate, 3¨phenylpropionate, phosphate, pivalate, propionate,
stearate, succinate,
sulfate, tartrate, thiocyanate, p¨toluenesulfonate, undecanoate, valerate
salts, and the like.
100331 Salts derived from appropriate bases include alkali metal,
alkaline earth metal,
ammonium and N (C1_4alky1)4 salts. Representative alkali or alkaline earth
metal salts include
sodium, lithium, potassium, calcium, magnesium, and the like. Further
pharmaceutically
acceptable salts include, when appropriate, nontoxic ammonium, quaternary
ammonium, and
amine cations formed using counterions such as halide, hydroxide, carboxylate,
sulfate, phosphate,
nitrate, loweralkyl sulfonate and aryl sulfonate.
100341 Unless otherwise stated, structures depicted herein are also
meant to include all
isomeric (e.g., enantiomeric, diastereomeric, and geometric (or
conformational)) forms of the
structure; for example, the R and S configurations for each asymmetric center,
Z and E double
bond isomers, and Z and E conformational isomers. Therefore, single
stereochemical isomers as
well as enantiomeric, diastereomeric, and geometric (or conformational)
mixtures of the present
compounds are within the scope of the invention. Unless otherwise stated, all
tautomeric forms of
the compounds of the invention are within the scope of the invention.
Additionally, unless
otherwise stated, structures depicted herein are also meant to include
compounds that differ only
in the presence of one or more isotopically enriched atoms. For example,
compounds having the
present structures including the replacement of hydrogen by deuterium or
tritium, or the
replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope
of this invention.
Such compounds are useful, for example, as analytical tools, as probes in
biological assays, or as
therapeutic agents in accordance with the present invention. In certain
embodiments, a warhead
moiety, le, of a provided compound comprises one or more deuterium atoms.
11
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
100351 As used herein, the term "inhibitor" is defined as a compound
that binds to and /or
inhibits elF4E with measurable affinity. In certain embodiments, an inhibitor
has an IC50 and/or
binding constant of less than about 100 uM, less than about 50 uM, less than
about 22.5uM, less
than about 15uM, or less than about 7.5uM.
100361 The terms "measurable affinity" and "measurably inhibit," as
used herein, means a
measurable change in elF4E activity between a sample comprising a compound of
the present
invention, or composition thereof, and eIF4E, and an equivalent sample
comprising elF4E, in the
absence of said compound, or composition thereof.
3. Description of Exemplary Embodiments:
100371 In one aspect, the present invention provides a compound of
Formula I:
R3 R2
HN---µ
NQ-0-R1
( R4) n
(I),
or a pharmaceutically acceptable salt thereof, wherein:
Xis C, CR4, or N;
R1 is H, C1_6 alkyl optionally substituted 1-6 times by halogen, -OR, -N(R)2,
or -C(0)-N(R)2;
R2 is a 3-6 membered monocyclic saturated carbocyclic ring optionally
substituted 1-6 time by
halogen or -OR', C1-6 alkyl optionally substituted 1-6 time by halogen or -
OR', or C1-6 alkyl
optionally substituted 1 time by a 3-6 membered monocyclic saturated
carbocyclic ring or a
phenyl ring, wherein the 3-6 membered monocyclic saturated carbocyclic ring
and phenyl ring
are optionally substituted 1-6 times by halogen or -OR';
12
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
% ,R5)rr (R5) m R5)m R5)m ' R5)m
cz?(R5)m
C Z
/ Z
/
¨ ¨
\ /N
\ /N
N \ /
0=C 0 0=C 0=C 0=C 0=C
\ \ \ \
\
R1 is OH OH , OH OH OH
OH
R5)m R5)m 4R5)m R5)m
Z Z S
/ / _
0 S
¨ _NI ¨ ¨
\ /N
\ /N
\ /N
\ /
0=C 0=C 0=C 0=C
\O \ \ \
H OH ,or OH -
, , OH
each le is independently halogen, -0R1, or C1.6 alkyl optionally substituted 1-
6 times by halogen;
each R5 is independently halogen or C1-6 alkyl optionally substituted 1-6
times by halogen;
each R is independently H, C1.6 alkyl optionally substituted 1-6 times by
halogen, -OR', or -N(R')2,
or a 3-6 membered monocyclic saturated carbocyclic ring optionally substituted
1-6 times by
halogen;
each R' is independently H or C1-6 alkyl optionally substituted 1-6 times by
halogen;
m is 0 or 1; and
n is 0, 1, or 2.
100381 As defined generally above, X is C, CR4, or N, wherein R4 is
as defined and described
in embodiments herein.
100391 In some embodiments, X is C. In some embodiments, X is CR4.
In some embodiments,
XisN.
100401 In some embodiments, X is selected from those depicted in
Table 1, below.
100411 As defined generally above, R1 is H, C1-6 alkyl optionally
substituted 1-6 times by
halogen, -OR, -N(R)2, or -C(0)-N(R)2, wherein each R is independently as
defined and described
in embodiments herein.
100421 In some embodiments, R1 is H. In some embodiments, R1 is C1-6
alkyl optionally
substituted 1, 2, 3, 4, 5, or 6 times by halogen, -OR, or -N(R)2. In some
embodiments, R1 is
unsubstituted C1.6 alkyl. In some embodiments, R1 is C1.6 alkyl substituted 1,
2, 3, 4, 5, or 6 times
13
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
by halogen. In some embodiments, RI- is C1-6 alkyl substituted 1, 2, 3, 4, 5,
or 6 times by -OR. In
some embodiments, RI- is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by -
N(R)2. In some
embodiments, RI- is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by -C(0)-
N(R)2.
100431 In some embodiments, RI- is selected from:
NH2
=
100441 In some embodiments, RI- is or N
100451 In some embodiments, RI- is selected from those depicted in
Table 1, below.
100461 As defined generally above, R2 is a 3-6 membered monocyclic
saturated carbocyclic
ring optionally substituted 1-6 time by halogen or -OR', C1-6 alkyl optionally
substituted 1-6 time
by halogen or -OR', or C1_6 alkyl optionally substituted 1 time by a 3-6
membered monocyclic
saturated carbocyclic ring or a phenyl ring, wherein the 3-6 membered
monocyclic saturated
carbocyclic ring and phenyl ring are optionally substituted 1-6 times by
halogen or -OR', wherein
each R' is independently as defined and described in embodiments herein.
100471 In some embodiments, R2 is a 3, 4, 5, or 6 membered
monocyclic saturated carbocyclic
ring optionally substituted 1, 2, 3, 4, 5, or 6 time by halogen or -OR'. In
some embodiments, R2 is
an unsubstituted 3, 4, 5, or 6 membered monocyclic saturated carbocyclic ring.
In some
embodiments, R2 is a 3, 4, 5, or 6 membered monocyclic saturated carbocyclic
ring substituted 1,
2, 3, 4, 5, or 6 time by F.
100481 In some embodiments, R2 is C1.6 alkyl optionally substituted
1, 2, 3, 4, 5, or 6 time by
halogen or -OR'. In some embodiments, R2 is unsubstituted CI-6 alkyl. In some
embodiments, R2
is C1.6 alkyl optionally substituted 1, 2, 3, 4, 5, or 6 time by F.
100491 In some embodiments, R2 is C1_6 alkyl optionally substituted
1 time by a 3, 4, 5, or 6
membered monocyclic saturated carbocyclic ring or a phenyl ring, wherein the
3, 4, 5, or 6
membered monocyclic saturated carbocyclic ring and phenyl ring are optionally
substituted 1, 2,
3, 4, 5, or 6 times by halogen or -OR'. In some embodiments, R2 is C1_6 alkyl
optionally substituted
1 time by an unsubstituted 3, 4, 5, or 6 membered monocyclic saturated
carbocyclic ring or an
unsubstituted phenyl ring.
14
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
\\7(1----
100501 In some embodiments, R2 is \--3---, 41--",
., õ 'r#7', 6
9, --,0
L---3_, or I* . In some
embodiments, R2 is ---1
100511 In some embodiments, R2 is selected from those depicted in
Table 1, below.
(R5) (R5) m
,R5)m
1 i
S 1 S
N
\ /
0=C 0A, 0=c
\
\
100521 As defined generally above, R3 is OH , OH
OH ,
R5)m R5)m R5)m r Z R5)m R5)m
CR5)m
r Z
/
S S S 0/ S/
II NcõN , ,N \
,_ õ /N _IV
\ / \
/N
0=C 0=C 0=C 0=C 0=0 0=0
\ \ \ \ \ \
OH OH OH OH OH
, , , , , OH
,or
R5)m
s
¨
N
\ /
0=C
\
OH
, wherein each of le and m is independently as defined and described in
embodiments herein.
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
,R5)
( R5) m
N
S
_
0=C 0
\
100531 In some embodiments, R3 is OH . In some embodiments, R3
is OH .
R5)
R5)rn
S S
¨
N \ /
=
0=C 0=C
\ \
In some embodiments, R3 is OH . In some embodiments, R3 is OH
. In some
R5)m (.7cR5)m
/
S Sj ,
N ," N
/)...2c
0=C 0=C ,/õ
\ \
embodiments, R3 is OH . In some
embodiments, R3 is OH . In some
R5)m R5)m
0 S
\1N \ /
0=C 0=C
\ \
embodiments, le is OH . In some
embodiments, le is OH . In some
CR5)m R5)m
S
¨
\ /N
\ /N
0=C 0=C
\ \
embodiments, R3 is OH . In some embodiments, R3 is OH .
100541 In some embodiments, R3 is selected from:
16
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
F
S S S S 0
N N \
S N /N \ / \
_
0 ,õ, 0 0 0 0 ,õ.. 0=C
\ 0
OH OH OH , OH OH OH
OH
0=C%-N
.-== 0
\
OH , OH ,and OH
,
R5)
V , m
/
S
0
\ /N
HO
100551 In some embodiments, R3 is . In
some embodiments, R3 is
s,,
4-N(R5)m
, ,...___I__\N
y5.7m,,,,
o=c o=c
\ \
OH In some embodiments, R3 is OH . In some
embodiments, R3 is
17
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
AI¨ S'S t \ (R5 NH
iml ____________________________________________________ /
oR5)m Oc
\
OH . In some embodiments, It3 is OH . In some
embodiments, R3 is
R5)m
r
/
S
¨
N
\ /
0=C
\
/0
S ''
F F
¨
¨
9
F
_
0 ¨\ \ / N
\/N
)
HO _____________________________________________________ \ ie.,N
0
0
[0056] In some embodiments, R3 is selected from OH
OH
>',
0
1110 =-.
N
\ /
s , s =..., \ /NI 7-1
¨ o=c
\
o o o o 0
OH OH OH OH , and / .
, , , ,
[0057] In some embodiments, It3 is selected from those depicted in
Table 1, below.
100581 As defined generally above, each R4 is independently halogen,
-OW, or C1-6 alkyl
optionally substituted 1-6 times by halogen, wherein le is as defined and
described in
embodiments herein.
[0059] In some embodiments, R4 is halogen. In some embodiments, R4
is F. In some
embodiments, R4 is Cl.
[0060] In some embodiments, R4 is -OW. In some embodiments, R4 is -
OH. In some
embodiments, R4 is -OR', wherein It' is C1.6 alkyl optionally substituted 1,
2, 3, 4, 5, or 6 times
by halogen, -OR, -N(R)2, or -C(0)-N(R)2. In some embodiments, R4 is -OW,
wherein Itl is
18
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
unsubstituted Cl_6 alkyl. In some embodiments, R4 is -01e, wherein RI is C1_6
alkyl substituted 1,
2, 3, 4, 5, or 6 times by F.
[0061] In some embodiments, R4 is C1.6 alkyl optionally substituted
1, 2, 3, 4, 5, or 6 times by
halogen. In some embodiments, R4 is unsubstituted C4_6 alkyl. In some
embodiments, R4 is C1-6
alkyl substituted 1, 2, 3, 4, 5, or 6 times by F.
F
F
[0062] In some embodiments, R4 is selected from -OH, F, Cl, 0
F F
0
F F
NH2
,40C)T
[0063] In some embodiments, R4 is selected from those depicted in
Table 1, below.
[0064] As defined generally above, each R5 is independently halogen
or C1.6 alkyl optionally
substituted 1-6 times by halogen.
[0065] In some embodiments, R5 is halogen. In some embodiments, R5
is F. In some
embodiments, R5 is Cl.
[0066] In some embodiments, R5 is Cl_6 alkyl optionally substituted
1, 2, 3, 4, 5, or 6 times by
halogen. In some embodiments, R5 is unsubstituted Cl_6 alkyl. In some
embodiments, R5 is C1-6
alkyl substituted 1, 2, 3, 4, 5, or 6 times by F. In some embodiments, R5 is -
CH3. In some
embodiments, R5 is -CF3. In some embodiments, R5 is t-butyl.
100671 In some embodiments, R5 is -OR. In some embodiments, R5 is -
OCH3.
[0068] In some embodiments, R5 is selected from those depicted in
Table 1, below.
[0069] As defined generally above, each R is independently H, C1.6
alkyl optionally substituted
1-6 times by halogen, -OR', or -N(R')2, or a 3-6 membered monocyclic saturated
carbocyclic ring
optionally substituted 1-6 times by halogen, wherein each R' is independently
as defined and
described in embodiments herein.
[0070] In some embodiments, R is H.
100711 In some embodiments, R is C1.6 alkyl optionally substituted
1, 2, 3, 4, 5, or 6 times by
halogen, -OR', or -N(R')7. In some embodiments, R is unsubstituted C1-6 alkyl.
In some
embodiments, R is C1.6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by halogen.
In some embodiments,
R is Cl_6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by F. In some
embodiments, R is C1-6 alkyl
19
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
substituted 1, 2, 3, 4, 5, or 6 times by -OR'. In some embodiments, R is C1_6
alkyl substituted 1, 2,
3, 4, 5, or 6 times by -N(R')2.
100721 In some embodiments, R is a 3, 4, 5, or 6 membered monocyclic
saturated carbocyclic
ring optionally substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some
embodiments, R is an
unsubstituted 3, 4, 5, or 6 membered monocyclic saturated carbocyclic ring. In
some embodiments,
R is a 3, 4, 5, or 6 membered monocyclic saturated carbocyclic ring
substituted 1, 2, 3, 4, 5, or 6
times by F.
100731 In some embodiments, R is selected from:
o
100741 In some embodiments, R is selected from those depicted in
Table 1, below.
100751 As defined generally above, each R' is independently H or
C1_6 alkyl optionally
substituted 1-6 times by halogen.
100761 In some embodiments, R' is hydrogen.
100771 In some embodiments, R' is C1.6 alkyl optionally substituted
1, 2, 3, 4, 5, or 6 times by
halogen. In some embodiments, R' is unsubstituted C1-6 alkyl. In some
embodiments, R' is C1-6
alkyl substituted 1, 2, 3, 4, 5, or 6 times by F.
100781 In some embodiments, R' is selected from:
/Cy
100791 In some embodiments, R' is selected from those depicted in
Table 1, below.
100801 As defined generally above, m is 0 or 1.
100811 In some embodiments, m is 0. In some embodiments, m is 1.
100821 In some embodiments, m is selected from those depicted in
Table 1, below.
100831 As defined generally above, n is 0, I, or 2.
100841 In some embodiments, n is 0. some embodiments, n is 1. In
some embodiments, n is
2.
100851 In some embodiments, n is selected from those depicted in
Table 1, below.
100861 In some embodiments, the present invention provides a
compound of Formula II:
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
R5)m
\ /
R2
0=C FIN4 I
OH
0¨R1
( R4 n
or a pharmaceutically acceptable salt thereof, wherein each of RI-, R2, R4, ¨
5,
K m, and n is as defined
above and described in embodiments herein, both singly and in combination.
100871 In some embodiments, the present invention provides a
compound of Formulae II-a to
II-c.
7
R5)m R5)m
\ /N
R2 \ /
R2
0=C HN4
\OH
0¨R1
OH OH
( R4)
n 0¨R1
0¨R1
(II-a) (II-b) (II-c)
or a pharmaceutically acceptable salt thereof, wherein each of R2, R4, ¨ 5,
K m, and n is as defined
above and described in embodiments herein, both singly and in combination.
100881 In some embodiments, the present invention provides a
compound of Formula III:
R5)m
/
\ /
0=C
OH
0¨R1
( R4 ) n
(III)
21
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
or a pharmaceutically acceptable salt thereof, wherein each of RI, R4, R5, m,
and n is as defined
above and described in embodiments herein, both singly and in combination.
100891 In some embodiments, the present invention provides a
compound of Formulae III-a to
TTT-c:
/ 5 \
S V
/ V
/
¨ S S
N
\ / ¨
N \ /
¨
N
S
0=C HN \ / 4 1 S S
\OH N 0=C HN-- 1 R4) o=c HN4 I
0 _____________________________ R1 \OH
OH
(R4)
i n 0¨R1
0¨R1
(III-a) (III-b) (III-c)
or a pharmaceutically acceptable salt thereof wherein each of RI-, R4, R5, m,
and n is as defined
above and described in embodiments herein, both singly and in combination.
100901 Tn some embodiments, the present invention provides a
compound of Formulae TV-a to
IV-f:
7 7 7
s s s
_ ¨
¨
N N N
\ /
S S
0=0 HN¨. I
\ N 0=C HN¨<., I o¨c HN-- 1
\ N
OH \ N
OH OH
0¨R1
R4
0¨R1
R4 0¨R1
(IV-a) (IV-b) (IV-
c)
s s s
¨ ¨ ¨
N N N
S S S
0=0 HN--. I 0¨C ¨
HN¨<\ I 00 HN¨<, I
1
0¨R1
\ N \ N 0¨R1 ¨ \ N
0¨R
OH OH OH
R4
R4
(IV-e) (IV-0
(IV-d)
or a pharmaceutically acceptable salt thereof wherein each of RI- and le is as
defined above and
described in embodiments herein, both singly and in combination.
100911 In some embodiments, the present invention provides a
compound of Formula V:
22
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
R3 R2
I
H õR11
( R4) X
(V)
or a pharmaceutically acceptable salt thereof, wherein R" is H, halogen, C1-6
alkyl, -0-phenyl, or
-0-C1_6 alkyl, wherein C1_6 alkyl is optionally substituted by phenyl or -0-
phenyl, wherein phenyl
is optionally substituted; and each of X, le, le, R4, and n is as defined
above and described in
embodiments herein, both singly and in combination.
100921 In some embodiments, R" is H. In some embodiments, R" is
optionally substituted C1-
6 alkyl. In some embodiments, R" is unsubstituted C1-6 alkyl. In some
embodiments, R" is methyl,
ethyl, propyl, isopropyl, butyl, isobutyl, or t-butyl. In some embodiments,
lel is ethyl.
100931 In some embodiments, R" is -0-phenyl, wherein phenyl is
unsubsituted. In some
embodiments, R" is -0-phenyl, wherein phenyl is substituted with an optional
substitutent as
\-0 ill
described herein. In some embodiments, R" is
100941 In some embodiments, R11 is -0-C1.6 alkyl, wherein C1-6 alkyl
is optionally substituted
by phenyl. In some embodiments, R" is -0-C1-6 alkyl, wherein C1-6 alkyl is
optionally substituted
by 0-phenyl. In some embodiments, R" is
100951 In some embodiments, the present invention provides a
compound of Formula VI:
R
R3 2
I
H N
0
0---.1LR12
R13
(VI)
or a pharmaceutically acceptable salt thereof, wherein each of R12 and R13 is
independently H or
optionally substituted C1-6 alkyl; and wherein each of R2 and R3 is as defined
above and described
in embodiments herein, both singly and in combination.
23
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
[0096] In some embodiments, R12 is H. In some embodiments, RI' is
optionally substituted C1-
6 alkyl. In some embodiments, RI-2 is unsubstituted C1-6 alkyl. In some
embodiments, RI-2 is methyl,
ethyl, propyl, isopropyl, butyl, isobutyl, or t-butyl. In some embodiments,
Ru2 is methyl.
[0097] In some embodiments, R13 is H. In some embodiments, R13 is
optionally substituted C1-
6 alkyl. In some embodiments, RI-3 is unsubstituted C1-6 alkyl. In some
embodiments, RI-3 is methyl,
ethyl, propyl, isopropyl, butyl, isobutyl, or t-butyl. In some embodiments,
Ri3 is methyl.
[0098] In some embodiments, RI-2 is H, and R13 is optionally
substituted C1.6 alkyl. In some
embodiments, each of RI-2 and RI-3 is optionally substituted C1-6 alkyl.
[0099] In some embodiments, each of R12 and R13 is H. In some
embodiments, each of R12 and
R13 is methyl.
[00100] In some embodiments, the present invention provides a compound of
Formulae VH-a
or
R3 Q R2 R3 R2
H NI R14)
n
S
(VII- a) (V11-13)
or a pharmaceutically acceptable salt thereof, wherein each R" is
independently H, -OH, halogen,
-C1_6 alkyl, -0-C1_6 alkyl, or phenyl, wherein -C1_6 alkyl, -0-C1_6 alkyl, and
phenyl are optionally
substituted; and each of le, le, and n is as defined above and described in
embodiments herein,
both singly and in combination.
[00101] In some embodiments, R" is H. In some embodiments, R" is -OH. In some
embodiments, R1-4 is halogen. In some embodiments, R1-4 is optionally
substituted -C1-6 alkyl. In
some embodiments, RIA is unsubstituted -C1-6 alkyl. In some embodiments, R" is
methyl, ethyl,
propyl, isopropyl, butyl, isobutyl, or t-butyl. In some embodiments, RIA is -0-
C1.6 alkyl, wherein
C1-6 alkyl is optionally substituted. In some embodiments, R" is -0-C1.6
alkyl, wherein C1-6 alkyl
is unsubstituted. In some embodiments, R" is optionally substituted phenyl.
[00102] In some embodiments, the present invention provides a compound of
Formula VIII:
R2
R3
H N >R15)t
I
(VIII)
24
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
or a pharmaceutically acceptable salt thereof, wherein each RI' is
independently H, -OH, halogen,
-C1-6 alkyl, or -0-C1-6 alkyl, wherein -C1-6 alkyl and -0-C1-6 alkyl are
optionally substituted; Y is
0, CH2, or CHR15; t is 0, 1, 2, 3, or 4; and each of R2 and R3 is as defined
above and described in
embodiments herein, both singly and in combination.
[00103] In some embodiments, RI-5 is H. In some embodiments, R15 is -OH. In
some
embodiments, R15 is halogen. In some embodiments, 105 is optionally
substituted -C1-6 alkyl. In
some embodiments, R1-5 is unsubstituted -C1-6 alkyl. In some embodiments, RI-5
is methyl, ethyl,
propyl, isopropyl, butyl, isobutyl, or t-butyl. In some embodiments, R1-5 is -
0-C1.6 alkyl, wherein
C1-6 alkyl is optionally substituted. In some embodiments, RI-5 is -0-C1.6
alkyl, wherein C1.6 alkyl
is unsubstituted.
[00104] In some embodiments, Y is 0, CH2, or CHR15. In some embodiments, Y is
0. In some
embodiments, Y is CH2. In some embodiments, Y is CHR15
.
[00105] In some embodiments, t is 0. In some embodiments, t is 1. In some
embodiments, t is
2. In some embodiments, t is 3. In some embodiments, t is 4.
1001061 In some embodiments, the present invention provides a compound of
Table 1, or a
pharmaceutically acceptable salt thereof
[00107] In some embodiments, the present invention provides a compound of
Table 2, or a
pharmaceutically acceptable salt thereof.
[00108] In some embodiments, the present invention provides a compound
selected from those
depicted in the Exemplification section, or a pharmaceutically acceptable salt
thereof
Table 1. Exemplary Compounds
s s s s
.N
S
HN-<, I 0 HN-4 0
CI
OH OH OH
OH
OH
0 F CI CI
CI
1-1 1-2 1-3 1-4
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
...-- Y ...--
1 s / s / s /
_\
N
µ ,N
/N
< S
0 HN¨<\ 1 0 HN¨, 1 0
N 0 HN¨
j, I
OH N OH N
I N OH OH N
Ol<FF
o---6
0--.- N cr.
F
1-5 F 1-6 1-7 1-8
CS1. S-S-ji S
\,,
\ /(N
S \ N
' K is , N
S
]\¨H/KN ¨<\ I
0 S IHN-4 1
S
0 HN¨<, I 0 HN¨, 1
OH N OH N
OH N
N
F F OH
o7
0 F 0 F 0"--N,
CI F
1-11
1-12
1-9 1-10
V 7
S S /
S
¨\ ¨
\ /N S N \> , N
/ s
¨ s
H¨, I 0
0 N
0 1-1N-4, 1 FIN4 1
OH N 0
N OH N N
OH
A F OH
OH
1-13 1-14 1-15 0 F
1-16
7
/ 7 7
S / /
S S
--
N
\ ,N
0 S N
HN-4 1 ,S \ K s _
s
N 0 HN¨k, I 0 HN¨ I
OH 0 HN4
OH N OH N
0
OH N
NH2 0"-' o
1-17 1-18 1-19 1-20
7 ,
/
S
----
S N N S N S N
\ / S
S S S
0 HN-4 \ 0 1-1N----4. 1
0 HN-4. 0 HN4
1
OH N OH N
OH N
OH
N
OH
1-21 1-22 1-23
1-24
V
7 V /
S
/ /
S
¨ ¨
S N N N \ ,N
_ s 0
HN¨<, I
0 HN4 1
0 OH N
N
OH N OH N
OH
"---
0-'--
1-25 F 0 F 0
1-26 1-27
1-28 F
26
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
s s s s
0 HN-4, HN---K= HN--"N HN--4.
0 0 0
N N N N
O OH OH H OH
0 0 0
0
F F F
F
1-29 1-30 1-31 1-
32
S S S
/
_- -- S
N N
\ ,N ________________________________________________________________
S
0
F
HN-<,. I 0
N
OH N OH OH N
OF F OH N
^74, 0
?..-'.1 F
,,--1,
1-33 1-34 H 1-35 1-
36 v F
0
0,, =-,
7 7
S S _
_
_-
- N
N N \ /N \ /
S
RN-4 1 I
oI 0 HN4 I 0
HN4 I
0 0 HN-4 1
N f
of
0 N
OH N OH N OH
OH F
F
0 r,...-1,
,71,...
1-37 1-38 1-39 v F 1-
40 v F
S S --
0 N
HN-4 1 I HN-4 I I \ /N
0 0 0 I
I
N 1 N
OH 0
0
N
OH N
of oX OH f OH
ftLJ
0
F F
1-41 1-42 1-43 CI
1-44 CI
S 5
S / S
- --
-
N -- 0 N
I
/
...-- 0
HN-4 1
0 N I-IN-4, 1 0
OH
N
of 0)
Dj)
N
OH
OH N OH
1-46 Ofj
F 1-
48 CI
1-45 CI 1-47
F
7,
F
7 , / \ eN
/ S 0
S
S -
- N -
N ; /
N --
\ /
I 0 0 I S
HN-4.
OH
\ N 1
01
0 0 OH 0 0 HN-4 I
N
of OH
HN-4
N 0
OH N
of
of
1-50 F
1-51 F
1-49 F 1-
52
F
27
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
S 1 ¨
¨
¨ ¨
\ N s
N N \ /1'1 N
\ / ,S S \ /
-- 0.----1<iN-4. 1 I S
I ON H¨<, I
HN---- 0 HN---4
i
0 N N 0 0 NH N
0 OH N 0
/ )
K)
f
OH
0 Of
;
0
1-53 F 1-54 F
/ 1-55 F
HN F
1-56
7 ,
7 ,
/ S 7
0 /
¨ S
¨ 7
N
0 N \ iN
0
\
1) HN4 N
(0 S 0-11(1N¨e I
(
/0 OH HN-4 1
N
)
0 0 OH N
OH N
0
07
F
1-57 F 1-58 F F F 1-59 1-60
F
/ 7 ,
/
S S
_-
N \ i N N \ / N
N
0)-----( S
I
I
HNI-4 HN-4
ro 0
r0
OH N ' OH 0
N
)
7j
0
0
0 0--- F F
N OH OH N
CI F 1-63
1-61 1-62 1-64
7
N
¨ ¨ \ /
r)
N N N S
/ S r \ / r 0
HN4 1 1
HN4 1 HN4 OH
0 ro o r...0 0 0
o---J
N N N
OH
) OH
----J OH f
0 0 0 F
F F F 1-68
1-65 1-66 1-67
..,7
.,..,
/ 7 ,
S /
S
N
¨N
0
¨
¨ \ N
\ / I)I \ /,.
S I
S 0 HN¨<\
(-0
HN--. I 0 HN¨, I OH N 0 N
OH N OH
OH N
o)
o..---
0"-- 1-71 F 1-
72 F
0_,-
F
1-69 F 1-70
-----
/ S
S S S
_s, -- --
_ \
N 0
N
,N
µ
\ ,N
` __________ K s
0 HN¨% I FIN-4\
0 HN \/
¨<, I 0 N N
OH N OH OH
OH N
F
CI
01 F
F
F
1-73 --O ,0
1-74 1-75 1-76
28
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
.-- .-- ---
s s s s
¨\ ¨\
S S S S
0 H N-4, I 0 HN ¨<, I 0 HN¨<,
OH N OH N OH N OH N
F
CI
0 F F _.-0 N....,....0
1-77 1-78 1-79 1-80
_--
..-]s
/
S S
--__
\ /
µ _______________ K S 0 is S S
0 HN¨<µ I 0 HN-4. 1 HN--<.=N
OH N OH N OH N 0
OH
C1
F
F
F (),...---",0,-,
0,...õ----...0õ,
N.......-0
1-81 1-82 1-83 1-84
N,...--
/ S
/
S S
________________________________ _ \ ¨
--
N \ / N
\ /
S
]
HN S
---". 1 0 HN¨ I
-4, 1 0
0 0 HN
N OH N N OH
OH OH N
F
F F F 1
F
F
1-85 1-86 1-87
.-0 F F
...---
V , / .--- ----
S
S
--
N
\ / S OH S
HN--- I 0 HN¨ I 0 HN¨,
I
0
N
OH N OH N OH N
F
CI ....-0
F F
\,....-0
_--0
1-89 1-90 1-91 1-92
S S S S
0 H N ¨<\ I
OH N OH N
OH N 0
OH N
F CI
F
CI
1-93 ....",---C) 1-94 0 ..,...õ----Ø.--
1-95 0.,..õ------Ø.,
1-96
29
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
---
s s
_
N N
\ ,N
HN¨ 1 Orr HN¨<\ 1 0 HN---4
1 0
N N
OH OH N OH
CI
,.0 1-98
\...--O 1-99
1-97
0,õõ.-^....o....-
,-- ..--- ----- ..---
S S S S
¨ ¨
,
I 0 HN¨ 1 0 HN¨,
1
OH N OH N 0 OH N OH N
0---
1-100 ---0 1-101 .----0 1-102 F3C 0 1-
103
.---' / , / , ---
/ /
S S/ S/ S
¨ ¨
0
N N
/ S µ ,N
N ___________________________________________________________________ K s
0 0 HN¨<\ I
N N
OH N CF3 OH OH OH N
0...,..õõ.., 0...õ.-----..,
1-107
1-105 1-106
1-104
.--- -----
..--" "
/ S S
/ S
S
N _ __ \
N
\ /(N
S \ ,N
(
S i
0 HN4 I 0 HN¨(µ I 0 HN¨,
OH N = OH N OH N OH N
1-108 _...-0 ,0 1-109 1-110 ,0
1-111
HO
----
/
/
/
CI 0
S
ON H¨<µ, I 0 HN¨<, I 0 HN¨<\ I 0
OH N OH N OH N OH N
0,,,,,,-. N0
"...._....0
1-112 o,------- 1-113 r
I 1-114 1-115
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
/ S S
S _ ¨
_
N N N
\ / S
o1\1-- 1 0 HN¨
0
N
N OH OH
OH N
1
N r
0õ,,,, ,_,.___N,-
,, 0 1-118
1-116 1-117
V , V
/ S /
S
_
_
N N
HN4 1 0
0 N
N OH
OH
o.-----..,-0-õ,õ-------N------..,
0----C)'--1µ1
1-119 1-120
S S
N N
HN¨ 1 HN-- 1
0 0
N N
OH OH
1-121 1-122 .
Table 2. Exemplary Compounds
,--- .,-
..,(-
-\ ¨=\ _,,,
N N
"( S
0 HN- I 0 0 HN-
<\ I
OH N 40 OH OH N OH N
N
--
0
S /
0---/ 0
1-123
1-124 1-125 Oi 1-
126c
31
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
/
/ HO9
S / S
HN¨%
\
S _ __ \
0\\ ¨\
7 ________________________________________________________________________ \
,N
\ ___________________________________________________ K S
S /N
1
O HN¨ 1 0 HN¨, I OH N
N
OH N
OH N
I \
S 0
1-127 1-128 1-129 1-
130 CS).-......--.
0 .
=
Sp F F
F
FF F
N
1-
_______________ S \ ____ K s 1_\
OHN¨./( I 0 HN---4 0 HN¨<\
( S
OH N OH N OH N
0 HN4 I
OH N
1-131
1-132 0..õ--- 1-133 o -
1-134
S /
N.....-- -.....--
F F 0,
FE F
F S'rk
1
1 ,f\J S ¨ S
(31) HN _____________________________________________ 4 1 s
o HN¨ I
OH N S
O HN¨ I OH
N ---- 0 HN¨=
OH N S / OH N
S
CI
1-135 1-136
= 1-137
1-138 CI
S S S
.,.....2.\
\ /N \ ,N .._.)'- \ /N HN---
1
OH
(
N
O HN4 I 0 HN¨<\ I 0 HN¨k\ I
OH N OH N"--"Nrio OH
N S /
S /
1-142
1-139 1-140 1-141
32
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
,N
S \ s
s
sOs0
N
I 04
s
S OH
OH N
S
1-143 1-144 1-145 1-146
F F
\ /
ON
,N
HN-4.
OH
1-147 1-148
1001091 The compounds of this invention may be prepared or isolated, in
general, by synthetic
and/or semi-synthetic methods known to those skilled in the art, methods
illustrated in the
following Schemes, and by methods described in detail in the Examples, below.
The scope of the
disclosure is not to be construed as limited to specific embodiments disclosed
in these Schemes,
however, which are illustrative only. At least some of the compounds
identified herein as
"Intermediates", e.g. compounds with numbers preceded by "Int-", are
contemplated as
compounds of the disclosure.
1001101 In the Schemes, it is understood by one skilled in the art of organic
synthesis that the
functionality present on various portions of the molecule should be compatible
with the reagents
and reactions proposed. Substituents not compatible with the reaction
conditions will be apparent
to one skilled in the art, and alternate methods are therefore indicated (for
example, use of
protecting groups or alternative reactions). Protecting group chemistry and
strategy is well known
in the art, for example, as described in detail in "Protecting Groups in
Organic Synthesis", T. W.
Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entire
contents of which are
hereby incorporated by reference. The starting materials for the Schemes are
either commercially
available or are readily prepared by one skilled in the art of organic
synthesis from known materials
using standard methods.
1001111 General principles of organic chemistry and synthesis, well known in
the art, are
described in, for example, "Organic Chemistry", Thomas Sorrell, University
Science Books,
33
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Sausalito: 1999; "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith,
M.B. and March,
J., John Wiley & Sons, New York: 2001; and "Comprehensive Organic Synthesis",
2nd Ed., Ed.:
Knochel, P. and Molander, G.A., Elsevier, Amsterdam: 2014; the entire contents
of each of which
are hereby incorporated by reference. For example, certain embodiments below
refer to leaving
groups. Suitable leaving groups are well known in the art, as described in,
for example, the
preceding references. Such leaving groups include, but are not limited to,
halogen, alkoxy,
sulphonyloxy, optionally substituted al kyl sul
phonyl oxy, optionally substituted
alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, and diazonium
moieties. Examples of
suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonyl
(mesyl), tosyl,
triflate, nitro-phenyl sulfonyl (nosyl), and bromo-phenylsulfonyl (brosyl).
Scheme 1
R2 R3
S S R2
H
R3¨LG 2N4 I
0¨R1 0¨R1
A ( R4 ) n ( R4)
n
Intermediate A
Intermediate B
Compound I
1001121 In some embodiments, a compound of formula I is prepared by the
coupling reaction
depicted in Scheme 1 above, wherein TG is a leaving group, and each of X, n,
RI-, R2, R3, and 1=Z4
is independently as defined in embodiments herein, wherein each of RI-, R2,
R3, and le optionally
and independently comprises a protecting group.
Scheme 2
R2 R3
S R2
LG-- I HN4 I
R3¨NH2 N
0 RI
0¨R1
X R4 \ X (
R4) n
n
Intermediate C
Intermediate D Compound I
1001131 In some embodiments, a compound of formula I is prepared by the
coupling reaction
depicted in Scheme 2 above, wherein LG is a leaving group, and each of X, n,
R2, R3, and R4
is independently as defined in embodiments herein, wherein each of R1, le, R3,
and R4 optionally
and independently comprises a protecting group.
34
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
4. Formulation and Administration
4.1 Pharmaceutically acceptable compositions
[00114] According to another embodiment, the invention provides a composition
comprising a
compound of this invention, or a pharmaceutically acceptable derivative
thereof, and a
pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of
compound in
compositions of this invention is such that is effective to measurably inhibit
elF4E, or a mutant
thereof, in a biological sample or in a patient. In certain embodiments, the
amount of compound
in compositions of this invention is such that is effective to measurably
inhibit eIF4E, or a mutant
thereof, in a biological sample or in a patient. In certain embodiments, a
composition of this
invention is formulated for administration to a patient in need of such
composition. In some
embodiments, a composition of this invention is formulated for oral
administration to a patient.
[00115] In some embodiments, the invention provides a pharmaceutical
composition
comprising a compound of Formula (I), or a pharmaceutically acceptable salt
thereof, and a
pharmaceutically acceptable carrier, adjuvant, or vehicle.
1001161 In some embodiments, the invention provides a pharmaceutical
composition
comprising a compound of Formulae (II) to (VII), (II-a) to (VII-a), (II-b) to
(VII-b), or a
pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable
carrier, adjuvant, or
vehicle.
[00117] In some embodiments, the invention provides a pharmaceutical
composition
comprising a compound of Table 1, or a pharmaceutically acceptable salt
thereof, and a
pharmaceutically acceptable carrier, adjuvant, or vehicle.
[00118] In some embodiments, a compound of the invention, or a
pharmaceutically acceptable
derivative or composition thereof, is administered in a single composition as
a single dosage form.
[00119] The term "patient," as used herein, means an animal, preferably a
mammal, and most
preferably a human.
[00120] The term "pharmaceutically acceptable carrier, adjuvant, or
vehicle" refers to a non-
toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological
activity of the
compound with which it is formulated. Pharmaceutically acceptable carriers,
adjuvants or vehicles
that may be used in the compositions of this invention include, but are not
limited to, ion
exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as
human serum albumin,
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate,
partial glyceride
mixtures of saturated vegetable fatty acids, water, salts or electrolytes,
such as protamine sulfate,
disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride,
zinc salts,
colloidal silica, magnesium tri silicate, polyvinyl pyrroli done, cellulose-
based substances,
polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes,
polyethylene-
polyoxypropylene-block polymers, polyethylene glycol and wool fat.
[00121] A "pharmaceutically acceptable derivative" means any non-toxic salt,
ester, salt of an
ester or other derivative of a compound of this invention that, upon
administration to a recipient,
is capable of providing, either directly or indirectly, a compound of this
invention or an inhibitorily
active metabolite or residue thereof
[00122] As used herein, the term "inhibitorily active metabolite or residue
thereof' means that
a metabolite or residue thereof is also an inhibitor of eIF4E, or a mutant
thereof.
[00123] Compositions of the present invention may be administered orally,
parenterally, by
inhalation spray, topically, rectally, nasally, buccally, vaginally or via an
implanted reservoir. The
term "parenteral" as used herein includes subcutaneous, intravenous,
intramuscular, intra-articular,
intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and
intracranial injection or
infusion techniques. Preferably, the compositions are administered orally,
intraperitoneally or
intravenously. Sterile injectable forms of the compositions of this invention
may be aqueous or
oleaginous suspension. These suspensions may be formulated according to
techniques known in
the art using suitable dispersing or wetting agents and suspending agents. The
sterile injectable
preparation may also be a sterile injectable solution or suspension in a non-
toxic parenterally
acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
Among the acceptable
vehicles and solvents that may be employed are water, Ringer's solution and
isotonic sodium
chloride solution. In addition, sterile, fixed oils are conventionally
employed as a solvent or
suspending medium.
[00124] For this purpose, any bland fixed oil may be employed including
synthetic mono- or
di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives
are useful in the
preparation of injectables, as are natural pharmaceutically-acceptable oils,
such as olive oil or
castor oil, especially in their polyoxyethylated versions. These oil solutions
or suspensions may
also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl
cellulose or similar
dispersing agents that are commonly used in the formulation of
pharmaceutically acceptable
36
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
dosage forms including emulsions and suspensions. Other commonly used
surfactants, such as
Tweens, Spans and other emulsifying agents or bioavailability enhancers which
are commonly
used in the manufacture of pharmaceutically acceptable solid, liquid, or other
dosage forms may
also be used for the purposes of formulation.
[00125] Pharmaceutically acceptable compositions of this invention may be
orally administered
in any orally acceptable dosage form including, but not limited to, capsules,
tablets, aqueous
suspensions or solutions. In the case of tablets for oral use, carriers
commonly used include lactose
and corn starch. Lubricating agents, such as magnesium stearate, are also
typically added. For
oral administration in a capsule form, useful diluents include lactose and
dried cornstarch. When
aqueous suspensions are required for oral use, the active ingredient is
combined with emulsifying
and suspending agents. If desired, certain sweetening, flavoring or coloring
agents may also be
added.
[00126] Alternatively, pharmaceutically acceptable compositions of this
invention may be
administered in the form of suppositories for rectal administration. These can
be prepared by
mixing the agent with a suitable non-irritating excipient that is solid at
room temperature but liquid
at rectal temperature and therefore will melt in the rectum to release the
drug. Such materials
include cocoa butter, beeswax and polyethylene glycols.
1001271 Pharmaceutically acceptable compositions of this invention may also be
administered
topically, especially when the target of treatment includes areas or organs
readily accessible by
topical application, including diseases of the eye, the skin, or the lower
intestinal tract. Suitable
topical formulations are readily prepared for each of these areas or organs.
1001281 Topical application for the lower intestinal tract can be
effected in a rectal suppository
formulation (see above) or in a suitable enema formulation. Topically-
transdermal patches may
also be used.
[00129] For topical applications, provided pharmaceutically acceptable
compositions may be
formulated in a suitable ointment containing the active component suspended or
dissolved in one
or more carriers. Carriers for topical administration of compounds of this
invention include, but
are not limited to, mineral oil, liquid petrolatum, white petrolatum,
propylene glycol,
polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
Alternatively,
provided pharmaceutically acceptable compositions can be formulated in a
suitable lotion or cream
containing the active components suspended or dissolved in one or more
pharmaceutically
37
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
acceptable carriers. Suitable carriers include, but are not limited to,
mineral oil, sorbitan
monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-
octyldodecanol, benzyl alcohol
and water.
1001301 For ophthalmic use, provided pharmaceutically acceptable compositions
may be
formulated as micronized suspensions in isotonic, pH adjusted sterile saline,
or, preferably, as
solutions in isotonic, pH adjusted sterile saline, either with or without a
preservative such as
benzylalkonium chloride. Alternatively, for ophthalmic uses, the
pharmaceutically acceptable
compositions may be formulated in an ointment such as petrolatum.
1001311 Pharmaceutically acceptable compositions of this invention may also be
administered
by nasal aerosol or inhalation. Such compositions are prepared according to
techniques well-
known in the art of pharmaceutical formulation and may be prepared as
solutions in saline,
employing benzyl alcohol or other suitable preservatives, absorption promoters
to enhance
bioavailability, fluorocarbons, and/or other conventional solubilizing or
dispersing agents.
1001321 Most preferably, pharmaceutically acceptable compositions of this
invention are
formulated for oral administration. Such formulations may be administered with
or without food.
In some embodiments, pharmaceutically acceptable compositions of this
invention are
administered without food. In other embodiments, pharmaceutically acceptable
compositions of
this invention are administered with food.
1001331 The amount of compounds of the present invention that may be combined
with the
carrier materials to produce a composition in a single dosage form will vary
depending upon the
host treated, the particular mode of administration. Preferably, provided
compositions should be
formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the
inhibitor can be
administered to a patient receiving these compositions.
1001341 It should also be understood that a specific dosage and treatment
regimen for any
particular patient will depend upon a variety of factors, including the
activity of the specific
compound employed, the age, body weight, general health, sex, diet, time of
administration, rate
of excretion, drug combination, and the judgment of the treating physician and
the severity of the
particular disease being treated. The amount of a compound of the present
invention in the
composition will also depend upon the particular compound in the composition.
4.2. Co-Administration with One or More Other Therapeutic Agent
38
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
[00135] Depending upon the particular condition, or disease, to be treated,
additional
therapeutic agents that are normally administered to treat that condition, may
also be present in the
compositions of this invention. As used herein, additional therapeutic agents
that are normally
administered to treat a particular disease, or condition, are known as
"appropriate for the disease,
or condition, being treated."
[00136] In some embodiments, the present invention provides a method of
treating a disclosed
disease or condition comprising administering to a patient in need thereof an
effective amount of
a compound disclosed herein or a pharmaceutically acceptable salt thereof and
co-administering
simultaneously or sequentially an effective amount of one or more additional
therapeutic agents,
such as those described herein. In some embodiments, the method includes co-
administering one
additional therapeutic agent. In some embodiments, the method includes co-
administering two
additional therapeutic agents. In some embodiments, the combination of the
disclosed compound
and the additional therapeutic agent or agents acts synergistically.
[00137] A compound of the current invention may also be used in combination
with known
therapeutic processes, for example, the administration of hormones or
radiation. In certain
embodiments, a provided compound is used as a radiosensitizer, especially for
the treatment of
tumors which exhibit poor sensitivity to radiotherapy.
[00138] A compound of the current invention can be administered alone or in
combination with
one or more other therapeutic compounds, possible combination therapy taking
the form of fixed
combinations or the administration of a compound of the invention and one or
more other
therapeutic compounds being staggered or given independently of one another,
or the combined
administration of fixed combinations and one or more other therapeutic
compounds. A compound
of the current invention can besides or in addition be administered especially
for tumor therapy in
combination with chemotherapy, radiotherapy, immunotherapy, ph ototh erapy,
surgical
intervention, or a combination of these. Long-term therapy is equally possible
as is adjuvant
therapy in the context of other treatment strategies, as described above.
Other possible treatments
are therapy to maintain the patient's status after tumor regression, or even
chemopreventive
therapy, for example in patients at risk.
[00139] One or more other therapeutic agent may be administered separately
from a compound
or composition of the invention, as part of a multiple dosage regimen.
Alternatively, one or more
other therapeutic agents may be part of a single dosage form, mixed together
with a compound of
39
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
this invention in a single composition. If administered as a multiple dosage
regime, one or more
other therapeutic agent and a compound or composition of the invention may be
administered
simultaneously, sequentially or within a period of time from one another, for
example within 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 20, 21,22, 23, or
24 hours from one another.
In some embodiments, one or more other therapeutic agent and a compound or
composition of the
invention are administered as a multiple dosage regimen within greater than 24
hours apart.
[00140] As used herein, the term "combination," "combined," and related terms
refers to the
simultaneous or sequential administration of therapeutic agents in accordance
with this invention.
For example, a compound of the present invention may be administered with one
or more other
therapeutic agent simultaneously or sequentially in separate unit dosage forms
or together in a
single unit dosage form. Accordingly, the present invention provides a single
unit dosage form
comprising a compound of the current invention, one or more other therapeutic
agent, and a
pharmaceutically acceptable carrier, adjuvant, or vehicle.
[00141] The amount of a compound of the invention and one or more other
therapeutic agent
(in those compositions which comprise an additional therapeutic agent as
described above) that
may be combined with the carrier materials to produce a single dosage form
will vary depending
upon the host treated and the particular mode of administration. Preferably, a
composition of the
invention should be formulated so that a dosage of between 0.01 - 100 mg/kg
body weight/day of
a compound of the invention can be administered.
[00142] In those compositions which comprise one or more other therapeutic
agent, the one or
more other therapeutic agent and a compound of the invention may act
synergistically. Therefore,
the amount of the one or more other therapeutic agent in such compositions may
be less than that
required in a monotherapy utilizing only that therapeutic agent. In such
compositions a dosage of
between 0.01 ¨ 1,000 jig/kg body weight/day of the one or more other
therapeutic agent can be
administered.
1001431 The amount of one or more other therapeutic agent present in the
compositions of this
invention may be no more than the amount that would normally be administered
in a composition
comprising that therapeutic agent as the only active agent. Preferably the
amount of one or more
other therapeutic agent in the presently disclosed compositions will range
from about 50% to 100%
of the amount normally present in a composition comprising that agent as the
only therapeutically
active agent. In some embodiments, one or more other therapeutic agent is
administered at a dosage
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
of about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about
80%, about 85%,
about 90%, or about 95% of the amount normally administered for that agent. As
used herein, the
phrase "normally administered" means the amount an FDA approved therapeutic
agent is approved
for dosing per the FDA label insert.
1001441 The compounds of this invention, or pharmaceutical compositions
thereof, may also be
incorporated into compositions for coating an implantable medical device, such
as prostheses,
artificial valves, vascular grafts, stents and catheters. Vascular stents, for
example, have been used
to overcome restenosis (re-narrowing of the vessel wall after injury).
However, patients using
stents or other implantable devices risk clot formation or platelet
activation. These unwanted
effects may be prevented or mitigated by pre-coating the device with a
pharmaceutically
acceptable composition comprising a kinase inhibitor. Implantable devices
coated with a
compound of this invention are another embodiment of the present invention.
4.2.1. Exemplary Other Therapeutic Agents
1001451 In some embodiments, one or more other therapeutic agent is a Poly ADP
ribose
polymerase (PARP) inhibitor. In some embodiments, a PARP inhibitor is selected
from olaparib
(Lynparza , Astra7eneca); rucaparib (Rubraca , Clovis Oncology); niraparib
(Zejula , Tesaro);
talazoparib (MDV3800/BMN 673/LT00673, Medivation/Pfizer/Biomarin); veliparib
(ABT-888,
AbbVie); and BGB-290 (BeiGene, Inc.).
1001461 In some embodiments, one or more other therapeutic agent is a hi stone
deacetylase
(HDAC) inhibitor. In some embodiments, an HDAC inhibitor is selected from
vorinostat
(Zolinza , Merck); romidepsin (Istodax , Celgene); panobinostat (Farydak ,
Novartis);
belinostat (Beleodaq , Spectrum Pharmaceuticals); entinostat (SNDX-275, Syndax
Pharmaceuticals) (NCT00866333); and chi dami de (Epidaza , 1-1131-8000, Chi
pscreen
Biosciences, China).
1001471 In some embodiments, one or more other therapeutic agent is a CDK
inhibitor, such as
a CDK4/CDK6 inhibitor. In some embodiments, a CDK 4/6 inhibitor is selected
from palbociclib
(Ibrance , Pfizer); ribociclib (Kisqali , Novartis); abemaciclib (Ly2835219,
Eli Lilly); and
trilaciclib (G1T28, Gl Therapeutics).
1001481 In some embodiments, one or more other therapeutic agent is a
phosphatidylinositol 3
kinase (PI3K) inhibitor. In some embodiments, a PI3K inhibitor is selected
from idelalisib
41
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
(Zydelig , Gilead), alpeli sib (BYL719, Novartis), taseli sib (GDC-0032,
Genentech/Roche),
pictilisib (GDC-0941, Genentech/Roche); copanlisib (BAY806946, Bayer); duveli
sib (formerly
IPI-145, Infinity Pharmaceuticals); PQR309 (Piqur Therapeutics, Switzerland);
and TGR1202
(formerly RP5230, TG Therapeutics)
1001491 In some embodiments, one or more other therapeutic agent is a platinum-
based
therapeutic, also referred to as platins. Platins cause cross-linking of DNA,
such that they inhibit
DNA repair and/or DNA synthesis, mostly in rapidly reproducing cells, such as
cancer cells. In
some embodiments, a platinum-based therapeutic is selected from cisplatin
(Platinol , Bristol-
Myers Squibb); carboplatin (Paraplatin , Bristol-Myers Squibb; also, Teva;
Pfizer); oxaliplatin
(Eloxitin Sanofi-Aventis); nedaplatin (Aqupia , Shionogi), picoplatin
(Poniard
Pharmaceuticals); and satraplatin (JIM-216, Agennix).
[00150] In some embodiments, one or more other therapeutic agent is a taxane
compound,
which causes disruption of microtubules, which are essential for cell
division. In some
embodiments, a taxane compound is selected from paclitaxel (Taxol , Bristol-
Myers Squibb),
docetaxel (Taxotere , Sanofi-Aventis; Docefrez , Sun Pharmaceutical), albumin-
bound
paclitaxel (Abraxaneg; Abraxis/Celgene), cabazitaxel (Jevtana , Sanofi-
Aventis), and SID530
(SK Chemicals, Co.) (NCT00931008).
[00151] In some embodiments, one or more other therapeutic agent is a
nucleoside inhibitor, or
a therapeutic agent that interferes with normal DNA synthesis, protein
synthesis, cell replication,
or will otherwise inhibit rapidly proliferating cells.
[00152] In some embodiments, a nucleoside inhibitor is selected from
trabectedin (guanidine
alkylating agent, Yondelis , Janssen Oncology), mechlorethamine (alkylating
agent, Valchlor ,
Aktelion Pharmaceuticals); vincristine (Oncovin , Eli Lilly; Vincasar , Teva
Pharmaceuticals;
Marqi b o , Talon Therapeutics); tem ozol omi de (prodrug to alkylating agent
5 -(3 -m ethyl tri azen-
1-y1)-imidazole-4-carboxamide (MTIC) Temodar , Merck), cytarabine injection
(ara-C,
antimetabolic cytidine analog, Pfizer), lomustine (alkylating agent, CeeNU ,
Bristol-Myers
Squibb, Gleostine , NextSource Biotechnology); azacitidine (pyrimidine
nucleoside analog of
cytidine, Vidaza , Celgene), omacetaxine mepesuccinate (cephalotaxine ester)
(protein synthesis
inhibitor, Synribog; Teva Pharmaceuticals); asparaginase Envinia chrysanthemi
(enzyme for
depletion of asparagine, Elspar , Lundbeck; Erwinaze , EUSA Pharma); eribulin
mesylate
(microtubule inhibitor, tubulin-based antimitotic, Halaven , Eisai);
cabazitaxel (microtubule
42
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
inhibitor, tubulin-based antimitotic, Jevtana , Sanofi-Aventis); capacetrine
(thymidylate synthase
inhibitor, Xeloda , Genentech); bendamustine (bifunctional mechlorethamine
derivative,
believed to form interstrand DNA cross-links, Treanda , Cephalon/Teva);
ixabepilone (semi-
synthetic analog of epothilone B, microtubule inhibitor, tubulin-based
antimitotic, Ixempra ,
Bristol-Myers Squibb); nelarabine (prodrug of deoxyguanosine analog,
nucleoside metabolic
inhibitor, Arranon , Novartis); clorafabine (prodrug of ribonucleotide
reductase inhibitor,
competitive inhibitor of deoxycytidine, Clotar , Sanofi-Aventis); and
trifluridine and tipiracil
(thymidine-based nucleoside analog and thymidine phosphorylase inhibitor,
Lonsurf , Taiho
On col ogy)
1001531 In some embodiments, one or more other therapeutic agent is a kinase
inhibitor or
VEGF-R antagonist. Approved VEGF inhibitors and kinase inhibitors useful in
the present
invention include. bevacizumab (Avastin , Genentech/Roche) an anti-VEGF
monoclonal
antibody; ramucirumab (Cyramza , Eli Lilly), an anti-VEGFR-2 antibody and ziv-
aflibercept,
also known as VEGF Trap (Zaltrapg; Regeneron/Sanofi). VEGFR inhibitors, such
as regorafenib
(Stivarga , Bayer); vandetanib (Caprelsa , AstraZeneca); axitinib (Inlyta ,
Pfizer); and
lenvatinib (Lenvima , Eisai); Raf inhibitors, such as sorafenib (Nexavar ,
Bayer AG and Onyx);
dabrafenib (Tafinlar , Novartis); and vemurafenib (Zelboraf ,
Genentech/Roche); MEK
inhibitors, such as cobimetanib (Cotellic , Exelexis/Genentech/Roche);
trametinib (Mekinist ,
Novartis); Bcr-Abl tyrosine kinase inhibitors, such as imatinib (Gleevec ,
Novartis); nilotinib
(Tasigna , Novartis); dasatinib (Sprycel
BristolMyersSquibb); bosutinib (Bosulif , Pfizer);
and ponatinib (Inclusig , Ariad Pharmaceuticals); Her2 and EGFR inhibitors,
such as gefitinib
(Iressa , AstraZeneca); erlotinib (Tarceeva , Genentech/Roche/Astellas);
lapatinib (Tykerb ,
Novartis); afatinib (Gilotrif , Boehringer Ingelheim); osimertinib (targeting
activated EGFR,
Tagrisso , AstraZeneca); and brigatinib (Alunbrig , Ariad Pharmaceuticals); c-
Met and
VEGFR2 inhibitors, such as cabozanitib (Cometriq , Exelexis), and multikinase
inhibitors, such
as sunitinib (Sutent , Pfizer), pazopanib (Votrient , Novartis), ALK
inhibitors, such as crizotinib
(Xalkori , Pfizer), ceritinib (Zykadia , Novartis), and alectinib (Alecenza ,
Genentech/Roche),
Bruton's tyrosine kinase inhibitors, such as ibrutinib (Imbruvica ,
Pharmacyclics/Janssen), and
Flt3 receptor inhibitors, such as midostaurin (Rydapt , Novartis).
1001541 Other kinase inhibitors and VEGF-R antagonists that are in development
and may be
used in the present invention include tivozanib (Aveo Pharmaecuticals);
vatalanib
43
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
(Bayer/Novartis); lucitanib (Clovis Oncology); dovitinib (TKI258, Novartis);
Chiauanib
(Chipscreen Biosciences); CEP-11981 (Cephalon); linifanib (Abbott
Laboratories); neratinib
(HKI-272, Puma Biotechnology); radotinib (Supect , IY5511, Il-Yang
Pharmaceuticals, S.
Korea); ruxolitinib (Jakafi , Incyte Corporation); PTC299 (PTC Therapeutics);
CP-547,632
(Pfizer); foretinib (Exelexis, GlaxoSmithKline); quizartinib (Daiichi Sankyo)
and motesanib
(Amgen/Takeda).
[00155] In some embodiments, one or more other therapeutic agent is an mTOR
inhibitor,
which inhibits cell proliferation, angiogenesis and glucose uptake. In some
embodiments, an
mTOR inhibitor is everolimus (Afinitor , Novartis); temsirolimus (Torisel ,
Pfizer); and
sirolimus (Rapamune , Pfizer)
[00156] In some embodiments, one or more other therapeutic agent is a
proteasome inhibitor.
Approved proteasome inhibitors useful in the present invention include
bortezomib (Velcade ,
Takeda); carfilzomib (Kyprolis , Amgen); and ixazomib (Ninlaro , Takeda).
[00157] In some embodiments, one or more other therapeutic agent is a growth
factor
antagonist, such as an antagonist of platelet-derived growth factor (PDGF), or
epidermal growth
factor (EGF) or its receptor (EGFR). Approved PDGF antagonists which may be
used in the
present invention include olaratumab (Lartruvog; Eli Lilly). Approved EGFR
antagonists which
may be used in the present invention include cetuximab (Erbitux , Eli Lilly);
necitumumab
(Portrazza , Eli Lilly), panitumumab (Vectibix , Amgen); and osimertinib
(targeting activated
EGFR, Tagrisso , AstraZeneca).
[00158] In some embodiments, one or more other therapeutic agent is an
aromatase inhibitor.
In some embodiments, an aromatase inhibitor is selected from exemestane
(Aromasing, Pfizer);
anastazole (Arimidex , AstraZeneca) and letrozole (Femara , Novartis).
[00159] In some embodiments, one or more other therapeutic agent is an
antagonist of the
hedgehog pathway. Approved hedgehog pathway inhibitors which may be used in
the present
invention include sonidegib (Odomzog, Sun Pharmaceuticals); and vismodegib
(Erivedgeg,
Genentech), both for treatment of basal cell carcinoma.
[00160] In some embodiments, one or more other therapeutic agent is a folic
acid inhibitor.
Approved folic acid inhibitors useful in the present invention include
pemetrexed (Alimta , Eli
Lilly).
44
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
[00161] In some embodiments, one or more other therapeutic agent is a CC
chemokine receptor
4 (CCR4) inhibitor. CCR4 inhibitors being studied that may be useful in the
present invention
include mogamulizumab (Poteligeo , Kyowa Hakko Kirin, Japan).
[00162] In some embodiments, one or more other therapeutic agent is an
isocitrate
dehydrogenase (IDH) inhibitor. IDH inhibitors being studied which may be used
in the present
invention include AG120 (Celgene; NCT02677922); AG221 (Celgene, NC102677922,
NCT02577406); BAY1436032 (Bayer, NCT02746081); lDH305 (Novartis, NCT02987010).
[00163] In some embodiments, one or more other therapeutic agent is an
arginase inhibitor.
Arginase inhibitors being studied which may be used in the present invention
include AEB1102
(pegylated recombinant arginase, Aeglea Biotherapeutics), which is being
studied in Phase 1
clinical trials for acute myeloid leukemia and myelodysplastic syndrome
(NCT02732184) and
solid tumors (NCT02561234), and CB-1158 (Calithera Biosciences).
[00164] In some embodiments, one or more other therapeutic agent is a
glutaminase inhibitor.
Glutaminase inhibitors being studied which may be used in the present
invention include CB-839
(Calithera Biosciences).
1001651 In some embodiments, one or more other therapeutic agent is an
antibody that binds to
tumor antigens, that is, proteins expressed on the cell surface of tumor
cells. Approved antibodies
that bind to tumor antigens which may be used in the present invention include
rituximab
(Rituxan , Genentech/BiogenIdec); ofatumumab (anti-CD20, Arzerra ,
GlaxoSmithKline);
obinutuzumab (anti -CD20, Gazyva , Genentech), ibritumomab (anti -CD20 and
Yttrium-90,
Zevalin , Spectrum Pharmaceuticals); daratumumab (anti-CD38, Darzalex ,
Janssen Biotech),
dinutuximab (anti-glycolipid GD2, Unituxing, United Therapeutics); trastuzumab
(anti-1-IER2,
Herceptin , Genentech); ado-trastuzumab emtansine (anti-HER2, fused to
emtansine, Kadcyla ,
Genentech); and pertuzumab (anti -HER2, Penj eta , Genentech); and brentuximab
vedotin (anti -
CD30-drug conjugate, Adcetris , Seattle Genetics).
[00166] In some embodiments, one or more other therapeutic agent is a
topoisomerase inhibitor.
Approved topoisomerase inhibitors useful in the present invention include
irinotecan (Onivyde ,
Merrimack Pharmaceuticals), topotecan (Hycamtin , GlaxoSmithKline).
Topoisomerase
inhibitors being studied which may be used in the present invention include
pixantrone (Pixuvri ,
CTI Biopharma).
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
[00167] In some embodiments, one or more other therapeutic agent is an
inhibitor of anti-
apoptotic proteins, such as BCL-2. Approved anti-apoptotics which may be used
in the present
invention include venetoclax (Venclexta , AbbVie/Genentech); and blinatumomab
(Blincyto ,
Amgen). Other therapeutic agents targeting apoptotic proteins which have
undergone clinical
testing and may be used in the present invention include navitoclax (ABT-263,
Abbott), a BCL-2
inhibitor (NCT02079740).
[00168] In some embodiments, one or more other therapeutic agent is an
androgen receptor
inhibitor. Approved androgen receptor inhibitors useful in the present
invention include
enzalutami de (Xtandi , A stell as/Medivati on); approved inhibitors of
androgen synthesis include
abiraterone (Zytiga , Centocor/Ortho); approved antagonist of gonadotropin-
releasing hormone
(GnRH) receptor (degaralix, Firmagong, Ferring Pharmaceuticals).
[00169] In some embodiments, one or more other therapeutic agent is a
selective estrogen
receptor modulator (SERM), which interferes with the synthesis or activity of
estrogens.
Approved SERMs useful in the present invention include raloxifene (Evista ,
Eli Lilly).
1001701 In some embodiments, one or more other therapeutic agent is an
inhibitor of bone
resorption. An approved therapeutic which inhibits bone resorption is
Denosumab (Xgeva ,
Amgen), an antibody that binds to RANKL, prevents binding to its receptor
RANK, found on the
surface of osteoclasts, their precursors, and osteoclast-like giant cells,
which mediates bone
pathology in solid tumors with osseous metastases. Other approved therapeutics
that inhibit bone
resorption include bisphosphonates, such as zoledronic acid (Zometa ,
Novartis).
[00171] In some embodiments, one or more other therapeutic agent is an
inhibitor of interaction
between the two primary p53 suppressor proteins, MDMX and MDM2. Inhibitors of
p53
suppression proteins being studied which may be used in the present invention
include ALRN-
6924 (Aileron), a stapled peptide that equipotently binds to and disrupts the
interaction of MDMX
and MDM2 with p53. ALRN-6924 is currently being evaluated in clinical trials
for the treatment
of AML, advanced myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma
(PTCL)
(NCT02909972; NCT02264613).
[00172] In some embodiments, one or more other therapeutic agent is an
inhibitor of
transforming growth factor-beta (TGF-beta or TGFB). Inhibitors of TGF-beta
proteins being
studied which may be used in the present invention include NIS793 (Novartis),
an anti-TGF-beta
antibody being tested in the clinic for treatment of various cancers,
including breast, lung,
46
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
hepatocellular, colorectal, pancreatic, prostate and renal cancer (NCT
02947165). In some
embodiments, the inhibitor of TGF-beta proteins is fresolimumab (GC1008;
Sanofi-Genzyme),
which is being studied for melanoma (NCT00923169); renal cell carcinoma
(NCT00356460); and
non-small cell lung cancer (NCT02581787) Additionally, in some embodiments,
the additional
therapeutic agent is a TGF-beta trap, such as described in Connolly et al.
(2012) Int'l J. Biological
Sciences 8:964-978. One therapeutic compound currently in clinical trials for
treatment of solid
tumors is M7824 (Merck KgaA - formerly MSB0011459X), which is a bispecific,
anti-PD-
Ll/TGFB trap compound (NCT02699515); and (NCT02517398). M7824 is comprised of
a fully
human IgG1 antibody against PD-L1 fused to the extracellular domain of human
TGF-beta
receptor II, which functions as a TGF13 "trap."
1001731 In some embodiments, one or more other therapeutic agent is selected
from
glembatumumab vedotin-monomethyl auristatin E (M1VIAE) (Celldex), an anti-
glycoprotein NMB
(gpNMB) antibody (CR011) linked to the cytotoxic MMAE. gpNMB is a protein
overexpressed
by multiple tumor types associated with cancer cells' ability to metastasize.
1001741 In some embodiments, one or more other therapeutic agent is an
antiproliferative
compound. Such antiproliferative compounds include, but are not limited to
aromatase inhibitors;
antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors;
microtubule active
compounds; alkylating compounds; histone deacetylase inhibitors; compounds
which induce cell
differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR
inhibitors;
antineoplastic antimetabolites; platin compounds; compounds
targeting/decreasing a protein or
lipid kinase activity and further anti-angiogenic compounds; compounds which
target, decrease or
inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists;
anti-androgens;
methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors;
bisphosphonates;
biological response modifiers; antiproliferative antibodies; heparanase
inhibitors; inhibitors of Ras
oncogenic isoforms, telomerase inhibitors, proteasome inhibitors, compounds
used in the
treatment of hematologic malignancies, compounds which target, decrease or
inhibit the activity
of Flt-3, Hsp90 inhibitors such as 17-AAG (17-allylaminogeldanamycin,
NSC330507), 17-
DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-
504,
CNF1010, CNF2024, CNF1010 from Conforma Therapeutics; temozolomide
(Temodal'''); kinesin
spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline,
or
47
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
pentamidine/chlorpromazine from CombinatoRx; MEK inhibitors such as ARRY142886
from
Array BioPharma, AZd6244 from AstraZeneca, PD181461 from Pfizer and
leucovorin.
1001751 The term "aromatase inhibitor" as used herein relates to a compound
which inhibits
estrogen production, for instance, the conversion of the substrates
androstenedione and
testosterone to estrone and estradiol, respectively. The term includes, but is
not limited to steroids,
especially atamestane, exemestane and formestane and, in particular, non-
steroids, especially
aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone,
ketokonazole,
vorozole, fadrozole, anastrozole and letrozole. Exemestane is marketed under
the trade name
Arom asinTm. Formestane is marketed under the trade name LentaronTM. Fadrozole
is marketed
under the trade name AfemaTM. Anastrozole is marketed under the trade name
ArimidexTM.
Letrozole is marketed under the trade names FemaraTM or FemarTM.
Aminoglutethimide is
marketed under the trade name OrimetenTM. A combination of the invention
comprising a
chemotherapeutic agent which is an aromatase inhibitor is particularly useful
for the treatment of
hormone receptor positive tumors, such as breast tumors.
1001761 The term "antiestrogen" as used herein relates to a compound which
antagonizes the
effect of estrogens at the estrogen receptor level. The term includes, but is
not limited to tamoxifen,
fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen is marketed
under the trade name
NolvadexTM. Raloxifene hydrochloride is marketed under the trade name
EvistaTM. Fulvestrant can
be administered under the trade name FaslodexTM. A combination of the
invention comprising a
chemotherapeutic agent which is an anti estrogen is particularly useful for
the treatment of estrogen
receptor positive tumors, such as breast tumors.
1001771 The term "anti-androgen" as used herein relates to any substance which
is capable of
inhibiting the biological effects of androgenic hormones and includes, but is
not limited to,
bicalutamide (CasodexTm). The term "gonadorelin agonist" as used herein
includes, but is not
limited to abarelix, goserelin and goserelin acetate. Goserelin can be
administered under the trade
name ZoladexTM.
1001781 The term "topoisomerase I inhibitor" as used herein includes,
but is not limited to
topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-
nitrocamptothecin and the
macromolecular camptothecin conjugate PNU-166148. Irinotecan can be
administered, e.g. in the
form as it is marketed, e.g. under the trademark CamptosarTM. Topotecan is
marketed under the
trade name HycamptinTM.
48
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1001791 The term "topoisomerase II inhibitor" as used herein
includes, but is not limited to the
anthracyclines such as doxorubicin (including liposomal formulation, such as
CaelyxTm),
daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones
mitoxantrone and
losoxantrone, and the podophillotoxines etoposide and teniposide. Etoposi de
is marketed under
the trade name EtopophosTm. Teniposide is marketed under the trade name VM 26-
Bristol
Doxorubicin is marketed under the trade name AcriblastinTM or AdriamycinTM.
Epirubicin is
marketed under the trade name FarmorubicinTM. Idarubicin is marketed. under
the trade name
ZavedosTM. Mitoxantrone is marketed under the trade name Novantron.
1001801 The term "microtubule active agent" relates to microtubule
stabilizing, microtubule
destabilizing compounds and microtublin polymerization inhibitors including,
but not limited to
taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as
vinblastine or vinblastine
sulfate, vincristine or vincristine sulfate, and vinorelbine; discodermolides;
cochicine and
epothilones and derivatives thereof Paclitaxel is marketed under the trade
name TaxolTm.
Docetaxel is marketed under the trade name TaxotereTm. Vinblastine sulfate is
marketed under the
trade name Vinblastin R.PTM. Vincristine sulfate is marketed under the trade
name FarmistinTM.
1001811 The term "alkylating agent" as used herein includes, but is
not limited to,
cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel).
Cyclophosphamide
is marketed under the trade name CyclostinTM. Ifosfamide is marketed under the
trade name
HoloxanTM.
1001821 The term "hi stone deacetylase inhibitors" or "HDAC
inhibitors" relates to compounds
which inhibit the histone deacetylase and which possess antiproliferative
activity. This includes,
but is not limited to, suberoylanilide hydroxamic acid (SAHA).
1001831 The term "antineoplastic antimetabolite" includes, but is not
limited to, 5-fluorouracil
or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds, such as 5-
azacytidine and
decitabine, methotrexate and edatrexate, and folic acid antagonists such as
pemetrexed.
Capecitabine is marketed under the trade name XelodaTM. Gemcitabine is
marketed under the trade
name GemzarTM.
1001841 The term "platin compound" as used herein includes, but is
not limited to, carboplatin,
cis-platin, cisplatinum and oxaliplatin. Carboplatin can be administered,
e.g., in the form as it is
marketed, e.g. under the trademark CarboplatTM. Oxaliplatin can be
administered, e.g., in the form
as it is marketed, e.g. under the trademark EloxatinTM.
49
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1001851 The term "compounds targeting/decreasing a protein or lipid kinase
activity; or a
protein or lipid phosphatase activity; or further anti-angiogenic compounds"
as used herein
includes, but is not limited to, protein tyrosine kinase and/or serine and/or
threonine kinase
inhibitors or lipid kinase inhibitors, such as a) compounds targeting,
decreasing or inhibiting the
activity of the platelet-derived growth factor-receptors (PDGFR), such as
compounds which target,
decrease or inhibit the activity of PDGFR, especially compounds which inhibit
the PDGF receptor,
such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib, SU101,
SU6668 and GFB-
111; b) compounds targeting, decreasing or inhibiting the activity of the
fibroblast growth factor-
receptors (FGFR); c) compounds targeting, decreasing or inhibiting the
activity of the insulin-like
growth factor receptor I (IGF-lR), such as compounds which target, decrease or
inhibit the activity
of IGF-IR, especially compounds which inhibit the kinase activity of IGF-I
receptor, or antibodies
that target the extracellular domain of IGF-I receptor or its growth factors,
d) compounds targeting,
decreasing or inhibiting the activity of the Trk receptor tyrosine kinase
family, or ephrin B4
inhibitors; e) compounds targeting, decreasing or inhibiting the activity of
the AxI receptor
tyrosine kinase family; f) compounds targeting, decreasing or inhibiting the
activity of the Ret
receptor tyrosine kinase; g) compounds targeting, decreasing or inhibiting the
activity of the
Kit/SCFR receptor tyrosine kinase, such as imatinib; h) compounds targeting,
decreasing or
inhibiting the activity of the C-kit receptor tyrosine kinases, which are part
of the PDGFR family,
such as compounds which target, decrease or inhibit the activity of the c-Kit
receptor tyrosine
kinase family, especially compounds which inhibit the c-Kit receptor, such as
imatinib; i)
compounds targeting, decreasing or inhibiting the activity of members of the c-
Abl family, their
gene-fusion products (e.g. BCR-Abl kinase) and mutants, such as compounds
which target
decrease or inhibit the activity of c-Abl family members and their gene fusion
products, such as
an N-phenyl-2-pyrimidine-amine derivative, such as imatinib or nilotinib (AMN1
07); PD180970;
AG957, NSC 680410, PD173955 from ParkeDavis, or dasatinib (BMS-354825), j)
compounds
targeting, decreasing or inhibiting the activity of members of the protein
kinase C (PKC) and Raf
family of serine/threonine kinases, members of the MEK, SRC, JAK/pan-JAK, FAX,
PDK1,
PKB/Akt, Ras/MAPK, PI3K, SYK, TYK2, BTK and TEC family, and/or members of the
cyclin-
dependent kinase family (CDK) including staurosporine derivatives, such as
midostaurin;
examples of further compounds include UCN-01, safingol, BAY 43-9006,
Bryostatin 1,
Perifosine; llmofosine; RO 318220 and RO 320432, GO 6976; lsis 3521;
LY333531/LY379196;
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
isochinoline compounds; FTIs; PD184352 or QAN697 (a P 13K inhibitor) or AT7519
(CDK
inhibitor); k) compounds targeting, decreasing or inhibiting the activity of
protein-tyrosine kinase
inhibitors, such as compounds which target, decrease or inhibit the activity
of protein-tyrosine
kinase inhibitors include imatinib mesylate (GleevecTM) or tyrphostin such as
Tyrphostin A23/RG-
50810; AG 99; Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490;
Tyrphostin B44;
Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556,
AG957 and
adaphostin (4- { [(2,5- dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl
ester; NSC
680410, adaphostin); 1) compounds targeting, decreasing or inhibiting the
activity of the epidermal
growth factor family of receptor tyrosine kinases (EGFRI ErbB2, ErbB3, ErbB4
as homo- or
heterodimers) and their mutants, such as compounds which target, decrease or
inhibit the activity
of the epidermal growth factor receptor family are especially compounds,
proteins or antibodies
which inhibit members of the EGF receptor tyrosine kinase family, such as EGF
receptor, ErbB2,
ErbB3 and ErbB4 or bind to EGF or EGF related ligands, CP 358774, ZD 1839, ZM
105180,
trastuzumab (HerceptinTm), cetuximab (ErbituxTm), Iressa, Tarceva, OSI-774, C1-
1033, EKB-569,
GW-2016, E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-pyrrolo-
12,3-d]pyrimidine
derivatives; m) compounds targeting, decreasing or inhibiting the activity of
the c-Met receptor,
such as compounds which target, decrease or inhibit the activity of c-Met,
especially compounds
which inhibit the kinase activity of c-Met receptor, or antibodies that target
the extracellular
domain of c-Met or bind to HGF, n) compounds targeting, decreasing or
inhibiting the kinase
activity of one or more JAK family members (JAK1/JAK2/JAK3/TYK2 and/or pan-
JAK),
including but not limited to PRT-062070, SB-1578, baricitinib, pacritinib,
momelotinib, VX-509,
AZD-1480, TG-101348, tofacitinib, and ruxolitinib; o) compounds targeting,
decreasing or
inhibiting the kinase activity of PI3 kinase (PI3K) including but not limited
to ATU-027, SF-1126,
DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparli sib, pi ctreli sib, PF-
4691502, BYL-719,
dactolisib, XL-147, XL-765, and idelalisib; and; and q) compounds targeting,
decreasing or
inhibiting the signaling effects of hedgehog protein (Hh) or smoothened
receptor (SMO) pathways,
including but not limited to cyclopamine, vismodegib, itraconazole,
erismodegib, and IPI-926
(saridegib).
[00186] The term "PI3K inhibitor- as used herein includes, but is not limited
to compounds
having inhibitory activity against one or more enzymes in the
phosphatidylinosito1-3-kinase
family, including, but not limited to PI3Ka, PI3K1, P131(6, P131q3, PI3K-C2a,
PI3K-C213, PI3K-
51
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
C27, Vps34, p110-a, p110-13, p110-7, p110-6, p85-a, p85-0, p55-7, p150, p101,
and p87. Examples
of PI3K inhibitors useful in this invention include but are not limited to ATU-
027, SF-1126, DS-
7423, PBI-05204, GSK-2126458, Z STK-474, buparlisib, pictrelisib, PF-4691502,
BYL-719,
dactolisib, XL-147, XL-765, and idelalisib.
1001871 The term "Bc1-2 inhibitor" as used herein includes, but is not limited
to compounds
having inhibitory activity against B-cell lymphoma 2 protein (Bc1-2),
including but not limited to
ABT-199, ABT-731, ABT-737, apogossypol, Ascenta's pan-Bc1-2 inhibitors,
curcumin (and
analogs thereof), dual B c1-2/B cl-xL inhibitors (Infinity Pharm
aceuti cal s/N ovarti s
Pharmaceuticals), Genasense (63139), HA14-1 (and analogs thereof; see
W02008118802),
navitoclax (and analogs thereof, see US7390799), NH-1 (Shenayng Pharmaceutical
University),
obatoclax (and analogs thereof, see W02004106328), S-001 (Gloria
Pharmaceuticals), TW series
compounds (Univ. of Michigan), and venetoclax. In some embodiments the Bc1-2
inhibitor is a
small molecule therapeutic. In some embodiments the Bc1-2 inhibitor is a
peptidomimetic.
1001881 The term "BTK inhibitor- as used herein includes, but is not limited
to compounds
having inhibitory activity against Bruton's Tyrosine Kinase (BTK), including,
but not limited to
AVL-292 and ibrutinib.
1001891 The term "SYK inhibitor" as used herein includes, but is not limited
to compounds
having inhibitory activity against spleen tyrosine kinase (SYK), including but
not limited to PRT-
062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib.
1001901 Further examples of BTK inhibitory compounds, and conditions treatable
by such
compounds in combination with compounds of this invention can be found in
W02008039218
and W02011090760, the entirety of which are incorporated herein by reference.
1001911 Further examples of SYK inhibitory compounds, and conditions treatable
by such
compounds in combination with compounds of this invention can be found in
W02003063794,
W02005007623, and W02006078846, the entirety of which are incorporated herein
by reference.
1001921 Further examples of PI3K inhibitory compounds, and conditions
treatable by such
compounds in combination with compounds of this invention can be found in
W02004019973,
W02004089925, W02007016176, US8138347, W02002088112, W02007084786,
W02007129161, W02006122806, W02005113554, and W02007044729 the entirety of
which
are incorporated herein by reference.
52
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1001931 Further examples of JAK inhibitory compounds, and conditions treatable
by such
compounds in combination with compounds of this invention can be found in
W02009114512,
W02008109943, W02007053452, W02000142246, and W02007070514, the entirety of
which
are incorporated herein by reference.
1001941 Further anti-angiogenic compounds include compounds having another
mechanism for
their activity, e.g. unrelated to protein or lipid kinase inhibition e.g.
thalidomide (lhalomidTM) and
TNP-470.
1001951 Examples of proteasome inhibitors useful for use in combination with
compounds of
the invention include, but are not limited to bortezomib, di sulfiram,
epigallocatechin-3-gallate
(EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and MLN9708.
1001961 Compounds which target, decrease or inhibit the activity of a protein
or lipid
phosphatase are e.g. inhibitors of phosphatase 1, phosphatase 2A, or CDC25,
such as okadaic acid
or a derivative thereof
1001971 Compounds which induce cell differentiation processes include, but are
not limited to,
retinoic acid, a- y- or 6- tocopherol or a- y- or 6-tocotrienol.
1001981 The term cyclooxygenase inhibitor as used herein includes, but is not
limited to, Cox-
2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and
derivatives, such as celecoxib
(CelebrexTm), rofecoxib (VioxxTm), etoricoxib, valdecoxib or a 5-alkyl-2-
arylaminophenylacetic
acid, such as 5-methy1-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid,
lumiracoxib.
1001991 The term "bisphosphonates" as used herein includes, but is
not limited to, etridonic,
clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and
zoledronic acid. Etridonic
acid is marketed under the trade name DidronelTM. Clodronic acid is marketed
under the trade
name BonefosTM. Tiludronic acid is marketed under the trade name SkelidTM.
Pamidronic acid is
marketed under the trade name ArediaTM. Alendronic acid is marketed under the
trade name
FosamaxTM. Ibandronic acid is marketed under the trade name BondranatTM.
Risedronic acid is
marketed under the trade name ActonelTM. Zoledronic acid is marketed under the
trade name
ZometaTM. The term "mTOR inhibitors" relates to compounds which inhibit the
mammalian target
of rapamycin (mTOR) and which possess antiproliferative activity such as
sirolimus
(Rapamuneg), everolimus (CerticanTm), CCI-779 and ABT578.
53
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1002001 The term "heparanase inhibitor" as used herein refers to compounds
which target,
decrease or inhibit heparin sulfate degradation. The term includes, but is not
limited to, P1-88. The
term "biological response modifier" as used herein refers to a lymphokine or
interferons.
1002011 The term "inhibitor of Ras oncogenic isoforms", such as H-Ras, K-Ras,
or N-Ras, as
used herein refers to compounds which target, decrease or inhibit the
oncogenic activity of Ras;
for example, a "farnesyl transferase inhibitor" such as L-744832, DK8G557 or
R115777
(ZarnestraTm). The term "telomerase inhibitor" as used herein refers to
compounds which target,
decrease or inhibit the activity of telomerase. Compounds which target,
decrease or inhibit the
activity of telomerase are especially compounds which inhibit the telomerase
receptor, such as
telomestatin.
1002021 The term "methionine aminopeptidase inhibitor" as used herein refers
to compounds
which target, decrease or inhibit the activity of methionine aminopeptidase.
Compounds which
target, decrease or inhibit the activity of methionine aminopeptidase include,
but are not limited
to, bengamide or a derivative thereof.
1002031 The term "proteasome inhibitor" as used herein refers to compounds
which target,
decrease or inhibit the activity of the proteasome. Compounds which target,
decrease or inhibit the
activity of the proteasome include, but are not limited to, Bortezomib
(VelcadeTM) and MLN 341.
1002041 The term "matrix metalloproteinase inhibitor" or ("MMP" inhibitor) as
used herein
includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic
inhibitors,
tetracycline derivatives, e.g. hydroxamate peptidomimetic inhibitor batimastat
and its orally
bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat
(NSC 683551)
BMS-279251, BAY 12-9566, TAA211 , 1V11V1I270B or AAJ996.
1002051 The term "compounds used in the treatment of hematologic malignancies"
as used
herein includes, but is not limited to, FMS-like tyrosine kinase inhibitors,
which are compounds
targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase
receptors (Flt-3R),
interferon, 1-13-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK
inhibitors, which are
compounds which target, decrease or inhibit anaplastic lymphoma kinase.
1002061 Compounds which target, decrease or inhibit the activity of FMS-like
tyrosine kinase
receptors (Flt-3R) are especially compounds, proteins or antibodies which
inhibit members of the
Flt-3R receptor kinase family, such as PKC412, midostaurin, a staurosporine
derivative, SU11248
and MLN518.
54
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
[00207] The term "HSP90 inhibitors" as used herein includes, but is not
limited to, compounds
targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90;
degrading, targeting,
decreasing or inhibiting the HSP90 client proteins via the ubiquitin
proteosome pathway.
Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of
HSP90 are
especially compounds, proteins or antibodies which inhibit the ATPase activity
of HSP90, such as
17-allylamino,17-demethoxygeldanamycin (17AAG), a geldanamycin derivative;
other
geldanamycin related compounds; radicicol and HDAC inhibitors.
[00208]
The term "antiproliferative antibodies" as used herein includes, but is
not limited to,
trastuzum ab (HerceptinTm), Trastuzum ab-DM1, erb i tux, bevaci zum ab
(AvastinTm), rituxim ab
(Rituxan*), PR064553 (anti-CD40) and 2C4 Antibody. By antibodies is meant
intact monoclonal
antibodies, polyclonal antibodies, multispecific antibodies formed from at
least 2 intact antibodies,
and antibodies fragments so long as they exhibit the desired biological
activity.
[00209] For the treatment of acute myeloid leukemia (AML), compounds of the
current
invention can be used in combination with standard leukemia therapies,
especially in combination
with therapies used for the treatment of AML. In particular, compounds of the
current invention
can be administered in combination with, for example, farnesyl transferase
inhibitors and/or other
drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-
C, VP-16,
Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
[00210] Other anti-leukemic compounds include, for example, Ara-C, a
pyrimidine analog,
which is the f-alpha-hydroxy ribose (arabinosi de) derivative of deoxycytidine
Also included is
the purine analog of hypoxanthine, 6-mercaptopurine (6-MP) and fludarabine
phosphate.
Compounds which target, decrease or inhibit activity of histone deacetylase
(HDAC) inhibitors
such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA) inhibit the
activity of the
enzymes known as histone deacetylases. Specific HDAC inhibitors include MS275,
SAHA,
FK228 (formerly FR901228), Trichostatin A and compounds disclosed in US
6,552,065 including,
but not limited to, N-hydroxy-344-[[[2-(2-methy1-1H-indo1-3-y1)-ethyli-
amino]methyl]pheny1]-
2E-2-propenamide, or a pharmaceutically acceptable salt thereof and N-hydroxy-
3-[4-[(2-
hydroxyethyl) { 2-(1H-indo1-3 -y Dethy1]-amino]m ethyl]phenyl] -2E-2-
propenamide, or a
pharmaceutically acceptable salt thereof, especially the lactate salt.
Somatostatin receptor
antagonists as used herein refer to compounds which target, treat or inhibit
the somatostatin
receptor such as octreotide, and S0M230. Tumor cell damaging approaches refer
to approaches
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
such as ionizing radiation. The term "ionizing radiation" referred to above
and hereinafter means
ionizing radiation that occurs as either electromagnetic rays (such as X-rays
and gamma rays) or
particles (such as alpha and beta particles). Ionizing radiation is provided
in, but not limited to,
radiation therapy and is known in the art. See Hellman, Principles of
Radiation Therapy, Cancer,
in Principles and Practice of Oncology, Devita et al., Eds., 4th Edition, Vol.
1 , pp. 248-275 (1993).
[00211] Also included are EDG binders and ribonucleotide reductase inhibitors.
The term
"EDG binders" as used herein refers to a class of immunosuppressants that
modulates lymphocyte
recirculation, such as FTY720. The term -ribonucleotide reductase inhibitors"
refers to pyrimidine
or purine nucleoside analogs including, but not limited to, fludarabine and/or
cytosine arabinosi de
(ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine
(especially in combination
with ara-C against ALL) and/or pentostatin. Ribonucleotide reductase
inhibitors are especially
hydroxyurea or 2-hydroxy-1H-isoindole-1 ,3 -di one derivatives.
[00212] Also included are in particular those compounds, proteins or
monoclonal antibodies of
VEGF such as 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a
pharmaceutically
acceptable salt thereof, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine
succinate;
AngiostatinTM; EndostatinTM; anthranilic acid amides; ZD4190; Zd6474; SU5416;
SU6668;
bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, such as
rhuMAb and
RHUFab, VEGF aptamer such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors,
VEGFR-2 IgGI
antibody, Angiozyme (RPI 4610) and Bevacizumab (AvastinTm).
[00213] Photodynamic therapy as used herein refers to therapy which uses
certain chemicals
known as photosensitizing compounds to treat or prevent cancers. Examples of
photodynamic
therapy include treatment with compounds, such as VisudyneTM and porfimer
sodium.
[00214] Angiostatic steroids as used herein refers to compounds which block or
inhibit
angiogenesis, such as, e.g., anecortave, triamcinolone, hydrocortisone, 11-a-
epihydrocotisol,
cortexolone, 17a-hydroxyprogesterone, corticosterone, desoxycorticosterone,
testosterone,
estrone and dexamethasone.
[00215] Implants containing corticosteroids refers to compounds, such as
fluocinolone and
dexamethasone.
[00216] Other chemotherapeutic compounds include, but are not limited to,
plant alkaloids,
hormonal compounds and antagonists; biological response modifiers, preferably
lymphokines or
56
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA
or siRNA; or
miscellaneous compounds or compounds with other or unknown mechanism of
action.
[00217] The structure of the active compounds identified by code numbers,
generic or trade
names may be taken from the actual edition of the standard compendium "The
Merck Index" or
from databases, e.g. Patents International (e.g. IMS World Publications).
4.2.2. Exemplary Immuno-Oncology agents
[00218] In some embodiments, one or more other therapeutic agent is an immuno-
oncology
agent. As used herein, the term "an immuno-oncology agent" refers to an agent
which is effective
to enhance, stimulate, and/or up-regulate immune responses in a subject In
some embodiments,
the administration of an immuno-oncology agent with a compound of the
invention has a synergic
effect in treating a cancer.
[00219] An immuno-oncology agent can be, for example, a small molecule drug,
an antibody,
or a biologic or small molecule. Examples of biologic immuno-oncology agents
include, but are
not limited to, cancer vaccines, antibodies, and cytokines. In some
embodiments, an antibody is a
monoclonal antibody. In some embodiments, a monoclonal antibody is humanized
or human.
[00220] In some embodiments, an immuno-oncology agent is (i) an agonist of a
stimulatory
(including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory
(including a co-
inhibitory) signal on T cells, both of which result in amplifying antigen-
specific T cell responses.
[00221] Certain of the stimulatory and inhibitory molecules are members of the
immunoglobulin super family (IgSF). One important family of membrane-bound
ligands that bind
to co-stimulatory or co-inhibitory receptors is the B7 family, which includes
B7-1, B7-2, B7-H1
(PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-
H6.
Another family of membrane bound ligands that bind to co-stimulatory or co-
inhibitory receptors
is the TNF family of molecules that bind to cognate TNF receptor family
members, which includes
CD40 and CD4OL, OX-40, OX-40L, CD70, CD27L, CD30, CD3OL, 4-1BBL, CD137 (4-
1BB),
TRAIL/Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL,
TWEAKR/Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LT13R, LIGHT,
DcR3, HVEM, VEGUTL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1,
Lymphotoxin a/TNF13, TNFR2, TNFa, LT13R, Lymphotoxin al132, FAS, FASL, RELT,
DR6,
TROY, NGFR.
57
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
[00222] In some embodiments, an immuno-oncology agent is a cytokine that
inhibits T cell
activation (e.g., IL-6, IL-10, TGF-13, VEGF, and other immunosuppressive
cytokines) or a cytokine
that stimulates T cell activation, for stimulating an immune response.
[00223] In some embodiments, a combination of a compound of the invention and
an immuno-
oncology agent can stimulate T cell responses. In some embodiments, an immuno-
oncology agent
is: (i) an antagonist of a protein that inhibits T cell activation (e.g.,
immune checkpoint inhibitors)
such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA,
CD69,
Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIRL TIM-1,
and TIM-
4; or (ii) an agonist of a protein that stimulates T cell activation such as
B7-1, B7-2, CD28, 4-1BB
(CD137), 4-1BBL, ICOS, ICOS-L, 0X40, OX4OL, GITR, GITRL, CD70, CD27, CD40, DR3
and
CD28H.
[00224] In some embodiments, an immuno-oncology agent is an antagonist of
inhibitory
receptors on NK cells or an agonists of activating receptors on NK cells. In
some embodiments,
an immuno-oncology agent is an antagonists of KIR, such as lirilumab.
1002251 In some embodiments, an immuno-oncology agent is an agent that
inhibits or depletes
macrophages or monocytes, including but not limited to CSF-1R antagonists such
as CSF-1R
antagonist antibodies including RG7155 (W011/70024, W011/107553, W011/131407,
W013/87699, W013/119716, W013/132044) or FPA-008 (W011/140249; W013169264;
W014/036357).
[00226] In some embodiments, an immuno-oncology agent is selected from
agonistic agents
that ligate positive costimulatory receptors, blocking agents that attenuate
signaling through
inhibitory receptors, antagonists, and one or more agents that increase
systemically the frequency
of anti-tumor T cells, agents that overcome distinct immune suppressive
pathways within the
tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-L
1 /PD-1
interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal
antibody (e.g.,
daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes
such as IDO, or
reverse/prevent T cell energy or exhaustion) and agents that trigger innate
immune activation
and/or inflammation at tumor sites.
[00227] In some embodiments, an immuno-oncology agent is a CTLA-4 antagonist.
In some
embodiments, a CTLA-4 antagonist is an antagonistic CTLA-4 antibody. In some
embodiments,
an antagonistic CTLA-4 antibody is YERVOY (ipilimumab) or tremelimumab.
58
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1002281 In some embodiments, an immuno-oncology agent is a PD-1 antagonist. In
some
embodiments, a PD-1 antagonist is administered by infusion. In some
embodiments, an immuno-
oncology agent is an antibody or an antigen-binding portion thereof that binds
specifically to a
Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some
embodiments, a PD-1
antagonist is an antagonistic PD-1 antibody. In some embodiments, an
antagonistic PD-1 antibody
is OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP-514;
W02012/145493). In some embodiments, an immuno-oncology agent may be
pidilizumab (CT-
011). In some embodiments, an immuno-oncology agent is a recombinant protein
composed of
the extracellular domain of PD-L2 (B7-DC) fused to the Fc portion of IgGl,
called AMP-224.
[00229] In some embodiments, an immuno-oncology agent is a PD-Li antagonist.
In some
embodiments, a PD-L1 antagonist is an antagonistic PD-Li antibody. In some
embodiments, a
PD-Li antibody is MPDL3280A (RG7446; W02010/077634), durvalumab (MEDI4736),
BMS-
936559 (W02007/005874), and MSB0010718C (W02013/79174).
[00230] In some embodiments, an immuno-oncology agent is a LAG-3 antagonist.
In some
embodiments, a LAG-3 antagonist is an antagonistic LAG-3 antibody. In some
embodiments, a
LAG3 antibody is BMS-986016 (W010/19570, W014/08218), or IMP-731 or IMP-321
(W008/132601, W0009/44273).
[00231] In some embodiments, an immuno-oncology agent is a CD137 (4-1BB)
agonist. In
some embodiments, a CD137 (4-1BB) agonist is an agonistic CD137 antibody. In
some
embodiments, a CD137 antibody is urelumab or PF-05082566 (W012/32433).
[00232] In some embodiments, an immuno-oncology agent is a GITR agonist. In
some
embodiments, a GITR agonist is an agonistic GITR antibody. In some
embodiments, a GITR
antibody is BMS-986153, BMS-986156, TRX-518 (W0006/105021, W0009/009116), or
MK-
4166 (W011/028683).
[00233] In some embodiments, an immuno-oncology agent is an indoleamine (2,3)-
dioxygenase (IDO) antagonist. In some embodiments, an IDO antagonist is
selected from
epacadostat (INCB024360, Incyte); indoximod (NLG-8189, NewLink Genetics
Corporation);
capmanitib (INC280, Noyartis); GDC-0919 (Genentech/Roche); PF-06840003
(Pfizer),
BMS:F001287 (Bristol-Myers Squibb); Phy906/KD108 (Phytoceutica); an enzyme
that breaks
down kynurenine (Kynase, Kyn Therapeutics); and NLG-919 (W009/73620,
W0009/1156652,
W011/56652, W012/142237).
59
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
[00234] In some embodiments, an immuno-oncology agent is an 0X40 agonist. In
some
embodiments, an 0X40 agonist is an agonistic 0X40 antibody. In some
embodiments, an 0X40
antibody is 1VIEDI-6383 or 1VIEDI-6469.
[00235] In some embodiments, an immuno-oncology agent is an OX4OL antagonist.
In some
embodiments, an OX4OL antagonist is an antagonistic 0X40 antibody. In some
embodiments, an
OX4OL antagonist is RG-7888 (W006/029879).
[00236] In some embodiments, an immuno-oncology agent is a CD40 agonist. In
some
embodiments, a CD40 agonist is an agonistic CD40 antibody. In some
embodiments, an immuno-
oncol ogy agent is a CD40 antagonist. In some embodiments, a CD40 antagonist
is an antagonistic
CD40 antibody. In some embodiments, a CD40 antibody is lucatumumab or
dacetuzumab.
[00237] In some embodiments, an immuno-oncology agent is a CD27 agonist. In
some
embodiments, a CD27 agonist is an agonistic CD27 antibody. In some
embodiments, a CD27
antibody is varlilumab.
[00238] In some embodiments, an immuno-oncology agent is MGA271 (to B7H3)
(W011/109400).
1002391 In some embodiments, an immuno-oncology agent is abagovomab,
adecatumumab,
afutuzumab, alemtuzumab, anatumomab mafenatox, apolizumab, atezolimab,
avelumab,
blinatumomab, BMS-936559, catumaxomab, durvalumab, epacadostat, epratuzumab,
indoximod,
inotuzumab ozogamicin, intelumumab, ipilimumab, isatuximab, lambrolizumab,
MED14736,
MPDL3280 A, n i vol um ab, obi nutuzum ab, ocaratuzum ab, ofatum um ab, ol
atatum ab,
pembrolizumab, pidilizumab, rituximab, ticilimumab, samalizumab, or
tremelimumab.
[00240] In some embodiments, an immuno-oncology agent is an immunostimulatory
agent. For
example, antibodies blocking the PD-1 and PD-Li inhibitory axis can unleash
activated tumor-
reactive T cells and have been shown in clinical trials to induce durable anti-
tumor responses in
increasing numbers of tumor histologies, including some tumor types that
conventionally have not
been considered immunotherapy sensitive. See, e.g., Okazaki, T. et al. (2013)
Nat. Immunol. 14,
1212-1218; Zou et al. (2016) Sci. Transl. Med. 8. The anti-PD-1 antibody
nivolumab (Opdive,
Bristol-Myers Squibb, also known as ONO-4538, MDX1106 and BMS-936558), has
shown
potential to improve the overall survival in patients with RCC who had
experienced disease
progression during or after prior anti-angiogenic therapy.
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1002411 In some embodiments, the immunomodulatory therapeutic specifically
induces
apoptosis of tumor cells. Approved immunomodulatory therapeutics which may be
used in the
present invention include pomalidomide (Pomalyst , Celgene); lenalidomide
(Revlimid ,
Celgene); ingenol mebutate (Picato , LEO Pharma)
1002421 In some embodiments, an immuno-oncology agent is a cancer vaccine. In
some
embodiments, the cancer vaccine is selected from sipuleucel-T (Provenge ,
Dendreon/Valeant
Pharmaceuticals), which has been approved for treatment of asymptomatic, or
minimally
symptomatic metastatic castrate-resistant (hormone-refractory) prostate
cancer; and talimogene
laherparepvec (Imlygic , BioVex/Amgen, previously known as T-VEC), a
genetically modified
oncolytic viral therapy approved for treatment of unresectable cutaneous,
subcutaneous and nodal
lesions in melanoma. In some embodiments, an immuno-oncology agent is selected
from an
oncolytic viral therapy such as pexastimogene devacirepvec (PexaVec/JX-594,
SillaJen/formerly
Jennerex Biotherapeutics), a thymidine kinase- (TK-) deficient vaccinia virus
engineered to
express GM-C SF, for hepatocellular carcinoma (NCT02562755) and melanoma
(NCT00429312),
pelareorep (Reolysin , Oncolytics Biotech), a variant of respiratory enteric
orphan virus
(reovirus) which does not replicate in cells that are not RAS-activated, in
numerous cancers,
including colorectal cancer (NCT01622543); prostate cancer (NCT01619813); head
and neck
squamous cell cancer (NCT01166542); pancreatic adenocarcinoma (NCT00998322);
and non-
small cell lung cancer (NSCLC) (NCT 00861627); enadenotucirev (NG-348,
PsiOxus, formerly
known as ColoAd1), an adenovirus engineered to express a full length CD80 and
an antibody
fragment specific for the T-cell receptor CD3 protein, in ovarian cancer
(NCT02028117),
metastatic or advanced epithelial tumors such as in colorectal cancer, bladder
cancer, head and
neck squamous cell carcinoma and salivary gland cancer (NCT02636036); ONCOS-
102
(Targovax/formerly Oncos), an adenovirus engineered to express GM-CSF, in
melanoma
(NCT03003676), and peritoneal disease, colorectal cancer or ovarian cancer
(NCT02963831), GL-
ONC1 (GLV-1h68/GLV-1h153, Genelux GmbH), vaccinia viruses engineered to
express beta-
galactosidase (beta-gal)/beta-glucoronidase or beta-gal/human sodium iodide
symporter (hNIS),
respectively, were studied in peritoneal carcinomatosis (NCT01443260),
fallopian tube cancer,
ovarian cancer (NCT 02759588); or CG0070 (Cold Genesys), an adenovirus
engineered to express
GM-CSF, in bladder cancer (NCT02365818).
61
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
[00243] In some embodiments, an immuno-oncology agent is selected from JX-929
(SillaJen/formerly Jennerex Biotherapeutics), a TK- and vaccinia growth factor-
deficient vaccinia
virus engineered to express cytosine deaminase, which is able to convert the
prodrug 5-
fluorocytosine to the cytotoxic drug 5-fluorouracil; TGO1 and TGO2
(Targovax/formerly Oncos),
peptide-based immunotherapy agents targeted for difficult-to-treat RAS
mutations; and TILT-123
(TILT Biotherapeutics), an engineered adenovirus designated: Ad5/3-E2F-de1ta24-
hTNFu-lRES-
h1L20; and VSV-GP (ViraTherapeutics) a vesicular stomatitis virus (VSV)
engineered to express
the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV), which can
be further
engineered to express antigens designed to raise an antigen-specific CD8+ T
cell response.
[00244] In some embodiments, an immuno-oncology agent is a T-cell engineered
to express a
chimeric antigen receptor, or CAR. The T-cells engineered to express such
chimeric antigen
receptor are referred to as a CAR-T cells.
[00245] CARs have been constructed that consist of binding domains, which may
be derived
from natural ligands, single chain variable fragments (scFv) derived from
monoclonal antibodies
specific for cell-surface antigens, fused to endodomains that are the
functional end of the T-cell
receptor (TCR), such as the CD3-zeta signaling domain from TCRs, which is
capable of generating
an activation signal in T lymphocytes. Upon antigen binding, such CARs link to
endogenous
signaling pathways in the effector cell and generate activating signals
similar to those initiated by
the TCR complex.
[00246] For example, in some embodiments the CAR-T cell is one of those
described in U.S.
Patent 8,906,682 (June; hereby incorporated by reference in its entirety),
which discloses CAR-T
cells engineered to comprise an extracellular domain having an antigen binding
domain (such as a
domain that binds to CD19), fused to an intracellular signaling domain of the
T cell antigen
receptor complex zeta chain (such as CD3 zeta). When expressed in the T cell,
the CAR is able to
redirect antigen recognition based on the antigen binding specificity. In the
case of CD19, the
antigen is expressed on malignant B cells. Over 200 clinical trials are
currently in progress
employing CAR-T in a wide range of
indications.
[https ://clini caltri al s . gov/ct2/results?term=chimeri
c+antigen+receptors&pg=1] .
[00247] In some embodiments, an immunostimulatory agent is an activator of
retinoic acid
receptor-related orphan receptor y (RORyt). RORyt is a transcription factor
with key roles in the
differentiation and maintenance of Type 17 effector subsets of CD4+ (Th17) and
CD8+ (Tc17) T
62
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
cells, as well as the differentiation of IL-17 expressing innate immune cell
subpopulations such as
NK cells. In some embodiments, an activator of RORyt is LYC-55716 (Lycera),
which is currently
being evaluated in clinical trials for the treatment of solid tumors
(NC102929862).
[00248] In some embodiments, an immunostimulatory agent is an agonist or
activator of a toll-
like receptor (TLR). Suitable activators of TLRs include an agonist or
activator of TLR9 such as
SD-101 (Dynavax). SD-101 is an immunostimulatory CpG which is being studied
for B-cell,
follicular and other lymphomas (NCT02254772). Agonists or activators of TLR8
which may be
used in the present invention include motolimod (VTX-2337, VentiRx
Pharmaceuticals) which is
being studied for squamous cell cancer of the head and neck (NCT02124850) and
ovarian cancer
(NC TO2431559).
[00249] Other immuno-oncology agents that may be used in the present invention
include
urelumab (BMS-663513, Bristol-Myers Squibb), an anti-CD137 monoclonal
antibody; varlilumab
(CDX-1127, Celldex Therapeutics), an anti-CD27 monoclonal antibody; BMS-986178
(Bristol-
Myers Squibb), an anti-0X40 monoclonal antibody; lirilumab (IPH2102/BMS-
986015, Innate
Pharma, Bristol-Myers Squibb), an anti-KIR monoclonal antibody; monalizumab
(IPH2201,
Innate Pharma, AstraZeneca) an anti-NKG2A monoclonal antibody; andecaliximab
(GS-5745,
Gilead Sciences), an anti-lVEMP9 antibody; MK-4166 (Merck & Co.), an anti-GITR
monoclonal
antibody.
[00250] In some embodiments, an immunostimulatory agent is selected from
elotuzumab,
mifamurtide, an agonist or activator of a toll-like receptor, and an activator
of RORyt.
[00251] In some embodiments, an immunostimulatory therapeutic is recombinant
human
interleukin 15 (rhIL-15). rhIL-15 has been tested in the clinic as a therapy
for melanoma and renal
cell carcinoma (NCT01021059 and NCT01369888) and leukemias (NCT02689453). In
some
embodiments, an immunostimulatory agent is recombinant human interleukin 12
(rhIL-12). In
some embodiments, an IL-15 based immunotherapeutic is heterodimeric IL-15
(hetIL-15,
Novartis/Admune), a fusion complex composed of a synthetic form of endogenous
IL-15
complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain
(IL15:slL-15RA),
which has been tested in Phase 1 clinical trials for melanoma, renal cell
carcinoma, non-small cell
lung cancer and head and neck squamous cell carcinoma (NCT02452268). In some
embodiments,
a recombinant human interleukin 12 (rhlL-12) is NM-IL-12 (Neumedicines, Inc.),
NCT02544724,
or NCT02542124.
63
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1002521 In some embodiments, an immuno-oncology agent is selected from those
descripted in
Jerry L. Adams ET. AL., "Big opportunities for small molecules in immuno-
oncology," Cancer
Therapy 2015, Vol. 14, pages 603-622, the content of which is incorporated
herein by reference in
its entirety. In some embodiments, an immuno-oncology agent is selected from
the examples
described in Table 1 of Jerry L. Adams ET. AL. In some embodiments, an immuno-
oncology
agent is a small molecule targeting an immuno-oncology target selected from
those listed in Table
2 of Jerry L. Adams ET. AL. In some embodiments, an immuno-oncology agent is a
small
molecule agent selected from those listed in Table 2 of Jerry L. Adams ET. AL.
1002531 In some embodiments, an immuno-oncology agent is selected from the
small molecule
immuno-oncology agents described in Peter L. Toogood, "Small molecule immuno-
oncology
therapeutic agents," Bioorganic & Medicinal Chemistry Letters 2018, Vol. 28,
pages 319-329, the
content of which is incorporated herein by reference in its entirety. In some
embodiments, an
immuno-oncology agent is an agent targeting the pathways as described in Peter
L. Toogood.
1002541 In some embodiments, an immuno-oncology agent is selected from those
described in
Sandra L. Ross et al., "Bispecific T cell engager (BiTE ) antibody constructs
can mediate
bystander tumor cell killing", PLoS ONE 12(8): e0183390, the content of which
is incorporated
herein by reference in its entirety. In some embodiments, an immuno-oncology
agent is a
bispecific T cell engager (BiTE ) antibody construct. In some embodiments, a
bispecific T cell
engager (BiTE ) antibody construct is a CD19/CD3 bispecific antibody
construct. In some
embodiments, a bispecific T cell engager (BiTE ) antibody construct is an
EGFR/CD3 bispecific
antibody construct. In some embodiments, a bispecific T cell engager (BiTE )
antibody construct
activates T cells. In some embodiments, a bispecific T cell engager (BiTE )
antibody construct
activates T cells, which release cytokines inducing upregulation of
intercellular adhesion molecule
1 (ICAM-1) and FAS on bystander cells. In some embodiments, a bispecific T
cell engager
(BiTE ) antibody construct activates T cells which result in induced bystander
cell lysis. In some
embodiments, the bystander cells are in solid tumors. In some embodiments, the
bystander cells
being lysed are in proximity to the BiTE -activated T cells. In some
embodiments, the bystander
cells comprise tumor-associated antigen (TAA) negative cancer cells. In some
embodiments, the
bystander cells comprise EGFR-negative cancer cells. In some embodiments, an
immuno-
oncology agent is an antibody which blocks the PD-L1/PD1 axis and/or CTLA4. In
some
embodiments, an immuno-oncology agent is an ex-vivo expanded tumor-
infiltrating T cell. In
64
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
some embodiments, an immuno-oncology agent is a bispecific antibody construct
or chimeric
antigen receptors (CARs) that directly connect T cells with tumor-associated
surface antigens
(TAAs).
Exemplary Immune Checkpoint Inhibitors
[00255] In some embodiments, an immuno-oncology agent is an immune checkpoint
inhibitor
as described herein.
[00256] The term -checkpoint inhibitor" as used herein relates to agents
useful in preventing
cancer cells from avoiding the immune system of the patient. One of the major
mechanisms of
anti-tumor immunity subversion is known as "T-cell exhaustion," which results
from chronic
exposure to antigens that has led to up-regulation of inhibitory receptors.
These inhibitory
receptors serve as immune checkpoints in order to prevent uncontrolled immune
reactions.
[00257] PD-1 and co-inhibitory receptors such as cytotoxic T-lymphocyte
antigen 4 (CTLA-4,
B and T Lymphocyte Attenuator (BTLA; CD272), T cell Immunoglobulin and Mucin
domain-3
(Tim-3), Lymphocyte Activation Gene-3 (Lag-3; CD223), and others are often
referred to as a
checkpoint regulators. They act as molecular -gatekeepers" that allow
extracellular information
to dictate whether cell cycle progression and other intracellular signaling
processes should
proceed.
[00258] In some embodiments, an immune checkpoint inhibitor is an antibody to
PD-1. PD-1
binds to the programmed cell death 1 receptor (PD-1) to prevent the receptor
from binding to the
inhibitory ligand PDL-1, thus overriding the ability of tumors to suppress the
host anti-tumor
immune response.
[00259] In one aspect, the checkpoint inhibitor is a biologic
therapeutic or a small molecule. In
another aspect, the checkpoint inhibitor is a monoclonal antibody, a humanized
antibody, a fully
human antibody, a fusion protein or a combination thereof In a further aspect,
the checkpoint
inhibitor inhibits a checkpoint protein selected from CTLA-4, PDL1, PDL2, PD1,
B7-H3, B7-H4,
BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2,
A2aR, B-7 family ligands or a combination thereof. In an additional aspect,
the checkpoint
inhibitor interacts with a ligand of a checkpoint protein selected from CTLA-
4, PDL1, PDL2, PD1,
B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-
15049,
CHK 1, CHK2, A2aR, B-7 family ligands or a combination thereof In an aspect,
the checkpoint
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
inhibitor is an immunostimulatory agent, a T cell growth factor, an
interleukin, an antibody, a
vaccine or a combination thereof. In a further aspect, the interleukin is IL-7
or IL-15. In a specific
aspect, the interleukin is glycosylated IL-7. In an additional aspect, the
vaccine is a dendritic cell
(DC) vaccine.
1002601 Checkpoint inhibitors include any agent that blocks or
inhibits in a statistically
significant manner, the inhibitory pathways of the immune system. Such
inhibitors may include
small molecule inhibitors or may include antibodies, or antigen binding
fragments thereof, that
bind to and block or inhibit immune checkpoint receptors or antibodies that
bind to and block or
inhibit immune checkpoint receptor ligands. Illustrative checkpoint molecules
that may be
targeted for blocking or inhibition include, but are not limited to, CTLA-4,
PDL1, PDL2, PD1,
B7-H3, B7-H4, BTLA, HVEM, GAL9, LAG3, TIM3, VISTA, KIR, 2B4 (belongs to the
CD2
family of molecules and is expressed on all NK, y6, and memory CD8+ (ct13) T
cells), CD160 (also
referred to as BY55), CGEN-15049, CHK 1 and CHK2 kinases, A2aR, and various B-
7 family
ligands. B7 family ligands include, but are not limited to, B7- 1, B7-2, B7-
DC, B7-H1, B7-H2,
B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7. Checkpoint inhibitors include
antibodies, or antigen
binding fragments thereof, other binding proteins, biologic therapeutics, or
small molecules, that
bind to and block or inhibit the activity of one or more of CTLA-4, PDL1,
PDL2, PD1, BTLA,
HVEM, TI1\43, GAL9, LAG3, VISTA, KIR, 2B4, CD 160 and CGEN-15049. Illustrative
immune
checkpoint inhibitors include Tremelimumab (CTLA-4 blocking antibody), anti-
0X40, PD-Ll
monoclonal Antibody (Anti-B7-H1; MEDI4736), MK-3475 (PD-1 blocker), Nivolumab
(anti-PD1
antibody), CT-011 (anti-PD1 antibody), BY55 monoclonal antibody, AMP224 (anti-
PDL1
antibody), BMS- 936559 (anti-PDL1 antibody), MPLDL3280A (anti-PDL1 antibody),
MSB0010718C (anti-PDL1 antibody), and ipilimumab (anti-CTLA-4 checkpoint
inhibitor).
Checkpoint protein ligands include, but are not limited to PD-L1, PD-L2, B7-
H3, B7-H4, CD28,
CD86 and TIM-3.
1002611 In certain embodiments, the immune checkpoint inhibitor is selected
from a PD-1
antagonist, a PD-Li antagonist, and a CTLA-4 antagonist. In some embodiments,
the checkpoint
inhibitor is selected from the group consisting of nivolumab (Opdivo0),
ipilimumab (Yervoy0),
and pembrolizumab (Keytrudag). In some embodiments, the checkpoint inhibitor
is selected from
nivolumab (anti-PD-1 antibody, Opdivo , Bristol-Myers Squibb); pembrolizumab
(anti-PD-1
antibody, Keytruda , Merck); ipilimumab (anti-CTLA-4 antibody, Yervoy ,
Bristol-Myers
66
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Squibb); durvalumab (anti-PD-Li antibody, Imfinzi , Astra7eneca); and
atezolizumab (anti-PD-
Li antibody, Tecentriq , Genentech).
[00262] In some embodiments, the checkpoint inhibitor is selected from the
group consisting
of lambrolizumab (MK-3475), nivolumab (BMS-936558), pidilizumab (CT-011), AMP-
224,
MDX-1105, MEDI4736, MPDL3280A, BMS-936559, ipilimumab, lirlumab, IPH2101,
pembrolizumab (Keytruda0), and tremelimumab.
[00263] In some embodiments, an immune checkpoint inhibitor is REGN2810
(Regeneron), an
anti-PD-1 antibody tested in patients with basal cell carcinoma (NCT03132636);
NSCLC
(NCT03088540); cutaneous squamous cell carcinoma (NCT02760498); lymphoma
(NCT02651662); and melanoma (NCT03002376); pidilizumab (CureTech), also known
as CT-
011, an antibody that binds to PD-1, in clinical trials for diffuse large B-
cell lymphoma and
multiple myeloma, avelumab (Bavencio , Pfizer/Merck KGaA), also known as
MSB0010718C),
a fully human IgG1 anti-PD-Li antibody, in clinical trials for non-small cell
lung cancer, Merkel
cell carcinoma, mesothelioma, solid tumors, renal cancer, ovarian cancer,
bladder cancer, head and
neck cancer, and gastric cancer; or PDR001 (Novartis), an inhibitory antibody
that binds to PD-1,
in clinical trials for non-small cell lung cancer, melanoma, triple negative
breast cancer and
advanced or metastatic solid tumors. Tremelimumab (CP-675,206; Astrazeneca) is
a fully human
monoclonal antibody against CTLA-4 that has been in studied in clinical trials
for a number of
indications, including: mesothelioma, colorectal cancer, kidney cancer, breast
cancer, lung cancer
and non-small cell lung cancer, pancreatic ductal adenocarcinoma, pancreatic
cancer, germ cell
cancer, squamous cell cancer of the head and neck, hepatocellular carcinoma,
prostate cancer,
endometrial cancer, metastatic cancer in the liver, liver cancer, large B-cell
lymphoma, ovarian
cancer, cervical cancer, metastatic anaplastic thyroid cancer, urothelial
cancer, fallopian tube
cancer, multiple myeloma, bladder cancer, soft tissue sarcoma, and melanoma
AGEN-1884
(Agenus) is an anti-CTLA4 antibody that is being studied in Phase 1 clinical
trials for advanced
solid tumors (NCT02694822).
[00264] In some embodiments, a checkpoint inhibitor is an inhibitor of T-cell
immunoglobulin
mucin containing protein-3 (TIM-3). TIM-3 inhibitors that may be used in the
present invention
include TSR-022, LY3321367 and MBG453. TSR-022 (Tesaro) is an anti-TIM-3
antibody which
is being studied in solid tumors (NCT02817633). LY3321367 (Eli Lilly) is an
anti-TIM-3
67
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
antibody which is being studied in solid tumors (NCT03099109). MBG453
(Novartis) is an anti-
TIM-3 antibody which is being studied in advanced malignancies (NCT02608268).
1002651 In some embodiments, a checkpoint inhibitor is an inhibitor of T cell
immunoreceptor
with Ig and ITIM domains, or TIGIT, an immune receptor on certain T cells and
NK cells TIGIT
inhibitors that may be used in the present invention include BMS-986207
(Bristol-Myers Squibb),
an anti-TIGIT monoclonal antibody (NCT02913313); OMP-313M32 (Oncomed); and
anti-TIGIT
monoclonal antibody (NCT03119428).
1002661 In some embodiments, a checkpoint inhibitor is an inhibitor of
Lymphocyte Activation
Gene-3 (LAG-3) LAG-3 inhibitors that may be used in the present invention
include BMS-
986016 and REGN3767 and IMP321 BMS-986016 (Bristol-Myers Squibb), an anti-LAG-
3
antibody, is being studied in glioblastoma and gliosarcoma (NCT02658981).
REGN3767
(Regeneron), is also an anti-LAG-3 antibody, and is being studied in
malignancies
(NC103005782). EV1P321 (Immutep S.A.) is an LAG-3-Ig fusion protein, being
studied in
melanoma (NCT02676869); adenocarcinoma (NCT02614833); and metastatic breast
cancer
(NCT00349934).
1002671 Checkpoint inhibitors that may be used in the present invention
include 0X40 agonists.
0X40 agonists that are being studied in clinical trials include PF-04518600/PF-
8600 (Pfizer), an
agonistic anti-0X40 antibody, in metastatic kidney cancer (NCT03092856) and
advanced cancers
and neoplasms (NCT02554812; NCT05082566); GSK3174998 (Merck), an agonistic
anti-0X40
antibody, in Phase 1 cancer trials (NCT02528357), MEDI0562
(Medimmune/AstraZeneca), an
agonistic anti-0X40 antibody, in advanced solid tumors (NCT02318394 and
NCT02705482),
MEDI6469, an agonistic anti-0X40 antibody (Medimmune/AstraZeneca), in patients
with
colorectal cancer (NCT02559024), breast cancer (NCT01862900), head and neck
cancer
(NCT02274155) and metastatic prostate cancer (NCT01303705); and BMS-986178
(Bristol-
Myers Squibb) an agonistic anti-0X40 antibody, in advanced cancers
(NCT02737475).
1002681 Checkpoint inhibitors that may be used in the present invention
include CD137 (also
called 4-1BB) agonists. CD137 agonists that are being studied in clinical
trials include
utomilumab (PF-05082566, Pfizer) an agonistic anti-CD137 antibody, in diffuse
large B-cell
lymphoma (NCT02951156) and in advanced cancers and neoplasms (NC102554812 and
NCT05082566); urelumab (BMS-663513, Bristol-Myers Squibb), an agonistic anti-
CD137
68
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
antibody, in melanoma and skin cancer (NCT02652455) and glioblastoma and
gliosarcoma
(NC TO2658981).
1002691 Checkpoint inhibitors that may be used in the present invention
include CD27 agonists.
CD27 agonists that are being studied in clinical trials include varlilumab
(CDX-1127, Celldex
Therapeutics) an agonistic anti-CD27 antibody, in squamous cell head and neck
cancer, ovarian
carcinoma, colorectal cancer, renal cell cancer, and glioblastoma
(NCT02335918); lymphomas
(NCT01460134); and glioma and astrocytoma (NCT02924038).
1002701 Checkpoint inhibitors that may be used in the present invention
include glucocorticoid-
induced tumor necrosis factor receptor (GITR) agonists GITR agonists that are
being studied in
clinical trials include TRX518 (Leap Therapeutics), an agonistic anti-GITR
antibody, in malignant
melanoma and other malignant solid tumors (NCT01239134 and NCT02628574);
GWN323
(Novartis), an agonistic anti-GITR antibody, in solid tumors and lymphoma (NCT
02740270),
INCAGN01876 (Incyte/Agenus), an agonistic anti-GITR antibody, in advanced
cancers
(NC T02697591 and NC TO3126110); MK-4166 (Merck), an agonistic anti-GITR
antibody, in solid
tumors (NCT02132754) and MEDI1873 (Medimmune/AstraZeneca), an agonistic
hexameric
GITR-ligand molecule with a human IgG1 Fe domain, in advanced solid tumors
(NCT02583165).
1002711 Checkpoint inhibitors that may be used in the present invention
include inducible T-
cell co-stimulator (ICOS, also known as CD278) agonists. ICOS agonists that
are being studied
in clinical trials include 1VIEDI-570 (Medimmune), an agonistic anti-ICOS
antibody, in lymphomas
(NCT02520791); GSK3359609 (Merck), an agonistic anti -ICOS antibody, in Phase
1
(NC102723955); JTX-2011 (Jounce Therapeutics), an agonistic anti-ICOS
antibody, in Phase 1
(NC102904226).
1002721 Checkpoint inhibitors that may be used in the present invention
include killer IgG-like
receptor (KIR) inhibitors KIR inhibitors that are being studied in clinical
trials include lirilumab
(IPH2102/BMS-986015, Innate Pharma/Bristol-Myers Squibb), an anti-KIR
antibody, in
leukemias (NCT01687387, NCT02399917, NCT02481297, NCT02599649), multiple
myeloma
(NCT02252263), and lymphoma (NCT01592370), IPH2101 (1-7F9, Innate Pharma) in
myeloma
(NCT01222286 and NCT01217203), and IPH4102 (Innate Pharma), an anti-KIR
antibody that
binds to three domains of the long cytoplasmic tail (K1R3DL2), in lymphoma
(NCT02593045).
1002731 Checkpoint inhibitors that may be used in the present invention
include CD47
inhibitors of interaction between CD47 and signal regulatory protein alpha
(SIRPa). CD47/SIRPa
69
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
inhibitors that are being studied in clinical trials include ALX-148 (Alexo
Therapeutics), an
antagonistic variant of (SIRPa) that binds to CD47 and prevents CD47/SIRPa-
mediated signaling,
in phase 1 (NCT03013218); TTI-621 (SIRPa-Fc, Trillium Therapeutics), a soluble
recombinant
fusion protein created by linking the N-terminal CD47-binding domain of SIRPa
with the Fc
domain of human IgGI, acts by binding human CD47, and preventing it from
delivering its "do
not eat" signal to macrophages, is in clinical trials in Phase 1 (NC102890368
and NCT02663518);
CC-90002 (Celgene), an anti-CD47 antibody, in leukemias (NCT02641002); and
Hu5F9-G4
(Forty Seven, Inc.), in colorectal neoplasms and solid tumors (NCT02953782),
acute myeloid
leukemia (NCT02678338) and lymphoma (NCT02953509)
1002741 Checkpoint inhibitors that may be used in the present invention
include CD73
inhibitors. CD73 inhibitors that are being studied in clinical trials include
MEDI9447
(Medimmune), an anti-CD73 antibody, in solid tumors (NCT02503774), and BMS-
986179
(Bristol-Myers Squibb), an anti-CD73 antibody, in solid tumors (NC102754141).
1002751 Checkpoint inhibitors that may be used in the present invention
include agonists of
stimulator of interferon genes protein (STING, also known as transmembrane
protein 173, or
TMEM173). Agonists of STING that are being studied in clinical trials include
1V1K-1454
(Merck), an agonistic synthetic cyclic dinucleotide, in lymphoma
(NCT03010176); and ADU-
S100 (MIW815, Aduro Biotech/Novartis), an agonistic synthetic cyclic
dinucleotide, in Phase 1
(NCT02675439 and NCT03172936).
1002761 Checkpoint inhibitors that may be used in the present invention
include CSF1R
inhibitors. CSF1R inhibitors that are being studied in clinical trials include
pexidartinib
(PLX3397, Plexxikon), a CSF1R small molecule inhibitor, in colorectal cancer,
pancreatic cancer,
metastatic and advanced cancers (NCT02777710) and melanoma, non-small cell
lung cancer,
squamous cell head and neck cancer, gastrointestinal stromal tumor (GIST) and
ovarian cancer
(NCT02452424), and IMC-CS4 (LY3022855, Lilly), an anti-CSF-1R antibody, in
pancreatic
cancer (NCT03153410), melanoma (NCT03101254), and solid tumors (NCT02718911),
and
BLZ945 (4-[2((1R,2R)-2-hydroxycyclohexylamino)-benzothiazol-6-
yloxyl]-pyridine-2-
carboxylic acid methylamide, Novartis), an orally available inhibitor of
CSF1R, in advanced solid
tumors (NCT02829723).
1002771 Checkpoint inhibitors that may be used in the present invention
include NKG2A
receptor inhibitors. NKG2A receptor inhibitors that are being studied in
clinical trials include
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
monalizumab (IPH2201, Innate Pharma), an anti-NKG2A antibody, in head and neck
neoplasms
(NCT02643550) and chronic lymphocytic leukemia (NCT02557516).
[00278] In some embodiments, the immune checkpoint inhibitor is selected from
nivolumab,
pembroli zum ab, i pili m um ab, avel um ab, durval um ab, atezoli zum ab, or
pi dili zum ab .
5. Uses
[00279] Compounds and compositions described herein are generally useful for
the inhibition
of eIF4E or a mutant thereof
[00280] The activity of a compound utilized in this invention as an
inhibitor of eIF4E, or a
mutant thereof, may be assayed in vitro, in vivo or in a cell line In vitro
assays include assays that
determine inhibition of eIF4E, or a mutant thereof. Alternate in vitro assays
quantitate the ability
of the inhibitor to bind to eIF4E. Detailed conditions for assaying a compound
utilized in this
invention as an inhibitor of eIF4E, or a mutant thereof, are set forth in the
Examples below.
[00281] Provided compounds are inhibitors of eIF4E and are therefore useful
for treating one
or more disorders associated with activity of eIF4E. Thus, in certain
embodiments, the present
invention provides a method for treating an eIF4E-mediated disorder comprising
the step of
administering to a patient in need thereof a compound of the present
invention, or pharmaceutically
acceptable composition thereof In certain embodiments, an eIF4E-mediated
disorder is an eIF4E-
mediated cancer. In some embodiments, an eIF4E-mediated cancer is selected
from breast cancer,
colorectal cancer, lung cancer, gli oblastom a, sarcomas, melanoma, prostate
cancer, and
lymphomas. In some embodiments, an eIF4E-mediated cancer is breast cancer.
[00282] As used herein, the terms "treatment,- "treat,- and "treating- refer
to reversing,
alleviating, delaying the onset of, or inhibiting the progress of a disease or
disorder, or one or more
symptoms thereof, as described herein. In some embodiments, treatment may be
administered
after one or more symptoms have developed. In other embodiments, treatment may
be
administered in the absence of symptoms. For example, treatment may be
administered to a
susceptible individual prior to the onset of symptoms (e.g., in light of a
history of symptoms and/or
in light of genetic or other susceptibility factors). Treatment may also be
continued after symptoms
have resolved, for example to prevent or delay their recurrence.
1002831 As used herein, the terms "eIF4E-mediated" disorders, diseases, and/or
conditions as
used herein means any disease or other deleterious condition in which eIF4E,
or a mutant thereof,
71
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
is known to play a role, including, but is not limited to, a cellular
proliferative disorder. In some
embodiments, a cellular proliferative disorder is cancer as described herein.
Cancer
1002841
Cancer includes, in some embodiments, without limitation, leukemias
(e.g., acute
leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute
myeloblastic leukemia,
acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic
leukemia, acute
erythrol eukemi a, chronic leukemia, chronic my el ocyti c leukemia, chronic
lymphocytic leukemia),
polycythemi a vera, lymphoma (e.g., Hodgkin's disease or n on-Hodgkin ' s
disease), Wal den strom ' s
macroglobulinemia, multiple myeloma, heavy chain disease, and solid tumors
such as sarcomas
and carcinomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma,
osteogenic
sarcoma, chordoma, angiosarcoma, endotheliosarcoma,
lymphangiosarcoma,
lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor,
leiomyosarcoma,
rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian
cancer, prostate
cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat
gland carcinoma,
sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas,
cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell
carcinoma,
hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma,
Wilm's tumor,
cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell
lung carcinoma,
bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, glioblastoma
multi form e (GBM,
also known as glioblastoma), medulloblastoma, craniopharyngioma, ependymoma,
pinealoma,
hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma,
neurofibrosarcoma,
meningioma, melanoma, neuroblastoma, and retinoblastoma).
[00285] In some embodiments, the cancer is glioma, astrocytoma, glioblastoma
multiforme
(GBM, also known as glioblastoma), medulloblastoma, craniopharyngioma,
ependymoma,
pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma,
neurofibrosarcoma, meningioma, melanoma, neuroblastoma, or retinoblastoma.
1002861 In some embodiments, the cancer is acoustic neuroma, astrocytoma (e.g.
Grade I ¨
Pilocytic Astrocytoma, Grade II ¨ Low-grade Astrocytoma, Grade III ¨
Anaplastic Astrocytoma,
or Grade IV ¨ Glioblastoma (GBM)), chordoma, CNS lymphoma, craniopharyngioma,
brain stem
glioma, ependymoma, mixed glioma, optic nerve glioma, subependymoma,
medulloblastoma,
72
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
m eni ngi om a, metastatic brain tumor, ol i goden drogl i om a, pituitary
tumors, primitive
neuroectodermal (PNET) tumor, or schwannoma. In some embodiments, the cancer
is a type
found more commonly in children than adults, such as brain stem glioma,
craniopharyngioma,
ependym om a, juvenile pilocytic astrocytoma (TPA), medulloblastom a, optic
nerve glioma, pineal
tumor, primitive neuroectodermal tumors (PNET), or rhabdoid tumor. In some
embodiments, the
patient is an adult human. In some embodiments, the patient is a child or
pediatric patient.
[00287] Cancer includes, in another embodiment, without limitation,
mesothelioma,
hepatobilliary (hepatic and billiary duct), bone cancer, pancreatic cancer,
skin cancer, cancer of
the head or neck, cutaneous or intraocular melanoma, ovarian cancer, colon
cancer, rectal cancer,
cancer of the anal region, stomach cancer, gastrointestinal (gastric,
colorectal, and duodenal),
uterine cancer, carcinoma of the fallopian tubes, carcinoma of the
endometrium, carcinoma of the
cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease,
cancer of the
esophagus, cancer of the small intestine, cancer of the endocrine system,
cancer of the thyroid
gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma
of soft tissue, cancer
of the urethra, cancer of the penis, prostate cancer, testicular cancer,
chronic or acute leukemia,
chronic myeloid leukemia, lymphocytic lymphomas, cancer of the bladder, cancer
of the kidney
or ureter, renal cell carcinoma, carcinoma of the renal pelvis, non-Hodgkins's
lymphoma, spinal
axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall
bladder cancer,
multiple myeloma, cholangiocarcinoma, fibrosarcoma, neuroblastoma,
retinoblastoma, or a
combination of one or more of the foregoing cancers
[00288] In some embodiments, the cancer is selected from hepatocellular
carcinoma, ovarian
cancer, ovarian epithelial cancer, or fallopian tube cancer; papillary serous
cystadenocarcinoma or
uterine papillary serous carcinoma (UPSC); prostate cancer; testicular cancer;
gallbladder cancer;
hepatocholangiocarcinoma; soft tissue and bone synovial sarcoma;
rhabdomyosarcoma;
osteosarcoma, chondrosarcoma, Ewing sarcoma, anaplastic thyroid cancer,
adrenocortical
adenoma, pancreatic cancer, pancreatic ductal carcinoma or pancreatic
adenocarcinoma,
gastrointestinal/stomach (GIST) cancer, lymphoma, squamous cell carcinoma of
the head and neck
(SCCHN), salivary gland cancer, glioma, or brain cancer, neurofibromatosis-1
associated
malignant peripheral nerve sheath tumors (MPNST); Waldenstrom's
macroglobulinemia; or
medulloblastoma.
[00289] In some embodiments, the cancer is selected from
hepatocellular carcinoma (HCC),
73
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
hepatoblastoma, colon cancer, rectal cancer, ovarian cancer, ovarian
epithelial cancer, fallopian
tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous
carcinoma (UPSC),
hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma,
rhabdomyosarcoma,
osteosarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic
cancer, pancreatic
ductal carcinoma, pancreatic adenocarcinoma, glioma, neurofibromatosis-1
associated malignant
peripheral nerve sheath tumors (1\,/fPNST), Waldenstrom's macroglobulinemia,
or
medulloblastoma.
1002901 In some embodiments, the cancer is a solid tumor, such as a sarcoma,
carcinoma, or
lymphoma Solid tumors generally comprise an abnormal mass of tissue that
typically does not
include cysts or liquid areas In some embodiments, the cancer is selected from
renal cell
carcinoma, or kidney cancer; hepatocellular carcinoma (HCC) or hepatoblastoma,
or liver cancer,
melanoma, breast cancer, colorectal carcinoma, or colorectal cancer, colon
cancer, rectal cancer,
anal cancer; lung cancer, such as non-small cell lung cancer (NSCLC) or small
cell lung cancer
(SCLC); ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, or
fallopian tube cancer;
papillary serous cystadenocarcinoma or uterine papillary serous carcinoma
(UPSC); prostate
cancer; testicular cancer; gallbladder cancer; hepatocholangiocarcinoma; soft
tissue and bone
synovial sarcoma; rhabdomyosarcoma; osteosarcoma; chondrosarcoma; Ewing
sarcoma;
anaplastic thyroid cancer; adrenocortical carcinoma; pancreatic cancer;
pancreatic ductal
carcinoma or pancreatic adenocarcinoma; gastrointestinal/stomach (GIST)
cancer; lymphoma;
squamous cell carcinoma of the head and neck (SCCHN); salivary gland cancer;
glioma, or brain
cancer; neurofibromatosis-1 associated malignant peripheral nerve sheath
tumors (IVIPNST);
Waldenstrom's macroglobulinemia; or medulloblastoma.
1002911 In some embodiments, the cancer is selected from renal cell carcinoma,
hepatocellular
carcinoma (HCC), hepatoblastoma, colorectal carcinoma, colorectal cancer, col
on cancer, rectal
cancer, anal cancer, ovarian cancer, ovarian epithelial cancer, ovarian
carcinoma, fallopian tube
cancer, papillary serous cystadenocarcinoma, uterine papillary serous
carcinoma (UPSC),
hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma,
rhabdomyosarcoma,
osteosarcoma, chondrosarcoma, anaplastic thyroid cancer, adrenocortical
carcinoma, pancreatic
cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, brain
cancer,
neurofibromatosis-1 associated malignant peripheral nerve sheath tumors
(MPNST),
Waldenstrom's macroglobulinemia, or medulloblastoma.
74
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1002921 In some embodiments, the cancer is selected from hepatocellular
carcinoma (HCC),
hepatoblastoma, colon cancer, rectal cancer, ovarian cancer, ovarian
epithelial cancer, ovarian
carcinoma, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine
papillary serous
carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial
sarcoma,
rhabdomyosarcoma, osteosarcoma, anaplastic thyroid cancer, adrenocortical
carcinoma,
pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma,
glioma,
neurofibromatosis-1 associated malignant peripheral nerve sheath tumors
(MPNST),
Waldenstrom's macroglobulinemia, or medulloblastoma.
1002931 In some embodiments, the cancer is hepatocellular carcinoma (HCC). In
some
embodiments, the cancer is hepatoblastoma. In some embodiments, the cancer is
colon cancer. In
some embodiments, the cancer is rectal cancer. In some embodiments, the cancer
is ovarian
cancer, or ovarian carcinoma. In some embodiments, the cancer is ovarian
epithelial cancer. In
some embodiments, the cancer is fallopian tube cancer. In some embodiments,
the cancer is
papillary serous cystadenocarcinoma. In some embodiments, the cancer is
uterine papillary serous
carcinoma (UPSC). In some embodiments, the cancer is hepatocholangiocarcinoma.
In some
embodiments, the cancer is soft tissue and bone synovial sarcoma. In some
embodiments, the
cancer is rhabdomyosarcoma. In some embodiments, the cancer is osteosarcoma.
In some
embodiments, the cancer is anaplastic thyroid cancer. In some embodiments, the
cancer is
adrenocortical carcinoma. In some embodiments, the cancer is pancreatic
cancer, or pancreatic
ductal carcinoma In some embodiments, the cancer is pancreatic aden ocarci n
om a. In some
embodiments, the cancer is glioma. In some embodiments, the cancer is
malignant peripheral
nerve sheath tumors (MPNST). In some embodiments, the cancer is
neurofibromatosis-1
associated MPNST. In some embodiments, the cancer is Waldenstrom's
macroglobulinemia. In
some embodiments, the cancer is medulloblastoma.
1002941 In some embodiments, the cancer is Acute Lymphoblastic Leukemia (ALL),
Acute
Myeloid Leukemia (AML), Adrenocortical Carcinoma, Anal Cancer, Appendix
Cancer, Atypical
Teratoid/Rhabdoid Tumor, Basal Cell Carcinoma, Bile Duct Cancer, Bladder
Cancer, Bone
Cancer, Brain Tumor, Astrocytoma, Brain and Spinal Cord Tumor, Brain Stem
Glioma, Central
Nervous System Atypical Teratoid/Rhabdoid Tumor, Central Nervous System
Embryonal
Tumors, Breast Cancer, Bronchial Tumors, Burkitt Lymphoma, Carcinoid Tumor,
Carcinoma of
Unknown Primary, Central Nervous System Cancer, Cervical Cancer, Childhood
Cancers,
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia
(CML),
Chronic My eloproliferative Disorders, Colon Cancer, Colorectal Cancer,
Craniopharyngioma,
Cutaneous T-Cell Lymphoma, Ductal Carcinoma In Situ (DCIS), Embryonal Tumors,
En dom etri al Cancer, Ependym obl astom a, Ep en dym
om a, Esophageal Cancer,
Esthesioneuroblastoma, Ewing Sarcoma, Extracranial Germ Cell Tumor,
Extragonadal Germ Cell
Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer, Fibrous Histiocytoma of
Bone, Gallbladder
Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal
Stromal Tumors
(GIST), Germ Cell Tumor, Ovarian Germ Cell Tumor, Gestational Trophoblastic
Tumor, Glioma,
Hairy Cell Leukemia, Head and Neck Cancer, Heart Cancer, Hepatocellul ar
Cancer, Hi sti ocytosi s,
Langerhans Cell Cancer, Hodgkin Lymphoma, Hypopharyngeal Cancer, Intraocular
Melanoma,
Islet Cell Tumors, Kaposi Sarcoma, Kidney Cancer, Langerhans Cell
Histiocytosis, Laryngeal
Cancer, Leukemia, Lip and Oral Cavity Cancer, Liver Cancer, Lobular Carcinoma
In Situ (LCIS),
Lung Cancer, Lymphoma, AIDS-Related Lymphoma, Macroglobulinemia, Male Breast
Cancer,
Medulloblastoma, Medulloepithelioma, Melanoma, Merkel Cell Carcinoma,
Malignant
Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Midline
Tract Carcinoma
Involving NUT Gene, Mouth Cancer, Multiple Endocrine Neoplasia Syndrome,
Multiple
Myeloma/Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syndrome,
Myelodysplastic/NIyeloproliferative Neoplasm, Chronic Myelogenous Leukemia
(CML), Acute
Myeloid Leukemia (ANIL), Myeloma, Multiple Myeloma, Chronic My
eloproliferative Disorder,
Nasal Cavity Cancer, Paranasal Sinus Cancer, Nasopharyngeal Cancer,
Neuroblastom a, Non-
Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cancer, Oral Cavity Cancer,
Lip Cancer,
Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Cancer,
Papillomatosis,
Paraganglioma, Paranasal Sinus Cancer, Nasal Cavity Cancer, Parathyroid
Cancer, Penile Cancer,
Pharyngeal Cancer, Ph eoch rom ocytom a, Pineal Parenchymal Tumors of
Intermediate
Differentiation, Pineoblastoma, Pituitary Tumor, Plasma Cell Neoplasm,
Pleuropulmonary
Blastoma, Breast Cancer, Primary Central Nervous System (CNS) Lymphoma,
Prostate Cancer,
Rectal Cancer, Renal Cell Cancer, Clear cell renal cell carcinoma, Renal
Pelvis Cancer, Ureter
Cancer, Transitional Cell Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary
Gland Cancer,
Sarcoma, Sezary Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine
Cancer, Soft
Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Neck Cancer with Occult
Primary,
Squamous Cell Carcinoma of the Head and Neck (HNSCC), Stomach Cancer,
Supratentorial
76
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Primitive Neuroectodermal Tumors, T-Cell Lymphoma, Testicular Cancer, Throat
Cancer,
Thymoma, Thymic Carcinoma, Thyroid Cancer, Transitional Cell Cancer of the
Renal Pelvis and
Ureter, Triple Negative Breast Cancer (TNBC), Gestational Trophoblastic Tumor,
Unknown
Primary, Unusual Cancer of Childhood, Urethral Cancer, Uterine Cancer, Uterine
Sarcoma,
Waldenstrom Macroglobulinemia, or Wilms Tumor.
[00295] In certain embodiments, the cancer is selected from bladder cancer,
breast cancer
(including TNBC), cervical cancer, colorectal cancer, chronic lymphocytic
leukemia (CLL),
diffuse large B-cell lymphoma (DLBCL), esophageal adenocarcinoma,
glioblastoma, head and
neck cancer, leukemia (acute and chronic), low-grade gli om a, lung cancer
(including
adenocarcinoma, non-small cell lung cancer, and squamous cell carcinoma),
Hodgkin's lymphoma,
non-Hodgkin lymphoma (NHL), melanoma, multiple myeloma (MM), ovarian cancer,
pancreatic
cancer, prostate cancer, renal cancer (including renal clear cell carcinoma
and kidney papillary cell
carcinoma), and stomach cancer.
[00296] In some embodiments, the cancer is small cell lung cancer, non-small
cell lung cancer,
colorectal cancer, multiple myeloma, acute myeloid leukemia (AML), acute
lymphoblastic
leukemia (ALL), pancreatic cancer, liver cancer, hepatocellular cancer,
neuroblastoma, other solid
tumors or other hematological cancers.
[00297] In some embodiments, the cancer is small cell lung cancer, non-small
cell lung cancer,
colorectal cancer, multiple myeloma, or AML.
[00298] The present invention further features methods and compositions for
the diagnosis,
prognosis and treatment of viral-associated cancers, including human
immunodeficiency virus
(HIV) associated solid tumors, human papilloma virus (1-IPV)-16 positive
incurable solid tumors,
and adult T-cell leukemia, which is caused by human T-cell leukemia virus type
I (HTLV-I) and
is a highly aggressive form of CD4+ T-cell leukemia characterized by clonal
integration of HTLV-
I in leukemic cells (See https://clinicaltrials.gov/ct2/show/study/
NCT02631746); as well as virus-
associated tumors in gastric cancer, nasopharyngeal carcinoma, cervical
cancer, vaginal cancer,
vulvar cancer, squamous cell carcinoma of the head and neck, and Merkel cell
carcinoma. (See
https://clinicaltrials.gov/ct2/show/study/NCT02488759; see
also
http s : //clinic al tri al s . gov/ct2/show/study/NC TO240886;
https://clinicaltrials.govict2/show!
NCT02426892)
77
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1002991 In some embodiments, the present invention provides a method for
treating a tumor in
a patient in need thereof, comprising administering to the patient compound I,
or a pharmaceutical
salt or composition thereof, and an immuno-oncology agent as described herein.
In some
embodiments, the tumor comprises any of the cancers described herein. In some
embodiments, the
tumor comprises melanoma cancer. In some embodiments, the tumor comprises
breast cancer. In
some embodiments, the tumor comprises lung cancer. In some embodiments the
tumor comprises
small cell lung cancer (SCLC). In some embodiments, the tumor comprises non-
small cell lung
cancer (NSCLC).
1003001 In some embodiments, the tumor is treated by arresting further growth
of the tumor. In
some embodiments, the tumor is treated by reducing the size (e.g., volume or
mass) of the tumor
by at least 5%, 10%, 25%, 50%, 75%, 90% or 99% relative to the size of the
tumor prior to
treatment. In some embodiments, tumors are treated by reducing the quantity of
the tumors in the
patient by at least 5%, 10%, 25%, 50%, 75%, 90% or 99% relative to the
quantity of tumors prior
to treatment.
1003011 In some embodiments, an eIF4E-mediated disorder, disease, and/or
condition is
obesity. See for example, Conn et al., "The major cap-binding protein elF4E
regulates lipid
homeostasis and diet-induced obesity," Nature Metabolism volume 3, pages 244-
257, the content
of which is incorporated herein by reference in its entirety.
1003021 In some embodiments, an eIF4E-mediated disorder, disease, and/or
condition is a
fibrotic disease. See for example, Nho et al., "Translational control of the
fibroblast-extracellular
matrix association: An application to pulmonary fibrosis," Translation 2013;
1: e23934, the
content of which is incorporated herein by reference in its entirety. In some
embodiments, an
elF4E-mediated disorder, disease, and/or condition is idiopathic pulmonary
fibrosis (IPF). In some
embodiments, an eIF4E-mediated disorder, disease, and/or condition is
pulmonary hypertension.
In some embodiments, an elF4E-mediated disorder, disease, and/or condition is
kidney fibrosis.
In some embodiments, an eIF4E-mediated disorder, disease, and/or condition is
liver fibrosis. In
some embodiments, an eIF4E-mediated disorder, disease, and/or condition is
osteogenesis
imperfecta. In some embodiments, an elF4E-mediated disorder, disease, and/or
condition is
scurby. In some embodiments, an elF4E-mediated disorder, disease, and/or
condition is
scleroderma or systemic sclerosis. In some embodiments, an elF4E-mediated
disorder, disease,
78
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
and/or condition is keloids. In some embodiments, a compound as described
herein is used to
control fibroblast-extracellular matrix association.
1003031 In some embodiments, an eIF4E-mediated disorder, disease, and/or
condition is a heart
disease. See for example, Zeitz et al., "Translating Translation to Mechanisms
of Cardiac
Hypertrophy," J. Cardiovasc. Dev. Dis. 2020, 7, 9; doi:10.3390/jcdd7010009,
the content of which
is incorporated herein by reference in its entirety. In some embodiments, an
elF4E-mediated
disorder, disease, and/or condition is cardiac hypertrophy. In some
embodiments, an elf4E-
mediated disorder, disease, and/or condition is heart failure. In some
embodiments, an eIF4E-
mediated disorder, disease, and/or condition is arrhythmia. In some
embodiments, an eIF4E-
mediated disorder, disease, and/or condition is ischemia. In some embodiments,
an efF4E-
mediated disorder, disease, and/or condition is cardiac stress.
1003041 In some embodiments, an eIF4E-mediated disorder, disease, and/or
condition is pain
or neuroinflammation. See for example, Mody et al., "eIF4E phosphorylation
modulates pain and
neuroinflammation in the aged,- GeroScience (2020) 42:1663-1674, the content
of which is
incorporated herein by reference in its entirety. In some embodiments, an
eIF4E-mediated
disorder, disease, and/or condition is chronic pain. In some embodiments, an
eIF4E-mediated
disorder, disease, and/or condition is acute pain. In some embodiments, an
eIF4E-mediated
disorder, disease, and/or condition is inflammatory pain in the aged. In some
embodiments, an
eIF4E-mediated disorder, disease, and/or condition is neuropathic pain. In
some embodiments, an
eIF4E-mediated disorder, disease, and/or condition is age-associated low-grade
inflammation. In
some embodiments, an efF4E-mediated disorder, disease, and/or condition is
chronic
inflammation. In some embodiments, an eIF4E-mediated disorder, disease, and/or
condition is
acute inflammation.
1003051 In some embodiments, an eIF4E-mediated disorder, disease, and/or
condition is an
inflammatory disease. See for example, William et al., "eIF4E-Binding Proteins
1 and 2 Limit
Macrophage Anti-Inflammatory Responses through Translational Repression of IL-
10 and
Cyclooxygenase-2," J Immunol 2018; 200:4102-4116, the content of which is
incorporated herein
by reference in its entirety. In some embodiments, an eIF4E-mediated disorder,
disease, and/or
condition is an auto-immune disease.
1003061 In some embodiments, an eIF4E-mediated disorder, disease, and/or
condition is
Alzheimer's disease (AD). See for example, Ghosh et al., "Alzheimer's disease-
related
79
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
dysregulation of mRNA translation causes key pathological features with
ageing," Translational
Psychiatry (2020) 10:192, the content of which is incorporated herein by
reference in its entirety.
In some embodiments, an eIF4E-mediated disorder, disease, and/or condition is
a
neurodegenerative condition. In some embodiments, a compound as described
herein is used to
reduce or remove Amyloid-13 (A13) plaques and/or phosphorylated tau tangles.
Viral Infections
[00307] In certain embodiments, an efF4E-mediated disorder, disease, and/or
condition is an
viral infection. Accordingly, in certain embodiments, the present invention
provides a method for
treating a viral infection comprising administering to a patient in need
thereof a compound of the
present invention, or pharmaceutically acceptable composition thereof. In some
embodiments, a
viral infection is a viral infection of the respiratory tract. In some
embodiments, a viral infection
is an upper respiratory tract infection. In some embodiments, a viral
infection is a lower respiratory
tract infection.
[00308] In some embodiments, the present invention provides a method for
treating a disease
or condition associated with a viral infection, comprising administering to a
patient in need thereof
a compound of the present invention, or pharmaceutically acceptable
composition thereof. In some
embodiments, a disease or condition associated with a viral infection is
pneumonia.
[00309] In certain embodiments, the present invention provides a method for
inhibiting viral
replication comprising administering to a patient in need thereof a compound
of the present
invention, or pharmaceutically acceptable composition thereof
[00310] As used herein, the term "virus" refers to microscopic infectious
organism that
reproduces inside living cells. A virus consists essentially of a core of
nucleic acid surrounded by
a protein coat, and has the ability to replicate only inside a living cell,
for example as a viral
infection.
[00311] As used herein, the term "viral replication" refers to the
production of additional virus
by the occurrence of at least one viral life cycle. A virus, for example
during a viral infection, may
subvert the host cells normal functions, causing the cell to behave in a
manner determined by the
virus. For example, a viral infection may result in a cell producing a
cytokine, or responding to a
cytokine, when the uninfected cell does not normally do so. Many viruses (e.g.
influenza and many
animal viruses) have viral envelopes covering their protein capsids. The
envelopes typically are
derived from portions of the host cell membranes (phospholipids and proteins),
but include some
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
viral glycoproteins. Functionally, viral envelopes are used to help viruses
enter host cells.
Glycoproteins on the surface of the envelope serve to identify and bind to
receptor sites on the
host's membrane. The viral envelope then fuses with the host's membrane,
allowing the capsid and
viral genome to enter and infect the host.
1003121 In some embodiments, a virus is an enveloped virus selected from DNA
viruses, such
as Herpesviruses, Poxviruses, and Hepadnaviruses; RNA viruses, such as
Flavivirus, Togavirus,
Coronavirus, Hepatitis D, Orthomyxovirus, Paramyxovirus, Rhabdovirus,
Bunyavirus, Filovirus
and Retroviruses.
1003131 In some embodiments, a virus is a human pathogen, such as influenza,
RSV, HIV,
Rotavirus, New Castle Disease Virus, Marek Disease Virus, Metapneumovirus,
Parainfluenza
viruses, Coronaviruses (including for example, SARS-CoV, SARS-CoV-2, HcoV-
HKU1, HcoV-
NL63 and TGEV), Hepatitis C virus, Flaviviruses (such as Dengue virus,
Japanese Encephlitis
virus, Kunjin virus, Yellow fever virus and West Nile virus), Filoviruses
(such as Ebola virus and
Marburg Virus), Caliciviruses (including Norovirus and Sapovirus), Human
Papilloma Virus,
Epstein Barr Virus, Cytomegalovirus, Varicella Zoster virus, and Herpes
Simplex Virus amon,
Birnaviridae, Chrysoviridae, Cystoviridae, Hypoviridae, Partitiviridae,
Reoviridae (such as
Rotavirus), Totiviridae, Nidovirales, Arteriviridae, Coronaviridae (such as
Coronavirus and
SARS), Roniviridae, Astroviridae, Barnaviridae, Bromoviridae, Caliciviridae,
Closteroviridae,
Comoviridae, Dicistroviridae, Flaviviridae (such as Yellow fever virus, West
Nile virus, Hepatitis
C virus, and Dengue fever virus), Flexiviridae, Hepeviridae (such as Hepatitis
E virus),
Leviviridae, Luteoviridae, Marnaviridae, Narnaviridae, Nodaviridae
Picornaviridae (such as
Poliovirus, the common cold virus, and Hepatitis A virus), Potyviridae,
Sequiviridae, Tetraviridae,
Togaviridae (such as Rubella virus and Ross River virus), Tombusviridae, and
Tymoviridael,
Bornaviridae (such as Boma disease virus), Filoviridae (such as Ebola virus
and Marburg virus,
Paramyxoviridae (such as Measles virus, and Mumps virus), Rhabdoviridae (such
as Rabies virus),
Arenaviridae (such as Lassa fever virus), Bunyaviridae (such as Hantavirus),
and
Orthomyxoviridae (such as Influenza viruses).
1003141 In some embodiments, a virus is a coronavirus. In some embodiments, a
coronavirus
is selected from the following:
= Alphacoronavirus
o Colacovirus
81
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Bat coronavirus CDPHE15
o Decacovirus
Bat coronavirus HKU10
Rhinolophus ferrumequinum alphacoronavirus HuB-2013
o Duvinacovirus
Human coronavirus 229E
o Luchacovirus
Lucheng Rn rat coronavirus
o Minacovirus
Ferret coronavirus
Mink coronavirus 1
o Minunacovirus
Miniopterus bat coronavirus 1
Miniopterus bat coronavirus HKU8
o Myotacovirus
Myotis ricketti alphacoronavirus Sax-2011
o Nyctacovirus
Nyctalus velutinus alphacoronavirus SC-2013
o Pedacovirus
Porcine epidemic diarrhea virus
Scotophilus bat coronavirus 512
o Rhinacovirus
1-?hinolophus bat coronavirus HKU2
o Setracovirus
Human coronavirus NL63
NL63-related bat coronavirus strain BtKYNI,63-9b
o Tegacovirus
Alphacoronavirus 1 ¨ type species
= Betacoronavirus
o Embecovirus
Betacoronavirus 1
82
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Human coronavirus 0C43
China Rattus coronavirus HKU24
Human coronavirus HKUI
Murine coronavirus ¨ type species
o Hibecovirus
Bat Hp-betacoronavirus Zhejiang2013
o Merbecovirus
Hedgehog coronavirus 1
Middle East respiratory syndrome-related coronavirus (MERS-CoV)
Pipistrellus bat coronavirus HKU5
Tylonycteris bat coronavirus HKU4
o Nobecovirus
Rouse ttus bat coronavirus GCCDC I
Rouse ttus bat coronavirus HKU9
o Sarbecovirus
Severe acute respiratory syndrome-related coronavirus
Severe acute respiratory syndrome coronavirus (SARS-CoV)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2,
COVID-19)
= Deltacoronavirus
o Andecovirus
Wigeon coronavirus HKU20
o Buldecovirus
Bulbul coronavirus HKU1 1 ¨ type species
Porcine coronavirus HKU15
Munia coronavirus HKU13
White-eye coronavirus HKU16
o Herdecovirus
Night heron coronavirus HKU19
o Moordecovirus
Common moorhen coronavirus HKU2 I
83
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
= Gammacoronavirus
o Cegacovirus
Beluga whale coronavirus SW I
o Igacovirus
Avian coronavirus ¨ type species
1003151
In some embodiments, a coronavirus is SARS-CoV (severe acute
respiratory
syndrome coronavirus) In some embodiments, a coronavirus is SARS-CoV-2, which
is the virus
string caused COVID-19 (Coronavirus Disease-2019).
1003161 In some embodiments, a virus is a human rhinovirus. In some
embodiments, a virus is
an influenza virus. In some embodiments, a virus is a picornavirus (e.g.,
rhinovirus). In some
embodiments, a virus is a human parainfluenza virus. In some embodiments, a
virus is a human
respiratory syncytial virus. In some embodiments, a virus is an adenovirus. In
some embodiments,
a virus is an enterovirus. In some embodiments, a virus is a metapneumovirus.
1003171 In some embodiments, a virus is selected from the group consisting of
Ebola and
Marburg virus (Filoviridae); Ross River virus, chikungunya virus, Sindbis
virus, eastern equine
encephalitis virus (Togaviridae, Alphavirus), vesicular stomatitis virus
(Rhabdoviridae,
Vesiculovirus), Amapari virus, Pichinde virus, Tacaribe virus, Junin virus,
Machupo virus
(Arenaviridae, Mammarenavirus), West Nile virus, dengue virus, yellow fever
virus (Flaviviridae,
Flavivirus); human immunodeficiency virus type 1 (Retroviridae, Lentivirus);
Moloney murine
leukemia virus (Retroviridae, Gammaretrovirus); influenza A virus
(Orthomyxoviridae);
respiratory syncyti al virus (Paramyxovi ri dae, Pneum ovirinae, Pneum
ovirus); vaccini a virus
(Poxviridae, Chordopoxvirinae, Orthopoxvinis); herpes simplex virus type 1,
herpes simplex virus
type 2 (Herpesviridae, Alphaherpesvirinae, Simplexvirus), human
cytomegalovirus
(Herpesviridae, Betaherpesvirinae, Cytomegalovirus); Autographa
californica
nucleopolyhedrovirus (Baculoviridae, Alphabaculoviridae) (an insect virus);
Ebola and Marburg
virus (Filoviridae); Semliki Forest virus, Ross River virus, chikungunya
virus, O'nyong-nyong
virus, Sindbis virus, eastern/western/Venezuelan equine encephalitis virus
(Togaviridae,
Alphavirus); rubella (German measles) virus (Togaviridae, Rubivirus); rabies
virus, Lagos bat
virus, Mokola virus (Rhabdoviridae, Lyssavirus); Amapari virus, Pichinde
virus, Tacaribe virus,
Junin virus, Machupo virus, Guanarito virus, Sabia virus, Lassa virus
(Arenaviridae,
Mammarenavirus); West Nile virus, dengue virus, yellow fever virus, Zika
virus, Japanese
84
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
encephalitis virus, St. Louis encephalitis virus, tick-borne encephalitis
virus, Omsk hemorrhagic
fever virus, Kyasanur Forest virus (Flaviviridae, Flavivirus); human hepatitis
C virus (Flaviviridae,
Hepacivirus); human immunodeficiency virus type 1 (Retroviridae, Lentivirus);
influenza A/B
virus (Orthomyxovi ri dae, the comm on Flu virus); respiratory syncyti al
virus (Paramyxoviridae,
Pneumovirinae, Pneumovirus); Hendra virus, Nipah virus (Paramyxoviridae,
Paramyxovirinae,
Henipavirus); measles virus (Paramyxoviridae, Paramyxovirinae, Morbillivirus);
variola major
(smallpox) virus (Poxviridae, Chordopoxvirinae, Orthopoxvirus); human
hepatitis B virus
(Hepadnaviridae, Orthohepadnavirus); hepatitis delta virus (hepatitis D virus)
(unassigned Family,
Deltavirus); herpes simplex virus type 1, herpes simplex virus type 2
(Herpesviridae,
Alphaherpesvirinae, Simplexvinis); human cytomegalovinis (Herpesviridae,
Betaherpesvirinae,
Cytomegalovirus).
1003181 In some embodiments, a virus is selected from the following virus
families:
= Adenoviridae, Papillomaviridae, Polyomaviridae, Herpesviridae and
Poxviridae; these
include, but are not limited to: adenovirus, herpes simplex-1, herpes simplex-
2, Varicella-
zoster, Epstein-Barr virus, cytomegalovirus, human herpes virus 8, human
papilloma virus,
BK virus, JC virus, chicken pox and small pox;
= Hepadnaviridae, including, but not limited to hepatitis B virus;
= Parvoviridae, including but not limited to human bocavirus and parvovirus
B19;
= Astroviridae, Caliciviridae, Picornaviridae, Coronoviridae, Flaviviridae,
Retroviridae,
Togaviridae, Hepeviridae; these include, but are not limited to human
astrovirus, Norwalk
virus, coxsackievirus, hepatitis A, poliovirus, rhinovirus, severe acute
respiratory
syndrome virus (SARS), hepatitis C virus, yellow fever virus, dengue virus,
West Nile
virus, Rubella virus, hepatitis E virus Arenaviridae, Bunyaviridae,
Filoviridae,
Orthomyxoviridae, Paramyxoviridae and Rhabdoviridae; these include, but are
not limited
to influenza virus, Guanarito virus, Junin virus, Lassa virus, Machupo virus,
Sabia virus,
Cimean-Congo hemorrhagic fever virus, Ebola virus, Marburg virus, Measelse
virus,
Mumps virus, Parainfluenza virus Respiratory syncytial virus, human
metapneumovirus,
Hendra virus, Hipah virus, Rabies virus, Reoviridae including but not limited
to Toravirus,
Orbivirus, Coltivirus, Banna virus. Hepatitis D virus. Additional viruses
include:
Rhabdoviridae, including, but not limited to vesicular stomatitis virus.
Picornaviridae,
including, but not limited to Foot and mouth disease virus, Pestiviridae
including, but not
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
limited to Classical swine fever and Bovine viral diarrhea. Arteriviridae
including, but not
limited to equine arteritis virus, porcine reproductive and respiratory
syndrome virus,
lactate dehydrogenase elevating virus and simian haemorrhagic fever virus.
Coronaviridae
including, but not limited to infectious bronchitis virus, transmissible
gastroenteritis
coronoavirus, bovine coronavirus, feline coronavirus, canine coronavirus,
moust hepatitis
virus, Toroviridae including, but not limited to Berne virus, Breda virus.
Orthomyxoviridae
including, but not limited to avian influenza virus, swine influenza virus.
Reoviridae
including, but not limited to Bluetongue virus. Clroviridae including, but not
limited to
chicken anemia virus, porcine circovi rus- 1, porcine ci rovirus-2, psittacine
beak and feather
disease virus, pigeon circovinis, canary circovirus and goose circovinis.
Asfarviridae
including, but not limited to African swin fever virus. Retroviridae
including, but not
limited to Avian leucosis virus, Rous sarcoma virus, mouse mammary tumor
virus, murine
leukemia virus, feline leukemia virus, boine leukemia virus, Walleye dermal
sarcoma virus,
Simian and feline immunodeficiency viruses, simian foamy virus. Flaviviridae
including,
but not limited to Tick-borne encephalitis virus, Japanese encephalitis virus,
St. Louis
encephalitis virus, Israel turkey meningoencephalomyelitis virus, Sitiawan
virus,
Wesselsbron virus and louping ill virus. Paramyxoviridae including, but not
limited to
canine distemper virus, phocine distemper virus, cetacean morbillivirus,
Newcastle disease
virus, rinder pest virus. Most Confirmed PS-Interception-Susceptible Enveloped
Viruses
are RNA Viruses: Ebola and Marburg virus (Filoviridae); Ross River virus,
chikungunya
virus, Sindbis virus, eastern equine encephalitis virus (Togaviridae,
Alphavirus), vesicular
stomatitis virus (Rhabdoviridae, Vesiculovirus), Amapari virus, Pichinde
virus, Tacaribe
virus, Junin virus, Machupo virus (Arenaviridae, Mammarenavirus), West Nile
virus,
dengue virus, yellow fever virus (Flaviviridae, Flavivirus); human
immunodeficiency virus
type 1 (Retroviridae, Lentivirus); Moloney murine leukemia virus
(Retroviridae,
Gammaretrovirus); influenza A virus (Orthomyxoviridae); respiratory syncytial
virus
(Paramyxoviridae, Pneumovirinae, Pneumovirus) Confirmed PS-Interception-
Susceptible
Enveloped DNA Viruses are: vaccinia virus (Poxviridae, Chordopoxvirinae,
Orthopoxvirus); herpes simplex virus type 1, herpes simplex virus type 2
(Herpesviridae,
Alphaherpesvirinae, Simplexvirus); human cytomegalovirus (Herpesviridae,
Betaherpesvirinae, Cytomegalovirus); Autographa californica
nucleopolyhedrovirus
86
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
(Baculoviridae, Alphabaculoviridae) (an insect virus) Prospected PS-
Interception-
Susceptible Important Enveloped RNA Viruses are: Ebola and Marburg virus
(Filoviridae);
Semliki Forest virus, Ross River virus, chikungunya virus, O'nyong-nyong
virus, Sindbis
virus, eastern/western/Venezuelan equine encephalitis virus (Togaviridae,
Alphavirus);
rubella (German measles) virus (Togaviridae, Rubivirus); rabies virus, Lagos
bat virus,
Mokola virus (Rhabdoviridae, Lyssavirus); Amapari virus, Pichinde virus,
Tacaribe virus,
Junin virus, Machupo virus, Guanarito virus, Sabia virus, Lassa virus
(Arenaviridae,
Mammarenavirus); West Nile virus, dengue virus, yellow fever virus, Zika
virus, Japanese
encephalitis virus, St Louis encephalitis virus, tick-borne encephalitis
virus, Omsk
hemorrhagic fever virus, Kyasanur Forest virus (Flaviviridae, Flavivints);
human hepatitis
C virus (Flaviviridae, Hepacivirus); human immunodeficiency virus type 1
(Retroviridae,
Lentivirus), influenza A/B virus (Orthomyxoviridae, the common flu virus),
respiratory
syncytial virus (Paramyxoviridae, Pneumovirinae, Pneumovirus), Hendra virus,
Nipah
virus (Paramyxoviridae, Paramyxovirinae, Henipavirus); measles virus
(Paramyxoviridae,
Paramyxovirinae, Morbillivirus) Prospected PS-Interception-Susceptible
Enveloped DNA
Viruses are: variola major (smallpox) virus (Poxviridae, Chordopoxvirinae,
Orthopoxvirus); human hepatitis B virus (Hepadnaviridae, Orthohepadnavirus);
hepatitis
delta virus (hepatitis D virus) (unassigned Family, Deltavirus); herpes
simplex virus type
1, herpes simplex virus type 2 (Herpesviridae, Alphaherpesvirinae,
Simplexvirus); human
cytom egal ovirus (Herpesviri dae, Betaherpesvirinae, Cytom egal ovirus)
[00319] In some embodiments, the present invention provides a method for
treating a viral
infection, which comprises treating diseases caused by viral induced or
associated injuries and
diseases (necrosis, inflammation, sclerosis) in tissues including, but not
limited to: eye (retina,
sclera, lens, iris, pupil, cornea, macula, retinal blood vessels, optic
nerve), ear (ear canal, bones of
middle ear, tympanic membrane, Eustachian, cochlear nerve, vestibular nerve,
semicircular canals,
cochlea), nose (naris, vestibule, turbinates, sinuses), oral cavity and
oropharynx (lips, gingiva, hard
and soft palates, salivary glands, uvula, tonsils, adenoids, teeth), central
nervous system and
associated structures (brain, cerebrum, cerebellum, olvactory bulb,
hypothalamus, reticular
formation, medulla oblongata, meninges, ventricles, thalamus, pineal gland),
peripheral and
enteric nervous systems (autonomic nerves, sympathetic nerves, parasympathetic
nerves, sensory
nerves, ganglion cells, ganglia), skin (epidermis, dermis, adnexal structures,
sebaceous glands, hair
87
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
follicles, stratum corneum, granular cells, spinous cells, sweat glands),
respiratory tract (larynx,
trachea, bronchi, bronchioles, lung, alveoli, pleura), digestive tract
(pharynx, esophagus, stomach,
small intestine, duodenum, jejunum, ileum, colon, rectum, appendix, anus),
liver (intra- and extra-
hepatic bile ducts, gallbladder, liver, hepatocytes, ductules, canals of
Hering), pancreas (endocrine
pancreas, exocrine pancreas, pancreatic ducts, pancreatic acini), urinary
tract (renal cortex, renal
tubules, renal pelvis, glomeruli, ureters, urinary bladder, urethra), male
genital tract (prostate,
testes, scrotum, epididymis, vas deferens, glans, foreskin, corpus spongiosum,
corpus cavernosum,
Cowper's gland), female genital tract (ovary, fimbria, fallopian tubes,
uterus, endometrium,
endocervix, endocervical glands, cervix, ectocervix, vagina, labia, placenta),
endocrine system
(pineal glands, pituitary gland, thyroid gland, parathyroid glands, adrenal
glands, adrenal cortex,
adrenal medulla), cardiovascular system (heart, pericardium, myocardium,
endocardium, atria,
ventricles, coronary arteries, tricuspid valve, aortic valve, mitral valve,
pulmonic valve, aorta,
arteries, arterioles, capillaries, venules, veins, inferior vena cava,
superior vena cava, pulmonary
artery, pulmonic vein), musculoskeletal system (bones, tendons, ligaments,
skeletal muscle,
smooth muscle, fascia) and blood (platelets, red blood cells, white blood
cells, and all their
precursors, and bone marrow).
1003201 In certain embodiments, a compound or a composition of the invention
is administered
nasally to a patient. In other embodiments, a compound or a composition of the
invention is
administered to a patient through pulmonary inhalation.
1003211 The compounds and compositions, according to the method of the present
invention,
may be administered using any amount and any route of administration effective
for treating or
lessening the severity of a disease, disorder, and/or condition. The exact
amount required will
vary from subject to subject, depending on the species, age, and general
condition of the subject,
the severity of the disease or condition, the particular agent, its mode of
administration, and the
like. The compounds and compositions, according to the method of the present
invention, are
preferably formulated in dosage unit form for ease of administration and
uniformity of dosage.
The expression "dosage unit form" as used herein refers to a physically
discrete unit of agent
appropriate for the patient to be treated. It will be understood, however,
that the total daily usage
of the compounds and compositions will be decided by the attending physician
within the scope
of sound medical judgment. The specific effective dose level for any
particular patient or organism
will depend upon a variety of factors including the disorder being treated and
the severity of the
88
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
disorder; the activity of the specific compound employed; the specific
composition employed; the
age, body weight, general health, sex and diet of the patient; the time of
administration, route of
administration, and rate of excretion of the specific compound employed; the
duration of the
treatment; drugs used in combination or coincidental with the specific
compound employed, and
like factors well known in the medical arts. The term "patient", as used
herein, means an animal,
preferably a mammal, and most preferably a human.
[00322] Pharmaceutically acceptable compositions of this invention can be
administered to
humans and other animals orally, rectally, parenterally, intracisternally,
intravaginally,
intraperitoneally, topically (as by powders, ointments, or drops), bucally, as
an oral or nasal spray,
or the like, depending on the severity of the disease or disorder being
treated. In certain
embodiments, the compounds of the invention may be administered orally or
parenterally at
dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about
1 mg/kg to about
25 mg/kg, of subject body weight per day, one or more times a day, to obtain
the desired
therapeutic effect.
1003231 Liquid dosage forms for oral administration include, but are not
limited to,
pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions,
syrups and
elixirs. In addition to the active compounds, the liquid dosage forms may
contain inert diluents
commonly used in the art such as, for example, water or other solvents,
solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl
acetate, benzyl alcohol,
benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide,
oils (in particular,
cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol,
tetrahydrofurfuryl
alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures
thereof Besides inert
diluents, the oral compositions can also include adjuvants such as wetting
agents, emulsifying and
suspending agents, sweetening, flavoring, and perfuming agents.
[00324] Injectable preparations, for example, sterile injectable aqueous or
oleaginous
suspensions may be formulated according to the known art using suitable
dispersing or wetting
agents and suspending agents. The sterile injectable preparation may also be a
sterile injectable
solution, suspension or emulsion in a nontoxic parenterally acceptable diluent
or solvent, for
example, as a solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be
employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride
solution. In addition,
sterile, fixed oils are conventionally employed as a solvent or suspending
medium. For this purpose
89
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
any bland fixed oil can be employed including synthetic mono- or diglycerides.
In addition, fatty
acids such as oleic acid are used in the preparation of injectables.
[00325] Injectable formulations can be sterilized, for example, by
filtration through a bacterial-
retaining filter, or by incorporating sterilizing agents in the form of
sterile solid compositions
which can be dissolved or dispersed in sterile water or other sterile
injectable medium prior to use.
[00326] In order to prolong the effect of a compound as described herein, it
is often desirable
to slow the absorption of the compound from subcutaneous or intramuscular
injection. This may
be accomplished by the use of a liquid suspension of crystalline or amorphous
material with poor
water solubility. The rate of absorption of the compound then depends upon its
rate of dissolution
that, in turn, may depend upon crystal size and crystalline form.
Alternatively, delayed absorption
of a parenterally administered compound form is accomplished by dissolving or
suspending the
compound in an oil vehicle. Injectable depot forms are made by forming
microencapsule matrices
of the compound in biodegradable polymers such as polylactide-polyglycolide.
Depending upon
the ratio of compound to polymer and the nature of the particular polymer
employed, the rate of
compound release can be controlled. Examples of other biodegradable polymers
include
poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also
prepared by
entrapping the compound in liposomes or microemulsions that are compatible
with body tissues.
[00327] Compositions for rectal or vaginal administration are preferably
suppositories which
can be prepared by mixing the compounds of this invention with suitable non-
irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a suppository wax
which are solid at
ambient temperature but liquid at body temperature and therefore melt in the
rectum or vaginal
cavity and release the active compound.
1003281 Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and
granules. In such solid dosage forms, the active compound is mixed with at
least one inert,
pharmaceutically acceptable excipient or carrier such as sodium citrate or
dicalcium phosphate
and/or a) fillers or extenders such as starches, lactose, sucrose, glucose,
mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates, gelatin,
polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol,
d) disintegrating
agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic
acid, certain silicates,
and sodium carbonate, e) solution retarding agents such as paraffin, f)
absorption accelerators such
as quaternary ammonium compounds, g) wetting agents such as, for example,
cetyl alcohol and
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i)
lubricants such as
talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium
lauryl sulfate, and
mixtures thereof. In the case of capsules, tablets and pills, the dosage form
may also comprise
buffering agents.
1003291 Solid compositions of a similar type may also be employed as
fillers in soft and hard-
filled gelatin capsules using such excipients as lactose or milk sugar as well
as high molecular
weight polyethylene glycols and the like. The solid dosage forms of tablets,
dragees, capsules,
pills, and granules can be prepared with coatings and shells such as enteric
coatings and other
coatings well known in the pharmaceutical formulating art. They may optionally
contain
pacifying agents and can also be of a composition that they release the active
ingredient(s) only,
or preferentially, in a certain part of the intestinal tract, optionally, in a
delayed manner. Examples
of embedding compositions that can be used include polymeric substances and
waxes. Solid
compositions of a similar type may also be employed as fillers in soft and
hard-filled gelatin
capsules using such excipients as lactose or milk sugar as well as high
molecular weight
polethylene glycols and the like.
1003301 The active compounds can also be in micro-encapsulated form with one
or more
excipients as noted above. The solid dosage forms of tablets, dragees,
capsules, pills, and granules
can be prepared with coatings and shells such as enteric coatings, release
controlling coatings and
other coatings well known in the pharmaceutical formulating art. In such solid
dosage forms the
active compound may be admixed with at least one inert diluent such as
sucrose, lactose or starch.
Such dosage forms may also comprise, as is normal practice, additional
substances other than inert
diluents, e.g., tableting lubricants and other tableting aids such a magnesium
stearate and
microcrystalline cellulose. In the case of capsules, tablets and pills, the
dosage forms may also
comprise buffering agents. They may optionally contain opacifying agents and
can also be of a
composition that they release the active ingredient(s) only, or
preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of embedding
compositions that can be
used include polymeric substances and waxes.
1003311 Dosage forms for topical or transdermal administration of a compound
of this invention
include ointments, pastes, creams, lotions, gels, powders, solutions, sprays,
inhalants or patches.
The active component is admixed under sterile conditions with a
pharmaceutically acceptable
carrier and any needed preservatives or buffers as may be required. Ophthalmic
formulation, ear
91
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
drops, and eye drops are also contemplated as being within the scope of this
invention.
Additionally, the present invention contemplates the use of transdermal
patches, which have the
added advantage of providing controlled delivery of a compound to the body.
Such dosage forms
can be made by dissolving or dispensing the compound in the proper medium.
Absorption
enhancers can also be used to increase the flux of the compound across the
skin. The rate can be
controlled by either providing a rate controlling membrane or by dispersing
the compound in a
polymer matrix or gel.
1003321 The following examples are provided for illustrative purposes only and
are not to be
construed as limiting this invention in any manner.
EXEMPLIFICATION
1003331 As depicted in the Examples below, in certain exemplary embodiments,
compounds
are prepared according to the following general procedures. It will be
appreciated that, although
the general methods depict the synthesis of certain compounds of the present
invention, the
following general methods, and other methods known to one of ordinary skill in
the art, can be
applied to all compounds and subclasses and species of each of these
compounds, as described
herein.
Example 1. Synthesis of Certain Compounds
Scheme 1: Route for Compound 787
Br ) _es
0 10 ..OB AJ
________________________________________________________ 0
¨0
Pd(dppf)Cl2, Na2003,
¨N
dioxane, H20, 85 C, 16 h 0
H2N ¨N
H2N
SM
787
Scheme 2: Route for Compounds 723-s, 730-s, 736-s, 737-s, 745-5, 757-s
92
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
OH 0 0
)MgBr
____________________________ F
F0 .-
THF, rt, overnight k PCC F 0
CH2Cl2, rt, 2 r ... i ... PTAT F
THF, rt, 16 IT )...õ
F 0 F 0 F 0
Br
723-1 723-2 723-3
723-4
0 S
NaSCNlIlIII HBr
...- F 3- Br---<,
Et0H, 80 C, 3 h k
SCN AcOH, 50 C, 1 h N F
F 0
723-5 723-s
r
_______________________________________________________________________________
,
S S S S
S
Br---4. 1 Br---4 Br-- Br F Br--4
1
N N F N F ---4, 1
N
0 0 F 0 F
0),F
F I CI F
730-s 736-s 737-s 745-s 757-
s
The same synthesis method used for other compounds 730-s, 736-s, 737-s, 745-s,
757-5.
,.
______________________________________________________________________________
.,
Scheme 3: Route for Compound 724-s
o 1 _
s Bi-----.N.-11.0-K, S S
Br-4 H 3. Br-4 I Mel, NaH .... Br___4
N K2003, DMF, 60 C, 16 h N THF, 60
C, 16 h N yoc
H
CI CI CI
568-8 724-1 724-s
Scheme 4: Route for Compound 726-s
O. 0,... HO 0
Cl lill CH3I
CI K2CO3, DMF, rt, 16 h i 1110 _______
Cl ,
THF, rt, overnight'''.
CI BrMg CI CI PCC
3,
CH2Cl2, rt, 1 h
CI CI
OH 0.-, CC 0
. =-=..
726-1 726-2 726-3
726-4
Br
S
0
S
PTAT H2ITA.NH2
..- 1... H2N¨ Cl
THF, rt, 1 h EtOH, 90 C, 1 h N
CI CI
0
0,... Cl I
726-5 726-s
Scheme 5: Route for Compound 731-s
93
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0 OH 0
0
I N BrMg"--J` PCC Br2
--. i =-= N --.
-'- I THE, rt, overnight I CH2Cl2, It, 2 h I CHCI3, 80 C,
16 h I
731-1 731-2 731-3 731-4
0
NaSCN HBr S CH3I S
..- Br --4 1 K2 Br--4
Et0H, 80 'C, 3 1 I AcOH, 40 'C, 1 h
\ SCN N i .õ.... CO3,
DMF, it, 16 h '
N i \
HO
Nr. OH
N 0
731-5 731-6
731-s
Scheme 6: Route for Compound 733-s
0 OH 0 0 S
I BrMg---j'r- PCC PTAT H2NANH2 S H2N ''.
4 1
0 THE, it, overnight el CH2C12, It, 2 h
THE, rt, 16 h Et0H, 70 C, 16 h N
Br
IP
733-1 733-2 733-3 733-4
733-5
S
t-BoONO, CuBr2 S 1313r, S F3C---0Tf
Br-4 1
Br---4.. 1 Br --4
MeCN, it, 2 h CH2C12, rt, 16 h K2CO3, DMF,
rt, 16 h N
N N
OH F F
733-6 733-7 733-s
Scheme 7: Route for Compounds 711-s, 746-s, 747-s, 751-s
S
Br¨µ \ _________________________________ 2... ,..,
r-4, 1
N K2CO3, DMF, rt, 16 h tiiN
OH 0'-==
733-7 741-s
..-
_______________________________________________________________________________
,
S S
S
Br Br-4. 1 Cl-
-µ N N
N
0r NH2
0--' -
0-'CI
0
746-s 747-s 751-s
The same synthesis method used for other compounds 746-s, 747-s, 751-s.
...
_______________________________________________________________________________
4
Scheme 8: Route for Compound 744-s
94
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0 0 OH 0
I Br
I
0 BrMg^-"1"' PCC
1110 seCalse2dCO2g,00MCF h A.,,, THE, it. 16 h A.... CH2Cl2,
rt, 2 h A.....
HO 0 0 0
744-1 744-2 744-3 744-4
0 S
-U,
PTAT . H2N NH2 S * H2N t-BuONO CuBr2
S
4 \ Br-4,
MeCN, it, 2 it
\
THF, it, 16 hEt0H, 70 `C, 12 it
Br N N
0
A
A
0
0
744-5 744-6
744-s
Scheme 9: Route for Compounds 749-s, 760-s, 772-s
0 OH 0 0
I A,,..,MgBr PCC PTAT
so THF, rt, 16 h'.. CH2Cl2, rt, 2 h... THF, rt, 16
Br
733-1 749-2 749-3 749-4
.-
_______________________________________________________________________________
__ .
0 S S
NaSCN HCl/dioxane 4 1
CI---4. I S
CI----(N F
Et0H 50 C 2 h 0 50 C 2 h N N s I
SCN
CY-
0.1,F
749-5 749-s 760-sE 772-s
The same synthesis method used for other compounds 760-s, 772-s,
Scheme 10: Route for Compound 750-s
0 OH 0
0
I A..._,MgBr 1-'0C PTAT
THE, rt, 16 h A,.. CH2Cl2, rt, 2 ri.A., THF, rt, 16 it
A,_
Br
0 0 0 0
744-2 750-1 750-2
750-3
S
s
H2NA NH2
_________________________ _ H2N---4, I
Et0H, 80 C, 2h N
..."
0
750-s
Scheme 11: Route for Compound 756-s
S S
CI¨ BBr3
__________________________________________________ 11, CI-4 1
N CH2C12, rt, overnight N
k..) OH
749-s 756-s
Scheme 12: Route for Compound 758-s
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
S S S
BBr, B r-.. t...) õ--...,..,-
-
Br 1 - __ 1.- Br¨µ 1 _____________________ 1.- Br¨µ
N CH2Cl2, rt, 5 h N K2CO3, DMF, it 16h
N
,,,--
F 0 F OH F 0-
-'''''' '`=
757-s 758-1
758-s
Scheme 13: Route for Compounds 761-s--764-s, 767-s, 770-s, 778-s--783-s, 791-s-
-792-s
o o OH o
1 I A.,_
F 40 .....õ---Br __ F MgBr .0 F PCC F
..- ...-
K2CO3, DMF, rt, 16 h THF, rt. 16 h ,, CH2Cl2, rt, 1 h
HO
761-1 761-2 761-3 761-4
0 0 S
PTAT F NaSCN F HCl/dioxane ci-4. 1
N
THF, rt, 1...tb Et0H, 90 C, 3 h rt, oyernig hi
Br 0 SCN
0 ."-------'0 _____________________________________________________ 0.----,-
0,
F
761-5 761-6 761-s
,- _______________________________________________________________________
S
S S
CI-4,µ 1 C1----- i CI-4. 1 S S
N C1--4. 1
N N CI-4 1
NI N
0'---'/0 0----N.'- -`
F
F F
762-s 763-s 764-s 767-s 770-
s
S S-
S S
CI ______________________________________ 4. S- i CI-4 1 a--4. 1
ci---4:. 1 ci--4. N N N N
N
F CI F
CI F
778-s 779-s 780-s 781-s 782-
s
\
0 S
S C I---4. \
S CI-4 1 N
CI--<s 1 N
F
N F F
0...--..õ0.,...
0,1
iI
F F L'O
783-s 791-s 792-s 1
The same synthesis method used for other compounds 762-s-764-s, 767-5, 770-s,
778-s-783-s, 791-s-792-s.
Scheme 14: Route for Compound 766-s
0
HCl/dioxane S
F 11.
I
.) '.. ,¨, S C N rt, overnight CI-4N F
F 1/4../
,...,..-1.
µ..." F
723-5 766-s
96
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Scheme 15: Route for Compounds I-1, 1-2, 1-5 to 1-16, 1-18, 1-20 to 1-52, 1-
54, 1-55, 1-57 to I-
59
(s/ /
ar.....fot,
s I -
NH2 ________________________________
N
N \ __ /N
Br ---4 1 ( S NaOH S
. 5 (
N Pd2(dba)3, x-phos, Cs2CO3, 0 HN¨ I
THF/Me0H, a. 2 h 0 HN¨<\ 1
Toluene, 110 C, 16 h / o N OH N
OH
CI OH I OH
568-8 721-2 CI I-1
CI
The same synthesis method used for other compounds 1-2, 1-510 1-16, 1-18, 1-
2010 1-52, 1-54, 1-55, 1-57 to 1-59.
Scheme 16: Route for Compounds 1-4 and 1-19
7 / 7
s - N
\ / S N
\ / S
H2N-4 1 CI N CI LICH ,--
N Pd2(dba)3, x-phos, Cs2CO3, 0 HN--4 1 HN-4. 1
CI THFiMe0H, rt, 2 h 0
CI
N N
Toluene, 110 C, 16 h o OH
/
CI
CI CI
1-4
The same synthesis method used for compound 1-19
Scheme 17: Route for Compound 1-3
7 / .7 / ei.c.2.() s s
--
---,s o
\ N ¨
, N
N _________________________________ NH2 \ / 3 HCl/dioxane \ /
3
Br--\\ I >
N Boc Pd2(dba)3, x-phos, Cs2CO3, , HN---4... rt, 4
h HN-4:, \
1 o N N Toluene, 110 "C, 16 h '''
N Boc 0
0 o i
H
/ /
o...,..._,..N.,....
CI
CI CI
724-s V 724-2 724-3
S 1
¨
N
LOH
THF/Me0H, rt, 2 h 0 HN---4 \
N
OH 1-1
oõ.--...,N,
CI
1-3
Scheme 18: Route for Compound 1-17
97
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
./
/ 0
S 1
S
I ''= OH ¨
S N
Br¨ I S
_________________________________________________ _
N Pd2(dba)3, x-phos, Cs2CO3,
0
NH2 Toluene, 110 C, 16 h N
OH
Off'
o,---...i.f,NH2
0
747-s 1-17 0
Scheme 19: Route for Compound 1-53
S
/ 1 0 v- /
S
S 1 '`=== 0"..
1 -- ¨
N
cI-4
N NH2 \ / s
I ________________________________________________ a-
N osoi Pd2(dba)3, x-phos, Cs2CO3, 0 HN----
\ 1
o,--13 Toluene, 120 C, 16 h 0 N 0
F ,
F
786-S 1-53
Scheme 20: Route for Compound 1-56
..--
i S /
S
¨ H _\
N \ ,N
\ / s H2N---"N'
HN--µ I TMA, toluene, rt, overnight HN HN¨/ I
0 0 N 0 /¨/ 0 N
/oõ..---...õ...õ0õ ¨NH
0"-----
F F
762-7 1-56
1003341 General information: All evaporations were carried out in vacno with a
rotary
evaporator. Analytical samples were dried in -memo (1-5 mmHg) at rt. Thin
layer chromatography
(TLC) was performed on silica gel plates, spots were visualized by UV light
(214 and 254 nm).
Purification by column and flash chromatography was carried out using silica
gel (200-300 mesh).
Solvent systems are reported as mixtures by volume. All NMR spectra were
recorded on a Bruker
400 (400 MHz) spectrometer. 1H chemical shifts are reported in 6 values in ppm
with the
deuterated solvent as the internal standard. Data are reported as follows:
chemical shift,
98
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad,
m = multiplet), coupling
constant (Hz), integration.
1003351 General information: All evaporations were carried out in
vacuo with a rotary evaporator.
Analytical samples were dried in vacuo (1-5 mmHg) at rt. Thin layer
chromatography (TLC) was performed
on silica gel plates, spots were visualized by UV light (214 and 254 inn).
Purification by column and flash
chromatography was carried out using silica gel (200-300 mesh). Solvent
systems are reported as mixtures
by volume. All NMR spectra were recorded on a Balker 400 (400 MHz)
spectrometer. 1H chemical shifts
are reported in 6 values in ppm with the deuterated solvent as the internal
standard. Data are reported as
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet,
q = quartet, br = broad, m =
multiple , coupling constant (Hz), integration.
1003361 LCMS spectra were obtained on an Agilent 1200 series 6110 or
6120 mass spectrometer with
electrospray ionization and excepted as otherwise indicated, the general LCMS
condition was as follows:
Method A (Agilent LCMS 1200-6110, Column: Waters X-Bridge C18 (50 mm x 4.6 mm
x 3.5
1..tm); Column Temperature: 40 C; Flow Rate: 3.0 mL/min; mobile phase: from
95% [water + 0.05% TFA]
and 5% [CH3CN +0.05% TFA] to 0% [water +0.05% TFA] and 100% [CH3CN +0.05% TFA]
in 0.8 min,
then under this condition for 0.4 min, finally changed to 95% [water + 0.05%
TFA] and 5% [CH3CN
0.05% TFA] in 0.01 min).
Method B (Agilent LCMS 1200-6110, Column: Waters X-Bridge C18 (50 mm x 4.6 mm
x 3.5
lam); Column Temperature: 40 C; Flow Rate: 2.0 mL/min; Mobile Phase: from 95%
[water + 0.05% TFA]
and 5% [CH3CN + 0.05% TFA] to 0% [water + 0.05% TFA] and 100% [CH3CN + 0.05 'A
TFA] in 1.6
min, then under this condition for 1.4 min, finally changed to 95% [water +
0.05% TFA] and 5% [CH3CN
+ 0.05% TFA] in 0.05 min and under this condition for 0.7 min.).
Method C (Agilent LCMS 1200-6120, Column: Waters X-Bridgc C18 (50 mm x 4.6 mm
x 3.5
tim); Column Temperature: 40 C; Flow Rate: 2.0 mL/min; Mobile Phase: from 95%
[water + 10 mM
NH4HC031 and 5% [CH3CN] to 0% [water + 10 mM NH4HC031 and 100% [CH3CN] in 1.6
min, then under
this condition for 1.4 min, finally changed to 95% [water + 10 mM NH4HCO3] and
5% [CH3CN] in 0.1
min and under this condition for 0.7 min.)
Method D (Agilent LCMS 1200-6120, Column: Waters X-Bridge CI8 (50 mm x 4.6 mm
x 3.5
lam); Column Temperature: 45 C; Flow Rate: 2.3 mL/min; Mobile Phase: from 95%
[water + 10 mM
NH4HC031 and 5% [CH3CN] to 0% [water + 10 mM NH4HC031 and 100% [CH3CN] in 1.75
min, then
under this condition for 0.8 min, finally changed to 95% [water + 10 mM
NH4HCO3] and 5% [CH3CN] in
0.1 min and under this condition for 0.1 min.)
Experimental Section
The synthesis of methyl 3-amino-6-(thiophen-2-yl)pyrazine-2-carboxylate (787)
99
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Br
0 N
________________________________________________ / 0 ¨S? N
¨0 ¨N Pd(dppf)C12, Na2CO3,
H2N
dioxane/H20, Ei5 C, 16 h
0 ¨N
H2N
SM
787
1003371 A mixture of SM (1.0 g, 4.31 mmol), 4,4,5,5-tetramethy1-2-(thiophen-2-
y1)-1,3,2-
dioxaborolane (1.36 g, 6.47 mmol), Pd(dppf)C12 (315 mg, 0.431 mmol) and Na2CO3
(1.84 g, 8.62 mmol)
in dioxane/H20 (v/v = 5/1, 10.0 mL) was stirred under N2 atmosphere at 85 C
for 16 h. When the reaction
was completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl
acetate = 3/1) to afford 787 (670 mg, 66.1% yield) as a brown solid.
The synthesis of 1-(4-(difluoromethoxy)pheny1)-3-methylbutan-1-01 (723-2)
OH
,.-^õr
F
F 0el THF, rt, oMgBvernight
F 0
723-1 723-2
1003381 To a solution of 723-1 (2.0 g, 11.6 mmol) in THF (20.0 mL) was added
isobutylmagnesium
bromide (1.0 M in THF, 17.4 mL, 17.4 mmol). The reaction was stirred at room
temperature overnight.
When the reaction was completed, it was poured into aq.NH4C1 (sat., 50.0 mL)
and extracted with Et0Ac
(80.0 mL x 3). The organic phase was combined, and washed with H20 (50.0 mL)
and brine (80.0 mL),
then dried with anhydrous Na2SO4, concentrated to give the crude product,
which was used directly in next
step without farther purification to afford 723-2 (1.30 g, 48.6% yield) as
yellow oil.
The synthesis of 1-(4-(difluoromethoxy)pheny1)-3-methylbutan-1-one (723-3)
OH 0
PCC
F
F.1,0 CH2Cl2, rt, 2 h
F
723-2 723-3
1003391 To a solution of 723-2 (1.30 g, 5.65 mmol) in CH2C12 (100 mL)
was added PCC (2.43 g, 11.3
mmol). The reaction was stirred at room temperature for 2 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 50/1) to afford
723-3 (1.20 g, 93.1% yield) as colorless oil.
The synthesis of 2-bromo-1-(4-(difluoromethoxy)pheny1)-3-methylbutan-l-one
(723-4)
100
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0 0
PTAT
F
F0 THF, rt, 16 h
B
F 0 r
723-3 723-4
1003401 A mixture of 723-3 (1.20 g, 5.26 mmol) and PTAT (2.96 g, 7.89 mmol) in
THF (50.0 mL) was
stirred at room temperature for 16 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (30.0 mL), and then extracted with Ft0Ac (50.0 mL x 2).
The organic layer was
combined, and washed with H20 (30.0 mL x 2) and Brine (30.0 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 723-4 (1.61 g, 100% yield) as brown oil.
The synthesis of 1-(4-(difluoromethoxy)pheny1)-3-methy1-2-thiocyanatobutan-l-
one (723-5)
0 0
NaSCN
F
F.-J= Br Et0H, 80 C, 3 h
F'O'' SCN
723-4 723-5
1003411 A mixture of 723-4 (1.61 g, 5.24 mmol) and NaSCN (849 mg, 10.5 mmol)
in Et0H (50.0 mL)
was stirred at 80 C for 3 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 723-5
(1.10 g, 73.5% yield) as a
yellow solid.
The synthesis of 2-bromo-4-(4-(difluoromethoxy)pheny1)-5-isopropylthiazole
(723-s)
0
HBr
Br-4
0 SCN AcOH, 60 C, 1 h
F
723-5 723-s
1003421 A mixture of 723-5 (1.10 g, 3.86 mmol) and HBr (2.0 M in AcOH, 5.0 mL)
in AcOH (10.0
mL) was stirred at 60 C for 1 h. When the reaction was completed, it was
poured into H20 (100 mL) and
extracted with Et0Ac (100 mL x 3). The organic phase was combined, and washed
with H20 (80.0 mL)
and brine (80.0 inL), then dried with anhydrous Na2SO4, concentrated and
purified by silica gel column
chromatography (petrol ether/ethyl acetate = 10/1) to afford 723-s (1.0 g,
74.5% yield) as yellow oil.
The synthesis of tert-butyl (2-(4-(2-bromo-5-isobutylthiazol-4-y1)-2-
chlorophenoxy)ethyl)carbamate (724-
1)
101
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
s BrN YLcyl< S
Br--4 H Br-4 1
N K2CO3, DMF, 60 C, 16 h
401 N 401
H
OH
CI CI
568-8 724-1
[00343] A mixture of 568-8 (300 mg, 0.865 mmol), tert-butyl (2-
bromoethyl)carbamate (233 mg, 1.04
mmol) and K2CO3 (239 mg, 1.73 mmol) in DMF (5.0 mL) was stirred at 60 'V for
16 h. When the reaction
was completed, it was poured into H20 (80.0 mL) and extracted with Et0Ac (80.0
mL x 3). The organic
phase was combined, and washed with H20 (50.0 mL) and brine (50.0 mL), then
dried with anhydrous
Na2SO4, concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 8/1)
to afford 724-1 (290 mg, 68.4% yield) as colorless oil.
The synthesis of tert-butyl (2-(4-(2-bromo-5-
isobutylthiazol-4-y1)-2-
chlorophenoxy)ethyl)(methyl)carbamate (724-s)
S S
Br¨µ I Mel, NaH .... Br.....4 1
N 0
H THF' 60 C, 16 h
o- -N -Boo N 110 Boc
1
0---N''=
CI CI
724-1 724-s
[00344] A mixture of 724-1 (200 mg, 0.408 mmol) and NaH (60% in mineral oil,
24.5 mg, 0.612 mmol)
in THE (8.0 mL) was stirred at room temperature for 1 h. Then the Mel (69.6
mg, 0.490 mmol) was added
into the reaction. The mixture was stirred at 60 C for 16 h. When the
reaction was completed, it was
quenched with H20 (50.0 mL) and extracted with Et0Ac (80.0 mL x 3). The
organic phase was combined,
and washed with H20 (50.0 mL) and brine (50.0 mL), then dried with anhydrous
Na2SO4, concentrated to
give the crude product, which was used directly in next step without farther
purification to afford 724-s
(180 mg, 87.5% yield) as colorless oil.
The synthesis of 3,5-dichloro-4-methoxybenzaldehyde (726-2)
102
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0,, 0.
CH3I
0 K2CO3, DMF, it 16h
CI CI CI CI
OH 0--.
726-1 726-2
1003451 A mixture of 726-1 (3.0 g, 15.7 mmol), CH3I (3.34 g, 23.6
mmol) and K2CO3 (4.33 g, 31.4
mmol) in DMF (10.0 mL) was stirred at room temperature for 16 h. When the
reaction was completed, it
was poured into H20 (100 mL) and extracted with Et0Ac (100 mL x 3). The
organic phase was combined,
and washed with H20 (80.0 mL) and brine (80.0 mL), then dried with anhydrous
Na2SO4, concentrated to
give the crude product, which was used directly in next step without farther
purification to afford 726-2
(2.10 g, 65.2% yield) as yellow oil.
The synthesis of 1-(3,5-dichloro-4-methoxypheny1)-4-methylpentan-1-ol (726-3)
HO
BrMg" _
0
CI CI
THF it, overnight
CI CI
o,
0.,_.
726-2 726-3
1003461 To a solution of 726-2 (2.10g. 10.2 mmol) in THF (20.0 mL) was added
isopentylmagnesium
bromide (1.0 M in THF, 15.4 mL, 15.4 mmol). The reaction was stirred at room
temperature overnight.
When the reaction was completed, it was poured into aq.NH4C1 (sat., 50.0 mL)
and extracted with Et0Ac
(80.0 mL x 3). The organic phase was combincd, and washed with H20 (50.0 mL)
and brine (50.0 mL),
then dried with anhydrous Na2SO4, concentrated and purified by silica gel
column chromatography (petrol
ether/ethyl acetate = 8/1) to afford 726-3 (1.60 g, 59.4% yield) as yellow
oil.
The synthesis of 143,5 -di chl oro-4-m ethoxyph eny1)-4-m ethyl pentan -1-one
(726-4)
HO 0
PCC ,
CH2Cl2, rt, 1 -1:1
CI CI CI CI
0 0
--. ---.
726-3 726-4
103
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1003471 To a solution of 726-3 (1.60 g, 5.77 mmol) in CH2C12 (80.0
mL) was added PCC (2.49 g, 11.5
mmol). The reaction was stirred at room temperature for 1 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 20/1) to afford
726-4 (1.30 g, 81.8% yield) as a yellow solid.
The synthesis of 2-bromo-1-(3,5-dichloro-4-methoxypheny1)-4-methylpentan-1-one
(726-5)
Br
0 0
PTAT
THF, rt, 1 h
CI CI CI CI
0 0
726-4 726-5
1003481 A mixture of 726-4 (1.30 g, 4.73 mmol) and PTAT (2.66 g, 7.09 mmol) in
THF (100 mL) was
stirred at room temperature for 1 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (50.0 mL), and then extracted with Et0Ac (80.0 mL x 2).
The organic layer was
combined, and washed with H20 (30.0 mL x 2) and Brine (50.0 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 726-5 (1.60 g, 100% yield) as brown oil.
The synthesis of 4-(3,5-diehloro-4-methoxypheny1)-5-isobutylthiazol-2-amine
(726-s)
Br
0
H2N NH2 CI
Et0H, 90 C, 1 h H2No _4
CI CI
0
CI
726-5 726-s
1003491 A mixture of 726-5 (1.60 g, 4.51 mmol) and thiourea (687 mg, 9.04
mmol) in Et0H (20.0 mL)
was stirred at 90 ct for 1 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 726-s
(800 mg, 53.4% yield) as a
yellow solid.
The synthesis of 1-(6-methoxypyridin-3-y1)-4-methylpentan-1-ol (731-2)
0 OH
BrMg r\11,7.)w
N ,
T F, rt, overnight
0 0
731-1 731-2
104
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1003501 To a solution of 731-1 (4.0 g, 29.2 mmol) in THF (40.0 mL) was added
isobutylmagnesium
bromide (1.0 M in THF, 43.8 mL, 43.8 mmol). The reaction was stirred at room
temperature overnight.
When the reaction was completed, it was poured into aq.NH4C1 (sat., 100 mL)
and extracted with Et0Ac
(80.0 niL x 3). The organic phase was combined, and washed with H20 (50.0 mL)
and brine (80.0 mL),
then dried with anhydrous Na2SO4, concentrated and purified by silica gel
column chromatography (petrol
ether/ethyl acetate = 8/1) to afford 731-2 (4.30 g, 70.4% yield) as yellow
oil.
The synthesis of 1-(6-methoxypyridin-3-y1)-4-methylpentan-1-one (731-3)
OH 0
PCC N
N
I Ii CH2Cl2, it, 2 h
731-2 731-3
1003511 To a solution of 731-2 (4.30g. 20.5 mmol) in CH2C12 (150 mL)
was added PCC (8.86 g, 41.1
mmol). The reaction was stirred at room temperature for 2 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 20/1) to afford
731-3 (4.0 g, 93.9% yield) as a yellow solid.
The synthesis of 2-bromo-1-(6-methoxypyridin-3-y1)-4-methylpentan-1-one (731-
4)
0 0
N Br2
CHCI3, 80 C, 16 h))N
o Br
731-3 731-4
1003521 A mixture of 731-3 (2.0 g, 9.66 mmol) and Br2 (1.68 g, 10.6
mmol) in CHC13 (100 mL) was
stirred at 80 C for 16 h. When the reaction was completed, it was
concentrated and solved with Et0Ac
(100 mL). The organic phase was washed with H20 (50.0 mL) and brine (50.0 mL),
then dried with
anhydrous Na2SO4 and concentrated to give the crude product, which was used
directly in next step without
farther purification to afford 731-4 (2.76 g, 100% yield) as brown oil.
The synthesis of 1-(6-hydroxypyridin-3-y1)-4-methyl-2-thiocyanatopentan-1-one
(731-5)
0 0
NaSCN
Br Et0H, 80 C, 3 h
HO SCN
731-4 731-5
1003531 A mixture of 731-4 (2.76 g, 9.66 mmol) and NaSCN (1.57 g, 19.3 mmol)
in Et0H (80.0 mL)
was stirred at 80 C for 3 h. When the reaction was completed, it was
concentrated and purified by silica
105
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
gel column chromatography (petrol ether/ethyl acetate = 1/1) to afford 731-5
(540 mg, 22.4% yield) as a
yellow solid.
The synthesis of 5-(2-bromo-5-isobutylthiazol-4-yOpyridin-2-ol (731-6)
0
HBr
HO SCN Br--µ AcOH, 40 C, 1 h N
N OH
731-5 731-6
1003541 A mixture of 731-5 (540 mg, 2.16 mmol) and HBr (2.0 M in AcOH, 2.0 mL)
in AcOH (5.0
mL) was stirred at 40 C for 1 h. When the reaction was completed, it was
poured into H20 (50.0 mL) and
extracted with Et0Ac (80.0 mL x 3). The organic phase was combined, and washed
with H20 (50.0 mL)
and brine (50.0 mL), then dried with anhydrous Na2SO4, concentrated and
purified by silica gel column
chromatography (petrol ether/ethyl acetate = 6/1) to afford 731-6 (230 mg,
34.0% yield) as yellow oil.
The synthesis of 2-bromo-5-i sobutyl -4-(6-m eth oxypyridin -3 -yl )th i azol
e (731-s)
BrN CH3I
K2003, DMF, it, 16 h oir¨
N OH N 0
731-6 731-s
1003551 A mixture of 731-6 (230 mg, 0.734 mmol), CH3I (156 mg, 1.10 mmol) and
K2CO3 (203 mg,
1.47 mmol) in DMF (3.0 mL) was stirred at room temperature for 16 h. When the
reaction was completed,
it was poured into H20 (50.0 mL) and extracted with Et0Ac (80.0 mL x 3). The
organic phase was
combined, and washed with H20 (50.0 mL) and brine (50.0 mL), then dried with
anhydrous Na2SO4,
concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 10/1) to afford
731-s (165 mg, 68.7% yield) as yellow oil.
The synthesis of 1-(4-methoxypheny1)-4-methylpentan-1-ol (733-2)
0 OH
BrMg---j""
THF, rt. overnight
0 0
733-1 733-2
106
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1003561 To a solution of 733-1 (10.0 g, 73.4 mmol) in THF (100 mL) was added
isopentylmagnesium
bromide (1.0 M in THF, 110 mL, 110 mmol). The reaction was stirred at room
temperature overnight.
When the reaction was completed, it was poured into aq.NH4C1 (sat., 200 mL)
and extracted with Et0Ac
(150 mL x 3). The organic phase was combined, and washed with H20 (100 mL) and
brine (100 mL), then
dried with anhydrous Na2SO4, concentrated and purified by silica gel column
chromatography (petrol
ether/ethyl acetate = 12/1) to afford 733-2 (13.5 g, 88.3% yield) as yellow
oil.
The synthesis of 1-(4-methoxypheny1)-4-methylpentan-1-one (733-3)
OH 0
PCC
CH2Cl2, rt, 2 h
733-2 733-3
1003571 To a solution of 733-2 (13.5 g, 65.5 mmol) in CH2C12 (500 mL)
was added PCC (28.3 g, 13.1
mmol). The reaction was stirred at room temperature for 2 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 30/1) to afford
733-3 (13.3 g, 99.5% yield) as a yellow solid.
The synthesis of 2-bromo-1-(4-methoxypheny1)-4-methylpentan-1-one (733-4)
O 0
PTAT
THF, rt, 16 h
Br
733-3 733-4
1003581 A mixture of 733-3 (11.0 g, 53.4 mmol) and PTAT (30.0 g, 80.1 mmol) in
THF (300 mL) was
stirred at room temperature for 16 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (150 mL), and then extracted with Et0Ac (200 mL x 2). The
organic layer was
combined, and washed with H20 (100 mL x 2) and Brine (150 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 733-4 (15.2 g, 100% yield) as brown oil.
1003591 The synthesis of 5-isobuty1-4-(4-methoxyphenyOthiazol-2-amine
(733-5)
107
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0
H2N NH2
N-4µ,
Et0H, 70 C, 16 h H 2
Br
0
733-4 733-5
1003601 A mixture of 733-4 (15.2 g, 53.4 mmol) and thiourea (8.12 g, 106.8
mmol) in Et0H (200 mL)
was stirred at 70 C for 16 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 733-5
(14.0 g, 100% yield) as a
yellow solid.
The synthesis of 2-bromo-5-isobuty1-4-(4-methoxyphenyOthiazole (733-6)
t-BuONO, CuBr2
H2N4 MeCN, Br-4N \
733-5 733-6
1003611 A mixture of 733-5 (14.0 g, 53.4 mmol), t-BuONO (8.25 g, 80.0 mmol)
and CuBr2 (17.9 g,
80.0 mmol) in CH3CN (200 mL) was stirred at room temperature for 2 h. When the
reaction was completed,
it was concentrated to give a crude product, which was purified by silica gel
column chromatography (petrol
ether/ethyl acetate = 20/1) to afford 733-6 (4.80 g, 27.6% yield) as yellow
oil.
The synthesis of 4-(2-bromo-5-isobutylthiazol-4-yl)phenol (733-7)
BBr3
Br--µ
CH2C12, rt, 16 h Br
OH
733-6 733-7
1003621 A mixture of 733-6 (2.40 g, 7.36 mmol) and BBr3 (17% in CH2C12, 18.4
mL, 18.4 mmol) in
CH2C12 (80.0 mL) was stirred at room temperature for 16 11. When the reaction
was completed, it was
washed with H20 (50.0 mL x 3). The organic layer was concentrated and purified
by silica gel column
chromatography (petrol ether/ethyl acetate = 6/1) to afford 733-7 (800 mg,
34.8% yield) as yellow oil.
The synthesis of 2-bromo-5-isobuty1-4-(4-(2,2,2-
trifluoroethoxy)phenyl)thiazole (733-s)
108
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
F3C-ThTf
Br--µ
K2CO3, DMF, rt, 16 h
OH
733-7 733-s
1003631 A mixture of 733-7 (200 mg, 0.641 mmol), 2,2,2-trifluoroethyl
trifluoromethanesulfonate (223
mg, 0.96 lmmol) and K2CO3 (177 mg, 1.28 mmol) in DMF (3.0 mL) was stirred at
room temperature for
16 h. When the reaction was completed, it was poured into H20 (50.0 mL) and
extracted with Et0Ac (80.0
mL x 3). The organic phase was combined, and washed with H20 (50.0 mL) and
brine (50.0 mL), then
dried with anhydrous Na2SO4, concentrated and purified by silica gel column
chromatography (petrol
ether/ethyl acetate = 10/1) to afford 733-s (183 mg, 72.5% yield) as yellow
oil.
The synthesis of 2-bromo-4-(4-ethoxypheny1)-5-isobutylthiazole (741-s)
Br--4 Br--
K2CO3, DMF, rt, 16 h
OH
733-7 741-s
1003641 A mixture of 733-7 (180 mg, 0.576 mmol), iodoethane (135 mg, 0.865
mmol) and K2CO3 (159
mg, 1.15 mmol) in DMF (3.0 mL) was stirred at room temperature for 16 h. When
the reaction was
completed, it was poured into H20 (50.0 mL) and extracted with Et0Ac (80.0 mL
x 3). The organic phase
was combined, and washed with H20 (50.0 mL) and brine (50.0 mL), then dried
with anhydrous Na2SO4,
concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 10/1) to afford
741-s (170 mg, 86.7% yield) as colorless oil.
The synthesis of 4-cyclopropoxybenzaldehyde (744-2)
0 0
Br
HO seCalse2dC ' DMF, ____________
2009C8 h A"-o
744-1 744-2
1003651 A mixture of 744-1 (5.0 g, 40.9 mmol), bromocyclopropane (9.91 g, 81.9
mmol) and C S2C 03
(26.7 g, 81.9 mmol) in DMF (30.0 mL) was stirred sealed at 200 C for 8 h.
When the reaction was
completed, it was poured into H20 (300 mL) and extracted with Et0Ac (200 mL x
3). The organic phase
109
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
was combined, and washed with H20 (100 x 2 mL) and brine (150 mL), then dried
with anhydrous Na2SO4,
concentrated to give the crude product, which was used directly in next step
without farther purification to
afford 744-2 (3.40g. 51.2% yield) as colorless oil.
The synthesis of 1-(4-cyclopropoxypheny0-4-methylpentan-1-ol (744-3)
0 I OH
401 I BrMg
THF, it. 16 h ____________________
0 0
744-2 744-3
1003661 To a solution of 744-2 (4.0 g, 24.7 mmol) in THF (30.0 mL) was added
isobutylmagnesium
bromide (1.0 M in THF, 37.0 mL, 37.0 mmol). The reaction was stirred at room
temperature for 16 h. When
the reaction was completed, it was poured into aq.N1H4C1 (sat., 100 mL) and
extracted with Et0Ac (80.0
mL x 3). The organic phase was combined, and washed with H20 (50.0 mL) and
brine (80.0 mL), then
dried with anhydrous Na2SO4, concentrated to give the crude product, which was
used directly in next step
without farther purification to afford 744-3 (3.80 g, 65.8% yield) as yellow
oil.
The synthesis of 1-(4-cyclopropoxypheny1)-4-methylpentan-1-one (744-4)
OH 0
PCC
CH2Cl2, rt, 2 h __________________________
0 0
744-3 744-4
1003671 To a solution of 744-3 (3.80 g, 16.2 mmol) in CH2C12 (200 mL) was
added PCC (6.99 g, 32.4
mmol). The reaction was stirred at room temperature for 2 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 20/1) to afford
744-4 (3.50 g, 92.8% yield) as a yellow solid.
The synthesis of 2-bromo-1-(4-cyclopropoxypheny1)-4-methylpentan-1-one (744-5)
0 0
PTAT
THE, rt, 16 h ____________________________
Br
0 0
744-4 744-5
1003681 A mixture of 744-4 (3.50g, 15.1 mmol) and PTAT (8.49g, 22.6 mmol) in
THF (200 mL) was
stirred at room temperature for 16 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (100 mL), and then extracted with Et0Ac (100 mL x 2). The
organic layer was
combined, and washed with H20 (50.0 mL x 2) and Brine (80.0 mL), then dried by
anhydrous Na2SO4. The
110
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 744-5 (4.69 g, 100% yield) as brown oil.
The synthesis of 4-(4-cyclopropoxypheny1)-5-isobutylthiazol-2-amine (744-6)
0
H2N NH2
H2N4
Et0H, 70 C, 12 h
Br
A"0 N 11101
0
744-5 744-6
1003691 A mixture of 744-5 (4.69 g, 15.1 mmol) and thiourea (2.29 g, 30.2
mmol) in Et0H (100 mL)
was stirred at 70 C for 12 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 744-6
(2.80 g, 64.4% yield) as a
yellow solid.
The synthesis of 2-bromo-4-(4-cyclopropoxypheny1)-5-isobutylthiazole (744-s)
t-BuONO, CuBr2
H2N-4,
MeCN, rt, 2 hl-
______________________________________ Br
C31-A 01\
744-6 744-s
1003701 A mixture of 744-6 (2.80 g, 9.71 mmol), t-BuONO (1.50 g, 14.6
mmol) and CuBr2 (3.26 g,
14.6 mmol) in CH3CN (100 mL) was stirred at room temperature for 2 h. When the
reaction was completed,
it was concentrated to give a crude product, which was purified by silica gel
column chromatography (petrol
ether/ethyl acetate = 20/1) to afford 744-s (1.20 g, 35.1% yield) as yellow
oil.
The synthesis of 2-cyclopropyl -1-(4-m eth oxyph enypeth an ol (749-2)
0 OH
I _____________________ MgBr
THF, rt, 16 hl
0 0
733-1 749-2
1003711 To a solution of 733-1 (5.0 g, 36.7 mmol) in THF (50.0 mL) was added
(cyclopropylmethyl)magnesium bromide (1.0 M in THF, 55.1 mL, 55.1 mmol). The
reaction was stirred at
room temperature for 16 h. When the reaction was completed, it was poured into
aq.NH4C1 (sat., 150 mL)
and extracted with Et0Ac (100 mL x 3). The organic phase was combined, and
washed with H20 (80.0
111
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
mL) and brine (80.0 mL), then dried with anhydrous Na2SO4, concentrated to
give the crude product, which
was used directly in next step without farther purification to afford 749-2
(5.50 g, 77.9% yield) as yellow
oil.
The synthesis of 2-cyclopropy1-1-(4-methoxyphenypethanone (749-3)
OH 0
PCC
CH2Cl2, rt, 2 h
0 0
749-2 749-3
1003721 To a solution of 749-2 (5.50 g, 28.6 mmol) in CH2C12 (100 mL)
was added PCC (12.3 g, 57.2
mmol). The reaction was stirred at room temperature for 2 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 30/1) to afford
749-3 (4.50 g, 82.7% yield) as a yellow solid.
The synthesis of 2-bromo-2-cyclopropy1-1-(4-methoxyphenyl)ethanone (749-4)
0 0
PTAT
THF, rt, 16 h
0 Br
0
749-3 749-4
1003731 A mixture of 749-3 (4.50g, 23.7 mmol) and PTAT (13.3 g, 35.5 mmol) in
THF (150 mL) was
stirred at room temperature for 16 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (100 mL), and then extracted with Et0Ac (100 mL x 2). The
organic layer was
combined, and washed with H20 (50.0 mL) and Brine (80.0 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 749-4 (6.37 g, 100% yield) as yellow oil.
The synthesis of 2-cyclopropy1-1-(4-methoxypheny1)-2-thiocyanatoethanone (749-
5)
0 0
NaSCN
Et0H, 50 C, 2 h
Br SC N
0 0
749-4 749-5
1003741 A mixture of 749-4 (2.50 g, 9.29 mmol) and NaSCN (1.50 g, 18.6 mmol)
in Et0II (80.0 mL)
was stirred at 50 C for 2 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 749-5
(1.50 g, 65.3% yield) as a
yellow solid.
The synthesis of 2-chloro-5-cyclopropy1-4-(4-methoxyphenyl)thiazole (749-s)
112
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0
0 CN
HCl/dioxane
S
0
749-5 749-s
1003751 A mixture of 749-5 (1.0 g, 4.04 mmol) in HC1/dioxane (4.0 M, 10.0 mL)
was stirred at 50 C
for 2 h. When the reaction was completed, it was concentrated and purified by
silica gel column
chromatography (petrol ether/ethyl acetate = 10/1) to afford 749-s (400 mg,
37.2% yield) as yellow oil.
The synthesis of 1-(4-cyclopropoxypheny1)-2-cyclopropylethanol (750-1)
0 OH
I /\Mg Br
_______________________________ =THE, rt, 16 h
0 0
744-2 750-1
1003761 To a solution of 744-2 (2.0 g, 12.3 mmol) in THF (20.0 mL) was added
isobutylmagnesium
bromide (1.0 M in THF, 18.5 mL, 18.5 mmol). The reaction was stirred at room
temperature for 16 h. When
the reaction was completed, it was poured into aq.N1H4C1 (sat., 100 mL) and
extracted with Et0Ac (80.0
mL x 3). The organic phase was combined, and washed with H20 (50.0 mL) and
brine (80.0 mL), then
dried with anhydrous Na2SO4, concentrated to give the crude product, which was
used directly in next step
without farther purification to afford 750-1 (2.30 g, 85.4% yield) as yellow
oil.
The synthesis of 1-(4-cyclopropoxypheny1)-2-cyclopropylethanone (750-2)
OH 0
PCC
CH2Cl2, rt, 2 h
/0 0
760-1 760-2
1003771 To a solution of 750-1 (2.30 g, 10.5 mmol) in CH2C12 (100 mL)
was added PCC (4.54 g, 21.1
nimol). The reaction was stirred at room temperature for 2 h. When the
reaction was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 20/1) to afford
750-2 (2.0 g, 87.8% yield) as a yellow solid.
The synthesis of 2-bromo-1-(4-cyclopropoxypheny1)-2-cyclopropylethanone (750-
3)
113
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0 0
PTAT
THF, rt, 16 h
Br
/10
750-2 750-3
1003781 A mixture of 750-2 (2.0 g, 9.26 mmol) and PTAT (5.21 g, 13.9 mmol) in
THF (100 mL) was
stirred at room temperature for 16 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (80.0 mL), and then extracted with Et0Ac (100 mL x 2).
The organic layer was
combined, and washed with H20 (50.0 mL) and Brine (80.0 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 750-3 (2.73 g, 100% yield) as brown oil.
The synthesis of 4-(4-cyclopropoxypheny1)-5-cyclopropylthiazol-2-amine (750-s)
0
H2N NH2
Br Et0H, 80 C, 2 h
CY-A
750-3 750-s
1003791 A mixture of 750-3 (2.73 g, 9.25 mmol) and thiourea (1.41 g, 18.5
mmol) in Et0H (50.0 mL)
was stirred at 80 'V for 2 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 750-s
(2.30 g, 91.3% yield) as a
yellow solid.
The synthesis of 4-(2-chloro-5-cyclopropylthiazol-4-yl)phenol (756-s)
ci BB r3
CI--µ
CH2Cl2, it, overnight
()
OH
749-s 756-s
1003801 A mixture of 749-s (2.60 g, 9.78 mmol) and BBr3 (17% in CH2C12, 19.6
mL, 19.6 mmol) in
CH2C12 (80.0 mL) was stirred at room temperature overnight. When the reaction
was completed, it was
washed with H20 (50.0 mL x 3). The organic layer was concentrated and purified
by silica gel column
chromatography (petrol ether/ethyl acetate = 6/1) to afford 756-s (900 mg,
36.5% yield) as yellow oil.
The synthesis of 4-(2-bromo-5-cyclopropylthiazol -4-y1)-3 -fl uo roph en ol
(758-1)
114
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Br-4 I
BBr3 Br-4
CH2Cl2, rt, 5 h
OH
757-s 758-1
1003811 A mixture of 757-s (400 mg, 1.22 mmol) and BBr3 (17% in CH2C12, 2.44
mL, 2.44 mmol) in
CH2C12 (100 mL) was stirred at room temperature for 5 h When the reaction was
completed, it was washed
with H20 (20.0 mL x 2). The organic layer was concentrated and purified by
silica gel column
chromatography (petrol ether/ethyl acetate = 6/1) to afford 758-1 (250 mg,
65.3% yield) as yellow oil.
The synthesis of 2-bromo-5-cyclopropy1-4-(2-fluoro-4-(2-
methoxyethoxy)phenyl)thiazole (758-s)
Br¨µ Br--
K2CO3, DM F, it, 16 h
OH
758-1 758-s
1003821 A mixture of 758-1 (250 mg, 0.796 mmol), 1-bromo-2-methoxyethane (166
mg, 1.19 mmol)
and K2CO3 (220 mg, 1.59 mmol) in DMF (3.0 mL) was stirred at room temperature
for 16 h. When the
reaction was completed, it was poured into H20 (50.0 mL) and extracted with
Et0Ac (80.0 mL x 3). The
organic phase was combined, and washed with H20 (50.0 mL) and brine (50.0 mL),
then dried with
anhydrous Na2SO4, concentrated and purified by silica gel column
chromatography (petrol ether/ethyl
acetate = 10/1) to afford 758-s (300 mg, 100% yield) as colorless oil.
The synthesis of 3-fluoro-4-(2-methoxyethoxy)benzaldehyde (761-2)
0 0
F
K2CO3, DMF, rt, 16 h
HO
F
761-1 761-2
1003831 A mixture of 761-1 (20.0 g, 143 mmol), 1-bromo-2-methoxyethane (29.8
g, 214 mmol) and
K2CO3 (39.5 g, 286 mmol) in DMF (200 mL) was stirred at room temperature for
16 h. When the reaction
was completed, it was poured into H20 (2.0 L) and extracted with Et0Ac (800 mL
x 3). The organic phase
was combined, and washed with H20 (500 mL) and brine (800 mL), then dried with
anhydrous Na2SO4,
concentrated to give the crude product, which was used directly in next step
without farther purification to
afford 761-2 (28.0 g, 99.0% yield) as colorless oil.
115
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
The synthesis of 2-cyclopropy1-1-(3-fluoro-4-(2-methoxyethoxy)phenyl)ethanol
(761-3)
0 OH
F I MgBr
THE, rt. 16 h
761-2 761-3
1003841 To a solution of 761-2 (3.0 g, 15.1 mmol) in THF (20.0 mL) was added
isobutylmagnesium
bromide (1.0 M in THF, 22.7 mL, 22.7 mmol). The reaction was stirred at room
temperature for 16 h. When
the reaction was completed, it was poured into aq.NH4C1 (sat., 80.0 mL) and
extracted with Et0Ac (80.0
mL x 3). The organic phase was combined, and washed with H20 (50.0 mL) and
brine (80.0 mL), then
dried with anhydrous Na2SO4, concentrated and purified by silica gel column
chromatography (petrol
ether/ethyl acetate = 8/1) to afford 761-3 (2.10 g, 54.6% yield) as yellow
oil.
The synthesis of methyl 2-cyclopropy1-1-(3-fluoro-4-(2-
methoxyethoxy)phenypethanone (761-4)
OH 0
PCC
CH2Cl2, rt, 1 h
0
761-3 761-4
1003851 To a solution of 761-3 (2.10 g, 8.26 mmol) in CH2C12 (100 mL)
was added PCC (3.56 g, 16.5
mmol). The reaction was stirred at room temperature for 1 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 20/1) to afford
761-4 (2.0 g, 96.0% yield) as a yellow solid.
The synthesis of 2-bromo-2-cyclopropy1-1-(3-fluoro-4-(2-
methoxyethoxy)phenypethanone (761-5)
0 0
PTAT
THF, rt, 1h0
Br
761-4 761-5
1003861 A mixture of 761-4 (2.0 g, 7.94 mmol) and PTAT (4.46 g, 11.9 mmol) in
THF (100 mL) was
stirred at room temperature for 1 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (50.0 mL), and then extracted with Et0Ac (80.0 mL x 2).
The organic layer was
combined, and washed with H20 (30.0 mL x 2) and Brine (50.0 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 761-5 (2.63 g, 100% yield) as brown oil.
The synthesis of 2-cyclopropy1-1-(3-fluoro-4-(2-methoxyethoxy)pheny1)-2-
thiocyanatoethanone (761-6)
116
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0 0
NaSCN
Br Et0H, 90 C, 3 h
0 SCN
761-5 761-6
1003871 A mixture of 761-5 (2.63 g, 7.94 mmol) and NaSCN (1.29 g, 15.9 mmol)
in Et0H (80.0 mL)
was stirred at 90 C for 3 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 761-6
(2.0 g, 81.4% yield) as a
yellow solid.
The synthesis of 2-chloro-5-cyclopropy1-4-(3-fluoro-4-(2-
methoxyethoxy)phenyl)thiazole (761-s)
0
HCl/dioxane
rt, overnight
SCN
761-6 761-s
1003881 A mixture of 761-6 (2.0 g, 6.46 mmol) in HC1/dioxane (20.0 mL) was
stirred at room
temperature overnight. When the reaction was completed, it was concentrated
and purified by silica gel
column chromatography (petrol ether/ethyl acetate = 10/1) to afford 761-s
(1.80 g, 84.9% yield) as yellow
oil.
The synthesis of 2-chloro-4-(4-(difluoromethoxy)pheny1)-5-isobutylthiazole
(766-s)
0
HCl/dioxane
F.1.0 SCN rt, overnigh; CI-4N
0.1.F
723-5 766-s
1003891 A mixture of 723-5 (2.0 g, 6.68 mmol) in HC1/dioxane (20.0 mL) was
stirred at room
temperature overnight. When the reaction was completed, it was concentrated
and purified by silica gel
column chromatography (petrol ether/ethyl acetate = 10/1) to afford 766-s
(1.60 g, 75.4% yield) as yellow
oil.
Table 1-1: Characterization Data for Compounds
Chemical Structure LCMS
117
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
723¨s Br Method A, Purity is 52.4%, Rt = 0.913
min; MS Calcd.:347.0;
--4s
MS Found: 347.9 nv + H] +.
01 F
724-s Br Method B, Purity is 86.2%, Rt = 2.467
min; MS Calcd.:502.1;
Y'e No MS Found.
CI
726-s H2N-4
Method A, Purity is 100%, Rt = 0.676 min; MS Calcd.:330.0;
MS Found: 331.0 rvi + H] +.
CI I
731-s Br
Method B, Purity is 85.1%, Rt = 1.801 min; MS Calcd.:326.0;
N MS Found: 326.9 [M + H] 1.
N 0
733¨s Br
Method A, Purity is 51.3%, Rt = 0.974 min; MS Calcd.:393.0;
MS Found: 393.9 nvi + H] +.
Orr
Method A, Purity is 98.6%, Rt = 1.046 min; MS Calcd.:413.0;
736-s Br Method
F MS Found: 413.8 rvi + H] .
)<F
0 F
CI
744-s Br Method A, Purity is 79.2%, Rt = 1.024
min; MS Calcd.:351.0;
¨K,
MS Found: 352.0 nvi + H] +.
o"A
747-s Br
Method B, Purity is 56.4%, Rt = 1.918 min; MS Calcd.:368.0;
(\SN
MS Found: 368.9 rvi + H] +.
NH2
1
750-s H2N---(\s Method A, Purity is 89.2%, Rt = 0.576
min; MS Calcd.:272.1;
MS Found: 273.2 nvi + H] I .
751-s ci Method B, Purity is 96.5%, Rt = 2.162
min; MS Calcd.:309.1;
MS Found: 310.0 [M + H] +.
118
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
756-s ci Method A, Purity is 97.5%, Rt = 0.767
min; MS Calcd.:251.0;
MS Found: 252.2 rvi + H]
OH
11-1NMR (400 MHz, CDC13) 6: 3.44 (2H, dd, J = 6.4, 1.2 Hz),
757-s Br-4 3.83 (3H, s), 5.09-5.17 (2H, m), 5.89
(1H, dd, J= 16.8, 10.0
Hz), 6.68 (1H, dd, J= 11.6, 2.4 Hz), 6.76 (1H, dd, J= 8.8, 2.4
Hz), 7.38 (1H, t, = 8.8 Hz).
0
758-s Br
Method A, Purity is 52.9%, Rt = 0.905 min; MS Calcd.:371.0;
K\SN
MS Found: 371.9 nvi + H]
Cl-e I Method B, Purity is 100%, Rt = 2.145
min; MS Calcd.:283.0;
760-s
MS Found: 284.0 nvi + H]
CI-4j
Method B, Purity is 98.7%, Rt = 2.142 min; MS Calcd.:327.0;
761-s
MS Found: 328.0 rvi + H]
762-s CI____(\s
Method B, Purity is 77.6%, Rt = 1.946 min; MS Calcd.:343.0;
MS Found: 344.0 irm + HI+.
Method B, Purity is 98.6%, Rt = 2.171 min; MS Calcd.:329.0;
763-s CIj
MS Found: 330.0 WI + H]
764-s Method A, Purity is 60.9%, Rt = 0.982
min; MS Calcd.:355.1;
MS Found: 356.0 um + H] +.
767-s
Method B, Purity is 98.8%, Rt = 2.220 min; MS Ca1cd.:325.1;
ci--41 I
MS Found: 326.0 rvi + H]
772-s
Method B, Purity is 96.6%, Rt = 2.297 min; MS Calcd.:329.0;
MS Found: 330.0 um + H]
OFF
780-s ci---ZN I Method A, Purity is 96.0%, Rt = 0.992
min; MS Calcd.:357.0;
MS Found: 358.0 [kr + H]
119
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
781-s ci¨e i
N Method A, Purity is 93.7%, Rt = 1.032 min; MS Calcd.:373.1;
MS Found: 374.0 [M + H] +.
---....õ-..
o o.-
CI
782- ci¨e I
N Method A, Purity is 90.6%, Rt = 0.921
min; MS Calcd.:329.1;
s
MS Found: 330.0 [M + H] +.
0.--,.-0-..
783-s
F
\
0
Method A, Purity is 70.4%, Rt = 0.825 min; MS Calcd.:345.1;
ch--(\s i
N MS Found: 346.0 [M + HI .
o--"o
F
CI---e 791-s Method B, Purity is 90.2%, Rt = 2.303 min; MS
Calcd.:393.1;
N
0 MS Found: 394.1 [M + HI +.
o------
F F
F
792 Method A, Purity is 94.4%, Rt = 0.940
min; MS Calcd.:343.1;
-s CI--< 1
N (3/¨,c)/ MS Found: 344.0 [M + H] +.
F
The synthesis of methyl 2-44-(3-chloro-4-hydroxypheny1)-5-isobutylthiazol-2-
yl)amino)-5-(thiophen-2-
yOnicotinate (721-2)
.--
S 0" _\
S 1 N
N NH2 \ /(
Br--4 1 ___________________________________ D. S
N Pd2(db2)3, x-phos, Cs2CO3, 0 0
OH Toluene 110 C 16 h /0 HN¨ I
N
CI 10
OH
568-8 721-2 CI
1003901 A mixture of 568-8 (150 mg, 0.433 mmol), methyl 2-amino-5-(thiophen-2-
vOnicotinate (102
mg, 0.433 mmol), Pd2(dba)3 (40.3 mg, 0.0433 mmol), X-phos (37.5 mg, 0.065
mmol) and Cs2CO3 (282 mg,
0.866 mmol) in toluene (5.0 mL) was stirred under N2 atmosphere at 110 C for
16 h. When the reaction
was completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl
acetate = 8/1) to afford 721-2 (100 mg, 46.2% yield) as a yellow solid.
The synthesis of 24(443 -chloro-4-hydroxypheny1)-5 4
sobutylthiazol-2-yl)am ino)-5 -(thiophen-2-
120
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
yl)nicotinic acid (I-1)
/(N
NaOH /KNI
0 HN¨( I THF/Me0H, rt, 2 tTi 0
0 N * OH N
OH OH
721-2 CI CI
1003911 To a solution of 721-2 (100 mg, 0.20 mmol) in McOH/THF/ H20 (v/v/v =
4/1/1, 5.0 mL) was
added NaOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room
temperature for 2 h. When the
reaction was completed, the resulting reaction was concentrated, then it was
diluted with H20 (15.0 mL)
and adjusted pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with
Et0Ac (10.0 mL x 2), and the
combined organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4,
and concentrated, the
residue was purified by washing with Me0H to afford 1-1 (20.0 mg, 20.6% yield)
as a white solid.
The synthesis of methyl 2-44-(4-(2-((tert-butoxycarbonyl)(methypamino)ethoxy)-
3-chlorophenyl)-5-
isobutylthiazol-2-y0amino)-5-(thiophen-2-y1)nicotinate (724-2)
/ 0
Br\
S
N 2,N s
N Boc Pd2(dba)3, x-phos, Cs2003, HN--µ
Toluene, 110 C, 16 h 0 N
Boc
CI
CI
724-s 724-2
1003921 A mixture of 724-s (186 mg, 0.369 mmol), methyl 2-amino-5-
(thiophen-2-yl)nieotinate (86.7
mg, 0.369 mmol), Pd2(dba)3 (34.3 mg, 0.0369 mmol), X-phos (32.0 mg, 0.0554
mmol) and Cs2CO3 (240
mg, 0.738 mmol) in toluene (5.0 mL) was stirred under N2 atmosphere at 110 C
for 16 h. When the reaction
was completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl
acetate = 6/1) to afford 724-2 (135 mg, 55.6% yield) as a yellow solid.
The synthesis of methyl 2-44-(3-chloro-4-(2-(methylamino)ethoxy)pheny1)-5-
isobutylthiazol-2-
yl)amino)-5 -(th oph en -2-yl)n coti n ate (724-3)
121
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
, N N
S HCl/dioxane \ s
HN¨µ rt, 4 h
0 0
Boc
CI
0 0
N N
---
CI
724-2 724-3
[00393] A mixture of 724-2 (135 mg, 0.205 mmol) in HC1/dioxane (5.0 mL) was
stirred at room
temperature for 4 h. When the reaction was completed, it was filtered and the
solid was dried to give the
crude product, which was used directly in next step without farther
purification to afford 724-3 (85.0 mg,
74.3% yield) as a yellow solid.
The synthesis of 24(4-(3-chloro-4-(2-(methylamino)ethoxy)pheny1)-5-
isobutylthiazol-2-yl)amino)-5-
(thiophen-2-yDnicotinic acid (I-3)
7
S LiOH S
0
HN-4 THF/Me0H, it, 2 h HN--
0
0 OH N N 40/
CI Cl
724-3
[00394] To a solution of 724-3 (85.0 mg, 0.153 mmol) in Me0H/THF/ H20 (v/v/v =
4/1/1, 3.0 mL)
was added LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room
temperature for 2 h. When the
reaction was completed, the resulting reaction was concentrated, then it was
diluted with H20 (15.0 mL)
and adjusted pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with
Et0Ac (10.0 mL x 2), and the
combined organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4,
and concentrated, the
residue was purified by prcp-HPLC and washing with McOH to afford 1-3 (25.0
mg, 30.2% yield) as a
brown solid.
The synthesis of 2 4(44442 -am i n o-2 -oxoeth oxy)ph eny1)-5
sobutylthiazol -2 -yOarn n o)-5 -(th oph en -2 -
yl)nicotinic acid (I-17)
122
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
S I OH
N N H2 S
Br¨µ
Pd2(dba)3, x-phos, Cs2CO3, 0 HN----µ
_NH2 Toluene, 110 C, 16 h OH
0.Thr NH2
0
747-s 1-17 0
1003951
A mixture of 747-s (130 mg, 0.352 mmol), 2-amino-5-(thiophen-2-
yl)nicotinic acid (93.0 mg,
0.422 mmol), Pd2(dba)3 (32.7 mg, 0.0352 mmol), X-phos (30.5 mg, 0.0528 mmol)
and Cs2CO3 (172 mg,
0.528 mmol) in toluene (5.0 mL) was stirred under N2 atmosphere at 110 C for
16 h. When the reaction
was completed, it was concentrated and purified by prep-HPLC to afford 1-17
(4.0 mg, 2.23% yield) as a
yellow solid.
The synthesis of methyl 2-04-(3-fluoro-4-(2-methoxyethoxy)pheny1)-5-
isobutylthiazol-2-y0amino)-5-
(thiophen-2-y1)nicotinate (1-53)
,
/ 0
I
N NH2 S
N 110
Pd2(dba)3, x-phos, Cs2CO3,
Toluene, 120 C, 16 h 0 N
0
786-s 1-53
1003961
A mixture of 786-s (200 mg, 0.547 mmol), 2-chloro-5-
(trifluoromethyl)nicotinic acid (148 mg,
0.657 mmol), Pd2(dba)3 (50.9 mg, 0.0547 mmol), X-phos (47.4 mg, 0.0821 mmol)
and Cs2CO3 (267 mg,
0.821 mmol) in toluene (5.0 mL) was stirred under N2 atmosphere at 110 C for
16 h. When the reaction
was completed, it was concentrated and purified by prep-HPLC to afford 1-53
(30.0 mg, 9.52% yield) as a
yellow solid.
The
synthesi s of 24(443 -fl uoro-4-(2-in eth oxyeth oxy)pli eny1)-5
sobutylth i azol -2-y1 )ain i n o)-N-(2-
(methylamino)ethyl)-5-(thiophen-2-yl)nicotinamide (1-56)
123
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
,
,N
\ / s H2N S
0
HN-4N TMA, toluene, rt, overnighi HN HN¨(
0
0
¨NH
762-7 1-56
1003971 To a mixture of 762-7 (200 mg, 0.369 mmol) and NI-methylethane-1,2-
diamine (32.8 mg,
0.443 mmol), in toluene (5.0 mL) was added (CH3)3A1 (2.5 M in toluene, 0.369
mL, 0.923 mmol). The
reaction was stirred at room temperature overnight When the reaction was
completed, it was concentrated
and purified by prep-HPLC to afford 1-56 (25.0 mg, 11.6% yield) as a yellow
solid.
Characterization Data for Exemplary Compounds
I# Chemical Structure LCMS 111 NMR (400 MHz, d6-
DMS0)
6: 0.93 (6H, d, J= 6.4 Hz), 1.86-1.89
s Method C, Purity is (1H, m), 2.72 (2H,
d, J= 7.2 Hz), 7.04
(1H, d, J= 8.4 Hz), 7.18 (1H, t, J=
Rt = \ 2.014 min; 4.0 Hz), 7.37-7.40 (1H, m), 7.53 (1H,
1
0 HN¨e I MS Calcd.: 485.0; MS d, J= 2.0 Hz),
7.60-7.63 (2H, m), 8.45
OH N
Found: 485.9 M + H]
(1H, d, J= 2.4 Hz), 8.92 (1H, d, J=
[
OH 2.4 Hz), 10.37 (1H,
s), 11.69 (1H, s),
CI 14.27 (1H, s).
Method C, Purity is
s 6: 1.33 (6H, d,./= 6.8
Hz), 3.34-3.39
N 94.1%, Rt = 1.884 min; (1H, m), 7.12-
7.27 (4H_ m), 7.60-7.65
/
2 (1H, m), 8.46 (1H, d,
j= 2.4 Hz), 8.96
0 H N ¨e I MS Calcd.: 487.0; MS
OH N (1H, d, J= 2.0 Hz), 11.60 (1H, s),
cy_Fc Found: 488.0 [M + H] 14.26 (1H, s).
6: 0.90 (6H, d, J= 6.8 Hz), 1.79-1.98
Method C, Purity is (2 H. m), 2.34 (3 H,
s), 2.69 (2H, d, J=
7.2 Hz), 2.83-2.87 (1.5 H, m), 4.12 (1.5
n
/N 90.6%, Rt = 2.024 mm; H, t, J= 5.6 Hz),
7.10-7.13 (1H, m),
3 H MS Calcd.: 542.0; MS 7.19 (1 H, d,
.1= 8.4 Hz), 7.47-7.50 (3
OH N
H, m), 7.59 (1H, d, .1= 2.4 Hz), 7.36
CI Found: 542.9 [M + H]
= (1H, d, J= 2.4 Hz), 8.60 (1H, d, J=
2.4 Hz), 14.61 (1 H, brs).
,
Method C, Purity is
s ' 6: 0.92 (6H, d, J= 6.8
Hz), 1.84-1.88
100%, Rt = 2.233 min; (1H, m), 2.74 (2H, d,
J= 7.2 Hz), 3.85
4 0" a MS Calcd.: 533.0; MS (3H, s), 7.15 (1H,
t,J = 4.0 Hz), 7.56-
H
OH N 7.60 (2H, m), 7.64
(2H, s), 8.43 (1H, d,
o Found: 533.8 [M + H] 1. J= 2.0 Hz), 8.87
(1H, d, ./= 2.4 Hz).
CI
124
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
.-/
s Method C, Purity is 6: 0.92 (6H, d, J=
6.4 Hz), 1.86-1.90
- (1H, m), 2.75 (2H, d,
J= 7.2 Hz), 3.89
µ N 100%, Rt = 2.089 min;
s - (3H, s), 7.17-7.26
(2H, m), 7.37-7.44
O HN¨<, I MS Calcd.: 483.0; MS
(2H, m), 7.60-7.64 (2H. m), 8.45 (1H,
OH N
d, J= 2.4 Hz), 8.93 (1H, d, J= 2.4 Hz),
Found: 483.9 [M H] 1.
o' 11.53 (1H, brs), 14.34
(1H, brs).
F
6:0.93 (6H, d, J= 6.8 Hz), 1.85-1.89
---
/ Method C, Purity is (1H, m), 2.71 (2H,
d, J= 7.2 Hz), 3.51
s
(3H, s), 6.46 (2H, d, J= 9.6 Hz), 7.18
-\ 96.5%, Rt = 1.811 min;
\ ,N (1H, dd, J= 4.8, 3.6
Hz), 7.60-7.70
6
ON H¨e I MS Calcd.: 465.0; MS
(3H, m), 7.95 (1H, d, J= 2.4 Hz), 8.46
OH N N, Found: 466.9 M + H] . (1H, d. J= 2.4
Hz), 8.93 (1H, d, J=
I [ '
2.4 HZ), 11.54 (1H, brs), 14.35 (1H,
N--- 0"¨
brs).
.., , Method C, Purity is
6: 0.88 (6H, d, J= 6.4 Hz), 1.83-1.90
s '
- N 100%, Rt = 1.956 min; (1H, m), 2.70
(2H, d, J= 6.4 Hz), 4.76-
4.82 (2H, m), 7.09-7.15 (3H, m), 7.52-
a HN-4 1 ..: MS
- OH N ' 7.60 (4H, m), 8.42
(1H, s), 8.89 (1H,
--)<FF Found: 533.9 [M + H] '. s), 11.51 (1H, s), 14.24 (1H, s).
MS Calcd: 5330
6: 0.67-0.71 (211, m), 0.79-0.84 (211,
n.
Method C, Purity is m), 0.93 (6H, d, J=
6.8 Hz), 1.87-1.91
s /
(1H, m), 2.73 (2H, d, J= 7.2 Hz), 3.87-
98.4%, Rt = 1.956 min;
\ õN 3.90 (1H, m), 7.12
(2H, d, J= 8.4 Hz),
8
O HN-e I MS Calcd.: 491.1; MS
7.18 (1H, dd, J= 4.8, 3.6 Hz), 7.53
OH N (2H, d, J= 8.8 Hz),
7.61-7.65 (2H, m),
Found: 492.0 [M + H] -P.
8.46 (1H, d, J= 2.4 Hz), 8.94 (1H, d, J
- 2.4 Hz), 11.52 (1H, brs).
,- 6: 0.91 (6H, d, J= 6.4
Hz), 1.83-1.90
s / Method C, Purity is
(1H, m), 2.75 (2H, d, J= 7.2 Hz), 7.15
N 100%, Rt = 2.054 min; (2H, dd, J= 4.8,
3.6 Hz), 7.57-7.62
\ /
9 s (3H, m), 7.67 (1H, dd,
J= 8.4, 2.0 Hz),
0 IHN-4, MS Calcd.: 553.1; MS
OH N F 7.83 (1H, d,J= 2.0
Hz), 8.41 (1H, d, J
0,-kFr Found: 553.8 [M + H] -P. = 2.4 Hz), 8.89 (1H, d, J= 2.4 Hz),
ci 11.53 (1H, brs), 14.31 (1H, brs).
,-
s / Method C, Purity is
6:0.90 (6H, d, J= 6.4 Hz), 1.83-1.90
\ ,,N 100%, Rt = 2.206 min; (1H, m), 2.77
(2H, d, J= 7.2 Hz), 7.15
O=N- MS Calcd.: 537.1; MS (1H, dd, J= 5.2,
3.6 Hz), 7.51-7.68
OH N F ,, (5H, m), 8.42 (1-H, d,
J= 2.4 Hz), 8.89
0F Found: 537.8 [M + H] -P. (1H, d, J= 2.4 Hz), 11.67 (1H, brs).
F
/
/ Method C, Purity is 6: 0.88 (6H, d, J=
6.4 Hz), 1.32 (3H, t,
s
N '
J= 7.2 Hz), 1.83-1.86 (1H, m), 2.69
-:\ 95.4%, Rt = 2.122 min-
\ õ (2H, d, J= 6.8 Hz),
4.03 (2H, q, J=
11
o HN-e I MS Calcd.: 479.0; MS
6.8 Hz), 6.96 (2H, d, J= 4.8 Hz), 7.14-
OH N Found: 480.0 M + H] 1.
7.16 (1H, m), 7.48 (2H, d, J= 4.8 Hz),
[
o'N 7.56-7.61 (2H, m),
8.42 (1H, d.. J= 2.4
125
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Hz), 8.90 (1H, d, J= 2.4 Hz), 11.51
(1H, brs), 14.28 (1H, brs).
ij Method C, Purity is 6: 0.88 (6H, d, J=
6.4 Hz), 1.78-1.81
(1H, m), 2.68 (2H, d, J¨ 6.8 Hz), 3.77
92.1%, Rt = 1.858 mm;
12 s (3H, s), 7.00 (2H, d,
J= 8.4 Hz), 7.40-
MS Calcd.: 464.0; MS 7.48 (3H, m), 7.53
(2H, d, J= 8.4 Hz),
O HN---e
OH
Found: 465.0 [M + H] 7.66 (2H, d, J= 7.2
Hz), 8.34 (1H, s),
10.27 (1H, s), 13.20 (1H, s).
6: 0.88 (6H, = 6.4 Hz),
1.88-1.90
Method C, Purity is
(1H, m), 2.67 (2H, d, J= 6.4 Hz), 6.82
100%, Rt = 1.939 min; (2H, d, J= 8.4 Hz),
7.15 (1H, q, J=
\ IN
13 4.4 Hz), 7.36 (2H, d,
J= 8.4 Hz), 7.57-
O HN¨e I MS Calcd.: 451.0; MS
7.61 (2H, m), 8.42 (1H, d, J= 2.8 Hz),
OH N
Found: 451.9 [M + H] . 8.89(1H, d, J= 2.4 Hz), 9.71 (1H,
OH brs), 11.52 (1H, brs).
6: 0.66-0.70 (2H, m), 0.78-0.83 (2H,
Method C, Purity is
LJ,Jm), 0.92 (6H, d, J= 6.4 Hz), 1.81-1.85
93.4%, Rt = 2.105 min; (1H, m), 2.71 (2H, d,
J= 7.2 Hz), 3.87-
14 s 3.90 (1H, m), 7.14
(2H, d, J= 8.8 Hz),
ON H_4.s. MS
Calcd.: 490.0; MS
7.41-7.49 (3H, m), 7.56 (2H, d.- J= 8.8
OH
Found: 490.9 [M + H] +. Hz), 7.69 (2H, d, J = 7.2 Hz), 8.36
(1H, s), 10.29 (1H, s), 13.26 (1H, s).
Method C, Purity is 6: 0.89 (6H, d, J= 6.8
Hz), 1.84-1.88
(1H, m), 2.72 (2H, d, J= 7.2 Hz), 7.10-
93.6%, Rt = 1.923 min;
/N 7.28 (4H, m), 7.47-
7.64 (4H, m), 8.43
O HN¨(.3 MS Calcd.: 501.1; MS
(1H, d, J= 2.4 Hz), 8.91 (1H, d, J=
OH N F1
Found: 502.0 M + H] +
2.4 Hz), 11.53 (1H, brs), 14.31 (1H,
[.
brs).
6:0.89 (6H, d, J= 6.4 Hz), 1.83-1.87
Method C, Purity is (1H, m), 2.70 (2H, d,
J= 6.8 Hz), 3.32
(3H, s), 3.66 (2H, t, J= 3.6 Hz), 6.99
100%, Rt = 2.060 min;
16 /N (2H, d, J = 8.4 Hz),
7.15 (1H, dd, =
MS Calcd.: 509.1; MS 5.2, 3.6 Hz), 7.49
(2H, d, J= 8.8 Hz),
- N
o
Found: 510.0 M + H]
7.57-7.62 (2H, m), 8.43 (1H, d. J= 2.4
[
Hz), 8.91 (1H, d, J = 2.4 Hz), 11.49
(1H, brs), 14.30 (1H, brs).
6:0.92 (6H, d, J= 6.8 Hz), 1.87-1.90
, Method C, Purity is
(1H, m), 2.72 (2H, d, J= 7.2 Hz), 4.47
s '
99.6%, Rt = 1.869 min; (2H, s), 7.01 (2H, d,
J= 8.8 Hz), 7.14-
17
\NS 7.16 (1H, m), 7.43 (1H, s), 7.53-7.55
MS Calcd.: 508.1; MS
- OH N (4H, m), 7.59 (1H, s),
8.41 (1H, d, J
NH
=
Found: 508.9 [M + H] ". 2.4 Hz), 8.69 (1H, d, J= 2.4 Hz), 13.99
(1H, brs).
Method C, Purity is 6: 3.59 (2H, d, J= 4.8
Hz), 3.77 (3H,
s), 5.13-5.18 (-2H, m), 6.01-6.08 (1H,
90.9%, Rt = 1.970 min-
'
\ /N m), 6.99 (2H, d, J=
8.4 Hz), 7.15 (1H,
18
ON I MS Calcd.: 449.1; MS
t, J= 3.6 Hz), 7.52-7.61 (4H, m), 8.43
OH N Found: 449.9 M + H]
(1H, d, J= 2.4 Hz), 8.90 (1H, d, J=
L. [
2.0 Hz-), 11.57 (1H, brs).
126
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Method B, Purity is 6: 0.65-0.66 (2H, m),
0.77-0.79 (2H,
s / m), 1.20 (0.67H, s),
1.83 (1H, dd, J=
100%, Rt = 2.136 min, 6.8, 1.2 Hz), 3.58
(1H, d,J= 6.0 Hz),
\ IN
2.262 min; MS Calcd.: 3.82-3.88 (1H, m),
5.13-5.18 (1H, m),
19
O HN-e I 5.92-6.08
(1H, m), 6.54-6.58 (1H, m),
OH N 475.1; MS Found: 475.9 7.08-7.16 (3H, m),
7.50-7.63 (4H, m),
o,6, 1_1\4 + H] . 8.43 (1H, t, J¨ 3.6 Hz), 8.90-8.92 (1H,
m).
Method B, Purity is 6: 1.85 (2H, dd, J=
6.4.- 1.6 Hz), 3.31-
LJ 3.34 (3H, m), 3.67-3.70 (2H, m), 4.14-
96.2%, Rt = 2.199 min;
20 s --, 4.16 (2H, m), 5.84-
5.90 (1H, m), 6.58
¨ s
MS Calcd.: 492.1; MS (1H, dd, J= 15.6, 2.4
Hz), 7.04-7.07
OH N
= Found: 492.9 M + H]
(2H, m), 7.44-7.58 (5H, m), 7.70-7.72
[ -P.
(2H, m), 8.39 (1H, s), 13.35 (1H, brs).
Method C, Purity is 6: 1.82 (1H, dd, J=
6.4, 1.6 Hz), 3.55
(1.38H, d,J= 5.67.2 Hz), 3.81 (3H, d,
100%, Rt = 1.944 min, J= 5.6 Hz), 5.13-5.20
(1.34H, m),
21 s `..= 1.986 min; MS Calcd.: 5.75-5.81 (0.34H,
m), 5.99-6.12 (1H,
m), 6.54-6.58 (1H, m), 7.01-7.06 (2H,
448.1; MS Found: 448.9 m), 7.31-7.35 (1H, m), 7.44 (2H, t, J=
= OH N
H] . 7.6 Hz), 7.57-7.62 (2H, m), 8.10 (1H,
d, J= 2.0 Hz).
6: 1.84 (2H, d, J= 5.6 Hz), 1.96 (1H, t,
Method C, Purity is J= 6.0 Hz), 3.33 (3H,
s), 3.69 (2H, s),
si
91.7%, Rt = 1.833 min;
22 4.13 (2H, d,J= 4.4
Hz), 5.92-5.97
(1H, m), 6.47-6.57 (1H, m), 7.01 (2H,
\ IN
HN- 1 MS Calcd.: 493.0; MS t. J= 5.2 Hz),
7.17 (1H, t, J= 4.0 Hz),
O OH N
o¨- Found: 494.0 M + H] '.50-7.64 (4H, m), 8.43-8.45 (1H, m),
[ '.
8.89-8.92 (1H, m), 10.81 (1H, s), 14.36
(1H, s).
6: 0.91 (6H, d, J= 6.4 Hz), 1.81-1.84
Method C, Purity is
(1H, m), 2.71 (2H, d, J= 7.2 Hz), 3.32
95.6%, Rt = 1.826 min; (3H, s), 3.67-3.69
(2H, m), 4.12-4.15
23 s --, (1H, m), 7.03 (2H,
d,./= 8.8 Hz),
¨ s
O HN--4 1 MS Calcd.: 508Ø, MS 7.41-7.56 (5H, m), 7.68-7.70 (2H,
d, J
OH N &hi
Found: 509.0 [M + H] -P. = 7.6 Hz), 8.38 (1H, s), 10.22 (1H, s),
13.28 (1H, s).
Method C, Purity is
6: 1.83 (3H, dd, J= 6.4. 1.6 Hz), 5.80
100%, Rt = 1.789 min, (1H, dd,./= 15.2, 6.8
1-1z), 6.57 (1H,
24
s -µ= 1.807 mm;
n. MS Calcd.: dd, J= 15.2, 1.6 Hz),
6.87 (2H, dd, J¨
6.4, 1.6 Hz), 7.39 (1H, t, J= 7.-2 Hz),
O HN \ 1
- ___(S
434.1; MS Found: 435.0 7.44-7.50 (4H, m), 7.66 (2H, d. J= 7.2
OH N
OH w + H] '. Hz), 7.80-7.84 (1H, m), 9.68 (1H, brs).
Method C, Purity is
6: 1.78-1.82 (3H, m), 3.83 (1H, s),
90.3%, Rt = 1.968 mm; 5.82-5.87 (1H, m),
6.26 (1H, d, J-
25 s `= MS Calcd.: 466.1; MS 15.6 Hz), 6.89-
7.00 (2H, m), 7.41-7.51
O HN µ 1
- --KS (1H, s), 10.39 (1H, brs), 13.36 (1H,
OH N Found: 466.9 [M + H] -P. brs)
F 0"--
127
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
6: 1.80 (2H, dd, J= 6.4, 1.2 Hz), 1.97
Method C, Purity is (0.26H, dd, J= 7.2,
1.2 Hz), 3.32 (3H,
_
d, J= 1.6 Hz), 3.67-3.70 (2H, m), 4.14-
95.6%, Rt = 1.966 min, 4.18 (2H, m), 4.81-
4.87 (0.46H, m),
26 \ IN 1.999 min; MS Calcd.: 5.06-5.17 (0.66H,
m), 5.82-5.98 (1H,
Hm--e I m), 6.21-6.26 (0.73 H,
m), 6.84-6.89
0 oH N
511.1; MS Found: 511.8 (1H, m), 6.91-6.97 (1H, m), 7.13-7.17
[NI + H] '. (1H, m), 7.35-7.41
(1H, m), 7.52-7.56
(2H, m), 8.42-8.44 (1H, m), 8.66-8.70
(1H, m).
Method C, Purity is 6: 1.80 (3H, dd, J=
6.8, 1.6 Hz), 3.83
/ 94.3%, Rt = 2.015 min .. (3H, s), 5.90-
5.96 (1H, m), 6.23-6.27
27
¨ -
, N ' (1H, m), 6.87-6.98
(2H, m), 7.17-7.19
\ / s
n HN--4N 7.64 (2H, m), 8.45
(1H, d, J= 2.4 Hz),
1 MS Calcd.: 467.1; MS (1H, m), 7.40 (1H,
t, J= 8.8 Hz), 7.59-
- OH
F
0, Found: 467.9 [M + H] .
8.90 (1 H, brs)
--
s / Method C, Purity is 6: 3.69 (2H, t, J= 6.0 Hz), 3.95 (1H, d,
¨\ J= 4.4 Hz), 5.21-5.26
(2H, m), 6.10-
\ iN 92.2%, Rt = 1.977 mm;
6.17 (1H, s), 7.22-7.32 (2H, m), 7.45-
28
0 HN¨e I MS Calcd.: 467.0; MS 7.52 (2H, m), 7.66-
7.70 (2H, m), 8.51
OH N
Found: 468.0 M + H] . (1H, d, J= 2.4 Hz), 8.98 (1H, d, J=
[ '
o' 2.4 Hz-), 11.71 (1H, s).
F
6: 3.33 (3H, s), 3.63-3.71 (4H, m),
Method C, Purity is
si 4.20-4.23 (2H, t, J= 4.4 Hz), 5.15-5.20
\,N 100%, Rt = 1.973 min;
(2H, m), 6.04-6.11 (1H_ m), 7.16-7.26
29 , HN--4S, 1 MS Calcd.: 511.0; MS (2H, m), 7.37-7.46
(2H, m), 7.60-7.63
- OH NI (2H, m), 8.45 (1H, d,
J= 2.4 Hz), 8.91
Found: 511.9 [M + H] . (1H, d, J¨ 2.4 Hz), 11.60(1H, s),
14.32 (1H, s).
6:0.92 (6H, d, J= 6.8 Hz), 1.86-1.90
Method C, Purity is (1H, m), 2.75 (2H, d,
J= 7.2 Hz), 3.71
si (2H, t, .1= 4.4 Hz), 4.22 (2H, t, .1= 4.4
97.0%, Rt = 2.608 min;
\ /4 Hz), 7.17-7.18
(1H, m), 7.19-7.26 (1H,
FIN-4! 1 Found: 527.8 M + H] = 12.4, 2.0 Hz),
7.60-7.64 (2H, m),
MS Calcd.: 527.0; MS m), 7.34-7.37 (1H, m),
7.42 (3H, dd, J
F [ +.
8.45 (2H, d, J=2.4 Hz), 8.93 (1H, d, J
=2.4 Hz), 11.52 (1 H, brs).
Method C, Purity is 6: 1.33 (6H, d, J= 6.8
Hz), 3.37-3.40
/ (4H, m), 3.71 (2H, q, J= 3.6 Hz), 4.23
95.8%, Rt = 2.001 min;
\ /4 (2H, t, J= 4.4
Hz), 7.17-7.41 (4H, m),
S, 1
0 HN---4 MS Calcd.: 513.0; MS 7.60-7.66 (2H, m),
8.46 (1H, d_ J= 2.4
31
OH N 0
0,0- Hz), 8.96 (1H, d, J= 2.4 Hz), 1'1.59
F Found: 513.9 [M + HI '.
(1H, brs), 14.33 (1H, brs).
Method B, Purity is
/ 6: 1.63-1.65 (4H, m), 1.81-1.82 (3H,
¨ 32 91.2%, Rt = 2.199 min; m), 2.14-2.15
(2H, m), 3.39-3.41 (2H,
\ iN
0 HN--(: 1 MS Calcd.: 539.0; MS m), 3.71 (2H, d,
J= 3.2 Hz), 4.23 (2H,
OH N d,.1= 3.6 Hz), 7.18-
7.27 (2H, m), 7.32-
F Found: 539.8 [M + H] ' . 7.41 (2H, m),
7.60-7.64 (2H, m), 8.45
128
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
(1H, d, J= 2.4 Hz), 8.94 (1H, s), 11.67
(1H, brs), 14.12 (1H, brs).
6: 0.92 (6H, d, J= 6.8 Hz), 1.85-1.90
Method C, Purity is
s (1H, m), 2.45-2.49
(3H_- m), 2.75 (2H,
N
97.5%, Rt = 2.165 min; d, J= 7.2 Hz), 6.86
(1H, dd, J= 3.6,
\ I
33 1.2 Hz), 7.14-7.51
(4H, m), 7.65 (2H,
0 HN-<I MS Calcd.: 515.1. MS
OH N d, J= 8.8 Hz), 8.38 (1H, d,J= 2.8
Found: 516.0 [M + H] Hz), 8.85 (1H, d, ./=
2.4 Hz), 11.56
O F
(1H, brs).
6: 0.91 (6H, d, J= 6.4 Hz), 1.86-1.89
s
Method C, Purity is (1H, m), 2.48-2.51
(3H. m), 2.72 (2H,
d, J= 7.2 Hz), 3.33 (3H-, s), 3.67-3.69
96.4%, Rt = 1.900 min; (2H, m), 4.12-4.14
(2H, m), 6.84-6.85
/N S
34 HN--4 (1H, m), 7.01 (2H, d,
J= 8.8 Hz), 7.39
OH N MS Calcd.: 523.0; MS
(1H, d, J= 3.6 Hz), 7.51 (2H, d, J=
= Found: 524.0 [M + H]
8.8 Hz), 8.37 (1H, d, J= 2.4 Hz), 8.80
(1H, d, J= 2.8 Hz-), 11.92 (1H, s),
14.23 (1H, s).
6: 0.91 (6H, d, J= 6.4 Hz), 1.86-1.89
(1H, m), 2.25 (3H, s), 2.72 (2H, d, J =
Method C, Purity is
7.2 Hz), 3.38 (3H. s), 3.67-3.69 (2H,
98.9%, Rt = 1.892 min; m), 4.12-4.14 (2H- ,
m), 6.84-6.85 (1H,
/N S
35 m), 7.01 (2H, d, J=
8.8 Hz), 7.16 (1H,
OH N MS Calcd.: 523.0; MS
s), 7.44 (1H.- s), 7.51 (2H, d,J= 8.8
LI Found: 524.0 [M + H] ". Hz), 8.41 (1H, d, J= 2.0 Hz), 8.85
(1H, d, J= 2.4 Hz), 11.57 (1H, s),
o.
14.24 (1H, s).
Method C, Purity is 6: 0.92 (6H, d, J= 6.4
Hz), 1.87-1.90
s (1H, m), 2.25 (3H, s), 2.75 (2H, d, J =
36 hN96.4%, Rt = 2.164 min; 6.4 Hz), 7.13-7.17
(1H, m), 7.25 (2H,
1; MS : 515 MS Calcd. . d, J= 8.4 Hz ), 7.31-
7.50 (2H, m), 7.65
o HN¨e I (2H, dd, J= 6.8, 2.0 Hz), 8.42 (1H, d,
OH N
7 Found: 515.9 [M + H] J= 2.8 Hz), 8.86- (1H, d,J= 2.8 Hz),
OF 11.54 (1H, brs).
6: 1.58-1.63 (4H, m), 1.80-1.81 (2H,
Method C, Purity is m), 2.11-2.13 (2H, m),
2.49 (3H, s),
2.51 (1H, s), 3.33 (3H, s), 3.67-3.70
98.6%, Rt = 2.136 min;
37 (2H, m), 4.12-4.15
(2H. m), 6.86 (1H,
O HN¨e I Calcd.: 535.1; MS dd, J= 4.0, 1.2
Hz), 7.0-2 (2H, d, J=
- OH N Found: 535.9 M + H]
8.8 Hz), 7.41 (1H, d,./= 3.6 Hz), 7.49
of [
(2H, d, J= 8.8 HZ), 8.38 (1H, d, J=
2.4 Hz), 8.85 (1H, d, J= 2.4 Hz).
6: 1.58-1.63 (4H, m), 1.80-1.81 (2H,
Method C, Purity is m), 2.10-2.11 (2H, m),
2.24 (3H, s),
/ 99.1%, Rt = 2.129 min; 2.51 (1H, s),
3.32 (3H, s), 3.67-3.69
38
(2H, m), 4.12-4.15 (2H. m), 7.01 (2H,
\
HN-e MSCalcd.: 535.1; MS d, J = 8.8 Hz),
7.08 (1H, s), 7.31 (1H,
- OH N d, J= 0.8 Hz), 7.49
(2H, d, J= 8.8 Hz),
of Found: 535.9 [M + H]
8.35 (1H, d, J= 2.4 Hz), 8.57 (1H, d, J
= 2.4 Hz), 14.53 (1H, brs).
129
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Method C, Purity is
6: 1.61-1.64 (4H, m), 1.82 (2H_- s), 2.16
s (2H, m), 2.25 (3H, s),
3.35 (1H, m),
97.2%, Rt = 2.184 min; 7.31 (1H, d,J= 37 Hz),
7.18 (1H, s),
39 /N 7.26(2H, d,J¨ 8.4 Hz),
7.45 (1H, d, J
0 H N I MS Calcd.: 527.1; MS =1.2 Hz), 7.62-
7.64 (2H, m), 8.42 (2H,
OH N
7 Found: 527.9 [M + H] d, J= 2.4 Hz), 8.89 (1H, d, J= 2.4 Hz),
11.53 (1H. brs).
6: 1.61-1.64 (4H, m), 1.82 (2H, s), 2.16
Method C, Purity is (2H, s), 2.48 (3H, s),
3.35 (1H, m),
s
6.86 (1H, q,J = 1.3 Hz), 7.31 (1H, d, J
=
/N 94.6%, Rt=2.184min; 37 Hz), 7.25 (2H,
d, J= 8.4 Hz),
0 H N-eI MS Calcd.: 527.1; MS 7.41 (1H, d, J= 3.6 Hz), 7.62-7.64
OH N
F (2H, m), 8.38 (1H, d, J= 2.4 Hz), 8.86
0F Found: 528.0 [M + H]
(1H, d, J= 2.8 Hz), 11.54 (1H, brs),
14.33 (1H, brs).
6: 0.92 (6H, d, J= 6.4 Hz), 1.86-1.87
Method C, Purity is (1H, m), 2.49 (3H, d,
J= 6.0 Hz), 2.74
s' (2H, d, J= 7.2 Hz), 3.33 (3H, s), 3.69-
¨ 96.1%, Rt = 1.917 min.
' 3.71 (2H, m), 4.21-
4.23 (2H. m), 6.86
41 H - N "
--K\S r-O MS Calcd.: 541.0; MS (1H, d, J= 2.8 Hz), 7.21-
7.26 (1H, m),
OH
Found: 542.0 M + H]
7.34-7.43 (3H, m), 8.38 (1H, d. J= 2.4
F ) [
Hz), 8.83 (1H, d J= 2.0 Hz). 11.54
(1H, s), 14.28 (1H, s).
6:0.92 (6H, d, J= 6.8 Hz), 1.86-1.90
Method C, Purity is (1H, m), 2.25 (3H, s),
2.758 (2H, d, J=
6.8 Hz), 3.33 (3H, s), 3.70 (2H, 1, J=
97.9%, Rt = 2.137 min;
4.4 Hz), 4.22 (2H. t J= 4.4 Hz), 7.18
42 \
MS Calcd.: 541.1; MS (1H, s), 7.24 (1H,
t,J= 8.8 Hz), 7.36
O
OH N (1H, d, J= 8.4 Hz), 7.40 (1H, d, J=
of Found: 541.9 [M + H]
2.0 Hz-), 7.43-7.46 (1H, m), 8.42 (1H,
d, J= 2.4 Hz), 8.86 (1H, d, J= 2.4 Hz).
6:0.92 (6H, d, J= 6.8 Hz), 1.86-1.89
(1H, m), 2.50 (3H, s), 2.73 (2H, d, J=
Method C, Purity is
7.2 Hz), 3.35 (3H, s), 3.71-3.73 (2H,
100%, Rt = 1.954 min; m), 4.22-4.25 (2H, m),
6.86 (1H, d, J
\ /NI
43 HN--e
MS Calcd.: 557.0; MS = 2.4 Hz), 7.23 (1H,
d, J= 8.8 Hz),
- N ,(01
7.40 (1H, d, J=3.6 Hz), 7.50-7.52 (1H,
OH
Found: 557.9 [M + H] m), 7.62 (111, d, J= 2.0 Hz), 8.38 (1H,
CI
d, J= 2.4 Hz), 8.82 (1H, d, J= 2.4 Hz),
11.68 (1H, s), 14.20 (1H, s).
6:0.93 (6H, d, J= 6.8 Hz), 1.86-1.90
Method C, Purity is (1H, m), 2.25 (3H, s),
2.74 (2H, d, J=
s I 6.8 Hz), 3.36 (3H, s), 3.72 (2H, t, J=
97.4% Rt = 2.180 min.
N 4.4 Hz), 4.24 (2H, t, J= 4.4 Hz), 7.17
44 s
(I, MS Calcd.: 557.1; MS (1H, s), 7.23 (1H, d, J= 8.8 Hz), 7.45
Found: 557.9 M + H]
OH N (1H, s), 7.52 (1H, dd, J= 8.8, 2.0 Hz),
of. [
7.63 (1H, d, J= 2.4 Hz), 8.42 (1H, d, J
= 2.4 Hz), 8.85 (1H, d, J= 2.4 Hz).
130
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
CDC136: 0.92 (6H, d, J= 6.4 Hz),
v Method C, Purity is
s / 1.54-1.63 (3H, m),
2.68 (2H, s), 3.46
- N 95.3%, Rt = 2.177 min;
(3H, s), 3.78 (2H, s), 4.15 (2H, s), 6.94
\ / = s
45 (1H, d, J¨ 7.6 Hz),
7.05 (1H, d, J -
(-01 MS Calcd.: 557.1; MS
OH N 3.6 Hz), 7.22 (1H, s),
7.26 (1H, s),
0) Found: 557.9 [M + H] '. 7.43 (1H, d, J=
5.6 Hz ), 7.52 (1H, d,J
CI
= 6.0 Hz ), 8.39 (1H, s), 8.59 (1H, s).
z Method C, Purity is 6: 0.89 (6H, d, J=
6.4 Hz), 1.52-1.63
s / (3H, m), 2.85-2.89
(2H, m), 3.33 (3H,
- N 100%, Rt = 1.914 min;
46 \ / = s s), 3.69-3.71 (2H, m),
4.21-4.23 (2H,
0_ HN---- N \ r,01 MS Calcd.: 541.0; MS m), 7.16-7.44
(4H, m), 7.59-7.61 (2H,
OH
Found: 542.0 M + H]
m), 8.45 (1H, d, J= 2.4 Hz), 8.88 (1H,
0) [ '.
F d, J=2.4 Hz), 12.05
(1H, s).
6:0.92 (6H, d, J= 6.8 Hz), 1.85-1.90
v Method C, Purity is (1H, m), 1.96-2.02
(2H_- m), 2.74 (2H,
s / d, J= 7.2 Hz), 3.27
(3H, s), 3.48-3.51
- N 99.6%, Rt = 2.117 min;
(2H, m), 4.13-4.16 (2H, m), 7.17-7.25
0 HN--4 1 ? MS Calcd.: 541.0; MS (2H, m), 7.34-7.43
(2H, m), 7.60-7.64
OH N
(2H, m), 8.45 (1H, d, J= 2.4 Hz), 8.92
F Found: 541.9 [M + H] '. (1H, d, J= 2.4
Hz), 11.52 (1H, s),
14.30 (1H, s).
6:0.93 (6H, d, J= 6.8 Hz), 1.86-1.90
Method C, Purity is (1H, m), 1.97-2.03
(2H.- m), 2.73 (2H,
d, J= 7.2 Hz), 3.27 (3H, s), 3.51-3.54
- N MS Calcd.: 557.0; MS (2H, m), 7.50-7.50
(1H, m), 7.60-7.64
0 98.5%, Rt = 2.164 min;
\ i = s (2H, m), 4.14-
4.17 (2H, m), 7.17-7.23
48 0 HN-4. 1
OH "--.
5)
- N
Found: 557.9 [M + HI -P (3H, m), 8.45 (1H, d,
J= 2.4 Hz), 8.92
.
ci (1H, d, J= 2.8 Hz),
11.60 (1H, s),
14.27 (1H, s).
6: 0.96 (3H, t, J= 7.2 Hz), 1.68 (2H, q,
J= 7.2 Hz), 2.85 (2H, t, J= 7.6 Hz),
Method C, Purity is
3.33 (3H, s), 3.69-3.72 (2H, m), 4.22
_ 100%, Rt = 2.023 min; (2H, t, J= 4.4
Hz), 7.18 (1H, dd, J=
\ IN
49 0 HN-e \ r,0I MS Calcd.: 513.1.' MS 4.2, 3.6 Hz),
7.25 (1H, t, J= 8.8 Hz),
- OH N 7.37 (1H, d, J= 8.4
Hz), 7.44 (1H, dd,
0) Found: 513.9 [M + H] -P. J= 12.4, 2.0 Hz),
7.59-7.64 (2H, m),
F
8.46 (1H, d, J= 2.4 Hz), 8.92 (1H, d, J
= 2.4 Hz), 11.62 (1H, brs).
6: 3.08 (2H, t, J= 2.0 Hz), 3.30 (3H,
s), 3.33 (3H. s), 3.61 (2H, t, J= 6.0
- N
v Method C, Purity is
\ Hz), 3.71 (2- Hz-
H, t,J= 4.4 -), 4.22 (2H,
s / o
100%, Rt = 1.865 mm; t. J = 4.4 Hz), 7.18
(1H, dd. J= 4.8,
'
\ I
50 Fini¨e 1 ,,,c)I MS Calcd.: 529.1. MS 3.6 Hz), 7.24
(1H, t, J= 8.8- Hz), 7.40
OH N (1H, d, J= 8.4 HZ), 7.47
(1H, dd, J=
0) Found: 529.9 [M + H] '. 12.8, 2.0 Hz),
7.60-7.65 (2H, m), 8.46
F
(1H, d, J= 2.4 Hz), 8.92 (1H, d, J=
2.8 Hz), 11.634 (1H, brs).
131
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
6: 0.92 (6H, d, J= 6.4 Hz), 1.87-1.90
riN Method C, Purity is (1H, m), 2.75 (2H,
d, J= 6.8 Hz), 3.34-
3.36 (3H, m), 3.71 (2H, t, J= 4.4 Hz),
- N 96.5%, Rt = 1.947 min;
4.22 (2H, t, J¨ 4.4 Hz), 7.24 (2H, t, J
51
0 \ IHN--4.8
N r.,0I MS Calcd.: 528.1; MS = 8.4 Hz), 7.34-
7.44 (2H, m), 7.83
OH
Found: 528.8 M + HI
(1H, d. J= 2.8 Hz), 7.96 (1H, d, J=
0) [ -P.
F 3.2 HZ), 8.76 (1H. d,
J= 2.4 Hz), 9.08
(1H, d, J= 2.4 1-1Z-), 11.65 (1H, brs).
6:0.93 (6H, d, J= 6.8 Hz), 1.85-1.92
F (1H, m), 2.75 (2H, d,
J= 7.2 Hz), 3.33
Method C, Purity is
(3H, s), 3.71 (2H, t, J= 4.4 Hz), 4.22
52
100%, Rt = 2.081 min; (2H, t, J= 4.4 Hz),
7.20-7.26 (2H, m),
¨ N
\ / 7.35-7.41 (1H, m),
7.44 (1H, d. J= 1.6
0 S 1 I ro MS Calcd.: 539.1; MS
Hz), 7.54 (1H, q, J= 8.0 Hz), 7.60-
OH N
0) Found: 540.0 [M + H] '. 7.67 (2H, m), 8.58
(1H, d, J= 2.4 Hz),
F 8.94 (1H, d, J= 2.4
Hz), 11.57 (1H,
brs), 14.24 (1H, brs).
6:0.92 (6H, d, J= 6.4 Hz), 1.86-1.90
Method C, Purity is
/ (1H, m), 2.75 (2H, d,
J= 6.8 Hz), 3.34
- N 100%, Rt = 2.586 min; (3H, s), 3.70-
3.70 (2H, m), 4.00 (3H,
\ i s 0-' s), 4.21-4.23 (2H, m),
7.17-7.26 (2H,
53 HN-- 1
0 N 5) MS Calcd.: 541.0; MS
0 m), 7.35-7.44 (2H, m),
7.61-7.65 (2H,
/
Found: 542.0 [M + HI '. m), 8.44 (1H, d, J= 2.4 Hz), 8.95 (1H,
F
d, J= 2.4 Hz), 11.16(1H, s).
6: 0.92 (6H, d, J= 6.4 Hz), 1.84-1.91
Method C, Purity is
(1H, m), 2.76 (2H, d, J= 7.2 Hz), 3.70-
96.4%, Rt = 1.998 min; 3.72 (2H, m), 4.21-
4.24 (2H, m), 7.20-
MS Calcd.: 528.0; MS
54 7.25 (2H, m), 7.35-
7.45 (2H, m), 7.68
o N .INN - - 4s roI
OH N (1H, q, J= 0.8 Hz),
7.90-7.91 (1H, m),
0) Found: 528.8 [M + H] 1. 9.20 (1H, m),
11.56 (1H, brs), 14.18
F
(1H, brs).
6: 0.93 (6H, d, J= 6.4 Hz), 1.85-1.92
s", Method C, Purity is (1H, m), 2.75 (2H,
d, J= 7.2 Hz), 3.33
(3H, s), 3.71 (2H, t, J= 4.4 Hz), 4.22
¨ 95.2%, Rt = 2.046 min;
\ ,N (2H, t, J= 4.4 Hz),
7.22-7.27 (1H, m),
55 0 HN-4
OH I ) r...0I MS Calcd.: 527.1;
MS 7.35-7.44 (2H, m), 7.67-7.71 (2H, m),
N
(: Found: 527.9 [M + HI . 8.04 (1H, q, J=
1.2 Hz), 8.60 (1H, d, J
F = 2.4 Hz), 9.00 (1H,
d, J= 2.4 Hz),
11.54 (1H, brs), 14.22 (1H, brs).
6: 0.92 (6H, d, J= 6.4 Hz), 1.86-1.89
Method C, Purity is
(1H, m), 2.35 (3H, s), 2.72-2.75 (4H,
_
\ iN 96.8%, Rt = 9.337 min; m), 3.33 (5H,
s), 2.69-2.71 (3H, m),
56 0 HN-e I 4.21-4.23 (2H, m),
7.19-7.26 (2H, m),
I MS Calcd.: 583Ø MS
NH NJ 0 ' 7.35-7.44 (2H, m),
7.60-7.61 (2H, m),
o Found: 584.2 [M + H] '. 8.52 (1H, d, J=
2.4 Hz), 8.79 (1H, d, J
HN F
\ = 2.4 Hz), 9.24 (1H,
s).
132
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
6: 0.92 (6H, d, J= 6.4 Hz), 1.86-1.90
(1H, m), 2.75 (2H, d, J= 7.2 Hz), 3.33
Method C, Purity is (3H, s), 3.69-3.72
(2H, m), 4.21-4.33
o / (2H, m), 6.64 (1H, dd,
J¨ 3.2, 2.0 Hz),
¨ N 96.4%, Rt = 2.024 min;
7.09 (1H, d,J= 3.2 Hz), 7.24 (1H, t, J
0 HN-4 \ 01 MS Calcd.: 511.1; MS
= 8.8 Hz), 7.36 (1H, d, J= 8.4 Hz),
OH N f Found: 511.9 M + H] 1.
7.43 (1H, dd, J= 12.8, 2.0 Hz), 7.80
o [
F (1H, d, J= 1.2 Hz),
8.54 (1H, t, J= 2.4
Hz), 8.95 (1H, d, J= 2.4 Hz), 11.54
(1H, brs), 14.29 (1H, brs).
6: 0.94 (6H, d, J= 6.8 Hz), 1.88-1.91
,- (1H, m), 2.74 (2H, d,
J= 6.8 Hz), 3.33-
/
Method C, Purity is
s / 3.34 (3H, m), 3.71
(2H, t,J= 4.4 Hz),
¨ N 98.1%, Rt = 2.149 min; 4.30 (2H, t, J=
4.4 Hz), 7.18 (1H, dd, J
\ s
58 0 HN4 1 = 4.8, 3.6 Hz ), 7.36
(1H, t, J= 8.8
OH N ro MS Calcd.: 577.1; MS
Hz), 7.60-7.64 (2H, m), 7.80-7.85 (2H,
F F F Found: 577.8 [M + H] 1. m), 8.46 (1H, d,
J= 2.4 Hz), 8.93 (1H,
d, J= 2.8 Hz), 11.55 (1H, brs), 14.30
(1H, brs).
6: 0.93 (6H, d, J= 6.8 Hz), 1.85-1.92
,- Method C, Purity is
/ (1H, m), 7.25 (2H, d,
J= 7.2 Hz), 3.69-
s
_ 0- 97.7%, Rt = 2.073 min;
3.71 (2H, m), 4.22-4.25 (2H, m), 7.12-
N
7.19 (2H, m), 7.26-7.34 (2H, m), 7.60-
HN--4. 1 e MS Calcd.: 527.1; MS
0 N 7.64 (2H, m), 8.46 (1H, d, J= 2.4 Hz),
OH
F Found: 527.9 [M + H] -P. 8.92 (1H, d, J= 2.4 Hz), 11.66 (1H,
brs), 14.24 (1H, brs).
Example 2. Synthesis of Certain Compounds
Scheme 1: Route for Compounds 787, 798, 808, 809
õ
_______________________________________________________________________________
___
'
Br o.B-0 _F-
¨
0 ly \ __ o
O
cpc
¨0 N Pd(dppf)Cl2, Na2CO3, 1.- (:),
(1/;1_ \ 0(:), / N
--?:
dioxane, H20, 85 C, 16 h ¨ /
H2N 0 ¨N ¨0 ¨0 ¨/
H2N H2N H2N H2N
SM 798 808
809
787
The same synthesis method used for other compounds 798, 808, 809. ,
Scheme 2: Route for Compounds 794-s, 796-s, 812-s, 813-s, 817-s, 822-s, 830-s,
831-s, 841-s,
842-s
133
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
0 OH 0
0
I
F BrMg'"1-- F PCC F PTAT F
0 THF, rt, 4 h CH202, rt, 2 h.- THF,
rt, 2 h
794-1 794-2 794-3
794-4
0 S
NaSCN _ F HCl/dioxane._ ci--4, 1
Et0H, 90 C, 5 h rt, 4 h N
SCN
0
794-5 794-sF
S S S S
CI--<S \ 1 CI----4 I CI-4 CI----4 1 CI¨c. I
N N N N N
F CI
F
F
796-s 812-s 813-s 817-s 822-s
S
S S S
Cl¨S 1 CI--4 I CI-4 I
N CI--4.
N N F i CI-
-4. 1 I
0
N N
..--
0
CI
r0 _...0
,0
___0 ,0
830-s 831-s 839-s 841-s 842-s
The same synthesis method used for other compounds 796-s, 812-s, 813-s, 817-s,
822-s, 830-s, 831-s, 841-s, 842-s.
.
..
Scheme 3: Route for Compound 795-s
O o
1 )=,-,,,MgBr ci OH 0
I
CI CH3I CI PCC CI
_____________________________________________ _
101 K2CO3, DMF, it, 16 h 101 THE, 0 C- rt,
16 h CH2Cl2, rt, 2 h
HO 0 ,..0 ..o
SM1 795-1 795-2
795-3
0 S S
PTAT , CI NaSCN 0 1 POCI3
THF, rt, 2 h Br
Et0H, 90 C, 5 h HN 100C, 5 h N
0--
0
CI CI
--
795-4 795-5 795-s
Scheme 4: Route for Compound 797-s
134
CA 03229560 2024-2-20
WO 2023/028235 PCT/US2022/041532
o o o,0 o
0
F 40 pr''---0-- F F ....-- PVC, Hz
F
K2CO3, DMF, it, overnigh-t
01 KOH, Me0H, it, overnight Me0H,
it, 21-7
HO ,0,----.0 ..--o-...----,0
SM2 797-1 797-2
797-3
0 0
PTAT ,.. F NaSCN F"111 HCl/dioxane,_ ,S
I
THF, it, 2 h Et0H, 90 C, 5 h rt, 4 h Ch---, 1 (.0
Br SCN N .õ..-0...,õ---,o
.--o-...-----0
0)
797-4 797-5
797-Fs
Scheme 5: Route for Compounds 802-s-805-s, 8H-s
0 OH
0
I ,\*
F Br ...--..,_,O., F
BrMg F PCC
HO F
K2003, DMF, it, 16 h .....0,--,0 So THF, it. 16 h CH2Cl2,
it, 2 n ,
. 0 --"-'.-----
-,0
5M3 802-1 802-2 802-
3
0 0
S
PTAT F NaSCN F HCl/dioxene,
ci___4 i I
... 1.- 0
THF, it, 2 h Et0H, 90 C, 5 h rt, 4 h N
.....0,.....o SCN
I
0
F
802-4 802-5
802-s
__________________________________________________________________________ ,
....,
0
s r _is 1 -T-- s
rj s
ci--4. i 0 Cl ¨4 = 0 CI-4. 1 r
I
N N
0-)0 I N CI----4..
N õ...0
of 0
0)
F F F
F
803-S 804-S 805-S 811-S
, The same synthesis method used for other compounds 803-5-805-s, 811-s. ,
Scheme 6: Route for Compounds 814-s, 818-s-820-s, 823-s, 824-s, 826-s, 827-s,
829-s, 835-
s-837-s, 840-s
135
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
S S S
CI---4 BBr3 i 131-----"--- ' CI-4, 1
N N
CH2Cl2, it, overnight
K2CO3,KC0 DMF, rt, overnight
CI CI CI
0 OH 0--.0,-,
..,
813-s 814-1 814-s
S
S S S S
S S CI-4 1
CI-4, I CH-4 i CI-4 1 CI-4 1
N N N CI---4 1 CI-4 1 N
N
N N
F
CI F
F
CI F
0..,..õ..----.,0..-- 00
0..õ.......-----,0...-L
,-- Oy=-
818-s 819-s 820-s 823-s 824-s 826-s
827-s
S S S S S CI-4 I CI--(.. I CI---4, I
CI----4 I CI---4 1 CI-4. S I
N N N N N N
F CI F ...õ.1..õ0 F õ.....L.....õ0
CI
829-s 832-s 835-s 836-s 837-s 840-s
The same synthesis method used for other compounds 818-s-820-s, 823-s, 824-s,
826-s, 827-s, 829-s, 835-5-837-5, 840-s.
Scheme 7: Route for Compounds 815-s, 825-s
o o o
HN---4, 1 BBr3
... HN¨ 1 Br '',-- ' ... HN-4\ \
N N N
CH2Cl2, rt, overnight K2CO3, DMF, rt, overnight
CF3 CF3 CF3
0 OH
---
816-5 815-1 815-2
.
_______________________________________________________________________________
__ .
S
H2N--4
NaOH H2N-4 1 S
N s 1
Et0H, 70 C, overnight N
CF3
CF3
815-s 0.......õ-
-......0,-
825-s
The same synthesis method used for other compound 825-s.
Scheme 8: Route for Compound 816-B
F
FE .4.. B-BC),... F
0 .0 F
F ________________ 1.
41111 Pd(dppf)C12, KOAC 0B
/
Y' Br C dioxane, 90 C, overnight 0
SM4 816-B
Scheme 9: Route for Compounds 816-s, 828-s
136
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
----
0
H2N¨e / Py, rtToFvernight FIN--< I THF 6 , 7; S
TFA/TESOH
N N N rt, 1 h
N
CI CI CI CI
816-1 816-2 816-3 816-4
F
F
'
a > .,F
0. =,.1' 5ic5 0 0 ---- is 1 ,s ,
816-B ____________________ HN--, ; NaOH , H2N--k. I H2N s--
I
K3PO4, Pd(0Ac)2, PCY3 N Ft0H, 70 C, overnight N N
toluene/H20, MW 150 C, 4 h.
CF3 CF3
0 ,.0 CF3
...-0
816-5 816-s
828-s
The same synthesis method
used for other compound 828-s._,
Scheme 10: Route for Compound 833-s
OH 0 0
0
,0 0 ? BrMg'''''j< ,C PCC ..,..0 PTAT ..õ.0 NaSCN
THF, it. 16 h I CH2C12. it, 2 h THF, it,
16 h Et0H, 90 'C, 3 h
Br
SCN
CI CI CI CI CI
833-1 833-2 833-3 833-4
833-5
S S S
HCl/dioxane3, ci--4 1 BBr3
= ____________________________________________________ CI---4 I 1 .= Cl
1
rt, 43 N CH2Cl2, It, overnight N K2CO3, DMF,
it, 2 h N
CI CI CI
,C OH s=-=-===
833-6 833-7 833-s
Scheme 11: Route for Compounds 1-60 to 1-75, 1-78 to 1-84, 1-86, 1-87, 1-89 to
1-101
o
(-ITN
S I N N N N
N NH2 \4,/ LiCH
C1-4\ 1 S
/ S
N Pd2(dba)3, X-Phos, Cs2CO3 Oi 1-
1\N¨ I THF/Me0H, it, 2 h 0 H(N¨ I
cy,' toluene, 120 C, 4 h /0 N OH
N
F 0----
0--
794-s 794-6 F 1-
60 F
The same synthesis method used for other compounds 1-61 to 1-75,1-78 to 1-84,1-
86,1-87, 1-89 to 1-101 .
Scheme 12: Route for Compounds 1-76, 1-77, 1-85, 1-88
--- ,.--
0 jotryo s / s /
_
..... ..õ, , ¨
s I N N
H2N-4 1 ' N -
HN-4. _
HN-4. 1
Pd2(dba)3, X-phos, Cs2CO3, 0 THF/Me0H rt, 2 h -- 0
OH
F toluene, 120 C, 4 h 0 N
N
F
-..,0....--..õ..0 F F
F
--...0,-..õ.0 F
-...Ø.---...0 F
815-s 815-3 1-
76
The same synthesis method used for compounds 1-77, 1-85, 1-88.
1003981 General information: All evaporations were carried out in
vacuo with a rotary evaporator.
Analytical samples were dried in vactto (1-5 mmHg) at rt. Thin layer
chromatography (TLC) was performed
137
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
on silica gel plates, spots were visualized by UV light (214 and 254 nm).
Purification by column and flash
chromatography was carried out using silica gel (200-300 mesh). Solvent
systems are reported as mixtures
by volume. All NMR spectra were recorded on a Bruker 400 (400 MHz)
spectrometer. 1H chemical shifts
are reported in 6 values in ppm with the deuterated solvent as the internal
standard. Data are reported as
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet,
q = quartet, br = broad, m =
multiplet), coupling constant (Hz), integration.
1003991 LCMS spectra were obtained on an Agilent 1200 series 6110 or 6120 mass
spectrometer with
electrospray ionization and excepted as otherwise indicated, the general LCMS
condition was as follows:
Method A (Agilent LCMS 1200-6110, Column: Waters X-Bridge C18 (50 mm x 4.6 mm
x 3.5
um); Column Temperature: 40 C; Flow Rate: 3.0 mL/min; mobile phase: from 95%
[water + 0.05% TFA]
and 5% [CH3CN + 0.05% TFA] to 0% [water + 0.05% TFA] and 100% WH3CN + 0.05%
TFA] in 0.8 min,
then under this condition for 0.4 min, finally changed to 95% [water + 0.05%
TFA] and 5% [CH3CN +
0.05% TFA] in 0.01 min).
Method B (Agilent LCMS 1200-6110, Column: Waters X-Bridge C18 (50 mm x 4.6 mm
x 3.5
um); Column Temperature: 40 C; Flow Rate: 2.0 mL/min; Mobile Phase: from 95%
[water + 0.05% TFA]
and 5% WH3CN + 0.05% TFA] to 0% [water + 0.05% TFA] and 100% WH3CN + 0.05 %
TFA] in 1.6
min, then under this condition for 1.4 min, finally changed to 95% [water +
0.05% TFA] and 5% [CH3CN
+ 0.05% TFA] in 0.05 min and under this condition for 0.7 min.).
Method C (Agilent LCMS 1200-6120, Column: Waters X-Bridge C18 (50 mm x 4.6 mm
x 3.5
um); Column Temperature: 40 C; Flow Rate: 2.0 mL/min; Mobile Phase: from 95%
[water + 10 mM
NH4HC031 and 5% [CH3CN] to 0% [water + 10 mM NH4HC031 and 100% [CH3CN] in 1.6
min, then under
this condition for 1.4 min, finally changed to 95% [water + 10 mM NH4HC031 and
5% [CH3CN] in 0.1
min and under this condition for 0.7 min.)
Method D (Agilent LCMS 1200-6120, Column: Waters X-Bridge C18 (50 mm x 4.6 mm
x 3.5
um); Column Temperature: 45 C; Flow Rate: 2.3 mL/min; Mobile Phase: from 95%
[water + 10 mM
NH4HC031 and 5% [CH3CN] to 0% [water + 10 mM NH4HC031 and 100% [CH3CN] in 1.75
min, then
under this condition for 0.8 min, finally changed to 95% [water + 10 mM
NH4HCO3] and 5% [CH3CN] in
0.1 min and under this condition for 0.1 min.)
Experimental Section
The synthesis of methyl 3-amino-6-(thiophen-2-yl)pyrazine-2-carboxylate (787)
138
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
B
0 N ________________ Br \
0 N
Pd(dppf)C12, Na2CO3,
¨0 ¨N
dioxane, H20, 85 C, 16 h
H2N 0 ¨N
H2N
SM
787
1004001 A mixture of SM (1.0 g, 4.31 mmol), 4,4,5,5-tetramethy1-2-(thiophen-2-
y1)-1,3,2-
dioxaborolane (1.36 g, 6.47 mmol), Pd(dppf)C12 (315 mg, 0.431 mmol) and Na2CO3
(1.84 g, 8.62 mmol)
in dioxane/H20 (v/v = 5/1, 10.0 mL) was stirred under N2 atmosphere at 85 C
for 16 h. When the reaction
was completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl
acetate = 3/1) to afford 787 (670 mg, 66.1% yield) as a brown solid.
The synthesis of 1-(3-fluoro-4-methoxypheny1)-4-methylpentan-1-ol (794-2)
0 OH
BrMg" F
THF, rt, 4 h
0 0
794-1 794-2
1004011 To a solution of 794-1 (2.0 g, 13.0 mmol) in THF (20.0 mL) was added
isopentylmagnesium
bromide (1.0 M in THF, 19.5 mL, 19.5 mmol). The reaction was stirred at room
temperature for 4 h. When
the reaction was completed, it was poured into aq.NH4C1 (sat., 50.0 mL) and
extracted with Et0Ac (80.0
mL x 3). The organic phase was combined, and washed with H20 (50.0 mL) and
brine (80.0 mL), then
dried with anhydrous Na2SO4, concentrated and purified by silica gel column
chromatography (petrol
ether/ethyl acetate = 10/1) to afford 794-2 (2.50 g, 85.1% yield) as yellow
oil.
The synthesis of 1-(3-fluoro-4-methoxypheny1)-4-methylpentan-1-one (794-3)
OH 0
PCC FJL¨
I
CH2Cl2, rt. 2 h
0 0
794-2 794-3
1004021 To a solution of 794-2 (2.50 g, 11.0 mmol) in CH2C12 (100 mL)
was added PCC (4.76 g, 22.1
mmol). The reaction was stirred at room temperature for 2 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 30/1) to afford
794-3 (2.30 g, 92.8% yield) as colorless oil.
The synthesis of 2-bromo-1-(3-fluoro-4-methoxypheny1)-4-methylpentan-1-one
(794-4)
139
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0 0
PTAT F
THF, rt, 2 h
Br
794-3 794-4
1004031 A mixture of 794-3 (2.30g. 10.3 mmol) and PTAT (5.78 g, 15.4 mmol) in
THF (50.0 mL) was
stirred at room temperature for 2 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (30.0 mL), and then extracted with Et0Ac (50.0 mL x 2).
The organic layer was
combined, and washed with H20 (30.0 mL x 2) and Brine (30.0 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 794-4 (3.30 g, 100% yield) as brown oil.
The synthesis of 1-(3-fluoro-4-methoxypheny1)-4-methy1-2-thiocyanatopentan-1-
one (794-5)
0 0
Fl NaSCN
Et0H, 90 C, 5 h
Br o SCN
794-4 794-5
1004041 A mixture of 794-4 (3.30 g, 10.9 mmol) and NaSCN (1.76 g, 21.8 mmol)
in Et0H (50.0 mL)
was stirred at 90 C for 5 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 794-5
(2.50 g, 81.6% yield) as a
yellow solid.
The synthesis of 2-chloro-4-(3-fluoro-4-methoxypheny1)-5-isobutylthiazole (794-
s)
0
HCl/dioxang ci-4
SCN rt, 4 h N
794-5 794-sF
1004051 A mixture of 794-5 (2.50 g, 8.90 mmol) in HC1/dioxane (4.0 M, 30.0 mL)
was stirred at room
temperature for 4 h. When the reaction was completed, it was concentrated and
purified by silica gel column
chromatography (petrol ether/ethyl acetate = 10/1) to afford 794-s (2.30 g,
86.3% yield) as yellow oil.
The synthesis of 3-chloro-4-methoxybenzaldehyde (795-1)
0 0
CI CH3I CI
II K2CO3, DMF, rt, 16
OP
HO
SM1 795-1
140
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1004061 A mixture of SM1 (3.0 g, 19.2 mmol), CH3I (4.08 g, 28.7 mmol) and
K2CO3 (5.29 g, 38.3
mmol) in DMF (10.0 mL) was stirred at room temperature for 16 h. When the
reaction was completed, it
was poured into H20 (100 mL) and extracted with Et0Ac (100 mL x 3). The
organic phase was combined,
and washed with H20 (80.0 mL) and brine (80.0 mL), then dried with anhydrous
Na2SO4, concentrated and
purified by silica gel column chromatography (petrol ether/ethyl acetate =
30/1) to afford 795-1 (3.10 g,
94.8% yield) as colorless oil.
The synthesis of 1-( 3 -chloro-4-methoxypheny1)-5 -methylhexan-1 -ol (795-2)
OH
CI (I) _____________ CI
THF, 0 C- rt, 16 h
795-1 795-2
1004071 To a solution of 795-1 (3.10 g, 18.2 mmol) in THF (30.0 mL)
was added (4-
methylpentyl)magnesium bromide (1.0 M in THF, 27.4 mL, 27.4 mmol) at 0 'C. The
reaction was stirred
at room temperature for 16 h. When the reaction was completed, it was poured
into aq.NH4C1 (sat., 50.0
mL) and extracted with Et0Ac (80.0 mL x 3). The organic phase was combined,
and washed with H20
(50.0 mL) and brine (80.0 mL), then dried with anhydrous Na2SO4, concentrated
and purified by silica gel
column chromatography (petrol ether/ethyl acetate = 10/1) to afford 795-2 (3.0
g, 64.1% yield) as colorless
oil.
The synthesis of 1-(3-chloro-4-methoxypheny1)-5-methylhexan-1-one (795-3)
OH 0
CI PCC CI
CH2Cl2, rt, 2 h
0 0
795-2 795-3
1004081 To a solution of 795-2 (3.0 g, 9.74 mmol) in CH2C12 (100 mL)
was added PCC (4.20 g, 19.5
mmol). The reaction was stirred at room temperature for 2 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 30/1) to afford
795-3 (2.50 g, 84.0% yield) as a white solid.
The synthesis of 2-bromo-1-(3-chloro-4-methoxypheny1)-5-methylhexan-1-one (795-
4)
0 0
CI PTAT CI
THF, rt, 2 h
Br
0 0
795-3 795-4
141
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1004091 A mixture of 795-3 (2.50 g, 9.81 mmol) and PTAT (5.52 g, 14.7 mmol) in
THF (50.0 mL) was
stirred at room temperature for 2 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (30.0 mL), and then extracted with Et0Ac (50.0 mL x 2).
The organic layer was
combined, and washed with H20 (30.0 mL x 2) and Brine (30.0 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 795-4 (3.30 g, 100% yield) as brown oil.
The synthesis of 4-( 3 -chloro-4-methoxypheny1)-5 sopentylthiazol-2 (3H)-one
(795-5)
0
CI NaSCN
Et0H, 90 C, 5 h HN
Br
0
ath
CI
795-4 795-5
1004101 A mixture of 795-4 (3.30 g, 9.89 mmol) and NaSCN (1.60 g, 19.8 mmol)
in Et0H (50.0 mL)
was stirred at 90 C for 5 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 10/1) to afford 795-5
(800 mg, 25.9% yield) as a
yellow solid.
The synthesis of 2-chloro-4-(3-chloro-4-methoxypheny1)-5-isopentylthiazole
(795-s)
0 POCI3 CI
HN ist 100 C, 5 h
4110
CI CI
795-5 795-s
1004111 A mixture of 795-5 (800 mg, 0.865 mmol) in POC13 (10.0 mL) was stirred
at 100 C for 5 h.
When the reaction was completed, it was concentrated, poured into H20 (80.0
mL) and extracted with
Et0Ac (80.0 mL x 3). The organic phase was combined, and washed with H20 (50.0
mL) and brine (50.0
mL), then dried with anhydrous Na2SO4, concentrated and purified by silica gel
column chromatography
(petrol ether/ethyl acetate = 20/1) to afford 795-s (450 mg, 53.1% yield) as
colorless oil.
The synthesis of 1-(3-fluoro-4-(2-methoxyethoxy)phenyl)ethanone (797-1)
142
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
0 0
K2003, DMF, rt, overnightrµ
HO 401
SM2 797-1
1004121 A mixture of SM2 (5.0 g, 32.4 mmol), 1-bromo-2-methoxyethane (5.41 g,
38.9 mmol) and
K2CO3 (8.96 g, 64.9 mmol) in DMF (20.0 mL) was stirred at room temperature
overnight. When the
reaction was completed, it was poured into H20 (200 mL) and extracted with
Et0Ac (150 mL x 3). The
organic phase was combined, and washed with H20 (100 mL) and brine (100 mL),
then dried with
anhydrous Na2SO4, concentrated to give the crude product, which was used
directly in next step without
farther purification to afford 797-1 (6.0 g, 87.1% yield) as colorless oil.
The synthesis of (E)-1-(3-fluoro-4-(2-methoxyethoxy)pheny1)-3-phenylprop-2-en-
l-one (797-2)
O,
KOH, Me0H, it overnight I ii
797-1 797-2
1004131 To a solution of 797-1 (6.0 g, 28.3 mmol) and benzaldehyde (3.00 g,
28.3 mmol) in Me0H
(750 mL) was added KOH (6.0 M in H20, 110 mL). The reaction was stirred at
room temperature overnight.
When the reaction was completed, it was filtered and the residue was washed
with H20 (5.0 mL) and cool
Me0H (10.0 mL) to afford 797-2 (2.00 g, 23.6% yield) as a white solid.
The synthesis of 1-(3-fluoro-4-(2-methoxyethoxy)pheny1)-3-phenylpropan-1-one
(797-3)
0 0
Pt/C, H2
Me0H, it, 2 h
0
797-2 797-3
1004141 A mixture of 797-2 (2.00 g, 6.66 mmol) and Pt/C (200 mg) in Me0H (50.0
mL) was stirred
under H2 atmosphere at room temperature for 2 h. When the reaction was
completed, it was filtered and the
filtrate was concentrated to give a crude product, which was used directly in
next step without farther
purification to afford 797-3 (1.60 g, 79.5% yield) as colorless oil.
The synthesis of 2-bromo-1-(3 -fluoro-4-(2-methoxyethoxy)pheny1)-3 -
phenylpropan-l-one (797-4)
143
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
0 0
F PTAT
THF, rt, 2 h-
Br
797-3 797-4
1004151 A mixture of 797-3 (1.60 g, 6.62 mmol) and PTAT (3.72 g, 9.92 mmol) in
'THF (50.0 mL) was
stirred at room temperature for 2 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (30.0 mL), and then extracted with Et0Ac (50.0 mL x 2).
The organic layer was
combined, and washed with H20 (30.0 mL x 2) and Brine (30.0 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 797-4 (2.00 g, 100% yield) as brown oil.
The synthesis of 1-(3 -fl uoro-4-(2-methoxyethoxy)pheny1)-3 -pheny1-2-thioc
yanatoprop an-1 -one (797-5)
0 0
NaSCN
Et0H, 90 00, 5 h
Br SON
797-4 797-5
1004161 A mixture of 797-4 (2.00 g, 5.25 mmol) and NaSCN (850 mg, 10.5 mmol)
in Et0H (50.0 mL)
was stirred at 90 C for 5 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 797-5
(1.00 g, 53.0% yield) as a
yellow solid.
The synthesis of 5 -benzy1-2-chloro-4- (3 -fluoro-4-(2-
methoxyethoxy)phenyl)thiazole (797-s)
0
HCl/dioxang
rt, 4 h 0
SCN N = f
0
797-5 797-s
1004171 A mixture of 797-5 (1.00 g, 2.78 mmol) in HC1/dioxane (4.0 M, 10.0 mL)
was stirred at room
temperature for 4 h. When the reaction was completed, it was concentrated and
purified by silica gel column
chromatography (petrol ether/ethyl acetate = 10/1) to afford 797-s (600 mg,
57.1% yield) as colorless oil.
The synthesis of 3-fluoro-4-(2-methoxyethoxy)benzaldehyde (802-1)
144
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0
F
K2CO3, DMF, rt, 16 h 11101
HO
SM3 802-1
1004181 A mixture of SM3 (1.50 g, 10.7 mmol), 1-bromo-2-methoxyethane (1.79 g,
12.8 mmol) and
K2CO3 (2.96 g, 21.4 mmol) in DMF (10.0 mL) was stirred at room temperature for
16 h. When the reaction
was completed, it was poured into H20 (100 mL) and extracted with Et0Ac (100
mL x 3). The organic
phase was combined, and washed with H20 (80.0 mL) and brine (80.0 mL), then
dried with anhydrous
Na2SO4, concentrated to give the crude product, which was used directly in
next step without farther
purification to afford 802-1 (2.00 g, 94.3% yield) as colorless oil.
The synthesis of 1-(3-fluoro-4-(2-methoxyethoxy)pheny1)-4,4-dimethylpentan-1-
ol (802-2)
OH
F
THF, rt. 16 h
802-1 802-2
1004191 To a solution of 802-1 (2.00 g, 10.1 mmol) in THF (20.0 mL)
was added (3,3-
dimethylbutyl)magnesium bromide (1.0 M in THF, 15.1 mL, 15.1 mmol). The
reaction was stirred at room
temperature for 16 h. When the reaction was completed, it was poured into
aq.NH4C1 (sat., 50.0 mL) and
extracted with Et0Ac (80.0 mL x 3). The organic phase was combined, and washed
with H20 (50.0 mL)
and brine (80.0 mL), then dried with anhydrous Na2SO4, concentrated and
purified by silica gel column
chromatography (petrol ether/ethyl acetate = 8/1) to afford 802-2 (2.90 g,
100% yield) as yellow oil.
The synthesis of 1-(3-fluoro-4-(2-methoxyethoxy)pheny1)-4,4-dimethylpentan-1-
one (802-3)
OH 0
PCC
CH2Cl2, rt, 2 h
802-2 802-3
1004201 To a solution of 802-2 (2.90 g, 10.2 mmol) in CH2C12 (100 mL)
was added PCC (4.40 g, 20.4
mmol). The reaction was stirred at room temperature for 2 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 30/1) to afford
802-3 (2.40 g, 83.4% yield) as colorless oil.
The synthesis of 2-bromo-1-(3-fluoro-4-(2-methoxyethoxy)pheny1)-4,4-
dimethylpentan-1-one (802-4)
145
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0 0
PTAT
=
THF, rt 2 h
Br
802-3 802-4
1004211 A mixture of 802-3 (2.40 g, 8.50 mmol) and PTAT (4.78 g, 12.8 mmol) in
'THF (50.0 mL) was
stirred at room temperature for 2 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (30.0 mL), and then extracted with Et0Ac (50.0 mL x 2).
The organic layer was
combined, and washed with H20 (30.0 mL x 2) and Brine (30.0 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 802-4 (3.10 g, 100% yield) as brown oil.
The synthesis of 1-(3-fluoro-4-(2-methoxyethoxy)pheny1)-4,4-dimethy1-2-
thiocyanatopentan-1-one (802-
5)
NaSCN
1.
Et0H, 90 C, 5 h
Br
0 S C N
802-4 802-5
1004221 A mixture of 802-4 (3.10 g, 8.58 mmol) and NaSCN (1.39 g, 17.2 mmol)
in Et0H (80.0 mL)
was stirred at 90 C for 5 h. When the reaction was completed, it was
concentrated and purified by silica
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 802-5
(1.70 g, 42.9% yield) as a
yellow solid.
The synthesis of 2-chloro-4-(3-fluoro-4-(2-methoxyethoxy)pheny1)-5-
neopentylthiazol e (802-s)
0
HCl/dioxane..
0
rt, 4 h
SCN N
0
ci-
802-5 802-s
1004231 A mixture of 802-5 (1.70 g, 5.01 mmol) in HC1/dioxane (4.0 M, 10.0 mL)
was stirred at room
temperature for 4 h. When the reaction was completed, it was concentrated and
purified by silica gel column
chromatography (petrol ether/ethyl acetate = 10/1) to afford 802-s (1.50 g,
83.7% yield) as yellow oil.
The synthesis of 2-chloro-5-(2-chloro-5-isobutylthiazol-4-yl)phenol (814-1)
146
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
S S
C1-4 I BBr3
CI¨K\ I
N 0 c N 0 C11-12C12, rt, overnight
CI
0 OH.-
813-s 814-1
[00424] A mixture of 813-s (4.70g. 14.9 mmol) and BBr3 (17% in CH2C12, 22.3
mL, 22.3 mmol) in
CH2C12 (80.0 mL) was stirred at room temperature overnight. When the reaction
was completed, it was
washed with H20 (50.0 mL x 3). The organic layer was concentrated and purified
by silica gel column
chromatography (petrol ether/ethyl acetate = 6/1) to afford 814-1 (1.70 g,
37.8% yield) as yellow oil.
The synthesis of 2-chloro-4-(4-chloro-3-(2-methoxyethoxy)pheny1)-5-
isobutylthiazole (814-s)
S S
CI-4 I Br'... '. ... CI-4 I
N K2CO3, DMF it, overnight 0 , , N 0
ci
ci
OH0.......,....-...Ø...-
814-1 814-s
[00425] A mixture of 814-1 (850 mg, 2.81 mmol), 1-bromo-2-methoxyethane (469
mg, 3.38 mmol) and
K2CO3 (776 mg, 5.6331.4 mmol) in DMF (8.0 mL) was stirred at room temperature
overnight. When the
reaction was completed, it was poured into H20 (100 mL) and extracted with
Et0Ac (100 mL x 3). The
organic phase was combined, and washed with H20 (80.0 mL) and brine (80.0 mL),
then dried with
anhydrous Na2SO4, concentrated and purified by silica gel column
chromatography (petrol ether/ethyl
acetate = 20/1) to afford 814-s (1.00 g, 98.7% yield) as yellow oil.
The synthesis of 2-(3-methoxy-4-(trifluoromethyl)pheny1)-4,4,5,5-tetramethy1-
1,3,2-dioxaborolane (816-
B)
- F0 Ot F
F B-B __
Pd(dppf)C12, KOAC B 0
dioxane, 90 C, overnight 6
SM4 816-B
[00426] A mixture of SM4 (5.0 g, 19.6 mmol), (Pin)2B (7.47 g, 29.4
mmol), Pd(dppf)C12 (1.43 g, 1.96
mmol) and KOAc (3.84 g, 39.2 mmol) in dioxane (50.0 mL) was stirred under N2
atmosphere at 90 C
147
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
overnight. When the reaction was completed, it was concentrated and purified
by silica gel column
chromatography (petrol ether/ethyl acetate = 5/1) to afford 816-B (5.50 g,
100% yield) as a yellow solid.
The synthesis of N-(4-chloro-5-formylthiazol-2-ypacetamide (816-2)
0 /JO 0
Ac20 ,s
H2N¨µ Py, rt, overnighl HN
CI CI
816-1 816-2
1004271 To a mixture of 816-1 (5.00 g, 30.8 mmol) in Pyridine (20.0
mL) was added Ac20 (4.70 g, 46.1
mmol). The reaction was stirred at room temperature overnight. When the
reaction was completed, it was
poured into H20 (200 mL) and extracted with Et0Ac (150 mL x 3). The organic
phase was combined, and
washed with H20 (100 mL) and brine (80.0 mL), then dried with anhydrous
Na2SO4, concentrated and
purified by silica gel column chromatography (petrol ether/ethyl acetate =
10/1) to afford 816-2 (5.50 g,
87.4% yield) as a white solid.
The synthesis of N-(4-chloro-5-(1-hydroxy-2-methylpropyl)thiazol-2-ypacetamide
(816-3)
h0 0
sx(13 --1MgBr
\ THF, rt. 161mr; OH
CI CI
816-2 816-3
1004281 To a solution of 816-2 (5.50 g, 26.9 mmol) in THF (40.0 mL) was added
isopropylmagnesium
bromide (1.0 M in THIF, 40.3 mL, 40.3 mmol). The reaction was stirred at room
temperature for 16 h. When
the reaction was completed, it was poured into aq.NH4C1 (sat., 100 mL) and
extracted with Et0Ac (80.0
mL x 3). The organic phase was combined, and washed with H20 (80.0 mL) and
brine (80.0 mL), then
dried with anhydrous Na2SO4, concentrated and purified by silica gel column
chromatography (petrol
ether/ethyl acetate = 3/1) to afford 816-3 (4.50 g, 67.3% yield) as a yellow
solid.
The synthesis of N-(4-chloro-5-isobutylthiazol-2-ypacetamide (816-4)
¨4( TFA/TES ¨4(
HN--/
\\ OH _______
CI CI
816-3 816-4
1004291 A solution of 816-3 (4.50 g, 18.1 mmol) in TFA/TES (v/v = 4/1, 50.0
mL) was stirred at room
temperature for 1 h. When the reaction was completed, it was concentrated, and
purified by silica gel
column chromatography (petrol ether/ethyl acetate = 8/1) to afford 816-4 (4.00
g, 95.0% yield) as a white
solid.
148
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
The synthesis of N-(5-isobuty1-4-(3-methoxy-4-(trifluoromethyl)phenyOthiazol-2-
yDacetamide (816-5)
FE
S
___________________________________________ HN--µ
H N 401
K3PO4, Pd(OAc)2, PCY3 N
toluene/H20, MW 150 C, 4 h.
CI CF3
816-4 816-5 ---C)
1004301 A mixture of 816-4 (1.00g, 4.30 mmol), 816-B (1.95 g, 6.45
mmol), Pd(OAc)2 (96.5 mg, 0.430
mmol), PCy3 (241 mg, 0.860 mmol) and K3PO4 (1.83 g, 8.60 mmol) in toluene/H20
(v/v = 10/1, 50.0 mL)
was stirred under N2 atmosphere at 150 C under microwave for 4 h. When the
reaction was completed, it
was concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 10/1) to
afford 816-5 (700 mg, 43.7% yield) as a yellow solid.
The synthesis of 5-isobuty1-4-(3-methoxy-4-(trifluoromethyl)phenyl)thiazol-2-
amine (816-s)
0
S
HN¨µ NaOH , H2N-4
N Et0H, 70 C, overnight N
CF3 CF3
0 0
816-5 816-s
1004311 A mixture of 816-5 (400 mg, 1.07 mmol) and NaOH (2.0 M in H20, 3.0 mL)
in Et0H (10.0
mL) was stirred at 70 C overnight. When the reaction was completed, it was
concentrated, and purified by
silica gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford
816-s (300 mg, 84.5% yield)
as a yellow solid.
The synthesis of N-(4-(3 -hydroxy-4-(trifluoromethvl)pheny1)-5 sobutylthiazol-
2-yl)acetamide (815-1)
o 0
S S
H N-4 BBr3
_________________________________________ HN-4
CH CI rt overnight
N 01 2 2 N 1110/
CF
3 CF3
0 OH
816-5 815-1
1004321 A mixture of 816-5 (900 mg, 2.42 mmol) and BBr3 (17% in CH2C12, 3.63
mL, 3.63 mmol) in
CH2C12 (30.0 mL) was stirred at room temperature overnight. When the reaction
was completed, it was
149
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
washed with H20 (20.0 mL x 3). The organic layer was concentrated and purified
by silica gel column
chromatography (petrol ether/ethyl acetate = 10/1) to afford 815-1 (440 mg,
50.8% yield) as a yellow solid.
The synthesis of N-(5 -isobuty1-4-(3-(2-methoxyethoxy)-4-
(trifluoromethyl)phenyl)thiazol-2-yDacetamide
(815-2)
0 0
Brr"- `= 1 HN--µ
N 0 K2003, DMF, rt, overnight N 0
C F3
C F3
OH
815-1 815-2
1004331 A mixture of 815-1 (440 mg, 1.23 mmol), 1-bromo-2-methoxyethane (205
mg, 1.47 mmol) and
K2CO3 (339 mg, 2.46 mmol) in DMF (5.0 mL) was stirred at room temperature
overnight. When the
reaction was completed, it was poured into H20 (80.0 mL) and extracted with
Et0Ac (80.0 mL x 3). The
organic phase was combined, and washed with H20 (50.0 mL) and brine (50.0 mL),
then dried with
anhydrous Na2SO4, concentrated and purified by silica gel column
chromatography (petrol ether/ethyl
acetate = 8/1) to afford 815-2 (240 mg, 46.9% yield) as a yellow solid.
The synthesis of 5-isobuty1-4-(3-(2-methoxyethoxy)-4-
(trifluoromethyl)phenyl)thiazol-2-amine (815-s)
0
--- is 1 S
HN¨< NaOH
N Et0H, 70 C, overnight
0
CF3 N
lib C F3
815-2 815-s
1004341 A mixture of 815-2 (240 mg, 0.576 mmol) and NaOH (2.0 M in H20, 2.0
mL) in Et0H (5.0
niL) was stirred at 70 C overnight. When the reaction was completed, it was
concentrated, and purified by
silica gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford
815-s (160 mg, 74.2% yield)
as a yellow solid.
The synthesis of 1-(4-chloro-3-methoxypheny1)-4,4-dimethylpentan-1-ol (833-2)
0 OH
I
0 BrMg< 0
.... 0
THE, rt. 16 h
CI CI
833-1 833-2
150
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1004351 To a solution of 833-1 (2.50 g, 14.7 mmol) in THF (20.0 mL)
was added (3,3-
dimethylbutyl)magnesium bromide (1.0 Mm THF, 22.0 mL, 22.0 mmol). The reaction
was stirred at room
temperature for 16 h. When the reaction was completed, it was poured into
aq.NH4C1 (sat., 50.0 mL) and
extracted with Et0Ac (80.0 mL x 3). The organic phase was combined, and washed
with H20 (50.0 mL)
and brine (80.0 mL), then dried with anhydrous Na2SO4, concentrated and
purified by silica gel column
chromatography (petrol ether/ethyl acetate = 8/1) to afford 833-2 (3.00 g,
79.7% yield) as yellow oil.
The synthesis of 1-(4-chloro-3-methoxypheny1)-4,4-dimethylpentan-1-one (833-3)
OH 0
O PCC 0
CH2Cl2, rt, 2 h
CI CI
833-2 833-3
1004361 To a solution of 833-2 (3.00 g, 11.7 mmol) in CH2C12 (100 mL)
was added PCC (5.04 g, 23.4
mmol). The reaction was stirred at room temperature for 2 h. When the reaction
was completed, it was
concentrated, and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 50/1) to afford
833-3 (2.80 g, 94.1% yield) as colorless oil.
The synthesis of 2-bromo-1-(4-chloro-3-methoxyphenyl )-4,4 -di m ethyl pentan -
1-one (833-4)
0 0
O PTAT 0
THF, it 16 h
Br
CI CI
833-3 833-4
1004371 A mixture of 833-3 (2.80 g, 11.0 mmol) and PTAT (6.18 g, 16.5 mmol) in
'THF (50.0 mL) was
stirred at room temperature for 16 h. When the reaction was completed, it was
concentrated, and the residual
was dissolved in H20 (30.0 mL), and then extracted with Et0Ac (50.0 mL x 2).
The organic layer was
combined, and washed with H20 (30.0 mL x 2) and Brine (30.0 mL), then dried by
anhydrous Na2SO4. The
solution was concentrated to give the crude product, which was used directly
in next step without farther
purification to afford 833-4 (3.70 g, 100% yield) as brown oil.
The synthesis of 1-(4-chloro-3-methoxypheny1)-4,4-dimethy1-2-thiocyanatopentan-
1-one (833-5)
0 0
O NaSCN 0
Et0H, 90 C, 3 h
Br SON
CI CI
833-4 833-5
1004381 A mixture of 833-4 (3.70 g, 11.0 mmol) and NaSCN (1.80 g, 22.2 mmol)
in Et0H (80.0 mL)
was stirred at 90 C for 3 h. When the reaction was completed, it was
concentrated and purified by silica
151
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
gel column chromatography (petrol ether/ethyl acetate = 3/1) to afford 833-5
(2.20 g, 63.6% yield) as a
yellow solid.
The synthesis of 2-chloro-4-(4-chloro-3-methoxypheny1)-5-neopentylthiazole
(833-6)
0 S
0 HCl/dioxane. ci¨ 1
---
rt, 4 h N
SCN
CI 01 CI
0
.-
833-5 833-6
1004391 A mixture of 833-5 (2.20 g, 4.04 mmol) in HC1/dioxane (4.0 M, 20.0 mL)
was stirred at room
temperature for 4 h. When the reaction was completed, it was concentrated and
purified by silica gel column
chromatography (petrol ether/ethyl acetate = 10/1) to afford 833-6 (1.30 g,
60.1% yield) as yellow oil.
The synthesis of 2-chloro-5-(2-chloro-5-neopentylthiazol-4-yl)phenol (833-7)
S S
CI¨µ 1 BBr3
3.. C1*----µ 1
N 0 CH2Cl2, rt, overnight N
0
CI CI
0 OH_..
833-6 833-7
1004401 A mixture of 833-6 (1.30 g, 3.94 mmol) and BBr3 (17% in CH2C12, 5.90
mL, 5.90 mmol) in
CH2C12 (30.0 mL) was stirred at room temperature overnight. When the reaction
was completed, it was
washed with H20 (20.0 mL x 3). The organic layer was concentrated and purified
by silica gel column
chromatography (petrol ether/ethyl acetate = 6/1) to afford 833-7 (560 mg,
45.0% yield) as yellow oil.
The synthesis of 2-chloro-4-(4-chloro-3-ethoxypheny1)-5-neopentylthiazole (833-
s)
S S
CI--- 1 ____________________ 3, CI¨µ 1
N 0 K2CO3, DMF, rt, 2 h N 0
CI CI
OH
833-7 833-s
1004411 A mixture of 833-7 (180 mg, 0.569 mmol), Eft (133 mg, 0.854 mmol)
and K2CO3 (157 mg,
1.14 mmol) in DMF (5.0 mL) was stirred at room temperature for 16 h. When the
reaction was completed,
152
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
it was poured into H20 (80.0 mL) and extracted with Et0Ac (80.0 mL x 3). The
organic phase was
combined, and washed with H20 (50.0 mL) and brine (50.0 mL), then dried with
anhydrous Na2SO4,
concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 10/1) to afford
833-s (140 mg, 71.4% yield) as yellow oil.
Characterization Data for Compounds
Chemical Structure LCMS
/ 0
798 (:). Method A, Purity is 83.3%, Rt = 0.765
min; MS Calcd.:233.1;
MS Found: 234.2 um + H] +.
NH
0
808 0,- Method B, Purity is 100%, Rt = 1.652
min; MS Calcd.:234.1;
MS Found: 235.1 [M + H] .
NH2
/ 0
809 0.- Method B, Purity is 100%, Rt = 1.660 min; MS Calcd.:234.1;
N
MS Found: 235.1 + H] +.
NH2
Method A, Purity is 73.4%, Rt = 0.961 min; MS Calcd.:299.1;
794-s MS Found: 300.0 nvi + H]
1HNMR (400 MHz, CDC13) 6: 0.91 (6H, d, J= 6.4 Hz), 1.52-
1.67 (3H, m), 2.85 (2H, dd, J= 8.0, 2.0 Hz), 3.94 (3H, s), 6.97
795-s
(1H, d, J= 8.8 Hz), 7.44 (1H, dd. J= 8.4, 2.0 Hz), 7.61 (1H, d,
J= 2.0 Hz).
CI
Method B, Purity is 54.5%, Rt = 2.319 min; MS Calcd.:313.1;
796-s MS Found: 314.1 [M + H] +.
0"--
F
Method A, Purity is 92.7%, Rt = 0.925 min; MS Calcd.:377.1;
797-s CH40 MS Found: 378.0 [M + H] +.
802-s r_oi Method A, Purity is 97.1%, Rt = 0.962
min; MS Calcd.:357.1;
MS Found: 358.0 [M + H] 1.
153
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
803-s ci---4, r Method B, Purity is 94.5%, Rt = 2.285
min; MS Calcd.:357.1;
sN
MS Found: 358.1 rvi + H] +.
oX
804-s CiN--(\s
---cr Method A, Purity is 90.9%, Rt = 1.005 min; MS Calcd.:371.1;
MS Found: 372.0 um + H]
805-s
CI-4! r) Method B PurY it is 90.2% Rt = 2.211
min- MS Calcd.:387.1-
0
MS Found: 388.1 rvi + H] +.
f
0
Method A, Purity is 90.9%, Rt = 1.030 min; MS Calcd.:383.1;
811-s ol MS Found: 384.0 [1\4 + H]
of
812-s
Method A, Purity is 81.3%, Rt = 0.954 min; MS Calcd.:299.1;
MS Found: 300.0 [NI + H]
CI-4 Method A, Purity is 64.4%, Rt ¨ 0.994
min; MS Ca1cd.:315.0;
813-s MS Found: 316.0 nvi + H]
I Method A, Purity is 98.8%, Rt = 0.976
min; MS Calcd.:359.1;
814-s
MS Found: 360.0 nvi + H]
815-s H2N---4.s I Method B, Purity is 90.9%, Rt = 1.919
min; MS Ca1cd.:374.1;
MS Found: 375.3 nvi + H] .
CF3
FF
816-B 0,n NO 1HNMR (400 MHz, CDCb) 5: 1.35 (12H, d,
J= 4.4 Hz), 3.95
(3H, s), 7.40 (4H, s), 7.44 (1H, d, J= 7.6 Hz), 7.56 (1H, d, J=
>.6o
'7'
7.6 Hz).
154
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
816-s Method B, Purity is 95.4%, Rt = 1.890
min; MS Calcd.:330.1;
MS Found: 331.1 nvi + H] +.
CF3
0
Method B, Purity is 100%, Rt = 2.324 min; MS Calcd.:295.1;
818-s MS Found: 296.2 nvi + H] +.
I Method A, Purity is 96.9%, Rt = 1.026 min; MS Calcd.:329.0;
819-s MS Found: 330.0 nvi + H]
Method A, Purity is 94.9%, Rt = 0.988 min; MS Calcd.:313.0;
820-s jjJMS Found: 314.0 [M + H] +.
822-s ci¨<\8
Method B, Purity is 96.1%, Rt = 2.315 min; MS Calcd.:313.1;
MS Found: 314.2 rvi + H]
823-s I Method A, Purity is 62.8%, Rt = 1.012
min; MS Calcd.:373.1;
MS Found: 374.0 rvi + H]
825-s H2N---eN I Method B, Purity is 95.3%, Rt = 2.005
min; MS Calcd.:388.1;
MS Found: 389.2 irm + HI .
cF3
Method A, Purity is 98.9%, Rt = 1.011 min; MS Calcd.:327.1;
826-s
MS Found: 328.0 nv + H] .
155
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
I 827-s Method B, Purity is 52.3%, Rt = 2.326 min; MS
Calcd.:371.1;
MS Found: 372.1 nvi + H] .
0,,,F
828-s H2N---<N8 I Method B, Purity is 88.9%, Rt = 2.019 min; MS
Calcd.:344.1;
MS Found: 345.2 um + H] +.
cF3
830-s / Method A, Purity is 97.1%, Rt = 1.025 min; MS
Calcd.:329.0;
MS Found: 333.0 FVI + H] +.
CI
831-s Method B, Purity is 91.4%, Rt = 2.269 min; MS
Calcd.:313.1;
MS Found: 314.1 [M + H] .
0
832-s Method B, Purity is 97.5%, Rt = 2.321 min; MS
Calcd.:327.1;
MS Found: 328.1 nvi + H] .
833-s I Method A, Purity is 96.2%, Rt = 1.032 min; MS
Calcd.:343.1;
MS Found: 344.0 nvi + H]
835-s
Method A, Purity is 97.1%, Rt = 0.984 min; MS Calcd.:373.1;
MS Found: 374.0 [M + H] +.
ci
836-s Method B, Purity is 84.7%, Rt = 2.455 min; MS
Calcd.:355.1;
NQMS Found: 356.2 [M + H] 1.
156
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
837-s Method A, Purity is 97.8%, Rt = 1.103
min; MS Caled.:371.1;
MS Found: 372.0 [M + H] +.
a
839-s ci-4 Method B, Purity is 87.3%, Rt = 2.355
min; MS Calcd.:309.1;
MS Found: 310.2 [M + H] +.
ci---( \s I Method A, Purity is 85.8%, Rt = 0.950 min; MS Calcd.:339.1;
840-s MS Found: 340.0 [M + HI+.
Method B, Purity is 99.2%, Rt = 1.803 min; MS Calcd.:311.1;
841-s MS Found: 294.3 [M I H] +.
0
842-s I
o Method B, Purity is 93.5%, Rt = 2.244
min; MS Calcd.:311.1;
MS Found: 312.1 [M + H] +.
The synthesis of methyl 3-44-(3-fluoro-4-methoxypheny1)-5-isobutylthiazol-2-
yl)amino)-6 -(thiophen-2-
yOpyrazine-2-carboxylate (794-6)
0
ekCS N-1)(0"
N N
N NH2
CI N /110 Pd2(dba)3, X-Phos, Cs2003 0¨\ FIN¨µ
toluene, 120 C, 4 h 0 N
794-s 794-6 F
1004421 A mixture of 794-s (200 mg, 0.667 mmol), methyl 3-amino-6-(thiophen-2-
yl)pyrazine-2-
carboxylate (157 mg, 0.667 mmol), Pd2(dba)3 (62.0 mg, 0.0667 mmol), X-phos
(57.8 mg, 0.100 mmol) and
Cs2CO3 (326 mg, 1.00 mmol) in toluene (10.0 mL) was stirred under N2
atmosphere at 120 C for 4 h.
When the reaction was completed, it was concentrated and purified by silica
gel column chromatography
157
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
(petrol ether/ethyl acetate = 8/1) to afford 794-6 (120 mg, 36.1% yield) as a
yellow solid.
The synthesis of 3 4(443 -fluoro-4-methoxypheny1)-5 sobutylthiazol-2 -
yDamino)-6-(thiophen-2 -
yl)pyrazine -2-carboxylic acid (1-60)
_\ _\
N N N N
LiOH
=
THF/Me0H, rt, 2 h O HN-
0 N 0H N
0--
794-6 F 1-60
1004431 To a solution of 794-6 (120 mg, 0.241 mmol) in Me0H/THF/ H20 (v/v/v =
4/1/1, 5.0 mL) was
added LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room
temperature for 2 h. When the
reaction was completed, the resulting reaction was concentrated, then it was
diluted with H20 (15.0 mL)
and adjusted pH to 4 - 5 with HCl (1.0 M). The mixture was extracted with
Et0Ac (10.0 mL x 2), and the
combined organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4,
and concentrated, the
residue was purified by washing with Me0H to afford 1-60 (55.0 mg, 47.2%
yield) as a yellow solid.
The synthesis of methyl 2-45-isobuty1-4-(3-(2-methoxyethoxy)-4-
(trifluoromethyl)phenylithiazol-2-
y0amino)-5-(thiophen-2-yOnicotinate (815-3)
0 S
1--12N--4 CI N \ / s
N
Pd2(dba)3, X-phos, Cs2CO3, 0 FIN N
toluene, 120 C, 4h 0
0 F
F
0
815-s 815-3
1004441
A mixture of 815-s (160 mg, 0.427 mmol), methyl 2-chloro-5-(thiophen-2-
yl)nicotinate (108
mg, 0.427 mmol), Pd2(dba)3 (39.7 mg, 0.0427 mmol), X-phos (37.0 mg, 0.0641
mmol) and Cs2CO3 (209
mg, 0.641 mmol) in toluene (10.0 mL) was stirred under N2 atmosphere at 120 C
for 4 h. When the reaction
was completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl
acetate = 8/1) to afford 815-3 (100 mg, 39.6% yield) as a yellow solid.
The synthesis of 2-45-isobuty1-4-(3-(2-methoxyethoxy)-4-
(trifluoromethyl)phenypthiazol-2-ypamino)-5-
(thiophen-2-yl)nicotinic acid (1-76)
158
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
S S
N N
\ / s
LiOH
HN-- 1 HN----4 1
0 THF/Me0H, rt, 2 h 0
N 0 N 0
0 / F OH F
F F
--, ,.--_,0 F --, ,---,,,,0
0 0 F
815-3 1-76
1004451 To a solution of 815-3 (100 mg, 0.169 mmol) in Me0H/THF/ H20 (v/v/v =
4/1/1, 3.0 mL) was
added LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room
temperature for 2 h. When the
reaction was completed, the resulting reaction was concentrated, then it was
diluted with H20 (15.0 mL)
and adjusted pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with
Et0Ac (10.0 mL x 2), and the
combined organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4,
and concentrated, the
residue was purified by washing with Me0H to afford 1-76 (60.0 mg, 61.5%
yield) as an off-white solid.
Characterization Data for Exemplary Compounds
1# Chemical Structure LCMS 111 NMR (400 MHz, d6-
DMS0)
/ Method C, Purity is 6: 0.93 (6H, d, .J=
6.4 Hz), 1.86-1.89
¨\ (1H, m), 2.76 (2H, d, J= 7.2 Hz), 3.89
100% Rt = 2.008 min;
),, /(N s
' (3H, s), 7.20-7.27
(2H, m), 7.38-7.45
0 HN¨<, I MS Calcd.: 484.1; MS (2H, m), 7.68 (1H,
dd, J= 5.2, 1.2 Hz),
OH N
Found: 484.9 [M + H] +
7.91 (1H, dd, J= 3.6, 1.2 Hz), 9.21
O¨ (1H, s), 11.50 (1H,
brs).
F
Method C, Purity is 6: 0.90 (6H, d, J= 6.4
Hz), 1.53-1.64
(3H, m), 2.88 (2H, t, J= 7.6 Hz), 3.91
98.9%, Rt = 2.113 min.
' (3H, s), 7.19-7.25
(2H, m), 7.56 (1H,
61 0 RN ,
MS Calcd.: 514.1; MS dd, .1= 8.4, 2.0 Hz),
7.64-7.68 (2H, m),
OH
7.90 (1H, d_ J= 3.6 Hz), 9.19 (1H, s),
Found: 514.9 [M + H] ".
11.69 (1H, brs).
o¨
a
RMethod C, Purity is 6: 0.89 (6H, d, J= 6.4
Hz), 1.52-1.62
¨ (3H, m), 2.87 (2H, t, J= 8.0 Hz), 3.89
N \
97.3%' Rt = 2.070 min-
/ ' (3H, s), 7.19-7.26 (2H, m), 7.37-7.45
62 o)--1--<1N--e 1 MS Calcd.: 498.1; MS (2H, m), 7.68
(1H, d, J = 4.8 Hz), 7.90
OH N
Found: 499.0 [M + H]
(1H, d, J= 2.8 Hz), 9.18 (1H, s), 11.54
'
(1H, brs).
o'"---
F
159
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
6: 3.37 (3H, s), 3.69 (2H, t, J= 4.4
Hz), 4.21 (2H. t, J= 4.4 Hz), 4.26 (2H,
Method C, Purity is
s), 7.16 (1H, di", J= 4.8, 4.0 Hz),
95.8%, Rt ¨ 2.024 min; 7.21-7.26 (4H, m),
7.34 (2H, d, J¨ 7.2
= s
63 Hz), 7.36-7.41 (1H,
m), 7.47 (1H, dd, J
f01 MS Calcd.: 561.1; MS =
OH N 12.8, 2.0 Hz), 7.58-
7.61 (2H, m),
Found: 561.8 [M + H] 8.44 (1H, d, J= 2.4 Hz), 8.85 (1H, d, J
= 2.0 Hz), 11.57 (1H, brs), 14.31 (1H- ,
brs).
6: 0.92 (6H, d, J= 6.8 Hz), 1.81-1.84
(1H, m), 2.73 (2H, d, J= 7.2 Hz), 3.34
Method C, Purity is
s (3H, s), 3.69-3.72
(2H, m), 4.22-4.24
N
95.5%, Rt = 2.018 min; (2H, m), 7.13 (1H, dd,
J= 4.8, 3.6 Hz),
64 7.26 (1H, t, J= 8.8 Hz), 7.36-7.53 (4H,
ti MS Calcd.: 526.1; MS
- OH m), 7.96 (1H, dd, J=
8.8, 2.4 Hz), 8.19
Found: 526.9 [M + H] +. (1H, d, J= 2.4 Hz), 8.55 (1H, d, J=
8.8 Hz), 11.35 (1H, brs), 13.87 (1H,
brs).
, Method C, Purity is 6: 0.86 (9H, s),
2.81 (2H, s), 3.33 (3H,
s ' s), 3.69-3.71 (2H, m),
4.20-4.23 (2H,
nun; 100%, Rt = 1.936i65 s m), 7.16-7.24 (2H, m), 7.32-7.41 (2H- ,
-
HN--µ :01 MS Calcd.: 541.0; MS m), 7.59-7.65 (2H, m), 8.45 (1H, d, J=
OH N
Found: 541.9 M + H]
2.4 Hz), 8.94 (1H, d, J= 2.4 Hz), 11.54
[
(1H, s).
6: 0.92 (6H, d, J= 6.8 Hz), 1.14 (3H, t,
J= 7.2 Hz), 1.86-1.90 (1H, m), 2.75
Method C, Purity is (2H, d, J= 6.8 Hz),
3.52 (2H, q, J=
7.2 Hz), 3.73-3.75 (2H, m), 4.20-4.23
94.6%, Rt = 2.112 min;
\ IN (2H, m), 7.17-
7.19 (1H, m), 7.25 (1H,
66
ro MS Calcd.: 541.1; MS t, J= 8.8 Hz),
7.34-7.37 (1H, m), 7.42
OH N
0) Found: 541.9 M + H]
(1H, dd, J= 12.8, 2.0 Hz), 7.60-7.64
[
(2H, m), 8.46 (1H, d, .1= 2.4 Hz), 8.93
(1H, d, J= 2.8 Hz), 11.55 (1H, brs),
14.31 (1H. brs).
6: 0.92 (6H, d, J= 6.4 Hz), 1.12 (6H,
d, J= 6.4 Hz), 1.84-1.91 (1H, m), 2.74
Method C, Purity is (2H, d, J= 7.2 Hz),
3.61-3.68 (1H, m),
3.73 (2H, t, J= 4.8 Hz), 4.19 (2H, t, J
99.2%, Rt = 2.165 min; =
4.8 Hz), 7.18 (1H, dd, J= 4.8, 4.0
67
HN-4= 3 r MS Calcd.: 555.2; MS Hz), 7.24 (1H, t,
J= 8.8 Hz), 7.33-
- OH N
0 Found: 556.2 M + H]
7.36 (1H, m), 7.42 (1H, dd, J= 8.8, 2.0
[
Hz), 7.59-7.63 (2H, m), 8.45 (1H, d, J
= 2.4 Hz), 8.91 (1H, d, J= 2.4 Hz),
11.51 (1H, brs), 14.28 (1H, brs).
Method C, Purity is 6: 0.92 (6H, d, J= 6.4
Hz), 1.86-1.90
(1H, m), 2.74 (2H, d, J= 6.4 Hz), 3.26
7" 99.7%, Rt = 2.057 min;
68 s (3H, s), 3.48 (2H, dd,
J= 5.2, 3.6 Hz),
HN--4 0 MS Calcd.: 571.2; MS 3.61 (2H, dd, J=
5.2, 3.6 Hz), 3.77
OH N
Of (2H, t, J= 4.4 Hz), 4.22 (2H, t, J= 4.8
Found: 572.2 [M + H]
Hz), 7.17-7.19 (1H, m), 7.24 (1H, t, J=
160
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
8.4 Hz), 7.34-7.44 (2H, m), 7.60-7.63
(2H, m), 8.45 (1H, d, J= 2.4 Hz), 8.92
(1H, d, J= 2.4 Hz), 11.53 (1H, brs),
14.32 (1H, brs).
Method C, Purity is 6: 0.89 (6H, d, J= 6.4
Hz), 1.53-1.66
s /
(3H, m), 2.87 (2H, t, J= 8.0 Hz), 3.89
\ 97.1%, Rt = 2.133 min; (3H, s), 7.17-
7.19 (1H, m), 7.24 (1H, t,
69 MS Calcd.: 497.0; MS J= 8.4 Hz), 7.38-
7.45 (2H, m), 7.60-
OH N 7.64 (2H, m), 8.45
(1H, d, J= 2.4 Hz),
Found: 497.9 [M + H] 8.92 (1H, d, J= 2.4
Hz), 11.53 (1H,
o¨ brs), 14.33 (1H, brs).
Method C, Purity is 6: 0.92 (6H, d, J= 6.4
Hz), 1.76-1.83
96.5%, Rt = 1.961 min; (1H, m), 2.73 (2H,
d,.1= 7.2 Hz), 3.89
(3H, s), 7.14-7.46 (4H, m), 7.61 (1H, d,
0 HNI MS Calcd.: 483.1; MS J= 4.4 Hz), 7.77 (11-1_ d, J= 2.4
Hz),
OH N
8.14 (1H, d,J= 8.8 Hz), 9.01 (1H, d, J
Found: 484.1 [M + H] ".
= 8.8 Hz), 11.58 (1H, s), 13.53 (1H, s).
S N Method C, Purity is 6: 0.92 (6H, d. J= 6.8 Hz), 1.79-1.85
(1H, m), 2.72 (2H, d,J= 7.2 Hz), 3.89
71 100%, Rt = 1.949 min;
(3H, s), 7.13-7.46 (4H, m), 7.58-7.59
0 HN I
Found: 484.1 M + H] MS Calcd.: 483.1; MS (1H, m), 7.73 (1H, t,
J= 2.8 Hz), 8.18
OH N
(1H, s), 9.71 (1H, d, J= 8.8 Hz), 10.74
[
o¨ (1H, s).
6: 0.90-0.96 (2H, m), 1.09-1.20 (3H,
m), 1.52-1.66 (4H, m), 1.72-1.76 (2H,
m), 2.75 (2H, d, J= 6.8 Hz), 3.33 (3H,
, Method C, Purity is
s ' s), 3,69-172 (2H, m), 4.21-413 (2H,
99.1%, Rt = 2.196 mm; m), 7.18 (1H, dd, J=
4.8, 3.6 Hz), 7.-25
s
72 0 HN--4 r,01 MS Calcd.: 567.2; MS (1H, t,J= 8.8
Hz), 7.33-7.36 (1H, m),
- OH N 7.42 (1H, dd, J= 12.4, 2.0 Hz), 7.61
0) Found: 568.2 [M + H] 1. (1H, dd, J= 5.2,
1.2 Hz), 7.64 (1H, dd,
J= 3.6, 0.8 Hz), 8.46 (1H, d, J= 2.4
Hz), 8.93 (1H. d,J= 2.4 Hz), 11.54
(1H, brs), 14.27 (1H, brs).
s Method C, Purity is
6: 0.93 (6H, d,./= 6.4 Hz), 1.86-1.93
¨\
\ /N 98.6%, Rt = 2.090 min; (1H, m), 2.75
(2H, d, J= 6.8 Hz), 3.89
73 0 HN¨<,S I MS Calcd.: 483.1; MS (3H, s), 7.11-7.33
(4H, m), 7.58-7.61
OH N (1H, m), 8.46 (1H, d,
J= 2.4 Hz), 8.88
Found: 484.1 [M + H] (1H, d, J= 2.8 Hz),
12.21 (1H, s).
161
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Sf Method C, Purity is 6: 0.94 (6H, d, J=
6.4 Hz), 1.88-1.92
(1H, m), 2.78 (2H, d, J= 6.8 Hz), 3.92
98.2%, Rt = 2.137 min; (3H, s), 7.16-7.20
(2H, iii), 7.30 (1H, d,
\
74 HN4 IMS Calcd.: 499.1; MS J= 1.6 Hz), 7.49 (1H_
d, J= 8.0 Hz),
OH N 7.60-7.64 (2H, m), 8.4-
6 (1H, d, J= 2.4
Found: 500.2 [M + H] -P. Hz), 8.93 (1H, d, J= 2.4 Hz) , 11.57
(1H, brs).
6: 0.93 (6H, d, J= 6.8 Hz), 1.87-1.91
s
OH N Method C, Purity is (1H, m), 2.75 (2H, d,
J= 7.2 Hz), 3.35
(3H, s), 3.72 (2H, t, J= 4.4 Hz), 4.25
96.6%, Rt = 2.131 min;
(2H, t,J= 4.4 Hz), 7.13-7.19 (2H, m),
75
MS Calcd.: 543.1; MS 7.31 (1H, d, J= 1.6
Hz), 7.47 (1H, d, J
LICI = 8.0 Hz), 7.50-7.54 (2H, m), 8.42
Found: 544.0 [M + H] ". (1H, d, J = 2.4 Hz), 8.66 (1H, d, J =
2.4 Hz), 14.27 (1H, brs).
6: 0.93 (6H, d, J= 6.4 Hz), 1.88-1.93
/ Method C, Purity is (1H, m), 2.81 (2H,
d, J= 7.2 Hz), 3.34
100%, Rt = 2.183 min; (3H, s), 3.71 (2H, d,
J = 4.4 Hz), 4.31
N
(2H, d, J= 4.4 Hz), 7.19(1H, dd, J=
76 = HN---(\s
- OH N MS Calcd.: 577.1; MS
5.2, 3.6 Hz), 7.33 (1H, d.- J= 8.4 Hz),
Found: 578.2 M + H]
7.42 (1H, s), 7.61-7.69 (3H, m), 8.47
F [
F (1H, d, J= 2.4 Hz),
8.94 (1H, d, J=
2.4 Hz), 11.57 (1H, brs).
6: 0.94 (6H, d, J= 6.4 Hz), 1.91-1.94
Method C, Purity is
(1H, m), 2.82 (2H, d, J= 7.2 Hz), 3.96
\ IN 98.9%, Rt = 2.173 min; (3H, s), 7.19
(1H, dd, ./ = 5.2, 3.6 Hz),
77 0 HN-e I MS Calcd.: 533.1; MS 7.33 (1H, d, J=
8.0 Hz), 7.41 (1H, s),
OH N 7.61-7.69 (3H, m),
8.47 (1H, d, J= 2.4
F Found: 534.1 [M + H] Hz), 8.94 (1H, d, J= 2.4 Hz), 11.56
F F (1H, brs).
6: 0.93 (6H, d, J= 6.8 Hz), 1.88-1.91
Method C, Purity is
¨\ (1H, m), 2.76 (1H, d, J= 7.2 Hz), 3.81
90.8%, Rt = 2.065 min; (3H, s), 6.94 (1H,
dd,J= 8.2, 2.4 Hz),
78 7.11-7.20 (3H, m),
7.37 (IH, t, .1=8.0
0 HN¨<\ MS Calcd.: 465.1; MS
OH N Hz), 7.60-7.64 (2H,
m), 8.46 (1H, d, J
Found: 465.9 [M + H] +. = 2.4 Hz), 8.93 (1H, d, J= 2.8 Hz),
11.55 (1H, brs), 14.31 (1H, brs).
6: 0.93 (6H, d. J= 6.4 Hz), 1.35 (3H, t,
Method C, Purity is J= 6.8 Hz), 1.86-1.93
(1H, m), 2.76
¨\ (2H, d. J= 7.2 Hz), 4.08 (2H, q, J=
/Kr\I s 100%, Rt = 2.121 min;
6.8 Hz-), 6.92 (1H_ d, J= 6.4 Hz), 7.09-
79
0 HN¨<\ I MS Calcd.: 479.1, MS 7.20 (3H, m), 7.35-
(1H, t, .1= 8.0 Hz),
OH N Found: 480.2 [M + H] 7.62 (2H, dd, J
=12.4, 4.4 Hz), 8.46
+.
(1H, d, J= 2.4 Hz), 8.94 (1H, d, J=
2.4 Hz), 11.55 (1H, brs).
162
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
6: 0.93 (6H, d, J= 6.4 Hz), 1.39 (3H, t,
/ Method C, Purity is J= 6.8 Hz), 1.87-
1.91 (1H, m), 2.77
¨\ (2H, d, J= 6.8 Hz),
4.18 (2H, q, J=
µ .N 99.0%, Rt = 2.182 min; -
80 \ /K /3 , 6.8 Hz), 7.15-7.20 (2H,
m), 7.28 (1H,
0 HN-, 1 MS Calcd.: 513.1; MS d, J = 1.6 Hz),
7.48 (1H, d, J= 8.0 Hz),
OH N
7.60-7.65 (2H, m), 8.46 (1H, d,J= 2.4
Found: 514.1 [M + HI +.
a Hz), 8.93 (1H, d,J= 2.4 Hz), 11.54
-....,o
(1H, brs), 14.31 (1H, brs).
.--
/
s Method C, Purity is 6: 0.93 (6H, d, J=
6.8 Hz), 1.37 (3H, t,
. J= 6.8 Hz), 1.86-1.90
(1H, m), 2.74
N 99.2%, Rt = 2.130 mm;
\ / (2H, d, J= 7.2 Hz),
4.13-4.19 (2H, m),
81 0 HN4 I MS Calcd.: 497.1; MS 7.11-7.30 (4H, m),
7.60-7.64 (2H, m),
OH N
8.46 (1H, d,J= 2.4 Hz), 8.93 (1H, d, J
Found: 498.1 [M + H]
F 1. _ 2.4 Hz), 11.60 (1H, s).
..---
S 1
Method C, Purity is 6: 0.89 (6H, d, J= 6.4
Hz), 1.55-1.62
¨
. (1H, m), 2.88 (2H, t,
.1= 7.6 Hz), 3.90
\ /N 93.8%, Rt = 2.152 mm;
(3H, s), 7.12-7.19 (2H, m), 7.26-7.34
82 s
0 i
MS Calcd.: 497.1; MS (2H, m), 7.60-7.65 (2H,
m), 8.46 (1H,
OH N i
d' J= 2.4 Hz), 8.94 (1H, d, J= 2.8 Hz),
Found: 498.1 [M + H] ". 11.55 (1H, brs).
F
_.-0
6:0.89 (6H, d,J= 6.4 Hz), 1.54-1.64
/ Method C, Purity is (3H, m), 2.88-2.92
(2H, m), 3.73 (2H,
. '
t J= 4.4 Hz), 4.26 (2H, t, J= 4.4 Hz),
- N 96.9%, Rt = 2.182 min. '
\ / s 7.17-7.20 (2H, m), 7.32
(1H, d,J= 2.0
83 0 HN---4
OH 1
MS Calcd.: 557.1; MS Hz), 7.50 (1H, d,J= 8.0
Hz), 7.60-
N
CI
Found: 558.1 [M + H] ". 7.64 (2H, m), 8.46 (1H, d,J= 2.4 Hz),
---"0-- 8.94 (1H, d,J= 2.4 Hz), 11.52 (1H,
brs), 14.29 (1H, brs).
6: 0.88 (6H, d, J= 6.4 Hz), 1.53-1.63
Method C, Purity is
s ' (3H, m), 2.88 (2H, t,
J= 7.6 Hz), 3.68-
¨ N 91.7%, Rt = 2.135 min; 3.71 (2H, m),
4.22-4.25 (2H, m), 7.13-
\ / s
84 0 HN-4 1
MS Calcd.: 541.1; MS 7.20 (2H, m), 7.26-7.35
(1H, m), 7.60-
OH N 7.64 (2H, m), 8.46 (1H,
d,J= 2.4 Hz),
F
Found: 542.2 [M + H] . 8.93 (1H, d,J= 2.4 Hz), 11.55(1H,
c'^--(:)---
brs) .
6: 0.90 (6H, d, J= 6.4 Hz), 1_57-1.64
Method C, Purity is
(3H, in), 2.93 (2H, t, J= 7.2 Hz), 3.71
¨
N 99.1%, Rt = 2.218 min; (2H, t,J= 7.2
Hz), 4.31 (2H, t, J= 4.4
\ / s
85 0 HN-4 1 MS Calcd.: 591.0; MS Hz), 7.18-7.19
(1H, m), 7.32 (1H, d, J
oh " = 8.4 Hz ),7.43 (1H,
s), 7.61-7.69 (3H,
F
F Found: 592.1 [M + H] ' m), 8.46 (1H, d, J= 2.4 Hz), 8.93 (1H,
F
d, J= 2.4 Hz), 11.55 (1H, brs).
163
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Method C, Purity is 6: 0.92 (6H, d, J= 6.4
Hz), 1.32 (6H,
/
s 99.2%, Rt = 2.161 min;
d, J= 6.0 Hz), 1.86-1.89 (1H, m), 2.74 (N
(2H, d, J= 7.2 Hz), 4.67-4.70 (1H, m),
86 0 HN¨<,
OH N MS Calcd.: 511.3; MS 7.12-7.31 (4H, m),
7.60-7.64 (2H, m),
Found: 512.3 M + H]
8.46 (1H, d, J= 2.4 Hz), 8.93 (1H, d, J
F [
=2.4 Hz), 11.56 (1H, s).
6: 0.92 (6H, d, J= 6.8 Hz), 1.11 (6H,
Method C, Purity is d, J= 6.0 Hz), 1.87-
1.91 (1H, m), 2.75
(2H, d, J= 7.2 Hz), 3.32-3.34 (1H, m).
\
3.61-3.68 (2H, m), 4.21 (2H, t, J= 4.4
--e
o OH HN N 97.0%, Rt = 2.165 min;
87 MS Calcd.: 555.1; MS Hz), 7.13-7.20
(2H, m), 7.26-7.35 (2H,
F m), 7.60-7.65 (2H, m),
8.46 (1H, d, J=
Found: 556.2 [M +
2.4 Hz), 8.94 (1H. d, J= 2.4 Hz), 11.55
(1H, brs), 14.32 (1H, brs).
6: 0.90 (6H, d, J= 6.8 Hz), 1.56-1.66
s Method C, Purity is (3H, m), 2.94 (2H, t, J= 8.0 Hz), 3.96
(3H, s), 7.18 (1H, dd, J= 4.8, 3.6 Hz),
\ iN 98.1%, Rt = 2.220 min.
' 7.32 (1H, d, J= 8.0
Hz), 7.42 (1H, s),
88 HN---scs MS Calcd.: 547.1; MS 7.61-7.64 (2H, m),
7.68 (1H, d, J= 8.4
OH N
Found: 548.2 M + H]
Hz), 8.46 (1H_ d,./= 2.4 Hz), 8.94
[
(1H, d, J= 2.4 Hz), 11.54 (1H, brs),
--O F F 14.36 (1H, brs).
6: 0.93 (6H, d, J= 6.4 Hz), 1.00 (6H,
Method C, Purity is d, J= 6.8 Hz), 1.87-
1.91 (1H, m), 2.03-
¨
N 95.5%, Rt = 2.228 min; 2.08 (1H, m),
2.74 (2H, t, J= 6.8 Hz),
s 3.88 (2H J= 6.4 Hz), 7
11-7 19
89
0 HN--4 I MS Calcd.: 525.1; MS (2H, m), 7.25-7.31 (2H, m), 7.60-7.64
OH
(2H, m), 8.46 (1H, d, J= 2.4 Hz), 8.93
F Found: 526.2 [M + H] (1H, d,./= 2.4 Hz),
11.53 (1H, brs),
14.31 (1H, brs).
s 6: 0.90 (6H, d, J= 6.4 Hz), 1.54-1.65
Method C, Purity is
(3H, m), 2.90 (2H, t,./= 8.0 Hz), 3.92
\ /N 98.7%, Rt = 2.188 min; (3H, s), 7.16-
7.19 (2H, m), 7.31 (1H, d,
90 MS Calcd.: 513.1; MS J= 1.6 Hz), 7.49
(1H_ d, J= 8.0 Hz),
OH N 7.60-7.64 (2H, m),
8.46 (1H, d, J= 2.4
Found: 514.2 [M + H] Hz), 8.93 (1H. d, J=
2.4 Hz) , 11.54
(1H, brs), 14.28 (1H, brs).
s Method C, Purity is
/N1 6: 0.88 (9H, s), 2.82
(2H, s), 3.88 (3H,
91.7%, Rt = 2.120 min; s), 7.11-7.13 (1H, m),
7.17-7.19 (1H,
( S
91 0 HN MS Calcd.: 497.1; MS m), 7.24-7.30 (2H,
m), 7.60-7.66 (2H,
-, I
OH N m), 8.46 (1H, d, J=
2.4 Hz), 8.95 (1H,
Found: 498.1 [M + H] +. d,J= 2.4 Hz), 11.59 (1H, brs).
164
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Method C, Purity is
6: 0.87 (9H, s), 1.36 (3H, t,./= 6.8
¨\
100%, Rt = 2.167 mm; Hz), 2.80 (1H. s), 4.14-
4.17 (2H, m),
92 0 HN MS Calcd.: 511.2; MS 4.67-4.70 (14, m),
7.10-7.27 (4H, m),
¨<\ I
OH N 7.55-7.57 (2H, m), 8.44
(1H, s), 8.80
Found: 512.2 [M + H] ". (1H, s), 13.10 (1H, s).
F
\---O
/
S / Method C, Purity is
6: 0.87 (9H, s), 1.38 (3H, t,J= 7.2
Hz), 2.84 (2H, s), 4.17 (2H, dd, J=
\ N 98.3%, Rt = 2.206 min; 14.0, 6.8 Hz),
7.13-7.19 (2H, m), 7.25
93 /K /s (1H, d, J= 1.2 Hz),
7.47 (1H, d, J=
0 HN¨ I MS Calcd.: 527.1; MS
OH N 8.4 Hz), 7.60-7.66 (2H,
m), 8.46 (1H,
Found: 528.2 [M + H] ' d, .1= 2.4 Hz), 8.95
(1H, d, .1= 2.4 Hz),
CI
11.56 (1H, brs), 14.33 (1H, brs).
-....,_o
6: 0.87 (9H, s), 2.81 (2H, s), 3.68-3.70
= / Method C, Purity is
(2H, m), 4.21-4.32 (2H, m), 7.10-7.13
_
\ ini 100%, Rt = 2.100 min; (1H, m), 7.13-
7.19 (1H, m), 7.25-7.31
94 HN----e 1 (2H, m), 7.60 (1H, dd,
J= 5.2, 0.8 Hz),
0
- OH N MS Calcd.: 547.1; MS
7.65 (1H, dd, J= 3.2, 0.8 Hz), 8.46
, F Found: 548.2 [M + HI ' (1H, d,J= 2.4 Hz),
8.95 (1H, d,J=
------Ø--
2.4 Hz), 11.56 (1H, brs).
6: 0.87 (9H, s), 2.84 (2H, s), 3.35 (3H,
/ Method C, Purity is s), 3.70-3.72 (2H,
m), 4.24 (2H, t, J=
4.4 Hz), 7.14-7.19 (2H, m), 7.28 (1H,
¨ N 96.4%, Rt = 2.157 mm;
n.
\ / s d, J= 1.6 Hz), 7.48
(1H, d, J= 8.0 Hz),
op, N
95 0 HN-- 1
MS Calcd.: 557.1; MS 7.61 (1H, dd, J= 4.8,
1.2 Hz), 7.65
CI
Found: 558.1 [M + H] ". _(1H, dd, J= 3.6, 1.2 Hz), 8.46 (1H, d, J
2.4 Hz), 8.95 (1H d J¨ 2.4 Hz)
, ,
,
11.57 (1H. brs).
6: 0.87 (9H, s), 1.00 (6H, d_'J= 6.8
= / Method C, Purity is
Hz), 2.03-2.07 (1H, in), 2.80 (1H, s),
¨ 95.9%, Rt = 2.259 min;
3.87 (2H, d,./= 6.4 Hz), 7.08-7.12
N
\ i s (1H, m), 7.18 (1H, q,J=
4.0 Hz), 7.25-
96
0 HN---4, MS Calcd.: 539.1; MS 7.29 (2H, m),
7.63 (2H, dd,J= 16.2,
OH N Found: 540.2 M + H] -P
3.6 Hz), 7.60-7.64 (2H, m), 8.46 (1H,
F [.
d, J= 2.4 Hz), 8.94 (1H, d, J= 2.4 Hz),
11.71 (1H, brs).
6: 0.88 (9H, s), 1.02 (6H, d.' J= 6.8
, Hz), 2.04-2.09 (1H, m),
2.83 (2H, s),
/ Method C, Purity is
s 3.90 (2H, d,J= 6.4 Hz),
7.14 (1H, dd,
N 100%, Rt = 2.300 min; J= 8.0, 1.6 Hz), 7.18 (1H, dd,J= 5.2,
\ / s
97 MS Calcd.: 555.1; MS 3.6 Hz), 7.25 (1H,
d, J= 1.6 Hz), 7.47
µ.. OH N (1H, d, J= 8.4 Hz),
7.61 (1H, dd, J=
a Found: 556.2 [M + H] ". 4.8, 1.2 Hz), 7.65 (1H, dd, J= 3.6, 1.2
0 Hz), 8.46 (1H. d, J=
2.4 Hz), 8.95
(1H, d, J= 2.4 Hz) , 11.56 (1H, brs).
165
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
6: 0.87 (9H, s), 1.35 (3H, t,./= 6.8
Li Method C, Purity is Hz), 2.82 (2H, s),
4.07 (2H, q, J= 6.8
-\ Hz), 6.92 (1H.' dd, J=
8.4, 2.0 Hz),
100%, Rt = 2.169 min;
7.06 (1H, s), 7.11 (1H, d, J= 7.2 Hz),
98
0 HN-<\ I MS Calcd.: 493.2; MS 7.18 (1H, t, J=
4.4 Hz), 7.34 (1H, t, J
OH N Found: 494.1 [M + H] = 8.0 Hz), 7.60
(1H, d, J= 5.2 Hz),
7.64 (1H, d, J= 7.2 Hz), 8.46 (1H, d, J
= 2.0 Hz), 8.93 (1H, d, J= 2.0 Hz).
6: 0.87 (9H, s), 2.83 (2H, s), 3.32 (3H,
s), 3.67 (2H, t. J= 4.4 Hz), 4.14 (2H, t,
N 98.0%, Rt = 2.083 min; Hz), 7.08 (1H,
s), 7.13 (1H.
Method C, Purity is
J= 4.4 Hz), 6.94 (1H. dd. J= 8.4, 2.0- d,
J= 8.0
s
99 HN-4 Hz), 7.18 (1H, dd_ J=
4.8, 4.0 Hz),
- N MS Calcd.: 523.2; MS
7.35 (1H, t, J= 8.0 Hz), 7.60 (1H, d, J
Found: 524.2 [M + H] ". = 4.8 Hz), 7.65 (1H, d, J= 3.6 Hz),
0
8.46 (1H, d, J= 2.4 Hz), 8.95 (1H, d, J
= 2.4 Hz), 11.60 (1H, brs).
s Method C, Purity is 6: 0.94 (6H, d, J=
6.4 Hz), 1.88-1.92
(1H, m), 2.75 (2H, d, J= 7.2 Hz), 3.81
,N 99.4%, Rt = 2.019 min;
100 \ s , (6H, s), 7.03 (1H, d,
J= 8.4 Hz), 7.10-
0 MS Calcd.: 496.1; MS 7.20 (3H, m), 7.63
(2H, dd, J = 12.4,
OH N
3.6 Hz), 8.47 (1H. d, J= 2.4 Hz), 8.95
Found: 496.2 [M + H]
(1H, d, J= 2.4 Hz), 11.82 (1H, brs).
101
-\
0 HN-<, I
(.0H N Method C, Purity is 6: 0.94 (6H, d, J=
6.4 Hz), 1.87-1.92
(1H, m), 2.76 (2H, d, J= 7.2 Hz), 3.85
98.6%, Rt = 2.071 min; (6H, s), 6.52 (1H, s),
6.71 (2H, d, J=
I MS Calcd.: 495.1; MS 2.0 Hz), 7.18 (1H. J=
4.0 Hz), 7.61-
0 7.65 (2H, m), 8.46-
(1H, d, J= 2.4 Hz),
Found: 496.2 [M + H] 8.94 (1H, d, J= 2.4
Hz), 11.76 (1H,
brs).
,o
Example 3. Compound Testing in Human eIF4E/4G2 Binding Assay
1004461 Human elF4E (aa 28-217) with a C-terminal His-tag was expressed in E.
coli in
inclusion bodies. The protein was solubilized with 8 M urea and purified under
denaturing
conditions using nickel-charged HisTrap HP columns (GE Healthcare). The
purified protein was
then refolded by diluting in 20 mM Hepes pH 7.0, 0.5 M NaC1, 1 mM DTT, 1 mM
EDTA, 0.5 M
arginine plus 6 M urea, and then dialyzing overnight into the same buffer
without the urea. The
protein was further dialyzed into 20 mM Hepes, pH 6.5, 50 mM NaCl, 1 mM EDTA,
1 mM DTT,
and concentrated using Hitrap SP sepharose FF columns (GE Healthcare). The
concentrated
protein was dialyzed into 20 mM Hepes, pH 7.0, 0.5M NaCl, 5 mM DTT and 10%
glycerol, and
stored at -80 C until use.
166
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1004471 Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series
in DMSO (10
concentration points). Compound solutions (1.2 l/well) were added into black
384-well
polypropylene microplates (Matrix, Thermal Scientific). Twenty-two microliters
per well of
Assay Buffer (50 mM NaPi, pH 6.5, 50 mMKC1, 1 mM DTT and 0.5 mg/ml gamma
globulin) and
eight microliters per well of 82.5 nM purified elF4E in Assay Buffer were
added. The samples
were incubated at room temperature (20-23 C) for 4 hours. Biotin labeled 4G2
peptide (Ac-Lys-
Gln-Tyr-Asp-Arg-Glu-Phe-Leu-Leu-Asp-Phe-Gln-Phe-Met-Pro-Lys(Aha-Bio)-NH2, 1.75
M
stock in DMSO) was diluted to 0.14 M in Assay Buffer (without DTT) and 5
l/well was added.
The samples were incubated at room temperature for 20 min. Five microliters
per well of 6.4 nM
Eu-streptavidin (Eu-SA, Perkin Elmer) and 80 nM Allophycocyanin (APC)-anti His
antibody
(Columbia Biosciences) in Assay Buffer (without DTT) were then added and the
samples were
incubated at room temperature for 20 min.
1004481 Assay signals were monitored by reading excitation at 340 nm and
emission
fluorescence at 615 nm and 665 nm on an Envision reader (Perkin Elmer).
Normalized TR-FRET
(time-resolved fluorescence resonance energy transfer) assay signal (Rn) was
calculated by the
formula:
Rn = [(A-Ba-C x D)/(D-Bd)] x (Dc- Bd)
Where A is the fluorescence intensity of the sample at 665 nm,
D is the fluorescence intensity of the sample at 615 nm,
Ba and Bd are plate backgrounds at 665 nm and 615 nm, respectively,
Dc is the fluorescence intensity of 0.78 nM Eu-SA in the assay buffer at 615
nm
The cross-talk factor (C) is determined by the following formula:
C = (Ac- Ba)/(Dc-Bd)
Where Ac is the fluorescence intensity of 0.78 nM Eu-SA in the assay buffer at
665 nm.
1004491 TC50 values were calculated using xT,Fit program (IT)BS). Table 2
below lists EC50
of some compounds, wherein A represents IC50 < 0.5 p.M; B represents 0.5 uM <
IC50 < 1 M;
and C represents IC50 > 1 M.
Table 2. IC50 of Certain Exemplary Compounds.
Comp. No. IC50 Comp. No. IC50 Comp. No. IC50
I-1 A 1-36 A 1-71
1-2 1-37 A 1-72 A
1-3 C 1-38 B 1-73
167
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1-4 A 1-39 A 1-74 A
1-5 1-40 A 1-75
1-6 1-41 A 1-76 A
1-7 A 1-42 A 1-77 A
1-8 A 1-43 A 1-78 A
1-9 A 1-44 A 1-79 A
I-10 A 1-45 A 1-80 A
I-11 A 1-46 A 1-81 A
1-12 B 1-47 A 1-82 A
1-13 C 1-48 A 1-83 A
1-14 B 1-49 B 1-84 A
1-15 B I-50 B 1-85
1-16 A 1-51 A 1-86 A
1-17 A 1-52 A 1-87 A
1-18 B 1-53 C 1-88 A
1-19 B 1-54 A 1-89 A
1-20 B 1-55 B 1-90 A
1-21 B 1-56 C 1-91 A
1-22 B 1-57 B 1-92 A
1-23 B 1-58 A 1-93 A
1-24 C 1-59 B 1-94 A
1-25 B 1-60 A 1-95 A
1-26 C 1-61 A 1-96 A
1-27 B 1-62 A 1-97 A
1-28 B 1-63 A 1-98 A
1-29 B 1-64 A 1-99
1-30 B 1-65 A I-100
1-31 B 1-66 A I-101
1-32 B 1-67 A 1-102 A
1-33 C 1-68 B 1-103 A
1-34 A 1-69 A
1-35 A 1-70 A
Comp. No. IC50 Comp. No. IC50 Comp. No. IC50
1-104 A 1-113 A 1-125 A
1-105 A 1-114 A 1-126 A
1-106 A 1-115 A 1-127 A
1-107 A I-116 C 1-128 A
1-108 A 1-117 C 1-129 A
1-109 A 1-118 A 1-130 B
1-1 10 A 1-122 A 1-141 A
I-111 B 1-123 A 1-148 C
1-112 A 1-124 A
168
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
Example 4. Synthesis of Certain Compounds
Scheme 1: Route for Compound 1-130
OH -..
0 __ /0 0 S Br 0
S /
e_OH
0--
Pd(dppf)C12, Na2CO3 \
¨N dioxane/H20, 85 C, 16 h
/
_____________________________________________________ 7. \
¨N ¨
H2N H2N
Scheme 2: Route for Compound 1-131
OH
S 0
o C1 6-0H
,--c_ s ....._
¨O ¨ N Pd(dppf)Cl2, Na2CO3 ¨CI ¨N
H2N dioxane/H20, 85 C, 2 h H2N
Scheme 3: Route for Compounds 104-s, 105-s, 107-s, 108-s, 109-s, 123-s, 126-s,
127-s, 112-s,
136-s, 141-s
Br
Cc
,..s.,...õ1., 0 0
BrMg HO PCC PTAT _
THF, it, 4 h CH2Cl2, it, 2 h THF, it, 2h
-=0 1.1
CF3 0 CF3 ...0 CF3 '0
CF3
104-1 104-2 104-3
104-4
CI \
SCN ii¨S
NaSCN HCl/clioxane..
Et0H, 90 C, 5 h
-,c) CF3 --..
0 CF3
104-5 104-s
169
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
r
_______________________________________________________________________________
__ 1
,S S S S S
Ci¨ I CI-4\ 1 CI--- I C1¨(\ 1 CI¨K= 1
N .I N N41# N N 0
N..--0 IC)
--0
105-s 107-s 108-s 109-s 123-
s
,S ,S S S 1
Cl¨e_el
Cl¨c\ f CI---<\
N N N N -' / N ¨
I s\ S
S /
S /
=
126-s 127-s 112-s 136-s 141-
s
The same synthesis method used for other compounds 105-s, 107-s, 108-s, 109-s,
123-s, 126-s, 127-s, 112-s, 136-s. 141-s
Scheme 4: Route for Compounds 102-s, 103-s, 106-s, 128-s, 113-s, 118-s, 122-s
s s s
ci--4, 1 BEir3 ci---4, Tf0".---'CF, CI-4s
N N N
CH2C12 rt overnight K2CO3, DMF, rt overnight'
...õ.õ...0 OH 0 CF3
---..--
102-1 102-s
,
S
S S S S
CI-4.
CI-41
, 1 DI-4 N CI-4. i S
N N N N
.,¨....o,..
103-s 106-s 128-s 113-s 118-s
122-s
, The same synthesis method used for other compounds 103-s, 106-s. 128-s, 113-
s, 118-5, 122-s.
Scheme 5: Route for Compound 110-s
OH 0 HO ..
OH 0
0
0 .8, I
0 I ¨ 0 BrM-^=,,I, .,,,0
, g
0 ___________________________________________________________________
PdC12(dppf), Na2003 THE rt, 4 h CH2Cl2, rt, 2 h
Br toluene, 100 C, overnight
110-1 110-2 110-3
110-4
0 0
S
PTAT NaSCN --- HCl/dioxane,C1-4
I
THF, rt, 2 h Br Et0H, 90 C. 5 h SCN rt, 4 h N
110-s
110-5 110-6
Scheme 6: Route for Compounds 124-s, 125-s, 139-s, 140-s
170
CA 03229560 2024-2-20
WO 2023/028235
PCT/US2022/041532
B>< o
<0 0 B 0
____4 S S
0 i.... HN-4 1 NaOH
1.' 1-12N---<.,, 1 V sl N
Pd(OAc)2, PCy3, K3PO4, Et0H, 90 C, overnight
N
----jCN N CI toluene/H20, MW 150 C, 12 h
H 0
0
124-4 124-1 C)-1
124-s 0¨/
, ______________________________________________
S
H2N¨<, 1 S S
N
H2N-4 JLJJ 1-12NI-
-- 1
N N
i
0 I 0
125-s (3---C 139-s 140-s
The same synthesis method used for other compounds 125-s, 139-s, 140-s.
Scheme 7: Route for Compounds 114-s, 121-s
0 )¨I 0 j OH 0
I PCC HO .,.....*..õ0 0
1 BrMg"--,
Ill K2CO3, DMF, rt, overnight ---T- 01 THE, rt, 4 Ii
'(o CH2C12, it, 2 113- I
114-1 114-2 114-3 114-4
S S
0 0
CI-4 CI----<\
1
I.-NT ..--....õ.õ..0 NaSCN HCl/dioxane. N
N
THF, it, 2 h I Et0H, 90 C, 5 11 I it, 4 h
Br SCN
-...r0
121-sar'-**---'1Y.'
114-5 114-6 114-s
The same synthesis method used
jor other compound 121-s.
Scheme 8: Route for Compounds 116-s, 117-s, 119-s, 120-s
S S S
Br"--.' "--Br CI---- (CH3)2NH.HCI Cl¨ 1
N K2003, DMF, 60 C. 16 h N
K2CO3, DMF, it, 16 h' N
I
OH0.,...,...-...Ø........õ,Br
0..õ...,,...0,..,...,,,,N.
116-1 116-s
,
_______________________________________________________________________________
___ .
S S
S
CI----<
N 1 CI-4 \
C1-- 1
N
N
i---- 0---,0-----N-
.....N.---..,
0..õ..."..Ø..---...õ.,.N..õ.....- I I--,
117-s 119-s 120-s
,._ The same synthesis method used for other compounds 117-s, 119-s, 120-s.
,
Scheme 9: Route for Compounds 1-102 to 1-121, 1-123, 1-126 to 1-128, 1-141
171
CA 03229560 2024-2-20
WO 2023/028235
PCT/US2022/041532
,e-
CI
1
N NH2 \ __ K s LiCH
. ( S
Pd2(dba)3, X-Phos, Cs2CO3 0 HN¨ I THF/Me0H, rt, 2h 0 HN¨ I
toluene, 120 C, 4 h 0 N CF3 OH N
CF3
/
0 CF3
104-s 104-6 1-104
_.-0
The same synthesis method used for other compounds 1-102, 1-103,1-105 to 1-
121, 1-123, 1-126 to 1-128,1-141.
Scheme 10: Route for Compounds 1-124, 1-125, 1-139, 1-140
,-- ---
yx....xis3
H2N--< 1 CI N
. \ / S LiOH
N Pd2(dba)3, X-Phos, Cs2CO3 0 HN--
1 THF/Me0H, rt, 2 h HN-4 i
0 N
toluene, 120 C, 4 h 0 N
OH
0 /
0---/ 0
0
124-s 124-2 0--/ 1-124
0--/
The same synthesis method used for other compounds 1-125,1-139, 1-140.
Scheme 11: Route for Compound 1-129
_
/ \ ¨\¨\ 0 ,, OH
\ ,N \ /N
\ /N Y- \ ____ K ,s , (
( s OH i. 0 HN¨ 1 LICH 0
HN¨ i
0 HN¨ I Cu(OAc)2, TEA 0 N THF/Me0H, rt, 2 h
OH N
0 N CH2Cl2, rt, overnight /
/
0 411
111-6 129-1 0 1-129 0
00
HO
Scheme 12: Route for Compound 1-130
s/
oµ\ ____________________ o
¨\ ____________________________________ \\ ¨\N S I /
HO/
' \ __ /N
\ i(
Cl¨ 1 H2N N __________ ¨0 LION S
. .
N HN¨ 1 HN¨<,
I
Pd2(dba)3, X-Phos, Cs2CO3 THF/Me0H, rt, 2 h
toluene, MW 120 uC, 3 h N N
0..,,,,
130-1 1-130
Os....õ---
O,..___
Scheme 13: Route for Compound 1-131
172
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Sr.) _______________________________________________________________________
rS7')
, 1
s _________________________________________________________ N
CI-4 1 ____ H2N K s LiOH N Pd2(dba)3, X-Phos,
Cs2CO3 0 HN4 I THF/Me0H, rt, 2 h 0 HIN¨ 1
toluene, MW 150 C, 4 h 0 N OH N
/
0,õ.-
131-2 1-131
Scheme 14: Route for Compounds 1-132, 1-137, 1-142 to 1-144
--..,... S --...---
c))_\
sr.....1,k I
¨0 S''N THF/M Sr-s.
CI----4 1 H2N S NaOH
d2dba3, X-phos, Cs2CO3 S
N ' 0) HN-4 1
N
Pe0H, 50 'C, 12 h
toluene, 120 C, overnight /0 OH N
0-.._-
132-1 0.,-- 1-132 0.,..õ,--
The same synthesis method used for other compounds 1-137, 1-142 to 1-144.
Scheme 15: Route for Compounds 1-133 to 1-136
F F FE FE
F F F
0,
4 c-
S ¨0 ¨N
1¨ \N
1¨\N
CI¨ 1 H2N \ ___ I( S LiOH
HN¨.
Pd2(dba)3, X-Phos, Cs2L,,L,3 THF/Me0H, rt, 2 h
0
0 N OH N
toluene, 120 C. 3 h /
133-1 1-
133
(-3-.......---
ci,....----
The same synthesis method used for other compounds 1-134 to 1-136
Scheme 16: Route for Compound 1-138
o,
0 Br
HO.
Br
S --= s
Br-4 1 H2N
0 OH
__________________________________________________________________ ...
N Pd2(dba)3, X-Phos, Cs2CO3 0 N
Pd(dppf)C12, Na2CO3 0
HN-4. 1
toluene, 110C, 16 h / dioxane/H20, 85 C, overnight
N
CI CI /0
CI
138-1 CI 138-2 CI
0 CI
==.
LiOH S
THF/Me0H, rt, 2 h 0
4,
HN
OH N
CI
1-138 Cl
Scheme 17: Route for Compound 1-145
173
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0
..,
I o
S "N "N
CI-- i N NH2 NaOH
N Pd2(dba)3, X-Phos, Cs2CO3 THF/Me0H,
it, 2 h 0
0 N OHHN¨%
N
toluene, 120 C, 16 h /
126-s 145-1 1-145
Scheme 18: Route for Compound 1-146
\ s
ci--µ 1 ¨0"¨Nill N¨ I LiOH
N Pd2(dba)3, X-Phos, Cs2C-3
r) / N-M-- -D THF/Me0H, rt, 2 h
toluene, 110 C, 16 h 0 S / 0
S /
S / 0
/ OH
126-s 146-1 1-146
Scheme 19: Route for Compound 1-147
FE
F F F F F
1 \ \N
S CI LION
H2N----K\ .
N
Te0H
Pd2(dba)3, X-Phos, Cs2CO3 0 N HF/M , rt, 2 FIN_ 1
toluene, 120 C, 4 h 0 N OH
N
/
139-s 147-1 1-147
Scheme 20: Route for Compounds 1-122 and 1-148
1 _
S Nr NH2 ¨ N LiOH , N
N
THF/Me0H, rt, 2 Pd2(tclobluae),TeX-1P2h000s6 C4s2h 00 3 0 \
N
/0 OH
122-s 1-148 1-122
1004501 General information: All evaporations were carried out in
vacuo with a rotary evaporator.
Analytical samples were dried in vacuo ( I -5 mmHg) at rt. Thin layer
chromatography (TLC) was performed
on silica gel plates, spots were visualized by UV light (214 and 254 urn).
Purification by column and flash
chromatography was carried out using silica gel (200-300 mesh). Solvent
systems are reported as mixtures
by volume. All NMR spectra were recorded on a Bruker 400 (400 MHz)
spectrometer. 1H chemical shifts
are reported in 6 values in ppm with the deuterated solvent as the internal
standard. Data are reported as
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet,
q = quartet, br = broad, m =
multiplet), coupling constant (Hz), integration.
1004511 LCMS spectra were obtained on an Agilent 1200 series 6110 or 6120 mass
spectrometer with
electrospray ionization and excepted as otherwise indicated, the general LCMS
condition was as follows:
174
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1004521 Method A (Agilent LCMS 1200-6110, Column: Waters X-Bridge C18 (50 mm x
4.6 mm x
3.5 im); Column Temperature: 40 C; Flow Rate: 3.0 mL/min; mobile phase: from
95% [water + 0.05%
TFA] and 5% [CH3CN + 0.05% TFA] to 0% [water + 0.05% TFA] and 100% [CH3CN +
0.05% TFA] in
0.8 min, then under this condition for 0.4 min, finally changed to 95% [water
+ 0.05% TFA] and 5%
[CH3CN + 0.05% TFA] in 0.01 min).
1004531 Method B (Agilent LCMS 1200-6110, Column: Waters X-Bridge C18 (50 mm x
4.6 mm x 3.5
lam); Column Temperature: 40 C; Flow Rate: 2.0 mL/min; Mobile Phase: from 95%
[water + 0.05% TFA]
and 5% [CH3CN + 0.05% TFA] to 0% [water + 0.05% TFA] and 100% [CH3CN + 0.05 %
TFA] in 1.6
min, then under this condition for 1.4 min, finally changed to 95% [water +
0.05% TFA] and 5% [CH3CN
+ 0.05% TFA] in 0.05 min and under this condition for 0.7 min.).
1004541 Method C (Agilent LCMS 1200-6120, Column: Waters X-Bridge C18 (50 mm x
4.6 mm x
3.5 ttm); Column Temperature: 40 'V; Flow Rate: 2.0 mL/min; Mobile Phase: from
95% [water + 10 mM
NH4HC031 and 5% [CH3CN] to 0% [water + 10 mM NH4HC0.31 and 100% [CH3CN] in 1.6
min, then under
this condition for 1.4 min, finally changed to 95% [water + 10 mM NH4HC031 and
5% [CH3CN] in 0.1
min and under this condition for 0.7 min.)
Experimental Section
1004551 The synthesis of methyl 2-amino-5-(thiophen-2-
yl)isonicotinate (130)
OH
\ 0 6s H \0)
0/ Br C.Tu 0
/
Pd(dppf)C12, Na2C031
dioxane/H20, 85 C, 16 h ¨N
H2N H2N
130-1 130
1004561 A mixture of 130-1 (1.00 g, 4.33 mmol), thiophen-2-ylboronic acid (831
mg, 6.49
mmol), Pd(dppf)C12 (316 mg, 0.433 mmol) and Na2CO3 (918 mg, 8.66 mmol) in
dioxane/H20 (v/v
= 5/1, 30.0 mL) was stirred under N2 atmosphere at 85 C for 16 h. When the
reaction was
completed, it was concentrated and purified by silica gel column
chromatography (petrol
ether/ethyl acetate = 3/1) to afford 130 (600 mg, 59.2% yield) as a yellow
solid.
1004571 The synthesis of methyl 2-amino-6-(thiophen-2-yl)nicotinate (131)
OH
6.0H ( S,
\/ _________________________________________________
¨0 )=N Pd(dppf)C12, Na2CO3 ¨0 1=N
H2N dioxane/H20, 85 C, 2 h H2N
131-1 131
175
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
[00458] A mixture of 131-1 (300 mg, 1.61 mmol), thiophen-2-ylboronic acid (309
mg, 2.41
mmol), Pd(dppf)C12 (118 mg, 0.161 mmol) and Na2CO3 (341 mg, 3.22 mmol) in
dioxane/H20 (v/v
= 5/1, 10.0 mL) was stirred under N2 atmosphere at 85 C for 2 h. When the
reaction was
completed, it was concentrated and purified by silica gel column
chromatography (petrol
ether/ethyl acetate ¨ 3/1) to afford 131 (200 mg, 53.2% yield) as a yellow
solid.
[00459] The synthesis of 1-(3-methoxy-5-(trifluoromethyl)pheny1)-4-
methylpentan-1-ol (104-
2)
0
HO
BrMg
THF, rt, 4 h
O 4 c31111
0 CF3
104-1 104-2
[00460] To a solution of 104-1 (2.00 g, 9.80 mmol) in THE (15.0 mL) was added
isopentylmagnesium bromide (1.0 M in THE, 14.7 mL, 14.7 mmol). The reaction
was stirred at
room temperature for 4 h. When the reaction was completed, it was poured into
aq.NH4C1 (sat.,
30.0 mL) and extracted with Et0Ac (60.0 mL x 3). The organic phase was
combined, and washed
with H20 (50.0 mL) and brine (50.0 mL), then dried with anhydrous Na2SO4,
concentrated and
purified by silica gel column chromatography (petrol ether/ethyl acetate =
10/1) to afford 104-2
(1.80 g, 66.5% yield) as yellow oil.
1004611 The synthesis of 1-(3-methoxy-5-(trifluoromethyl)pheny1)-4-
methylpentan-1-one
(104-3)
HO 0
PCC
CH2Cl2, rt, 2 h
CF3 CF3
104-2 104-3
[00462] To a solution of 104-2 (1.80 g, 6.51 mmol) in CH2C12 (100 mL) was
added PCC (2.81
g, 13.0 mmol). The reaction was stirred at room temperature for 2 h. When the
reaction was
completed, it was concentrated, and purified by silica gel column
chromatography (petrol
ether/ethyl acetate = 20/1) to afford 104-3 (1.40 g, 78.3% yield) as colorless
oil.
[00463] The synthesis of 2-bromo-1-(3-methoxy-5-(trifluoromethyl)pheny1)-4-
methylpentan-
1-one (104-4)
176
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Br
O 0
PTAT
THF, rt, 2 h
0 CF3 OF3
104-3 104-4
[00464] A mixture of 104-3 (L40 g, SAO mmol) and PTAT (2.87 g, 7.66 mmol) in
THF (50.0
mL) was stirred at room temperature for 2 h. When the reaction was completed,
it was
concentrated, and the residual was dissolved in H20 (30.0 mL), and then
extracted with Et0Ac
(50.0 mL x 2). The organic layer was combined, and washed with H20 (30.0 mL x
2) and Brine
(30.0 mL), then dried by anhydrous Na2SO4. The solution was concentrated to
give the crude
product, which was used directly in next step without farther purification to
afford 104-4 (1.80 g,
100% yield) as brown oil.
[00465] The synthesis of 1-(3-methoxy -5-
(trifluoromethyl)ph eny1)-4-m ethy1-2-
thi ocy anatop entan-1 -one (104-5)
Br SCN
O 0
NaSCN
Et0H, 90 C, 5 h
CF3 0 CF3
104-4 104-5
[00466] A mixture of 104-4 (1.80 g, 5.11 mmol) and NaSCN (828 mg, 10.2 mmol)
in Et0H
(30.0 mL) was stirred at 90 C for 5 h. When the reaction was completed, it
was concentrated and
purified by silica gel column chromatography (petrol ether/ethyl acetate =
3/1) to afford 104-5
(1.20 g, 70.9% yield) as a yellow solid.
[00467]
The synthesis of 2-chloro-5-isobuty1-4-(3-methoxy-5-
(trifluoromethyl)phenyl)thiazole
(104-s)
CI \
SCN
O S
N
HCl/dioxane
rt, 4 h
0 CF3
0 CF3
104-5 104-s
177
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1004681 A mixture of 104-5 (1.20 g, 3.63 mmol) in HC1/dioxane (4.0 M, 10.0 mL)
was stirred
at room temperature for 4 h. When the reaction was completed, it was
concentrated and purified
by silica gel column chromatography (petrol ether/ethyl acetate = 10/1) to
afford 104-s (1.00 g,
79.0% yield) as yellow oil.
1004691 The synthesis of 3 -(2-chl oro-5 -i sobutylthiazol-4-yl)phenol (102-
1)
S S
CI--- I BBr3 > CI-4 I
N 0 CH2Cl2, rt, overnight N 0
1 102-1
1004701 A mixture of! (1.10 g, 3.73 mmol) and BBr3 (17% in CH2C12, 9.32 mL,
9.32 mmol)
in CH2C12 (30.0 mL) was stirred at room temperature overnight. When the
reaction was completed,
it was washed with H20 (50.0 mL x 3). The organic layer was concentrated and
purified by silica
gel column chromatography (petrol ether/ethyl acetate = 4/1) to afford 102-1
(600 mg, 60.3%
yield) as a yellow solid.
1004711 The synthesis of 2-chloro-5-isobuty1-4-(3-(2,2,2-
trifluoroethoxy)phenyl)thiazole (102-
s)
S S
CI-4 I Tfa"--CF3 ,Ci-4 I
N K2CO3, DMF, it, overnight eli N 0
OH 0 CF
=-=.,,,, 3
102-1 102-s
1004721 A mixture of 102-1 (250 mg, 0.936 mmol), 2,2,2-trifluoroethyl
trifluoromethanesulfonate (326 mg, L40 mmol) and K2CO3 (388 mg, 2.81 mmol) in
DMf (5.0
mL) was stirred at room temperature overnight. When the reaction was
completed, it was poured
into H20 (80.0 mL) and extracted with Et0Ac (50.0 mL x 3). The organic phase
was combined,
and washed with 1-1-,0 (50.0 mL) and brine (50.0 mL), then dried with
anhydrous Na2SO4,
concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 15/1)
to afford 102-s (310 mg, 94.9% yield) as colorless oil.
178
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1004731 The synthesis of 4-ethyl-3-methoxybenzaldehyde (110-2)
0 9H 0
HO ¨ 0
0
PdC12(dppf), Na2CO3
Br toluene, 100 C, overnight
110-1 110-2
1004741 A mixture of 110-1 (4.00 g, 18.6 mmol), ethylboronic acid (2.07 g,
27.9 mmol),
Pd(dppf)C12 (1.36g, 1.86 mmol) and Na2CO3 (3.94 g, 37.2 mmol) in toluene (30.0
mL) was stirred
under N2 atmosphere at 100 C overnight. When the reaction was completed, it
was concentrated
and purified by silica gel column chromatography (petrol ether/ethyl acetate =
20/1) to afford 110-
2 (1.80 g, 59.0% yield) as black oil.
1004751 The synthesis of 1-(4-ethyl-3-methoxypheny1)-4-methylpentan-1-ol (110-
3)
0 OH
0
THF, rt, 4 h
110-2 110-3
1004761 To a solution of 110-2 (1.80 g, 11.0 mmol) in THF (20.0 mL) was added
isopentylmagnesium bromide (1.0 M in THF, 16.5 mL, 16.5 mmol). The reaction
was stirred at
room temperature for 4 h. When the reaction was completed, it was poured into
aq.NH4C1 (sat.,
50.0 mL) and extracted with Et0Ac (80.0 mL x 3). The organic phase was
combined, and washed
with H20 (50.0 mL) and brine (80.0 mL), then dried with anhydrous Na2SO4,
concentrated and
purified by silica gel column chromatography (petrol ether/ethyl acetate =
10/1) to afford 110-3
(1.90 g, 73.4% yield) as colorless oil.
1004771 The synthesis of 1-(4-ethyl-3-methoxypheny1)-4-methylpentan-1-one (110-
4)
OH 0
0 0
PCC
CH2Cl2, rt, 2 h
110-3 110-4
1004781 To a solution of 110-3 (1.90 g, 8.05 mmol) in CH2C12 (100 mL) was
added PCC (3.47
g, 16.1 mmol). The reaction was stirred at room temperature for 2 h. When the
reaction was
179
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
completed, it was concentrated, and purified by silica gel column
chromatography (petrol
ether/ethyl acetate = 20/1) to afford 110-4 (1.70 g, 90.2% yield) as colorless
oil.
1004791 The synthesis of 2-bromo-1-(4-ethy1-3-methoxypheny1)-4-methylpentan-1-
one (110-
5)
0 0
0
PTATo
THF, rt, 2 1JtJBr
110-4 110-5
1004801 A mixture of 110-4 (1.70 g, 7.26 mmol) and PTAT (4.09 g, 10.9 mmol) in
THF (50.0
mL) was stirred at room temperature for 2 h. When the reaction was completed,
it was
concentrated, and the residual was dissolved in H20 (30.0 mL), and then
extracted with Et0Ac
(50.0 mL x 2). The organic layer was combined, and washed with H20 (30.0 mL x
2) and Brine
(30.0 mL), then dried by anhydrous Na2SO4. The solution was concentrated to
give the crude
product, which was used directly in next step without farther purification to
afford 110-5 (2.30 g,
100% yield) as brown oil.
100481] The synthesis of 1-(4-ethyl-3 -methoxypheny1)-4-methyl-2-thi ocyanatop
entan-l-one
(110-6)
0 0
NaSCN
Br Et0H, 90 C, 5 h SCN
110-5 110-6
1004821 A mixture of 110-5 (2.30 g, 7.37 mmol) and NaSCN (1.198, 14.7 mmol) in
Et0H (60.0
mL) was stirred at 90 C for 5 h. When the reaction was completed, it was
concentrated and
purified by silica gel column chromatography (petrol ether/ethyl acetate =
3/1) to afford 110-6
(1.40 g, 65.3% yield) as a yellow solid.
1004831 The synthesis of 2-chloro-4-(4-ethyl-3-methoxypheny1)-5-
isobutylthiazole (110-s)
180
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
0
S
..0
HCl/dioxane..CI¨K\ 1
SCN rt, 4 h N 0
0
_.
110-6 110-s
1004841 A mixture of 110-6 (1.40 g, 4.81 mmol) in HC1/dioxane (4.0 M, 30.0 mL)
was stirred
at room temperature for 4 h. When the reaction was completed, it was
concentrated and purified
by silica gel column chromatography (petrol ether/ethyl acetate = 10/1) to
afford 110-s (1.20 g,
80.6% yield) as yellow oil.
1004851 The synthesis of N-(4-(benzo[d][1,3]dioxo1-5-y1)-5-
isobutylthiazol-2-ypacetamide
(124-1)
0---..
b o
(o 401 %0
_4 s
o 9 . HN-4 1
s,.,---
Pd(OAc)2, PCy3, K3PO4, toluene/H20, MW 150 C, 12 h N0
H 0
1 124-1 0-1
1004861 A mixture of! (600 mg, 2.59 mmol), 2-(benzo [cl][1 ,3] dioxo1-
5-y1)-4,4,5,5-tetramethyl-
1,3,2- dioxaborolane (962 mg, 3.88 mmol), Pd(OAc)2 (58.1 mg, 0.259 mmol), PCy3
(145 mg,
0.518 mmol) and K3PO4 (1.10 g, 5.18 mmol) in toluene/H20 (v/v = 10/1, 10.0 mL)
was stirred
under N2 atmosphere at 150 C under mircowave for 12 h. When the reaction was
completed, it
was concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate =
3/1) to afford 124-1 (600 mg, 73.0% yield) as a yellow solid.
1004871 The synthesis of 4-(benzo[d][1,3]dioxo1-5-y1)-5-
isobutylthiazol-2-amine (124-s)
0
HN-- 1 Na OH
,-- 0 H2N-----µ \
N Et0H, 90 C, overnight N 0
0 0
124-1 (3-1 124-s 0--/
181
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1004881 A mixture of 124-1 (600 mg, 1.89 mmol) and NaOH (2.0 M in H20, 4.0 mL)
in Et0H
(20.0 mL) was stirred at 90 C overnight. When the reaction was completed, it
was concentrated,
and purified by silica gel column chromatography (petrol ether/ethyl acetate =
1/1) to afford 124-
s (300 mg, 57.6% yield) as a yellow solid.
1004891 The synthesis of 3-isopropoxy-4-methylbenzaldehyde (114-2)
0 0
HO
K2CO3, DMF, rt, overnight
114-1 114-2
1004901 A mixture of 114-1 (3.00 g, 22.1 mmol), 2-iodopropane (5.62 g, 33.1
mmol) and K2CO3
(9.13 g, 66.2 mmol) in DMF (15.0 mL) was stirred at room temperature
overnight. When the
reaction was completed, it was poured into H20 (200 mL) and extracted with
Et0Ac (100 mL x
3). The organic phase was combined, and washed with H20 (80.0 mL) and brine
(80.0 mL), then
dried with anhydrous Na2SO4, concentrated and purified by silica gel column
chromatography
(petrol ether/ethyl acetate = 30/1) to afford 114-2 (3.40 g, 86.6% yield) as
colorless oil.
1004911 The synthesis of 1-(3-isopropoxy-4-methylpheny1)-4-
methylpentan-1-ol (114-3)
0 OH
oI BrMg---`---L
...rTHF, rt, 4 h -TO
114-2 114-3
1004921 To a solution of 114-2 (3.40 g, 19.1 mmol) in THE (30.0 mL) was added
isopentylmagnesium bromide (1.0 M in THE, 28.7 mL, 28.7 mmol). The reaction
was stirred at
room temperature for 4 h. When the reaction was completed, it was poured into
aq.NH4C1 (sat.,
50.0 mL) and extracted with Et0Ac (80.0 mL x 3). The organic phase was
combined, and washed
with ELO (50.0 mL) and brine (80.0 mL), then dried with anhydrous Na2SO4,
concentrated and
purified by silica gel column chromatography (petrol ether/ethyl acetate =
10/1) to afford 114-3
(3.10 g, 64.9% yield) as colorless oil.
1004931 The synthesis of 1-(3-isopropoxy-4-methylpheny1)-4-methylpentan-1-one
(114-4)
OH 0
PCC
CH2Cl2, rt, 2 h I
114-3 114-4
182
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
[00494] To a solution of 114-3 (3.10 g, 12.4 mmol) in CH2C12 (200 mL) was
added PCC (5.35
g, 24.8 mmol). The reaction was stirred at room temperature for 2 h. When the
reaction was
completed, it was concentrated, and purified by silica gel column
chromatography (petrol
ether/ethyl acetate = 20/1) to afford 114-4 (3.00 g, 97.6% yield) as colorless
oil.
[00495] The synthesis of 2-bromo-1-(3-i sopropoxy-4-methylpheny1)-4-
methylpentan-l-one
(114-5)
0 0
PTAT -y)
THF, rt, 2 h
Br
114-4 114-5
[00496] A mixture of 114-4 (3.00 g, 12.1 mmol) and PTAT (6.80 g, 18.1
mmol) in TI-IF (100
mL) was stirred at room temperature for 2 h. When the reaction was completed,
it was
concentrated, and the residual was dissolved in H20 (80.0 mL), and then
extracted with Et0Ac
(80.0 mL x 2). The organic layer was combined, and washed with H20 (30.0 mL x
2) and Brine
(30.0 mL), then dried by anhydrous Na2SO4. The solution was concentrated to
give the crude
product, which was used directly in next step without farther purification to
afford 114-5 (3.94 g,
100% yield) as brown oil.
[00497] The synthesis of 1-(3-isopropoxy-4-methylpheny1)-4-methy1-2-
thiocyanatopentan-1-
one (114-6)
0 0
NaSCN
Et0H, 9000, 5 h
Br SCN
114-5 114-6
1004981 A mixture of 114-5 (3.94 g, 12.1 mmol) and NaSCN (1.96 g, 24.2 mmol)
in Et0H (80.0
mL) was stirred at 90 C for 5 h. When the reaction was completed, it was
concentrated and
purified by silica gel column chromatography (petrol ether/ethyl acetate =
3/1) to afford 114-6
(2.50 g, 67.8% yield) as a yellow solid.
[00499] The synthesis of 2-chloro-5-isobuty1-4-(3-isopropoxy-4-
methylphenyl)thiazole (114-s)
183
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
S
0
¨ 1
HCl/dioxaneCIµ,
rt, 4 h N 01111
SCN
--.....0
114-6 114-s
1005001 A mixture of 114-6 (2.50 g, 8.20 mmol) in HC1/dioxane (4.0 M, 30.0 mL)
was stirred
at room temperature for 4 h. When the reaction was completed, it was
concentrated and purified
by silica gel column chromatography (petrol ether/ethyl acetate = 10/1) to
afford 114-s (1.50 g,
56.6% yield) as yellow oil.
1005011 The synthesis of 4-(3-(2-(2-bromoethoxy)ethoxy)pheny1)-2-chloro-5-
isobutylthiazole
(116-1)
S S
CI---4 I Br "----'sBr CI-4 1
N K2CO3, DMF, 60 C, 16 h 0 N is
OH0..,..¨...,o....--..õ..Br
1005021 102-1 116-1
1005031 A mixture of 102-1 (600 mg, 2.25 mmol), 1-bromo-2-(2-
bromoethoxy)ethane (1.41 g,
3.37 mmol) and K2CO3 (930 mg, 6.74 mmol) in DMF (10.0 mL) was stirred at 60 C
for 16 h.
When the reaction was completed, it was poured into H20 (100 mL) and extracted
with Et0Ac
(100 mL x 3). The organic phase was combined, and washed with H20 (80.0 mL)
and brine (80.0
mL), then dried with anhydrous Na2SO4, concentrated and purified by silica gel
column
chromatography (petrol ether/ethyl acetate = 10/1) to afford 116-1 (400 mg,
61.3% yield) as
colorless oil.
1005041 The synthesis of 24243 -(2-chl oro-5-i sobutylthi azol-4-
yl)phenoxy)ethoxy)-N,N-
dimethy 1 ethanamine (116-s)
184
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
CI-4 (CH3)2NH.HCI
N N 110
K2CO3, DMF, rt, 16 hi'.
Br N
116-1 116-s
1005051 A mixture of 116-1 (400 mg, 0.957 mmol), (CH3)2NH.HC1 (117 mg, 1.44
mmol) and
K2CO3 (396 mg, 2.87 mmol) in DIVE (10.0 mL) was stirred at room temperature
for 16 h. When
the reaction was completed, it was poured into H20 (100 mL) and extracted with
Et0Ac (100 mL
x 3). The organic phase was combined, and washed with H20 (80.0 mL) and brine
(80.0 mL), then
dried with anhydrous Na2SO4, concentrated and purified by silica gel column
chromatography
(petrol ether/ethyl acetate = 30/1) to afford 116-s (280 mg, 76.6% yield) as
yellow oil.
Chemical Structure LCMS
ca.
Method B, Purity is 98.0%, Rt = 1.685 min; MS Calcd.:234.1;
131 ¨0/ )N MS Found: 235.1 1M + HI+.
H2N
Method A, Purity is 97 5%, Rt = 0.971 min; MS Calcd.:349.1;
102-s N MS Found: 350.0 [M + H] +.
Ci-4s
103 Method A, Purity is 88.5%, Rt = 0.925
mm; MS Calcd.:313.1;
-S
MS Found: 314.0 [M + H] +.
ci Method A, Purity is 95.6%, Rt = 1.030 min; MS Calcd.:309.1;
106-s
MS Found: 310.0 [M + H] .
107-s
Method A, Purity is 92.3%, Rt = 1.008 mm; MS Calcd.:295.1;
MS Found: 296.0 [M + H]
185
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
Chemical Structure LCMS
108-s cI Method A, Purity is 84.8%, Rt = 1.043
min; MS Calcd.:309.1;
MS Found: 310.0 um + H] +.
-o
ch-e I Method B, Purity is 94.9%, Rt = 2.302
min; MS Calcd.:295.1;
109-s
MS Found: 296.2 [M + H] 1.
123 I Method B, Purity is 70.6%, Rt = 2.400
min; MS Calcd.:279.1;
-s
MS Found: 280.1 nvi + H] +.
I 110 Method B, Purity is 81.7%, Rt = 2.410
min; MS Calcd.:309.1;
-s
MS Found: 310.1 [M + H]
125-s 1-12N-4 Method A, Purity is 84.8%, Rt = 0.641
min; MS Calcd.:304.1;
MS Found: 305.1 rvi + H] +.
126-s Method A, Purity is 68.3%, Rt = 0.959
min; MS Calcd.:257.0;
MS Found: 258.2 rm + H]
s
127-s Method B, Purity is 85.6%, Rt = 2.260
min; MS Calcd.:257.0;
MS Found: 258.1 rvi + H]
I \
CI Method A, Purity is 65.9%, Rt = 0.953
min; MS Calcd.:333.0;
136-s N
S MS Found: 334.2 uvi + H] .
ci---(ss Method B, Purity is 94.4%, Rt = 1.783
min; MS Calcd.:382.2;
116-s
MS Found- 383.2 vvr + H]
cI Method B, Purity is 96.1%, Rt = 1.811
min; MS Calcd.:410.2;
117-s
MS Found: 411.3 [M + H] 1.
(
186
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
Chemical Structure LCMS
Method A, Purity is 78.8%, Rt = 0.614 min; MS Calcd.:236.1;
139-s 1-12N-4: I MS Found: 237.4 [M + H] 1.
140 s Method C, Purity is 90.3%, Rt = 1.834 min; MS
Calcd.:238.1;
-s IHN1¨(\ ,
MS Found: 239.4 [M + H] +.
" o
Method B, Purity is 83.1%, Rt = 1.778 min; MS Calcd.:382.2;
119-s 0--<\:
MS Found: 383.2 [M + H] +.
CI-4SN Method B, Purity is 78.0%, Rt = 1.845
min; MS Calcd.:410.2;
120-s
MS Found: 411.4 [M + H] +.
oc)--.=`N"=
121 ci--(ss,N Method A, Purity is 88.9%, Rt - 0.839 min, MS
Caled..297.1,
-s so
MS Found: 298.2 [M + H] .
122 Method A, Purity is 84.6%, Rt = 0.925 min; MS
Calcd.:325.1;
-s CI-4 I
MS Found: 326.3 [M + H] 1.
[00506] The synthesis of methyl 2-((5-isobuty1-4-(3-methoxy-5-
(trifluoromethyl)phenyl)thiazol-2-
yl)amino)-5-(thiophen-2-yl)nicotinate (104-6)
N ,N
N N H2 s
Pd2(dba)3, X-Phos, Cs2CO3 I
0 toluene, 120 C, 4 h N CF3
0 CF3
104-s 104-6
[00507] A mixture of 104-s (250 mg, 0.716 mmol), methyl 2-amino-5-(thiophen-
2-yOnicotinate (168
mg, 0.716 mmol), Pd2(dba)3 (66.6 mg, 0.0716 mmol), X-Phos (62.1 mg, 0.107
mmol) and Cs2CO3 (467
mg, 1.43 mmol) in toluene (10.0 mL) was stirred under N2 atmosphere at 120 C
for 4 h. When the reaction
187
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
was completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl
acetate = 8/1) to afford 104-6 (300 mg, 76.6% yield) as a yellow solid.
1005081 The synthesis of 24(5 -i sobuty1-4-(3 -methoxy-5 -
(trifluoromethyl)phenyl)thiazol-2-yl)amino) -
5-(thiophen-2-yOnicotinic acid (I-104)
..--- ...-
S S
\ ,N \ ,N
\ ____________ K S LiOH \ __ K s
O( HN¨ I THF/Me0H, it, 2 h 0 HN¨ I
0 N 101 CF3 OH N ilo CF3
/
104-6 1-104
.....-0 ,....0
1005091 To a solution of 104-6 (300 mg, 0.548 mmol) in THF/Me0H (v/v = 4/1,
10.0 mL) was added
LiOH (2.0 M in H20, 2.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction was
completed, the resulting reaction was concentrated, then it was diluted with
H20 (15.0 mL) and adjusted
pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with Et0Ac (10.0 mL x
2), and the combined
organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4, and
concentrated, the residue was
purified by washing with Me0H to afford 1-104 (250 mg, 85.5% yield) as a
yellow solid.
1005101 The synthesis of methyl 2-44-(benzo[d][1,31dioxo1-5-y1)-5-
isobutylthiazol-2-y0amino)-5-
(thiophen-2-yDnicotinate (124-2)
jOiri3 /
S
S 1 N
H2N¨ 1
N e Pd2(dba)3, X-Phos, Cs2CO3 0 l 0 HN-4\ 1
toluene, 120 C, 4 h
0 / N ON
124-s 124-2 0----/
1005111 A mixture of 124-s (300 mg, 1.09 mmol), methyl 2-chloro-5-
(thiophen-2-yl)nicotinate (276
mg, 1.09 mmol), Pd2(dba)3 (101 mg, 0.109 mmol), X-Phos (94.5 mg, 0.164 mmol)
and Cs2CO3 (533 mg,
1.64 mmol) in toluene (20.0 mL) was stirred under N2 atmosphere at 120 C for
4 h. When the reaction was
completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl acetate
= 8/1) to afford 124-2 (150 mg, 28.0% yield) as a yellow solid.
1005121 The synthesis of 2-((4-(benzo [d][1,31dioxol -5 -y1)-5 -i
sobutylthiazol-2-yDamino)-5 -(thiophen-
2-yOnicotinic acid (1-124)
188
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
\ / s LiOH
0
HN-4 THF/Me0H, rt, 2 h0 (EN-4
0 OH
N 1110 N
0 0
124-2 1-124 0---/
1005131 To a solution of 124-2 (150 mg, 0.304 mmol) in THF/Me0H (y/y = 4/1,
5.0 mL) was added
LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction was
completed, the resulting reaction was concentrated, then it was diluted with
H20 (15.0 mL) and adjusted
pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with EtOAc (10.0 mL x
2), and the combined
organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4, and
concentrated, the residue was
purified by washing with Me0H to afford 1-124 (30.0 mg, 20.6% yield) as a
yellow solid.
1005141 The synthesis of methyl 2-05-isobuty1-4-(3-
phenoxyphenyOthiazol-2-y0amino)-5-(thiophen-
2-yOnicotinate (129-1)
¨\
_\
1.1 .0H ,N
s ,N
s OH 0 HN4
O HN¨( I Cu(OAc)2, TEA 0
N
/0 N CH2Cl2, rt, overnight
0
111-6 HO 129-1
1005151 A mixture of 111-6 (120 mg, 0.258 mmol), phenylboronic acid
(94.3 mg, 0.773 mmol),
Cu(OAc)2 (77.2 mg, 0.387 mmol) and TEA (130 mg, 1.29 mmol) in CH2C12 (10.0 mL)
was stirred under
N2 atmosphere at room temperature overnight. When the reaction was completed,
it was concentrated and
purified by silica gel column chromatography (petrol ether/ethyl acetate =
3/1) to afford 129-1 (40.0 mg,
28.7% yield) as a yellow solid.
1005161 The synthesis of 24(5-isobuty1-4-(3-phenoxyphenyl)thiazol-2-y0amino)-5-
(thiophen-2-
yOnicotinic acid (1-129)
189
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
_\
,N iN
s
0 HN¨( I LiOH
0 N 4.1 THF/Me0H, rt, 2 h OH N
0 0
129-1 1-129
[00517] To a solution of 129-1 (40.0 mg, 0.0738 mmol) in THF/Me0H (v/v = 4/1,
3.0 mL) was added
LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction was
completed, the resulting reaction was concentrated, then it was diluted with
H20 (15.0 mL) and adjusted
pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with Et0Ac (10.0 mL x
2), and the combined
organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4, and
concentrated, the residue was
purified by washing with Me0H to afford 1-129 (20.0 mg, 51.3% yield) as a
yellow solid.
[00518] The synthesis of methyl 24(4-(3-ethoxypheny1)-5-
isobutylthiazol-2-yl)amino)-5-(thiophen-2-
yflisonicotinate (130-1)
ci
H2N N 130 ¨0 /(NI S
N
Pd2(dba)3, X-Phos, Cs2C07
toluene, MW 120 C, 3 h N
130-1
[00519] A mixture of 1 (300 mg, 1.02 mmol), 130 (239 mg, 1.02 mmol),
Pd2(dba)3 (94.9 mg, 0.102
mmol), X-Phos (88.4 mg, 0.153 mmol) and Cs2CO3 (499 mg, 1.53 mmol) in toluene
(10.0 mL) was stirred
under N2 atmosphere at 120 C under microwave for 3 h. When the reaction was
completed, it was
concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 8/1) to afford
130-1 (120 mg, 23.9% yield) as a yellow solid.
[00520] The synthesis of 24(443 -ethoxypheny1)-5 sobutylthiazol-2-
y0amino)-5 -( thiophen-2-
ypisonicotinic acid (I-130)
190
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
09¨\ 7 ,N ¨0 S LION N .H0 S
THF/Me0H, rt, 2 h HN¨,
N N
130-1 1-130
[00521] To a solution of 130-1 (120 mg, 0.243 mmol) in THF/Me0H (v/v = 4/1,
5.0 mL) was added
LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction was
completed, the resulting reaction was concentrated, then it was diluted with
H20 (15.0 mL) and adjusted
pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with Et0Ac (10.0 mL x
2), and the combined
organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4, and
concentrated, the residue was
purified by washing with Me0H to afford 1-130 (60.0 mg, 51.5% yield) as a
yellow solid.
[00522] The synthesis of methyl 2-04-(3-ethoxypheny1)-5-isobutylthiazol-2-
y0amino)-6-(thiophen-2-
y1)nicotinate (131-2)
0_7/ _______________________________ µ,,k)
¨0/ )=N c/iN
H 2N 131 S
N Pd2(dba)3, X-Phos, Cs2CO3' C)
toluene, MW 150 C 4h 0 N
1 131-2
[00523] A mixture of 1 (250 mg, 0.847 mmol), methyl 2-amino-6-(thiophen-2-
yDnicotinate (198 mg,
0.847 mmol), Pd2(dba)3 (78.8 mg, 0.0847 mmol), X-Phos (73.4 mg, 0.127 mmol)
and Cs2CO3 (414 mg,
1.27 mmol) in toluene (10.0 mL) was stirred under N2 atmosphere at 150 C
under microwave for 4 h.
When the reaction was completed, it was concentrated and purified by silica
gel column chromatography
(petrol ether/ethyl acetate = 8/1) to afford 131-2 (80.0 mg, 19.1% yield) as a
yellow solid.
[00524] The synthesis of 2-04-(3-ethoxypheny1)-5-i sobutylthiazol -2-y1 )am
ino)-6-(thi oph en -2-
yl)nicotinic acid (I-131)
191
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
Sp
_________ S LiOH N
O HN¨µI THF/Me0H, it, 2 h 0 HN¨(
/0
N OH N
131-2 1-131
1005251 To a solution of 131-2 (80.0 mg, 0.162 mmol) in THF/Me0H (v/y = 4/1,
3.0 mL) was added
LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction was
completed, the resulting reaction was concentrated, then it was diluted with
H20 (15.0 mL) and adjusted
pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with Et0Ac (10.0 mL x
2), and the combined
organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4, and
concentrated, the residue was
purified by washing with Me0H to afford 1-131 (30.0 mg, 38.6% yield) as an off-
white solid.
1005261
The synthesis of methyl 5 -(tert-butyl)-3 4(443 -ethoxypheny1)-5
sobutylthiazol-2-
yOamino)thiophene-2-carboxylate (132-1)
\
¨0
H2N )=-K s
N Pd2(dba)3, X-Phos, Cs2003 0 HN-4N
toluene, 120 C, overnight 0
1 132-1
1005271 A mixture of 1 (250 mg, 0.847 mmol), methyl 3-amino-6-(thiophen-2-
yl)pyrazine-2-
carboxylatc (181 mg, 0.847 mmol), Pd2(dba)3 (78.8 mg, 0.0847 mmol), X-Phos
(73.4 mg, 0.127 mmol) and
Cs2CO3 (414 mg, 1.27 mmol) in toluene (10.0 mL) was stirred under N2
atmosphere at 120 'V overnight.
When the reaction was completed, it was concentrated and purified by silica
gel column chromatography
(petrol ether/ethyl acetate = 8/1) to afford 132-1 (100 mg, 25.0% yield) as a
yellow solid.
1005281 The synthesis of
5 -(tert-butyl)-3 -44-(3-ethoxypheny1)-5 sobutylthiazol-2-
yOamino)thiophene-2-carboxylic acid (1-132)
192
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
¨ s NaOH ¨ S
0 HN--µ 1 1
0 N OTHF/Me0H, 50 'C,
12 h"0pHN--µ
OH N 1111
/
132-1 (:).,,,.- 1-132
1005291 To a solution of 132-1 (100 mg, 0.212 mmol) in THF/Me0H (v/v = 4/1,
5.0 mL) was added
LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at 50 C for 12 h. When
the reaction was completed,
the resulting reaction was concentrated, then it was diluted with H20 (15.0
mL) and adjusted pH to 4 - 5
with HC1 (1.0 M). The mixture was extracted with Et0Ac (10.0 mL x 2), and the
combined organic phase
washed with brine (10.0 mL), dried by anhydrous Na2SO4, and concentrated, the
residue was purified by
washing with Me0H to afford 1-132 (50.0 mg, 51.5% yield) as a yellow solid.
1005301 The synthesis of methyl 2-44-(3-ethoxypheny1)-5-isobutylthiazol-2-
yDamino)-5-
(trifluoromethypnicotinate (133-1)
F F F F
F
_______________________________ .,,,
0õ _...õ,(F
S ¨0 ¨N \ __ i_\N
( /N
Cl¨ 1 H2N S
N 0 Pd2(dba)3, X-Phos, Cs2C0:-
toluene, 120 C, 3 h /0 HN¨% I
1 0,._,--
133-1
CI-N,---
1005311 A mixture of 1 (250 mg, 0.847 mmol), methyl 2-amino-5-
(trifluoromethyOnicotinate (186 mg,
0.847 mmol), Pd2(dba)3 (78.8 mg, 0.0847 mmol), X-Phos (73.4 mg, 0.127 mmol)
and Cs2CO3 (414 mg,
1.27 mmol) in toluene (10.0 mL) was stirred under N2 atmosphere at 120 C for
3 h. When the reaction was
completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl acetate
= 8/1) to afford 133-1 (150 mg, 37.0% yield) as a yellow solid.
1005321 The synthesis of
24(443 -ethoxypheny1)-5 -isobutylthiazol-2-yDamino)-5 -
(trifluoromethypnicotinic acid (1-133)
193
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
FE F F
1¨\N 1¨\N
\ S LiOH \ S
0
N OTHF/Me0H, rt, 2 I- HN-
7- _________________________________________
/0 OH N
133-1 1-133
[00533] To a solution of 133-1 (150 mg, 0.313 mmol) in THF/Me0H (v/v = 4/1,
5.0 mL) was added
LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction was
completed, the resulting reaction was concentrated, then it was diluted with
H20 (15.0 mL) and adjusted
pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with Et0Ac (10.0 mL x
2), and the combined
organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4, and
concentrated, the residue was
purified by washing with Me0H to afford 1-133 (80.0 mg, 54.9% yield) as a
white solid.
[00534] The synthesis of methyl 5 -bromo-3 -((4-(3
,4-dichloropheny1)-5 sobutylthiazol-2-
yOamino)thiophene -2 -carboxylate (138-1)
0 Br
,o,t1---)-S-r- Br
¨ S
H2N
Br-- HN-4.,
N Pd2(dba)3, X-Phos, Cs2CO3 0 N
toluene, 110 C, 16h
CI CI
CI
1 138-1 CI
[00535] A mixture of 1 (3.50 g, 9.59 mmol), methyl 3-amino-5-bromothiophene-2-
carboxylate (2.26 g,
9.59 mmol), Pd2(dba)3 (891 mg, 0.959 mmol), X-Phos (831 mg, 1.44 mmol) and
Cs2CO3 (4.68 g, 14.4
mmol) in toluene (100 mL) was stirred under N2 atmosphere at 110 C for 16 h.
When the reaction was
completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl acetate
= 6/1) to afford 138-1 (1.50 g, 30.1% yield) as a yellow solid.
[00536] The synthesis of methyl 3 -((4-(3 ,4 -di chloropheny1)-5
sobutylthiazol-2-yl)amino)-5 -(3 -
methoxyphenyl)thiophene-2-carboxylate (138-2)
194
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
0 0...,
Br
4111 ' B 0
0 HN¨ HO-µ 1 _______________________ > S
0 N 0 HN
Pd(dppf)C12, Na2CO3 0
4 1
/ dioxane/H20, 85 C,
overnight N 0
CI /0
138-1 CI 138-2 CI
CI
1005371 A mixture of 138-1 (200 mg, 0.384 mmol), (3-methoxyphenyl)boronic
acid (87.6 mg, 0.577
mmol), Pd(dppf)C12 (28.1 mg, 0.0384 mmol) and Na2CO3 (81.4 mg, 0.768 mmol) in
dioxane/H20 (v/v =
5/1, 10.0 mL) was stirred under N2 atmosphere at 85 C overnight. When the
reaction was completed, it
was concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 3/1) to
afford 138-2 (70.0111g. 33.3% yield) as a yellow solid.
1005381 The synthesis of 3-44-(3,4-dichloropheny1)-5-isobutylthiazol-2-
yl)amino)-5-(3-
methoxyphenyl)thiophene-2-carboxylic acid (1-138)
0._ 0
S s
LION
THF/Me0H, rt, 2 h;
0 N 138-2 OH N
/
CI CI
1-138
CI CI
1005391 To a solution of 138-2 (70.0 mg, 0.128 mmol) in THF/Me0H (v/v = 4/1,
3.0 mL) was added
LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction was
completed, the resulting reaction was concentrated, then it was diluted with
H20 (15.0 mL) and adjusted
pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with Et0Ac (10.0 mL x
2), and the combined
organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4, and
concentrated, the residue was
purified by washing with Me0H to afford 1-138 (25.0 mg, 36.7% yield) as a
yellow solid.
1005401 The synthesis of methyl 2-((5-isobuty1-4-(thiophen-2-yOthiazol-2-
yDamino)nicotinate (145-1)
0
oLic.-
s \ s
ci____y
N. 1 N NH 2
'..- 0
N Pd2(dba)3, X-Phos, Cs2CO3 0
--
toluene, 120 C, 16 h /
126-s 145-1
195
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1005411 A mixture of 126-s (250 mg, 0.970 mmol), methyl 2-aminonicotinate (148
mg, 0.970 mmol),
Pd2(dba)3 (90.1 mg, 0.097 mmol), X-Phos (84.1 mg, 0.146 mmol) and Cs2CO3 (474
mg, 1.46 mmol) in
toluene (20.0 mL) was stirred under N2 atmosphere at 120 C for 16 h. When the
reaction was completed,
it was concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 8/1) to
afford 145-1 (180 mg, 49.7% yield) as a white solid.
1005421 The synthesis of 2-45-isobuty1-4-(thiophen-2-yl)thiazol-2-
yl)amino)nicotinic acid (1-145)
,S NaOH ,S
0 I 0 I
THF/Me0H, rt, 2 h
/0 OH
S S
145-1 1-145
1005431 To a solution of 145-1 (180 mg, 0.482 mmol) in THF/Me0H (v/v = 4/1,
5.0 mL) was added
NaOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction
was completed, the resulting reaction was concentrated, then it was diluted
with H20 (15.0 mL) and
adjusted pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with Et0Ac
(10.0 mL x 2), and the
combined organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4,
and concentrated, the
residue was purified by washing with Me0H to afford 1-145 (150 mg, 86.6%
yield) as a yellow solid.
1005441 The synthesis of methyl 1-(5-isobuty1-4-(thiophen-2-
yl)thiazol-2-yOpiperidine-3-carboxvlate
(146-1)
Pd2(dba)3, X-Phos, Cs2CO3 N
toluene, 110 C, 16 h 0 S
S 0
126-s 146-1
1005451 A mixture of 126-s (300 mg, 1.16 mmol), methyl piperidine-3-
carboxylate (167 mg, 1.16
mmol), Pd2(dba)3 (108 mg, 0.116 mmol), X-Phos (101 mg, 0.174 mmol) and Cs2CO3
(567 mg, 1.74 mmol)
in toluene (20.0 mL) was stirred under N2 atmosphere at 110 C for 16 h. When
the reaction was completed,
it was concentrated and purified by silica gel column chromatography (petrol
ether/ethyl acetate = 8/1) to
afford 146-1 (160 mg, 37.7% yield) as a yellow solid.
1005461 The synthesis of 1-(5-isobuty1-4-(thiophen-2-yl)thiazol-2-
yOpiperidine-3-carboxylic acid (I-
146)
196
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
\N¨e I LiOH S
I
N THF/Me0H, rt, 2
0 S 0 S
0
OH
146-1 1-146
1005471 To a solution of 883-1 (160 mg, 0.438 mmol) in THF/Me0H (v/v = 4/1,
3.0 mL) was added
LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction was
completed, the resulting reaction was concentrated, then it was diluted with
H20 (15.0 mL) and adjusted
pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with Et0Ac (10.0 mL x
2), and the combined
organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4, and
concentrated, the residue was
purified by washing with Me0H to afford 1-146 (120 mg, 78.0% yield) as a
yellow solid.
1005481 The synthesis of methyl 2-((4-(cyclohex-1-en-l-y1)-5-isobutylthiazol-2-
yOarnino)-5-
(trifluoromethyl)nicotinate (147-1)
F F
FE
0 ¨N
¨\N1
CI S
Pd2(dba)3, X-Phos, Cs2CO3 0
H N I
toluene, 120 C, 4 h 0
139-s 147-1
1005491 A mixture of 139-s (175 mg, 0.740 mmol), methyl 2-chloro-5-
(trifluoromethypnicotinate (177
mg, 0.740 mmol), Pd2(dba)3 (68.8 mg, 0.074 mmol), X-Phos (64.2 mg, 0.111 mmol)
and Cs2CO3 (362 mg,
1.11 mmol) in toluene (20.0 mL) was stirred under N2 atmosphere at 120 C for
411. When the reaction was
completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl acetate
= 8/1) to afford 147-1 (120 mg, 36.9% yield) as a yellow solid.
1005501 The synthesis of 24(4-(cyclohex-1-en-l-y1)-5-isobutylthiazol-2-
y0amino)-5-
(trifluoromethypnicotinic acid (1-147)
FE FE
1¨\N ¨\N1
S LiOH
THF/Me0H, rt, 2 h S
0 I
0 OH
147-1 1-147
197
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
1005511 To a solution of 147-1 (120 mg, 0.273 mmol) in THF/Me0H (v/v = 4/1,
3.0 mL) was added
LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction was
completed, the resulting reaction was concentrated, then it was diluted with
H20 (15.0 mL) and adjusted
pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with Et0Ac (10.0 mL x
2), and the combined
organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4, and
concentrated, the residue was
purified by washing with Me0H to afford 1-147 (100 mg, 86.1% yield) as a
yellow solid.
1005521 The synthesis of methyl 2-45-isobuty1-4-(3-(2-
methoxyethoxy)phenyl)thiazol-2-yl)amino)-5-
(thiophen-2-y1)nicotinate (1-148)
/ 0
S S
N N H2
CI¨µ e X-Phos, 4 Cs2C0
S
HN--
toluen, 120 C, h .. 0
0
122-s 1-148
1005531 A mixture of 122-s (1.50 g, 4.60 mmol), methyl 2-amino-5-
(thiophen-2-yl)nicotinate (1.08 g,
4.60 mmol), Pd2(dba)3 (428 mg, 0.460 mmol), X-Phos (399 mg, 0.691 mmol) and
Cs2CO3 (2.25 g, 6.91
mmol) in toluene (100 mL) was stirred under N2 atmosphere at 120 'C for 4 h.
When the reaction was
completed, it was concentrated and purified by silica gel column
chromatography (petrol ether/ethyl acetate
= 8/1) to afford 1-148 (1.00 g, 41.5% yield) as a yellow solid.
1005541 The synthesis of 2-05-isobuty1-4-(3-(2-methoxyethoxy)phenyl)thiazol-2-
yDamino)-5-
(thiophen-2-yl)nicotinic acid (1-122)
LiOH
S S
THF/Me0H, it, 2 h
HN¨µ HN-4
0 0
0 OH
1-148 1-122
1005551 To a solution of 1-148 (200 mg, 0.382 mmol) in THF/Me0H (v/v = 4/1,
5.0 mL) was added
LiOH (2.0 M in H20, 1.0 mL). The reaction was stirred at room temperature for
2 h. When the reaction was
completed, the resulting reaction was concentrated, then it was diluted with
H20 (15.0 mL) and adjusted
pH to 4 - 5 with HC1 (1.0 M). The mixture was extracted with Et0Ac (10.0 mL x
2), and the combined
198
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
organic phase washed with brine (10.0 mL), dried by anhydrous Na2SO4, and
concentrated, the residue was
purified by washing with Me0H to afford 1-122 (150 mg, 77.1% yield) as a
yellow solid.
I-# Chemical Structure LCMS 1H NMR
(400 MHz, d6-DMS0)
Method C, Purity is 6: 0.94 (6H, d, J= 6.8
Hz), 1.87-1.91
(1H, m), 2.75 (2H, d,.I= 7.2 Hz), 3.89
¨\
99.2%, Rt = 2.191 min; (1H, s), 7.16-7.18
(1H, iii), 7.23 (1H_
/(N
104 s), 7.39 (1H, s), 7.46 (1H, s),
7.59-7.61
0 HN-e I MS Calcd.: 533.1; MS
OH N CF3 (2H, m), 8.43 (1H, d,
J= 2.8 Hz), 8.89
Found: 534.1 [M + H] t (1H, d, J= 2.4 Hz), 11.52 (1H, brs),
,o 14.28 (1H, brs).
S 6: 0.92 (6H, d, J= 6.4
Hz), 1.85-1.92
Method C, Purity is
¨\ (1H, m), 2.76 (2H, d,
J= 7.2 Hz), 7.05-
99.1%, Rt = 2.120 min. 7.07 1H m 7.07-7.19 1H
m 7.23-
102 7.27 (2H, m), 7.42 (1H, t, J= 8.0
Hz),
0 HN¨e I MS Calcd.: 533.1; MS
OH N 7.60-7.64 (2H, m),
8.46 (1H, d, J= 2.0
Found: 534.2 [M + H] +. Hz), 8.92 (1H, d, J= 2.4 Hz), 11.55
(1H, brs), 14.28 (1H, brs).
." 6: 0.93 (6H, d, J= 6.4
Hz), 1.87-1.91
s Method C, Purity is (1H, m), 2.77 (2H,
d, J= 7.2 Hz), 4.30
(2H, dt, J= 30.4, 3.6 Hz), 4.77 (2H, dt,
N
98.4%, Rt = 2.064 mm;
J= 48.0, 3.6 Hz), 6.98 (1H, dd,J= 8.0,
103
0 MS Calcd.: 497.1; MS 2.0 Hz), 7.15-7.19
(3H, m), 7.36-7.40
OH (1H, m), 7.60-7.64
(2H, m), 8.46 (1H,
Found- 498 2 [M + H]
d, J= 2.4 Hz), 8.93 (1H, d, J= 2.4 Hz),
11.55 (1H. brs).
6: 0.89 (6H, d, J= 6.4 Hz), 1.35 (3H, t,
sv Method C, Purity is J= 6.8 Hz), 1.53-
1.65 (3H, m), 2.85-
2.91 (2H, m), 4.08 (2H, q, J= 6.8 Hz),
92.6%, Rt = 2.180 min; 6.92 (1H, dd,J= 8.4,
2.0 Hz), 7.11
\ / s
105 (1H, s), 7.14-7.19 (2H, m), 7.35
(1H,
HN--4,
MS Calcd.: 493.2; MS
t, J= 8.0 Hz), 7.59-7.63 (2H, m), 8.45
OH
Found: 494.2 [M + H] (1H, d, J= 2.4 Hz),
8.92 (1H, d, J=
2.4 Hz), 11.51 (1H, brs), 14.19 (1H,
brs).
6: 0.93 (6H, d, J= 6.4 Hz), 1.00 (3H, t,
J= 7.2 Hz), 1.76 (2H_ q, J= 6.8 Hz),
Method C, Purity is
1.86-1.91 (1H, m), 2.76 (2H, d, J= 7.2
98.4%, Rt = 2.175 min; Hz), 3.98 (2H. t. J=
6.4 Hz), 6.92 (1H,
\
106 dd, J= 8.0, 2.0 Hz), 7.11 (1H, s),
7.13-
HN---4
0 MS Calcd.: 493.2; MS
OH 7.19 (2H, m), 7.35
(1H, t, J= 8.0 Hz),
Found: 494.2 [M + H] +. 7.60-7.64 (2H, m), 8.46 (1H, d, J= 2.4
Hz), 8.93 (1H. d,J= 2.4 Hz), 11.54
(1H, brs), 14.27 (1H, brs).
199
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
I-# Chemical Structure LCMS 11-1 NMR
(400 MHz, d6-DMS0)
.-
s /
Method C, Purity is 6: 0.94 (6H, d, J= 6.8
Hz), 1.86-1.92
\N
( 1H, m), 2.19 (3H, s), 2.75 (2H, d, j=
96
\ l< _,,,,s .0% 2.133 min-
" Rt =
107
MS Calcd.: 479.1; MS m), 7.59-7.63 (2H, m),
8.45 (1H, d, J =
7.2 Hz), 3.84 (3H. s), 7.05-7.21 (4H,
OH N
Found: 480.2 [M + H].
2.4 Hz), 8.92 (1H, d, J= 2.4 Hz), 11.55
-P
(1H, brs).
,0
Method C, Purity is 6: 0.89 (6H, d, J= 6.4
Hz), 1.54-1.64
¨\ (3H, m), 2.19 (1H, s),
2.87 (2H, t, J
108 =
N 96.5%, Rt = 2.196 min; i< 7.6 Hz), 3.84
(1R s), 7.05-7.22 (2H,
0 HN-e OH N I MS Calcd.: 493.1; MS
m), 7.16-7.21 (2H, m), 7.59-7.62 (2H,
m), 8.45 (1H, d, J= 2.4 Hz), 8.91 (1H,
Found: 494.3 [M + HI '.
d, J= 2.4 Hz), 11.53 (1H_ brs).
,c)
6: 0.93 (6H, d, J= 6.4 Hz), 1.88-1.91
Method C, Purity is
(1H, m), 2.35 (3H, s), 2.75 (2H, d, J=
97.8%, Rt = 2.118 min; 7.2 Hz), 3.79 (3H, s),
6.77 (1H, s), 6.90
109 ro/¨H\N-45 I (1H, s), 6.99 (1H, s), 7.18 (1H,
dd, J=
MS Calcd.: 479.1; MS
OH N---"Nc.,..,,, - 5.2, 3.6 Hz), 7.60-
7.64 (2H, m), 8.46
i Found: 480.2 [M + H] . (1H, d. J= 2.8 Hz), 8.93 (1H, d, J=
--
2.4 Hz), 11.53 (1H, brs).
__.0
/
S 6: 0.93 (6H, d, J= 6.4 Hz), 1.23 (3H, t,
Method C, Purity is
¨\ J= 7.6 Hz), 1.88-1.91
(1H, in), 2.67
\ N 98.9 %, Rt =2.161 min; (2H, q, J= 7.2
Hz), 2.75 (2H, d, J=
123 /( 7.2 Hz), 7.17-7.22 (2H, m), 7.36-
7.44
0 Fini¨e I MS Calcd.: 463.2; MS
OH N ill (3H, m), 7.62 (1H, dd,
.1' 11.6, 3.6
Found: 464.2 [M + H] '. Hz), 8.46 (1H, d, J= 2.8 Hz), 8.93
(1H, d, J= 2.4 Hz), 11.54 (1H, brs).
,-- 6: 0.95 (6H, d, J= 6.4
Hz), 1.14-1.19
/
s Method C, Purity is (3H, m), 1.89-1.93
(1H, m), 2.60 (2H,
¨\ q, ./= 7.2 Hz), 2.76
(2H, d, ,/= 7_2 Hz),
N \ 98.1 %, Rt =2.182 min; / s 3.84 (3H, s),
7.09-7.22 (4H, m),
110 MS Calcd.:493.2; MS 7.62(2H_ dd_ J= 10.6, 3.2 Hz),
8.46
OH N
(1H, d, J= 2.4 Hz), 8.93 (1H, d, J=
Found: 494.3 [M + H] .
2.4 Hz), 11.54 ( H, brs), 14.25 (1H,
--o brs).
200
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
I-# Chemical Structure LCMS 11-1 NMR
(400 MHz, d6-DMS0)
/ Method C, Purity is 6: 0.88-0.92 (6H,
m), 1.85-1.89 (1H,
¨ m), 2.72 (2H, d, J=
7.2 Hz), 6.07 (1H,
N 94.1%, Rt = 2.036 min;
124
\ / ,5
HN--= 1 MS Calcd.: 479.1; MS (2H, m), 7.16-7.18 (1H, m), 7.58-7.61
s), 6.98 (1H, d,J= 8.0 Hz), 7.05-7.11
0 N
OH (2H, m), 8.45 (1H,
d,J= 2.4 Hz), 8.87
o---/
0 Found: 480.2M + H] -P.
(1H, d' J= 2.4 Hz), 12.24 (1H, brs).
;-/ 6: 0.93 (6H, d, J= 6.8
Hz), 1.68 (6H,
Method C, Purity is
¨\ s), 1.84-1.92 (1H, m),
2.72 (2H, d, J=
\ e
91.8%, Rt = 2.139 min; 6.8 Hz), 6.89 (1H_- d,
J= 8.4 Hz), 6.99-
125 0 HN-e I 7.02 (2H, m), 7.18 (1H, dd,J= 4.8,
4.0
OH N MS Calcd.: 507.1; MS
Hz), 8.45 (1H.' d,J= 2.4 Hz), 8.92
Found: 508.2 [M + H] -P. (1H, d, J= 2.4 Hz), 11.51 (1H, brs),
0--., 14.30 (1H, brs).
..- 6: 1.00 (6H, d, J= 6.8
Hz), 1.92-1.99
/ Method C, Purity is
s (1H, m), 2.84 (2H,
d,J= 7.2 Hz), 7.13-
¨\ 98.2%, Rt = 2.071 min;
7.19 (2H, m), 7.36 (1H, d,J= 2.8 Hz),
\ .,,KN is 1
7.53-7.55 (1H, m), 7.61-7.64 (2H, m),
126
MS Calcd.: 441.1; MS
8.46 (1H, d,J= 2.4 Hz), 8.93 (1H, d. J
OH N , Found: 442.2 [M + Hi . = 2.4 Hz), 11.51
(1H, brs), 14.33 (1H,
s / brs).
.,-
/
6: 0.96 (6H, d, J= 6.8 Hz), 1.89-1.92 Method C, Purity is
S (1H, m), 2.80 (2H,
d,J= 6.8 Hz), 7.18
¨\ 98.9%, Rt = 2.024 min;
(1H, dd, J= 4.8, 3.6 Hz), 7.45 (1H, dd,
127 J= 4.8, 1.2 Hz), 7.60-7.71 (3H, m),
0 HN MS Calcd.: 441.1; MS
¨\ I 7.71 (1H, s), 8.46 (1H, d, J= 2.4 Hz),
OH N Found: 442.2 [ M + H] -P. 8.93 (1H, d,J=
2.0 Hz), 11.53(1H,
I \ brs).
S
.---
/
S 6: 0.93 (6H, d, J= 6.8
Hz), 1.88-1.91
Method C, Purity is
¨\ (1H, m), 2.75 (2H, d,J= 6.8 Hz), 6.75
\ /N o HN¨<\ 100%, Rt = 1.969 min; (1H, d, J= 7.2
Hz), 7.01-7.02 (2H, m),
( s
111 7.17-7.26 (2H, m), 7.60-7.64 (2H,
m),
I MS Calcd.: 451.1; MS
OH N 8.46 (1H, d,J= 2.4
Hz), 8.93 (1H, d, J
Found: 452.2 [M + H] '. = 2.4 Hz), 9.48 (1H, brs), 11.54(1H,
brs).
HO
6: 0.90 (6H, d, J= 6.4 Hz), 1.86-1.88
CI Method C, Purity is (1H, m), 2.73 (2H,
d,J= 7.2 Hz), 5.17
\ (2H, s), 7.02 (1H, d,J= 8.0 Hz), 7.16-
92.3 %, Rt =2.202 min-
' 7.20 (3H, m), 7.33-
7.42 (4H, m), 7.48
128 0 HN-<, I
OH N MS Calcd.: 459.2; MS (2H, d, J= 7.2
Hz), 7.62 (2H, dd, J=
Found: 460.3 M + H] '
10.6, 3.2 Hz), 8.46 (1H, d,J= 2.4 Hz),
ei [.
8.93 (1H, d,J= 2.4 Hz), 11.57 (1H,
o
brs).
201
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
I-# Chemical Structure LCMS 11-1 NMR
(400 MHz, d6-DMS0)
-I
¨\ Method C, Purity is 6:0.86 (6H, d, J=
6.4 Hz), 1.80-1.84
\ e s
96.0%, Rt = 2.205 min; (1H, m), 2.69 (2H, d,
J= 7.2 Hz), 7.04-
129 0 HN¨<, I 7.13 4H m 7 17-7.20 2H m) 7.38-
( , ), = ( ¨
OH N MS Calcd.: 527.1; MS 7.50 (4H, m), 7.60-
7.64 (2H, m), 8.45
Found: 528.3 M + H] . (1H, d, J= 2.4 Hz), 8.92 (1H, d, J=
[ '
o 2.4 H.;), 11.54 (1H, brs).
41,1
6: 0.96 (3H, t, J= 7.2 Hz), 1.35 (3H, t,
Method C, Purity is
\ J= 7.2 Hz), 1.65-1.71
(2H, m), 2.85
N
\ 1( s 97.6%, Rt = 2.084 min; (2H, t, J= 7.6
Hz), 4.05-4.10 (2H, m),
112 6.90-6.93 (1H, m), 7.10-7.19 (3H,
m),
0 HN¨<\ I MS Calcd.: 465.1; MS
ON N 7.35 (1H, t, J = 7.6
Hz), 7.59-7.62 (2H,
Found: 466.2 [M + H] . m), 8.45 (1H, d, J = 2.8 Hz), 8.90 (1H,
d,./= 2.8 Hz), 11.54 (1H, brs).
0
--....----
/ 6: 0.92 (6H, d, J= 6.8
Hz), 1.35 (3H, t,
s Method C, Purity is
o _\ J= 7.2 Hz), 1.86-
1.90 (1H, m), 2.75
\ ,N 98.9%, Rt = 1.771 min; (2H, d, J= 7.2
Hz), 4.03-4.08 (2H, m),
6.80-6.90 (1H, m), 7.01-7.16 (4H, m),
130 HN¨ I MS Calcd.: 479.1; MS
N 7.21-7.22 (1H, m), 7.34 (1H, t, J= 8.0
Found: 480.1 [M + H] -P. Hz), 8.56-7.58 (1H, m), 8.41 (1H, s),
o- 11.53 (1H, brs).
....--
6: 0.98 (6H, d, J= 6.8 Hz), 1.36 (3H, t,
Sp J= 6.8 Hz), 1.92-1.99
(1H, m), 2.81
Method C, Purity is (2H, d, J= 7.2 Hz),
4.08 (2H, dd, J=
14.0, 6-.8 Hz), 6.91-6.93 (1H, m), 7.10
/(N s 100%, Rt = 2.042 min-
' (1H, s), 7.16 (1H, d,
J= 7.6 Hz), 7.27
131 0 HN¨<,. I MS Calcd.: 479.1; MS (1H, dd, J= 4.8, 3.6 Hz), 7.36
(1H, t, J
OH N
Found: 480.4 [M + H]
= 8.0 Hz), 7.62 (1H, d, J = 8.0 Hz),
-P.
7.89 (1H, dd, J= 5.2, 0.8 Hz), 8.03-
0 - 8.05 (1H, m), 8.35
(1H, d, ./= 8.0 Hz),
-....õ--
11.72 (1H, brs), 13.96 (1H, brs).
-=,,,,,,-
Method C, Purity is 6: 0.92 (6H, d. J= 6.8
Hz), 1.32-1.36
97.3%, Rt = 2.082 min
s''µk (12H, m), 1.7-1.87
(1H, m), 2.75 (2H,
.
' d, J= 6.8 Hz), 4.07
(2H, q, I- = 6.8 Hz),
132 o HN---(\s 1 MS Calcd.: 458.2; MS 6.89-6.92 (1H, m), 7.15-7.18
(2H, m),
OH N
LfJ Found: 459.3 [M + HI . 7.35 (1H, t, J= 8.0
Hz), 8.01 (1H, s),
10.18 (1H, brs), 13.03 (1H, brs).
0-....õ--
202
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
I-# Chemical Structure LCMS 11-1 NMR
(400 MHz, d6-DMS0)
FE
F 6: 0.91 (6H, d, J= 6.4 Hz), 1.35 (3H, t,
Method C, Purity is
J= 6.8 Hz), 1.86-1.89 (1H, m), 2.76
1 \N
99.0%, Rt = 2.081 min; (2H, d, J= 6.8 Hz),
4.05-4.10 (2H, m),
133 0 HN-<, I 6.91-6.94 (1H, m), 7.09-7.15 (2H,
m),
OH MS Calcd.: 465.1; MS
7.35 (1H, t, J= 8.0 Hz), 8.49 (1H, d, J
Found: 466.3 [M + H] -P. = 2.4 Hz), 8.93 (1H, d, J= 1.6 Hz),
11.96 (1H, brs).
0_F F
F1_,(N Method C, Purity is 6: 0.99 (6H, d_ J=
6.4 Hz), 1.91-1.98
_\
100%, Rt = 2.064 min; (1H, m), 2.85 (2H, d,
J = 7.2 Hz), 7.14
(1H, dd, J= 4.8, 3.6 Hz), 7.37 (1H, dd,
134 S MS Calcd.: 427.1; MS J= 3.6, 0.8 Hz), 7.55 (1H, dd,
J= 4.8,
o HN-<,, I
OH N Found: 428.2 M + H] . 1.2 Hz), 8.51 (1H,
d, J= 2.4 Hz), 8.96
---- [ '
(1H, d, J= 1.6 Hz), 11.79 (1H, brs).
S /
F F
F Method C, Purity is 6:0.95 (6H, d, J=
6.8 Hz), 1.88-1.91
(1H, m), 2.81 (2H, d,J= 7.2 Hz), 7.45
\ \N 135 ......)7- 98.9%, Rt ¨ 2.024 min.
\ i( S ' (1H, dd, ./= 4_8, 1.2
Hz), 7_63 (1H, dd,
0 HN-, I MS Calcd.: 441.1; MS J= 4.8, 3.2 Hz),
7.73 (1H, d, J= 2.0
OH Ni---0 Found: 442.2 [M + HI -P. Hz), 8.50 (1H, d,
J= 2.4 Hz), 8.95
(1H, d, J= 1.6- Hz), 11.81 (1H, brs).
,
S
si 6: 0.92 (6H, d, J= 6.8
Hz), 1.29 (6H,
\N Method C, Purity is d, J= 6.0 Hz), 1.83-
1.94 (1H, m), 2.76
91.3 % Rt =2.137 min- (2H, d, J¨ 6.8 Hz),
4.64-4.68 (1H, m),
' ' 6.90-6.93 (1H, m),
7.08 (1H, s), 7.19-
113 0 HN-<, I
OH N MS Calcd.: 493.2; MS 7.12 (2H, m), 7.34
(1H, t, J= 8.0 Hz),
7.60-7.65 (2H, m), 8.46 (1H, d,J= 2.4
Found: 494.2 [M + H] '.
Hz), 8.93 (1H, d, J= 2.4 Hz), 11.61
i (1H, brs).
/
s 6: 0.92 (6H, d, J= 6.8
Hz), 1.31 (6H,
Method C, Purity is
¨\ d, J= 5.6 Hz), 1.85-
1.92 (1 H, m), 2.17
93.4 %, Rt =2.203 min; (3H, s), 2.75 (2H, d,
J= 7.2 Hz), 4.57-
E14 0 FIN-<\ I 4.66 (1H, m), 7.04-7.09 (2H, m),
7.17-
OH N MS Calcd.: 507.4; MS
7.22 (2H, m), 7.60-7.64 (2H, m), 8.46
Found: 508.4 [M + H] '. (1H, d, J= 2.4 Hz), 8.93 (1H, d, J=
Nyo 2.4 Hz), 11.54 (1H,
brs).
203
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
I-# Chemical Structure LCMS 41 NMR
(400 MHz, d6-DMS0)
FE
F 6: 1.02 (6H, d, J= 6.4
Hz), 1.94-2.01
Method C, Purity is
(1H, m), 2.89 (2H, d, J= 7.2 Hz),
\ /(N ,S.--...2 96.7%, Rt = 2.200 min; 7.30-7.34 (1H,
m), 7.37 (1H, d, J= 4.0
136 0= HN- I OH N , MS Calcd.: 503.1; MS Hz),
7.43 (2H, t. J= 7.6 Hz), 7.53 (1H,
s / d, J= 4.0 Hz), 7.72 (2H, d, J= 7.2 Hz),
Found: 504.5 [M + H] '. 8.51 (1H, d,J= 2.4 Hz), 8.96 (1H, d,J
= 1.2 Hz), 11.82 (1H, brs).
6: 0.91 (6H, d, J= 6.4 Hz), 1.35 (3H, t,
Method C, Purity is J= 6.8 Hz), 1.80-1.83
(1H, in), 2.72
0% 96 (2H, d,./= 6.8 Hz),
4_04-4.09 (2H, m),
137 .
o') HN--<\s I ' Rt = 1888 min. 6.90-6.93 (1H,
m), 7.09 (1H, s), 7.15 N
OH MS Calcd.: 402.1; MS (1H, d, J= 8.0
Hz), 7.35 (1H, t,J= 8.0
Found: 403.3 M + H] Hz), 7.85 (1H. d, J=
5.6 Hz), 8.06
[ -P.
O- (1H, d, J= 5.6 Hz), 10.22 (1H, s),
13.19 (1H, brs).
o, 6: 0.92 (6H, d, J= 6.4
Hz), 1.82-1.85
Method C, Purity is (1H, m), 2.75 (2H, d, J= 7.2 Hz), 3.83
(3H, s), 7.01 (1H, dd,./= 8.0, 2.0 Hz),
90.9%, Rt = 2.174 min;
7.22 (1H, s), 7.27 (1H, d, J= 7.6 Hz),
138 ¨ s
0 I-IN--4 1 MS Calcd.: 532.0; MS 7.40 (1H, t, J=
7.6 Hz), 7.63 (1H, dd,J
OH N = 8.4, 2.0 Hz), 7.71
(1H, d, J= 8.4
Found: 533.2 [M + H] '
ci . Hz), 7.91 (1H d I 1 6 H ) 8.45
CI (1H, s), 10.28 (1H,
brs).
..] 6: 0.93 (6H, d, J= 6.4
Hz), 1.35 (3H, t,
0 I J= 6.8 Hz), 1.87-1.91
(1H, m), 2.76
Method C, Purity is
¨\ (2H, d, J= 6.8 Hz),
4.08 (2H, q, J=
N 100%, Rt = 2.067 min; 6.8 Hz), 6.64
(1H, dd,.I= 3.2, 1.6 Hz),
11 6.92 (1H, d, J= 8.0
Hz), 7.09-7.16
-- 0 HN¨ I MS Calcd.: 463.2. MS
OH N ' (2H, m), 7.35 (1H, t,
J= 8.0 Hz), 7.81
Found: 464.2 [M + H] ". (1H, d, J= 1.2 Hz), 8.54 (1H, d, J=
2.4 Hz), 8.96 (1H. d, J= 2.4 Hz), 11.57
\--0 (1H, brs), 14.25 (1H, brs).
6: 0.93 (6H, d, J= 6.8 Hz), 1.87-1.91
Method C, Purity is 100 (1H, m), 2.66 (6H, s), 2.74 (2H, d, J=
i 7.2 Hz), 3.13 (2H_ s),
3.76-3.83 (4H,
¨ N %, Rt =1.893 min; MS
\ i s m), 4.20 (2H, d,
J" = 4.8 Hz), 6.90 (1H,
116 HN-4 1
0 oH ry Calcd.: 566.3; MS dd, J= 8.0, 2.0 Hz),
7.13-7.20 (3H, m),
------0-----", Found: 567.4 [M + HI '. 7348..40 ((111-1-11,t j
.0
d.7=
874Hz),)78.5603(2(1-11},imd)., j
= 2.4 Hz), 15.01 (1H, brs).
/ 6: 0.92 (6H, d, J= 6.8
Hz), 1.19 (6H,
¨ Method C, Purity is 100 d, J= 7.2 Hz), 1.87-1.90 (1H, m), 2.74
\ ,N
117 (2H, d, J= 7.2 Hz), 3.14 (4H, d,J =
%,Rt =1.940 min; MS
7.2 Hz), 3.28-3.34 (2H, m), 3.83 (4H, t,
0 ---(,...---,... ....-- J= 4.4 Hz), 4.19 (2H,
t, J= 1.0 Hz), 3
204
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
I-# Chemical Structure LCMS 11-1 NMR
(400 MHz, d6-DMS0)
Calcd.: 594.3; MS 69 (1H, dd, J= 8.0,
2.0 Hz), 7.14-7.21
Found: 595.2 M + H] . (3H, m), 7.33 (1H, t, J= 8.0 Hz), 7.50-
[ +
7.54 (2H, m), 8.41 (1H, d, J= 2.4 Hz),
8.66 (1H, d, J= 2.8 Hz), 14.25 (1H,
brs).
..
S / Method C, Purity is
6: 0.93 (6H, d, J= 4.8 Hz), 1.66 (4H,
139
m), 1.82 (1H, s), 2.16 (2H, s), 2.29
¨\ n.
\ ,N
99.1%, Rt = 2.050 mi
'K S ' (2H, s), 2.64 (2H, d, J= 4.8 Hz), 5.84
MS Calcd.: 439.1; MS (1H, s), 7.16-7.27
(1H, m), 7.59 (2H,
O HN-<, I
s), 8.43 (1H, s), 8.84 (1H, s), 12.34
OH N Found: 440.3 [M + H] '.
(1H, brs).
.-- 6: 0.95 (6H, d, J= 6.4
Hz), 1.82-1.88
/ Method C, Purity is (1H, m), 2.42 (2H,
d, J= 2.0 Hz), 2.69
3
(2H, d, J= 7.2 Hz), 3.79 (2H, t, J= 5.6
140 /(
¨\N 99.4%, Rt = 1.917 min;
Hz), 4.21 (2H_' d' J= 2.4 Hz), 5.97
\
S-.....,2 MS Calcd.: 441.1; MS (1H, s), 7.18 (1H,
dd,J= 5.2, 3.6 Hz),
O HN4 1
OH Found: 442.2 [M + H]
7.60-7.63 (2H, m), 8.44 (1H, d,J= 2.4
N--\00 ".
Hz), 8.91 (1H. d,J= 2.4 Hz), 11.43
(1H, brs), 14.28 (1H, brs).
,-
/ Method B, Purity is 6: 0.99 (6H, d, J=
6.8 Hz), 1.89-1.96
S
(1H, m), 2.49 (3H, m), 2.79 (2H, d, J=
_\
97.8%, Rt = 2.324 min; 7.2 Hz), 6.80 (1H. d,
J= 2.4 Hz), 7.12-
141 \
S 7.18 (2H, m), 7.59-7.62 (2H, m), 8.44
MS Calcd.: 455.1; MS
0 HN¨ I (1H, d, J= 2.4 Hz),
8.90 (1H, d, J=
OH N
--- Found: 456.1 [M + H] '. 2.4 Hz), 11.48 (1H, brs), 14.32 (1H,
S / brs).
6: 0.93 (6H, d, J= 6.4 Hz), 1_87-1.91
= / Method C, Purity is
(1H, m), 2.34 (3H, s), 2.75 (2H, d, J=
¨ 6.8 Hz), 3.32 (3H, s),
3.67 (2H, t, J=
N 94.6%, Rt = 1.996 min;
\ / 4.4 Hz), 4.12 (2H, t,
J= 4.4 Hz), 6.77
118 0 HN-4ss 1 MS Calcd.: 523.2; MS (1H, s), 6.90 (1H, s), 7.18
(1H, t, J=
OH N
Found: 524.2 [M + H]
4.4 Hz), 7.59-7.64 (2H, m), 8.46 (1H,
-P.
0......õ....Ø..-- d, J= 2.4 Hz), 8.92 (1H, d, J= 2.4 Hz),
11.61 (1H, brs), 14.25 (1H, brs).
../.3:2\ Method C, Purity is 6: 0.99 (6H, d, J= 6.4 Hz), 1.85-1.92
(1H, m), 2.79-2.81 (2H, d,J= 7.2 Hz),
142
O s 99.9% Rt = 1.758 min-
' ' 7.12-7.14 (1H, m),
7.35-7.36 (1H, m),
HN--<. 1
OH N MS Calcd.: 364.0; MS 7.52-7.53 (1H, m),
7.89 (1H, d,J= 5.6 Found: 365.0 [M + H] _-
Hz), 8.13 (1H, d, J= 5.6 Hz), 10.23
s / '.
(1H, s), 13.21 (1H, brs).
205
CA 03229560 2024- 2- 20
WO 2023/028235 PCT/US2022/041532
I-# Chemical Structure LCMS 11-1 NMR
(400 MHz, d6-DMS0)
Method C, Purity is 6: 0.99 (6H, d. J= 6.4
Hz), 1.89-1.92
(1H, m), 2.82 (2H, d,J = 7.2 Hz), 7.15
100%, Rt = 2.023 min;
143 s (1H, dd, J= 5.2, 3.6 Hz), 7.37-7.38
¨ s MS Calcd.: 440.1; MS (1H, m), 7.46-7.57 (4H, m), 7.73-7.75
0 HN-- (2H, m), 8.55 (1H, s),
10.29 (1H, s),
N .--- Found: 441.3 [M + H] '.
OH 13.30 (1H_, brs).
s /
Method C, Purity is 6: 0.99 (6H, d, J= 6.4
Hz), 1.39 (9H,
S \ 1001%, Rt = 2.025 min; s), 1.87-1.91 (1H, m), 2.81 (2H, d, J=
7.2 Hz), 7.13 (1H.- dd, J= 5.2, 4.4 Hz),
144 0 S
MS Calcd.: 420.1; MS 7.35 (1H, dd, J=3.6,
0.8 Hz), 7.55
OH HN--- I (1H, dd, J= 5.2. 0.8
Hz), 8.13 (1H, s),
N _- Found: 421.3 [M + H] '.
10.20 (1H, s), 12- .99 (1H, brs).
S /
6: 0.99 (6H, d, J= 6.4 Hz), 1.93-1.99
Method C, Purity is
_\
(1H, m), 2.83 (2H, d,J = 7.2 Hz), 7.08-
N
\ / 86.5 %, Rt =1.834 min; 7.14 (2H, m),
7.35 (1H, d,J= 3.6 Hz),
145 0 I-N-e 1 7.53 (1H, d, J= 4.4 Hz), 8.36 (1H,
dd,
MS Calcd.: 359.1; MS
OH N J= 7.8, 1.6 Hz), 8.57
(1H, dd, J= 4.8,
s / Found: 360.2 [M + H] 1 2.0 Hz), 11.53 (1H,
brs), 14.03 (1H,
brs).
6: 0.95 (6H, d, J = 6.4 Hz), 1.57-1.62
Method C, Purity is (2H, m), 1.63-1.74
(1H, m), 1.82-7.85
(1H, m), 1.95-1.98 (1H, m), 2.71 (2H,
146
98.5%, Rt = 1.676 min;
\N-e 1 d, J= 7.2 Hz), 3.08-
3.19 (2H, m), 3.61-
/ MS Calcd.: 440.1; MS 3.88 (1H, m), 3.88-
3.92 (H, m), 7.08
0 (1H 7
S / Found: 441.3 [M + H] ". ' " dd J= 52 * ' 36 Hz) * '26
(1H, dd,
*
OH J= 3.6, 1.2 Hz), 7.46
(1H, dd,J= 5.2,
0.8 Hz), 12.51 (1H, brs).
6: 0.92 (6H, d. J= 6.4 Hz), 1.86-1.89
Method C, Purity is
(2H, m), 2.67-2.72 (2H, m), 2.79 (6H,
100%, Rt = 2.044 min; s), 3.12 (1H, s), 3.28-
3.29 (2H, m),
119 \ 1N S 3.81-3.83 (4H, m), 4.17 (2H, s),
6.98
0 NIN4 1 MS Calcd.: 566.2; MS
OH N gill (2H, d, J= 8.4 Hz),
7.15 (1H, t, J= 4.4
=...fr= 0,--,0,....N..-
I Found: 567.3 [M + H] +. Hz), 7.51-7.54
(4H, m), 8.41 (1H, d, J
= 2.4 Hz), 8.67 (1H, d, J= 2.0 Hz).
6: 0.92 (6H, d, J= 6.4 Hz), 1.15-1.21
Method B, Purity is (6H, m), 1.86-1.89
(2H, m), 2.67-2.72
(2H, m), 3.11 (4H, s), 3.15-3.22 (2H.
100%, Rt = 1.887 min-
' m), 3.83-3.84 (4H, m),
4.15-4.17 (2H,
\
120 l< ,---
a N -A,
HN 1
OH MS Calcd.: 584.2; MS m), 6.99 (2H, d,
J= 8.4 Hz), 7.15 (1H,
--"D"---i.:- Found: 595.3 [M + H] 1. dd, J= 4.8, 3.6 Hz), 7.51-7.54 (4H, m),
8.40(1H, d, ./= 2.8 Hz), 8.66 (1H, d,./
= 2.4 Hz),14.18 (1H, brs).
206
CA 03229560 2024- 2- 20
WO 2023/028235
PCT/US2022/041532
I-# Chemical Structure LCMS 11-1 NMR
(400 MHz, d6-DMS0)
FF
Method C, Purity is 6: 0.92 (6H, d, J= 6.4
Hz), 1.59-1.71
(4H, m), 1.80-1.83 (1H, m), 2.15 (2H,
\NI 99.9%, Rt = 2.043 min;
147 d, J= 2.4 Hz), 2.29 (2H, d, J= 2.0
Hz),
MS Calcd.: 425.0; MS 2.64 (2H, d,J= 6.8
Hz), 5.84 (1H, s),
HN-
OH N
Found: 426.3 [M + H] 8.44 (1H, d,J= 2.0
Hz), 8.82 (1H, s),
12.93 (1H, brs).
Method B, Purity is 6: 1.30 (3H, t, J= 7.6
Hz), 2.88-2.94
(2H, m), 3.33 (3H, s), 3.67-3.70 (2H.
N 99.9%, Rt = 1.925 min;
s m), 4.15-4.17 (1H, m), 7.14-7.20 (3H,
121 OH MS Calcd.: 481.1; MS m), 7.39 (1H, t, J= 8.0 Hz),
7.62-7.66
N
(2H, in), 8.47 (1H, d,J= 2.4 Hz), 8.94
Found: 482.2 [M + H] +.
(1H, d, J= 2.4 Hz), 11.85 (1H, brs).
6: 0.93 (6H, d, J= 6.8 Hz), 1.87-1.91
(1H, m), 2.76 (2H, d,J= 6.8 Hz), 3.33
Method C, Purity is (3H, s), 3.67-3.70
(2H, in), 4.13-4.16
(2H, m), 6.95 (1H, dd, J= 8.4, 2.0 Hz),
99.0%, Rt = 2.025 min;
s 7.11-7.20 (3H, m), 7.36 (1H, t, J= 8.0
122 n MS Calcd.: 509.1; MS Hz), 7.61 (1H_ dd_ J= 5.2, 0.8
Hz),
- OH "
Found: 510.3 M + H] 7.64 (1H, dd, =-5.2,
0.8 Hz), 8.46
[
(1H, d, J= 2.4 Hz), 8.93 (1H, d, J=
2.4 Hz), 11.56 (1H, brs), 14.33 (1H,
brs).
6: 0.92 (6H, d, J= 6.8 Hz), 1.86-1.90
Method B, Purity is (1H, m), 2.76 (2H,
d,J= 7.2 Hz), 3.33
(3H, s), 3.67-3.70 (2H, m), 3.95 (3H_
100%, Rt = 2.262 min;
s), 4.13-4.16 (2H, m), 6.94 (1H, dd, J=
148 0 HN---(\S
MS Calcd.: 523.2; MS 8.4, 2.0 Hz), 7.12-
7.20 (3H, m), 7.36
Found: 524.2 M + H]
(1H, t, J= 8.0 Hz), 7.61-7.64 (2H, m),
[
8.42 (1H, d,J= 2.4 Hz), 8.94 (1H, d, J
=2.8 Hz), 11.15 (1H, brs).
1005561 While a number of embodiments of this invention are described, it is
apparent that the
basic examples may be altered to provide other embodiments that utilize the
compounds and
methods of this invention. Therefore, it will be appreciated that the scope of
this invention is to
be defined by the specification and appended claims rather than by the
specific embodiments that
have been represented by way of example.
207
CA 03229560 2024- 2- 20
